{"cc8921613ee021525d93ec9a286f42376916b898": [["IntroductionVaccination is widely considered to be one of the greatest medical achievements of civilization and one of the top major breakthroughs of humanity.IntroductionFrom an almost empirical origin of vaccinology to the present vaccinomics, our knowledge has evolved substantially and we have learned important lessons.", [["civilization", "TREATMENT", 95, 107]]], ["Although the main target of a vaccine is direct protection against a particular microorganism or disease, the scope of vaccination has expanded with the discovery that vaccines can also protect unvaccinated people through herd protection, or even that certain vaccines can protect against additional diseases different from those that they were designed to prevent, through so-called heterologous effects.Effectiveness and Impact of VaccinationDisease prevention through vaccination is the most cost-effective health care intervention available.", [["people", "ORGANISM", 207, 213], ["people", "SPECIES", 207, 213], ["a vaccine", "TREATMENT", 28, 37], ["direct protection", "TREATMENT", 41, 58], ["a particular microorganism", "PROBLEM", 67, 93], ["disease", "PROBLEM", 97, 104], ["vaccination", "TREATMENT", 119, 130], ["vaccines", "TREATMENT", 168, 176], ["herd protection", "TREATMENT", 222, 237], ["certain vaccines", "TREATMENT", 252, 268], ["additional diseases", "PROBLEM", 289, 308], ["VaccinationDisease prevention", "TREATMENT", 433, 462], ["vaccination", "TREATMENT", 471, 482], ["main", "OBSERVATION_MODIFIER", 13, 17], ["target", "OBSERVATION_MODIFIER", 18, 24], ["disease", "OBSERVATION", 97, 104]]], ["The World Health Organization (WHO) estimates that every year immunization saves between two and three million lives across the world.", [["immunization saves", "TREATMENT", 62, 80]]], ["One hundred years ago, infectious diseases were the main cause of death worldwide, even in the most developed countries.", [["infectious diseases", "DISEASE", 23, 42], ["death", "DISEASE", 66, 71], ["infectious diseases", "PROBLEM", 23, 42], ["death", "PROBLEM", 66, 71], ["infectious", "OBSERVATION", 23, 33]]], ["Today, common childhood diseases of previous generations are becoming increasingly rare thanks to vaccines, and there are new vaccines on the horizon with the potential to prevent even more.Effectiveness and Impact of VaccinationMass immunization programs have proven successful at controlling or even eliminating disease (.", [["vaccines", "TREATMENT", 98, 106], ["the horizon", "TREATMENT", 138, 149], ["VaccinationMass immunization programs", "TREATMENT", 218, 255], ["new", "OBSERVATION_MODIFIER", 122, 125], ["vaccines", "OBSERVATION", 126, 134]]], ["Fig. 1.1 ).SmallPoxBefore a vaccination campaign eliminated all natural occurrences of smallpox in 1980, the disease threatened 60% of the world's population and killed 1 in 4 patients.", [["smallpox", "DISEASE", 87, 95], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["SmallPoxBefore a vaccination campaign", "TREATMENT", 11, 48], ["the disease threatened", "PROBLEM", 105, 127]]], ["Approximately 350 million people are estimated to have been spared from smallpox infection, and 40 million from dying, since the disease was eradicated.MeaslesBetween 2000 and 2014, deaths from measles dropped by 79% worldwide, preventing anPolioTotal eradication of polio is within our reach.PolioSince the creation of the Global Polio Eradication Initiative in 1988 by the WHO and its partners, reported cases of polio have fallen by 99%, with paralysis being prevented in an estimated ten million people.HaemophilusThe conjugate vaccines are effective tools for preventing Hib infections, which were the most common severe invasive childhood infections in industrialized countries.", [["smallpox infection", "DISEASE", 72, 90], ["deaths", "DISEASE", 182, 188], ["measles", "DISEASE", 194, 201], ["polio", "DISEASE", 267, 272], ["polio", "DISEASE", 415, 420], ["paralysis", "DISEASE", 446, 455], ["Hib infections", "DISEASE", 576, 590], ["infections", "DISEASE", 645, 655], ["people", "ORGANISM", 26, 32], ["people", "ORGANISM", 500, 506], ["Hib", "ORGANISM", 576, 579], ["people", "SPECIES", 26, 32], ["people", "SPECIES", 500, 506], ["smallpox infection", "PROBLEM", 72, 90], ["the disease", "PROBLEM", 125, 136], ["measles", "PROBLEM", 194, 201], ["anPolioTotal eradication of polio", "TREATMENT", 239, 272], ["paralysis", "PROBLEM", 446, 455], ["HaemophilusThe conjugate vaccines", "TREATMENT", 507, 540], ["Hib infections", "PROBLEM", 576, 590], ["severe invasive childhood infections", "PROBLEM", 619, 655], ["smallpox", "OBSERVATION_MODIFIER", 72, 80], ["infection", "OBSERVATION", 81, 90], ["disease", "OBSERVATION", 129, 136], ["Global", "OBSERVATION_MODIFIER", 324, 330], ["Polio Eradication", "OBSERVATION", 331, 348], ["paralysis", "OBSERVATION", 446, 455], ["infections", "OBSERVATION", 580, 590], ["most common", "OBSERVATION_MODIFIER", 607, 618], ["severe", "OBSERVATION_MODIFIER", 619, 625], ["invasive", "OBSERVATION_MODIFIER", 626, 634], ["childhood", "OBSERVATION_MODIFIER", 635, 644], ["infections", "OBSERVATION", 645, 655]]], ["Several prospective studies have shown an efficacy exceeding 90% from the first months of life.", [["Several prospective studies", "TEST", 0, 27]]], ["The impact of vaccination in different European countries is summarized in .", [["vaccination", "TREATMENT", 14, 25]]], ["Table 1 .1.DiphtheriaBefore vaccination against diphtheria became readily available in the 1980s, it is estimated that approximately one million cases occurred in the countries of Eastern Europe each year.", [["DiphtheriaBefore", "CHEMICAL", 11, 27], ["diphtheria", "DISEASE", 48, 58], ["DiphtheriaBefore vaccination", "TREATMENT", 11, 39], ["diphtheria", "PROBLEM", 48, 58]]], ["Although diphtheria is still present in some European countries and epidemics broke out in Eastern Europe during the 1990s, it is now drastically reduced thanks to vaccination.Invasive Pneumococcal DiseaseSeveral European countries have reported a significant decline in rates of invasive pneumococcal infection and mucosal forms of pneumococcal disease (mainly otitis and pneumonia) as a result of pneumococcal conjugate vaccination.", [["mucosal", "ANATOMY", 316, 323], ["diphtheria", "DISEASE", 9, 19], ["pneumococcal infection", "DISEASE", 289, 311], ["pneumococcal disease", "DISEASE", 333, 353], ["otitis", "DISEASE", 362, 368], ["pneumonia", "DISEASE", 373, 382], ["mucosal", "PATHOLOGICAL_FORMATION", 316, 323], ["pneumococcal", "SPECIES", 289, 301], ["pneumococcal", "SPECIES", 333, 345], ["pneumococcal", "SPECIES", 399, 411], ["diphtheria", "PROBLEM", 9, 19], ["epidemics", "PROBLEM", 68, 77], ["Invasive Pneumococcal DiseaseSeveral European countries", "TREATMENT", 176, 231], ["a significant decline", "PROBLEM", 246, 267], ["invasive pneumococcal infection", "PROBLEM", 280, 311], ["pneumococcal disease", "PROBLEM", 333, 353], ["mainly otitis", "PROBLEM", 355, 368], ["pneumonia", "PROBLEM", 373, 382], ["pneumococcal conjugate vaccination", "TREATMENT", 399, 433], ["diphtheria", "OBSERVATION", 9, 19], ["significant", "OBSERVATION_MODIFIER", 248, 259], ["decline", "OBSERVATION_MODIFIER", 260, 267], ["invasive", "OBSERVATION_MODIFIER", 280, 288], ["pneumococcal", "OBSERVATION_MODIFIER", 289, 301], ["infection", "OBSERVATION", 302, 311], ["mucosal", "ANATOMY", 316, 323], ["pneumococcal disease", "OBSERVATION", 333, 353], ["mainly", "OBSERVATION_MODIFIER", 355, 361], ["otitis", "OBSERVATION", 362, 368], ["pneumonia", "OBSERVATION", 373, 382]]], ["This benefit also seems to have spread to unvaccinated populations through indirect protection.Invasive Meningococcal DiseaseMass vaccination of children and adolescents with group A + C meningococcal conjugate vaccine, together with routine childhood immunization, have yielded reductions in hospitalization and mortality in Africa.", [["children", "ORGANISM", 145, 153], ["children", "SPECIES", 145, 153], ["adolescents", "SPECIES", 158, 169], ["C meningococcal conjugate vaccine", "SPECIES", 185, 218], ["indirect protection", "TREATMENT", 75, 94], ["Invasive Meningococcal DiseaseMass vaccination", "TREATMENT", 95, 141], ["group A + C meningococcal conjugate vaccine", "TREATMENT", 175, 218], ["routine childhood immunization", "TREATMENT", 234, 264]]], ["In Europe, meningococcal group C (MenC) infections and deaths decreased by more than 90% after the deployment in 1999 of a vaccination campaign with a MenC conjugate vaccine in the UK.", [["meningococcal group C (MenC) infections", "DISEASE", 11, 50], ["deaths", "DISEASE", 55, 61], ["meningococcal group C", "ORGANISM", 11, 32], ["UK", "GENE_OR_GENE_PRODUCT", 181, 183], ["meningococcal group C (MenC) infections", "PROBLEM", 11, 50], ["a vaccination campaign", "TREATMENT", 121, 143], ["a MenC conjugate vaccine", "TREATMENT", 149, 173]]], ["A similar result was found in other countries that included the MenC vaccine in their schedules, such as the Netherlands or Spain.RotavirusWithin 8 years of their initial introduction into Europe, rotavirus vaccines have been shown to be highly effective, with a substantial impact on the rotavirus gastroenteritis-related health care burden, including hospitalizations, nosocomial infections, and outpatient visits.", [["MenC", "CHEMICAL", 64, 68], ["gastroenteritis", "DISEASE", 299, 314], ["nosocomial infections", "DISEASE", 371, 392], ["rotavirus", "ORGANISM", 197, 206], ["rotavirus", "ORGANISM", 289, 298], ["rotavirus", "SPECIES", 197, 206], ["rotavirus", "SPECIES", 289, 298], ["the MenC vaccine", "TREATMENT", 60, 76], ["rotavirus vaccines", "TREATMENT", 197, 215], ["the rotavirus gastroenteritis", "PROBLEM", 285, 314], ["nosocomial infections", "PROBLEM", 371, 392], ["rotavirus gastroenteritis", "OBSERVATION", 289, 314]]], ["These findings are consistent in several studies and countries across Europe, and comparable with observations from Australia and the USA.", [["consistent in", "UNCERTAINTY", 19, 32]]], ["Some examples show a >95% effectiveness in the reduction of hospital admissions for rotavirus gastroenteritis in several European countries (Finland, Spain, France, and the UK) and a >60% reduction in the number of hospital admissions and emergency-department visits in countries with universal rotavirus vaccination (e.g., Austria, UK, Finland, and Belgium).Expanded and Unexpected EffectsThe main expected benefit from vaccination is protection against the pathogen for which it is designed.", [["rotavirus gastroenteritis", "DISEASE", 84, 109], ["rotavirus", "SPECIES", 295, 304], ["rotavirus gastroenteritis", "PROBLEM", 84, 109], ["universal rotavirus vaccination", "TREATMENT", 285, 316], ["vaccination", "TREATMENT", 421, 432], ["the pathogen", "PROBLEM", 455, 467], ["main", "OBSERVATION_MODIFIER", 394, 398]]], ["This is a direct effect on a particular target infection.", [["infection", "DISEASE", 47, 56], ["a particular target infection", "PROBLEM", 27, 56], ["infection", "OBSERVATION", 47, 56]]], ["For many years, however, epidemiological data indicated some unexpected, beneficial effects brought about indirectly by some vaccines.", [["epidemiological data", "TEST", 25, 45]]], ["These expanded and somewhat 1 . unexpected effects have broadened the benefits of vaccines.", [["vaccines", "TREATMENT", 82, 90]]], ["Using these mechanisms, it is possible to generate direct protection against antigens different from the immunogen contained in the vaccine (cross-protection), protect or even eradicate a disease without having to vaccinate the entire population (indirect protection), or even protect against pathogens different from those targeted by the vaccine (heterologous protection).Cross-Protection and Heterologous ImmunityThe concept of cross-protection denotes the ability of the immune system to recognize various antigens that differ from the immunogen, through certain flexibility in peptide recognition (crossimmunity).", [["antigens", "PROTEIN", 77, 85], ["antigens", "PROTEIN", 510, 518], ["the immunogen", "TREATMENT", 101, 114], ["the vaccine", "TREATMENT", 128, 139], ["cross-protection", "TREATMENT", 141, 157], ["a disease", "PROBLEM", 186, 195], ["indirect protection", "TREATMENT", 247, 266], ["pathogens", "PROBLEM", 293, 302], ["the vaccine (heterologous protection", "TREATMENT", 336, 372], ["Cross-Protection", "TREATMENT", 374, 390], ["the immunogen", "TREATMENT", 536, 549]]], ["For this reason, different antigens appear similar to the immune system, thereby challenging the theoretical specificity postulated by the clonal selection theory.", [["immune system", "ANATOMY", 58, 71], ["antigens", "PROTEIN", 27, 35], ["different antigens", "PROBLEM", 17, 35]]], ["In crossneutralization, antibodies elicited by vaccination with a certain serotype neutralize other serotypes in vitro.", [["antibodies", "PROTEIN", 24, 34], ["antibodies", "TREATMENT", 24, 34], ["vaccination", "TREATMENT", 47, 58], ["a certain serotype neutralize", "TREATMENT", 64, 93]]], ["Cross-protection means that immunization with a certain vaccine type provides clinically significant protection against infection or disease (or both) owing to another serotype, i.e., that the cross-neutralizing response has a functional impact.", [["infection", "DISEASE", 120, 129], ["Cross-protection means", "TREATMENT", 0, 22], ["immunization", "TREATMENT", 28, 40], ["a certain vaccine type", "TREATMENT", 46, 68], ["infection", "PROBLEM", 120, 129], ["disease", "PROBLEM", 133, 140], ["infection", "OBSERVATION", 120, 129]]], ["One example is the HPV vaccine.", [["HPV", "ORGANISM", 19, 22], ["the HPV vaccine", "TREATMENT", 15, 30]]], ["Immunity to HPV is type-specific.", [["HPV", "ORGANISM", 12, 15], ["HPV", "SPECIES", 12, 15]]], ["However, if we look at the phylogenetic tree that includes the various HPV types, we observe that some degree of crossprotection is possible, given the high level of homology of some viral types with vaccine types.", [["HPV", "ORGANISM", 71, 74], ["crossprotection", "PROBLEM", 113, 128], ["vaccine types", "TREATMENT", 200, 213], ["viral types", "OBSERVATION", 183, 194]]], ["This is the case, for instance, for HPV-31 and -35 (strictly related to HPV-16), and for HPV-45 (strictly related to HPV-18).", [["HPV-31", "ORGANISM", 36, 42], ["HPV-16", "ORGANISM", 72, 78], ["HPV-45", "ORGANISM", 89, 95], ["HPV-18", "ORGANISM", 117, 123], ["HPV-31", "SPECIES", 36, 42], ["HPV-45", "SPECIES", 89, 95], ["HPV", "TEST", 36, 39], ["HPV", "TEST", 72, 75], ["HPV", "TEST", 89, 92], ["HPV", "TEST", 117, 120]]], ["Another example can be seen with rotavirus vaccines.", [["rotavirus", "ORGANISM", 33, 42], ["rotavirus", "SPECIES", 33, 42], ["rotavirus vaccines", "TREATMENT", 33, 51]]], ["The antibodies elicited by these vaccines not only protect against those circulating strains sharing the same G or P variant as that contained in the vaccine strain, but also other non-matching G and P strains (heterotypic protection).", [["G", "GENE_OR_GENE_PRODUCT", 110, 111], ["antibodies", "PROTEIN", 4, 14], ["G or P variant", "DNA", 110, 124], ["The antibodies", "TEST", 0, 14], ["these vaccines", "TREATMENT", 27, 41], ["those circulating strains", "PROBLEM", 67, 92], ["the vaccine strain", "PROBLEM", 146, 164], ["other non-matching G and P strains", "PROBLEM", 175, 209], ["heterotypic protection", "TREATMENT", 211, 233]]], ["According to this, typespecific antibodies targeted at neutralizing VP7 or VP4 epitopes are not solely responsible for their protective effect.", [["VP7", "GENE_OR_GENE_PRODUCT", 68, 71], ["VP4", "GENE_OR_GENE_PRODUCT", 75, 78], ["typespecific antibodies", "PROTEIN", 19, 42], ["VP7", "PROTEIN", 68, 71], ["VP4 epitopes", "PROTEIN", 75, 87], ["typespecific antibodies", "TREATMENT", 19, 42], ["neutralizing VP7", "TREATMENT", 55, 71], ["VP4 epitopes", "TREATMENT", 75, 87]]], ["The comparable effectiveness of RV1 and RV5 reinforces this conclusion: neutralizing antibody titers induced by RV1 or RV5 consistently underestimates the protection conferred by the vaccine.", [["RV1", "CHEMICAL", 112, 115], ["RV5", "CHEMICAL", 119, 122], ["RV1", "SIMPLE_CHEMICAL", 32, 35], ["RV5", "SIMPLE_CHEMICAL", 40, 43], ["RV1", "GENE_OR_GENE_PRODUCT", 112, 115], ["RV1", "PROTEIN", 32, 35], ["RV5", "PROTEIN", 40, 43], ["RV1", "SPECIES", 32, 35], ["RV1", "SPECIES", 112, 115], ["RV5", "SPECIES", 119, 122], ["RV1", "TREATMENT", 32, 35], ["RV5", "TREATMENT", 40, 43], ["neutralizing antibody titers", "TEST", 72, 100], ["RV5", "PROBLEM", 119, 122]]], ["Other examples of this cross-reactivity have been confirmed in humans, involving influenza virus-specific immunity, or pneumococcal conjugate vaccines, among others.Cross-Protection and Heterologous ImmunityCross-protection was described five decades ago and later termed heterologous immunity.", [["humans", "ORGANISM", 63, 69], ["influenza virus", "ORGANISM", 81, 96], ["humans", "SPECIES", 63, 69], ["influenza virus", "SPECIES", 81, 96], ["humans", "SPECIES", 63, 69], ["pneumococcal", "SPECIES", 119, 131], ["influenza virus", "PROBLEM", 81, 96], ["pneumococcal conjugate vaccines", "TREATMENT", 119, 150], ["Cross-Protection", "TREATMENT", 165, 181], ["Heterologous ImmunityCross-protection", "TREATMENT", 186, 223]]], ["The initial observation was that CD8 + -T cells are able to cross-recognize peptides from two distinct viruses and may play roles not only in protective immunity, but also in immunopathology (autoimmunity).", [["CD8 + -T cells", "ANATOMY", 33, 47], ["immunopathology", "DISEASE", 175, 190], ["autoimmunity", "DISEASE", 192, 204], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD8", "PROTEIN", 33, 36], ["T cells", "CELL_TYPE", 40, 47], ["CD8", "TEST", 33, 36], ["T cells", "PROBLEM", 40, 47], ["two distinct viruses", "PROBLEM", 90, 110], ["distinct", "OBSERVATION_MODIFIER", 94, 102], ["viruses", "OBSERVATION", 103, 110]]], ["According to this phenomenon, memory T cells that are specific to one pathogen can become activated during infection with an unrelated heterologous pathogen.", [["memory T cells", "ANATOMY", 30, 44], ["infection", "DISEASE", 107, 116], ["memory T cells", "CELL", 30, 44], ["memory T cells", "CELL_TYPE", 30, 44], ["this phenomenon", "PROBLEM", 13, 28], ["memory T cells", "PROBLEM", 30, 44], ["one pathogen", "PROBLEM", 66, 78], ["infection", "PROBLEM", 107, 116], ["an unrelated heterologous pathogen", "PROBLEM", 122, 156]]], ["As such, previous host exposure to unrelated infectious agents can greatly alter immune response to an infection.", [["infection", "DISEASE", 103, 112], ["unrelated infectious agents", "TREATMENT", 35, 62], ["an infection", "PROBLEM", 100, 112], ["infection", "OBSERVATION", 103, 112]]], ["T cells recognize processed peptides that are presented at the cell surface in antigenbinding grooves of class I major histocompatibility class (MHC) proteins.", [["T cells", "ANATOMY", 0, 7], ["cell surface", "ANATOMY", 63, 75], ["T cells", "CELL", 0, 7], ["cell surface", "CELLULAR_COMPONENT", 63, 75], ["class I major histocompatibility class", "GENE_OR_GENE_PRODUCT", 105, 143], ["T cells", "CELL_TYPE", 0, 7], ["class I major histocompatibility class (MHC) proteins", "PROTEIN", 105, 158]]], ["At the same time, the T-cell receptor (TCR) binds to the peptide-MHC complex.", [["T-cell", "ANATOMY", 22, 28], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 22, 37], ["TCR", "GENE_OR_GENE_PRODUCT", 39, 42], ["T-cell receptor", "PROTEIN", 22, 37], ["TCR", "PROTEIN", 39, 42], ["MHC complex", "PROTEIN", 65, 76]]], ["Thus, a TCR that recognizes a given MHC-presented peptide may also recognize other peptides that fit into the appropriate MHC groove, and has amino acid chains that are able to bind to TCR.", [["TCR", "CHEMICAL", 8, 11], ["amino acid", "CHEMICAL", 142, 152], ["TCR", "CHEMICAL", 185, 188], ["amino acid", "CHEMICAL", 142, 152], ["TCR", "GENE_OR_GENE_PRODUCT", 8, 11], ["TCR", "GENE_OR_GENE_PRODUCT", 185, 188], ["TCR", "PROTEIN", 8, 11], ["MHC", "PROTEIN", 36, 39], ["MHC groove", "PROTEIN", 122, 132], ["TCR", "PROTEIN", 185, 188], ["other peptides", "PROBLEM", 77, 91], ["amino acid chains", "TREATMENT", 142, 159]]], ["This degeneration of the T-cell recognition is called molecular mimicry when the cross-reactive peptide has similar determinants and interacts with TCR in the same manner as the original peptide.", [["T-cell", "ANATOMY", 25, 31], ["TCR", "CHEMICAL", 148, 151], ["T-cell", "CELL", 25, 31], ["TCR", "GENE_OR_GENE_PRODUCT", 148, 151], ["TCR", "PROTEIN", 148, 151], ["the cross-reactive peptide", "PROBLEM", 77, 103], ["degeneration", "OBSERVATION", 5, 17]]], ["It is called alternative recognition when different determinants of the TCR are involved in recognition.", [["TCR", "CHEMICAL", 72, 75], ["TCR", "GENE_OR_GENE_PRODUCT", 72, 75], ["TCR", "PROTEIN", 72, 75]]], ["A third explanation for cross-reactivity is when a given T cell expresses two different TCRs as a result of an incomplete allelic exclusion of a second TCR chain; in this way, the two distinct TCRs formed may recognize different antigens.Cross-Protection and Heterologous ImmunityWhen the term cross-protection is applied to vaccination, it typically refers to heterosubtypic immunity defined as protection by virus (influenza is the best-known case) of one strain, against a challenge infection with other strains differing in subtype.", [["T cell", "ANATOMY", 57, 63], ["influenza", "DISEASE", 417, 426], ["infection", "DISEASE", 486, 495], ["T cell", "CELL", 57, 63], ["TCRs", "GENE_OR_GENE_PRODUCT", 88, 92], ["TCRs", "GENE_OR_GENE_PRODUCT", 193, 197], ["T cell", "CELL_TYPE", 57, 63], ["TCRs", "PROTEIN", 88, 92], ["TCR chain", "PROTEIN", 152, 161], ["TCRs", "PROTEIN", 193, 197], ["antigens", "PROTEIN", 229, 237], ["an incomplete allelic exclusion", "PROBLEM", 108, 139], ["a second TCR chain", "TREATMENT", 143, 161], ["Cross-Protection", "TREATMENT", 238, 254], ["Heterologous ImmunityWhen the term cross-protection", "TREATMENT", 259, 310], ["vaccination", "TREATMENT", 325, 336], ["heterosubtypic immunity", "TREATMENT", 361, 384], ["influenza", "PROBLEM", 417, 426], ["one strain", "PROBLEM", 454, 464], ["a challenge infection", "PROBLEM", 474, 495], ["other strains", "PROBLEM", 501, 514], ["infection", "OBSERVATION", 486, 495]]], ["However, very recently, cross-protective immunity has also been highlighted as one of the mechanisms for the unexpected beneficial effects of BCG vaccination on infections other than tuberculosis.", [["infections", "DISEASE", 161, 171], ["tuberculosis", "DISEASE", 183, 195], ["BCG vaccination", "TREATMENT", 142, 157], ["infections", "PROBLEM", 161, 171], ["tuberculosis", "PROBLEM", 183, 195], ["tuberculosis", "OBSERVATION", 183, 195]]], ["Researchers showed that BCG vaccination induces a long-lasting, nonspecific potentiation effect of heterologous T-helper responses, Th1 (IFN-gamma) and Th17 (IL-17 and IL-22), to non-mycobacterial stimulation.", [["T-helper", "GENE_OR_GENE_PRODUCT", 112, 120], ["Th1", "GENE_OR_GENE_PRODUCT", 132, 135], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 137, 146], ["Th17", "GENE_OR_GENE_PRODUCT", 152, 156], ["IL-17", "GENE_OR_GENE_PRODUCT", 158, 163], ["IL-22", "GENE_OR_GENE_PRODUCT", 168, 173], ["IFN-gamma", "PROTEIN", 137, 146], ["Th17", "PROTEIN", 152, 156], ["IL", "PROTEIN", 168, 170], ["BCG vaccination", "TREATMENT", 24, 39], ["Th17", "TEST", 152, 156], ["IL", "TEST", 158, 160], ["IL", "TEST", 168, 170], ["non-mycobacterial stimulation", "TREATMENT", 179, 208]]], ["Previously, 1 other authors had demonstrated that both effector and memory CD8+ cells had the potential to secrete IFN-gamma in the absence of related antigens.", [["memory CD8+ cells", "ANATOMY", 68, 85], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 115, 124], ["memory CD8+ cells", "CELL_TYPE", 68, 85], ["IFN-gamma", "PROTEIN", 115, 124], ["related antigens", "PROBLEM", 143, 159]]], ["According to these findings, vaccination can provide not only a heterosubtypic protection, but also heterologous protection through a crossimmunity mechanism.Indirect ProtectionThe term \"herd immunity\" was coined a century ago, but its use has become widespread in recent decades to describe the reduced risk of infection among susceptible individuals in a population, induced by the presence and proximity of vaccinated individuals.", [["infection", "DISEASE", 312, 321], ["vaccination", "TREATMENT", 29, 40], ["a heterosubtypic protection", "TREATMENT", 62, 89], ["heterologous protection", "TREATMENT", 100, 123], ["a crossimmunity mechanism", "TREATMENT", 132, 157], ["infection", "PROBLEM", 312, 321], ["vaccinated individuals", "PROBLEM", 410, 432], ["widespread", "OBSERVATION_MODIFIER", 251, 261], ["infection", "OBSERVATION", 312, 321]]], ["Herd immunity makes it possible to protect a whole community from infectious disease by immunizing a critical percentage of the population.", [["infectious disease", "DISEASE", 66, 84], ["infectious disease", "PROBLEM", 66, 84], ["infectious", "OBSERVATION", 66, 76]]], ["Just as a herd of sheep uses its sheer number to protect individual members from predators, herd immunity protects a community from infectious disease by virtue of the number of immune individuals.", [["infectious disease", "DISEASE", 132, 150], ["sheep", "ORGANISM", 18, 23], ["sheep", "SPECIES", 18, 23], ["sheep", "SPECIES", 18, 23], ["infectious disease", "PROBLEM", 132, 150], ["infectious", "OBSERVATION", 132, 142]]], ["The more members of a human herd are immunized, the better protected the whole population will be from an outbreak of disease.Indirect ProtectionThe terms herd immunity and herd effect are frequently used indistinctly, but they do not reflect the same concept.", [["human", "ORGANISM", 22, 27], ["herd", "ORGANISM_SUBDIVISION", 28, 32], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["a human herd", "TREATMENT", 20, 32], ["disease", "PROBLEM", 118, 125], ["Indirect Protection", "TREATMENT", 126, 145], ["disease", "OBSERVATION", 118, 125]]], ["Furthermore, herd immunity applies to immunization or infection, human to human transmission.", [["infection", "DISEASE", 54, 63], ["human", "ORGANISM", 65, 70], ["human", "ORGANISM", 74, 79], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 74, 79], ["immunization", "TREATMENT", 38, 50], ["infection", "PROBLEM", 54, 63], ["infection", "OBSERVATION", 54, 63]]], ["Conversely, the herd effect applies exclusively to immunization achieved by vaccination or other health intervention that reduces the probability of transmission.Indirect ProtectionVaccination has been revealed as an indirect way of protecting members of the community who cannot be vaccinated.", [["immunization", "TREATMENT", 51, 63], ["vaccination", "TREATMENT", 76, 87], ["other health intervention", "TREATMENT", 91, 116], ["Indirect ProtectionVaccination", "TEST", 162, 192]]], ["Vaccinated individuals protect themselves from disease, but also, moreover, they prevent the spread of the infectious agent and limit potential disease outbreaks.", [["individuals", "ORGANISM", 11, 22], ["disease", "PROBLEM", 47, 54], ["the infectious agent", "PROBLEM", 103, 123], ["potential disease outbreaks", "PROBLEM", 134, 161], ["disease", "OBSERVATION", 47, 54], ["infectious", "OBSERVATION", 107, 117]]], ["The herd effect achieved through vaccination for a given disease depends on the efficacy and coverage of the vaccine in addition to the transmissibility of the infection.Indirect ProtectionThere are numerous examples of herd immunity, illustrating the importance of indirect pro-tection for predicting the impact of vaccination programs.", [["infection", "DISEASE", 160, 169], ["herd", "ORGANISM_SUBDIVISION", 220, 224], ["vaccination", "TREATMENT", 33, 44], ["disease", "PROBLEM", 57, 64], ["coverage", "TREATMENT", 93, 101], ["the vaccine", "TREATMENT", 105, 116], ["the infection", "PROBLEM", 156, 169], ["Indirect Protection", "TREATMENT", 170, 189], ["indirect pro-tection", "TREATMENT", 266, 286], ["vaccination programs", "TREATMENT", 316, 336], ["infection", "OBSERVATION", 160, 169]]], ["The basis for the herd effect is that individuals who are immune to a disease act as a barrier in the spread of disease, slowing or preventing the transmission of disease to others.", [["a disease act", "PROBLEM", 68, 81], ["disease", "PROBLEM", 112, 119], ["disease", "PROBLEM", 163, 170], ["disease", "OBSERVATION", 112, 119]]], ["When a given proportion of the population -known as the herd immunity threshold -becomes immunized, the disease may no longer persist in this population.", [["immunized", "PROBLEM", 89, 98], ["the disease", "PROBLEM", 100, 111], ["no longer", "UNCERTAINTY", 116, 125]]], ["This threshold is defined based on the \"basic reproduction number\" (R 0 ), which represents the number of people in an unprotected population that could receive the disease from one infected individual.", [["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["the disease", "PROBLEM", 161, 172], ["infected", "OBSERVATION", 182, 190]]], ["The more contagious the disease, the higher this number, and thus the higher the threshold to be reached to protect the community.", [["The more contagious the disease", "PROBLEM", 0, 31], ["more", "OBSERVATION_MODIFIER", 4, 8], ["contagious", "OBSERVATION_MODIFIER", 9, 19], ["disease", "OBSERVATION", 24, 31], ["higher", "OBSERVATION_MODIFIER", 37, 43], ["higher", "OBSERVATION_MODIFIER", 70, 76]]], ["For example, measles, an extremely contagious disease, has a threshold of 95% to ensure community protection.", [["measles", "DISEASE", 13, 20], ["measles", "PROBLEM", 13, 20], ["an extremely contagious disease", "PROBLEM", 22, 53], ["community protection", "TREATMENT", 88, 108], ["extremely", "OBSERVATION_MODIFIER", 25, 34], ["contagious", "OBSERVATION_MODIFIER", 35, 45], ["disease", "OBSERVATION", 46, 53]]], ["On the other hand, mumps, which is not as contagious, needs a threshold of 80% (.", [["mumps", "DISEASE", 19, 24], ["mumps", "PROBLEM", 19, 24], ["mumps", "OBSERVATION", 19, 24]]], ["Fig. 1 A clear example of herd protection is the case of the meningococcal serogroup C conjugate vaccine in the UK, the Netherlands, and subsequently in other countries.", [["herd", "ORGANISM", 26, 30], ["meningococcal serogroup C conjugate", "ORGANISM", 61, 96], ["herd protection", "TREATMENT", 26, 41], ["the meningococcal serogroup C conjugate vaccine", "TREATMENT", 57, 104]]], ["The impact of this vaccine on the prevalence of the disease was higher than expected according to the population covered with the vaccine, also reducing the number of cases in a nonvaccinated population.", [["this vaccine", "TREATMENT", 14, 26], ["the disease", "PROBLEM", 48, 59], ["the vaccine", "TREATMENT", 126, 137], ["a nonvaccinated population", "TREATMENT", 176, 202], ["disease", "OBSERVATION", 52, 59]]], ["This indirect protection was due to the high efficacy of the vaccination at preventing nasopharyngeal carriage and thus, spreading of the pathogen to the rest of the population.Indirect ProtectionMass vaccination is the best way to rapidly increase herd immunity either for accelerating disease control and to rapidly increase coverage with a new vaccine or in the setting of an existing or potential outbreak, thereby limiting the morbidity and mortality that might result.Indirect ProtectionEven if the increase in population immunity is not sufficient to achieve infection elimination owing to low vaccine efficacy or insufficient coverage, the risk of infection among unvaccinated persons may still be reduced.", [["nasopharyngeal", "ANATOMY", 87, 101], ["infection", "DISEASE", 566, 575], ["infection", "DISEASE", 656, 665], ["nasopharyngeal", "ORGAN", 87, 101], ["persons", "ORGANISM", 685, 692], ["persons", "SPECIES", 685, 692], ["This indirect protection", "TREATMENT", 0, 24], ["the vaccination", "TREATMENT", 57, 72], ["nasopharyngeal carriage", "PROBLEM", 87, 110], ["the pathogen", "PROBLEM", 134, 146], ["Indirect ProtectionMass vaccination", "TREATMENT", 177, 212], ["herd immunity", "TREATMENT", 249, 262], ["accelerating disease control", "TREATMENT", 274, 302], ["rapidly increase coverage", "TREATMENT", 310, 335], ["a new vaccine", "TREATMENT", 341, 354], ["Indirect ProtectionEven", "TREATMENT", 474, 497], ["infection elimination", "PROBLEM", 566, 587], ["low vaccine efficacy", "TREATMENT", 597, 617], ["insufficient coverage", "TREATMENT", 621, 642], ["infection", "PROBLEM", 656, 665], ["nasopharyngeal", "ANATOMY", 87, 101], ["carriage", "OBSERVATION", 102, 110], ["increase", "OBSERVATION_MODIFIER", 505, 513], ["infection", "OBSERVATION", 656, 665]]], ["The paradox is that for an individual, with regard to vaccination in a population, the best option is that everybody else is vaccinated and the individual is not.", [["vaccination", "TREATMENT", 54, 65]]], ["This way the individual is protected from infection because of the herd effect, but suffers none of the potential adverse effects of vaccination.", [["infection", "DISEASE", 42, 51], ["infection", "PROBLEM", 42, 51], ["vaccination", "TREATMENT", 133, 144], ["infection", "OBSERVATION", 42, 51]]], ["Finally, these indirect effects may eventually be deleterious, if 1 as a consequence of reducing the risk of infection among those susceptible, there is a displacement of the risk of infection to other age groups and/ or to a more vulnerable population, as has been suggested for varicella or hepatitis A in certain scenarios.Heterologous (Nonpecific) Effects of VaccinationSome vaccines can broadly enhance immune responses to a range of distinct pathogens or even to other vaccines, indicating that immune protection may be influenced by previous exposure to unrelated microorganisms or microbial components.", [["infection", "DISEASE", 109, 118], ["infection", "DISEASE", 183, 192], ["varicella or hepatitis A", "DISEASE", 280, 304], ["hepatitis A", "SPECIES", 293, 304], ["infection", "PROBLEM", 109, 118], ["infection", "PROBLEM", 183, 192], ["varicella", "PROBLEM", 280, 289], ["hepatitis A", "PROBLEM", 293, 304], ["Heterologous (Nonpecific)", "TREATMENT", 326, 351], ["VaccinationSome vaccines", "TREATMENT", 363, 387], ["distinct pathogens", "PROBLEM", 439, 457], ["other vaccines", "TREATMENT", 469, 483], ["immune protection", "TREATMENT", 501, 518], ["unrelated microorganisms", "PROBLEM", 561, 585], ["microbial components", "PROBLEM", 589, 609], ["infection", "OBSERVATION", 109, 118], ["displacement", "OBSERVATION_MODIFIER", 155, 167], ["infection", "OBSERVATION", 183, 192], ["vulnerable", "OBSERVATION_MODIFIER", 231, 241], ["population", "OBSERVATION", 242, 252], ["suggested for", "UNCERTAINTY", 266, 279], ["varicella", "OBSERVATION", 280, 289], ["hepatitis", "OBSERVATION", 293, 302], ["microbial components", "OBSERVATION", 589, 609]]], ["First described for BCG vaccine, epidemiologists showed a reduction in mortality or hospitalization rates in the BCG-vaccinated population versus the nonvaccinated that could not be explained by the reduction in deaths due to the prevented pathogen.", [["deaths", "DISEASE", 212, 218], ["BCG vaccine", "TREATMENT", 20, 31], ["a reduction in mortality", "PROBLEM", 56, 80], ["hospitalization rates", "PROBLEM", 84, 105], ["the BCG", "TREATMENT", 109, 116], ["vaccinated population", "PROBLEM", 117, 138], ["the prevented pathogen", "PROBLEM", 226, 248], ["reduction", "OBSERVATION_MODIFIER", 58, 67]]], ["In recent years, a plethora .", [["plethora", "OBSERVATION", 19, 27]]], ["Fig. 1.2 Simple threshold concept of herd immunity.", [["herd", "ORGANISM_SUBDIVISION", 37, 41], ["herd immunity", "TREATMENT", 37, 50], ["1.2 Simple threshold", "OBSERVATION_MODIFIER", 5, 25]]], ["Relationship between the herd immunity threshold, (R 0 -1)/R 0 = 1-1/R 0 , and basic reproduction number, R 0 , in a randomly mixing homogeneous population.", [["the herd immunity threshold", "TEST", 21, 48], ["homogeneous", "OBSERVATION_MODIFIER", 133, 144], ["population", "OBSERVATION", 145, 155]]], ["Note the implications of ranges of R 0 , which can vary considerably between populations, for ranges of immunity coverage required to exceed the threshold .", [["immunity coverage", "TREATMENT", 104, 121]]], ["Expected and Unexpected Effects of Vaccination 1 of scientific papers have documented this unexpected effect of vaccination, and explained it as resulting from an indirect action of vaccines on the immune system, other than their specific expected effect.", [["immune system", "ANATOMY", 198, 211], ["immune system", "ANATOMICAL_SYSTEM", 198, 211], ["Vaccination", "TREATMENT", 35, 46], ["vaccination", "TREATMENT", 112, 123], ["vaccines", "TREATMENT", 182, 190], ["the immune system", "TREATMENT", 194, 211]]], ["These so-called heterologous effects of vaccines are now being explored not only for BCGthe most frequently studied in this regard -but also for polio, measles, influenza, rotavirus, and others.", [["measles", "DISEASE", 152, 159], ["influenza", "DISEASE", 161, 170], ["rotavirus", "DISEASE", 172, 181], ["measles", "ORGANISM", 152, 159], ["rotavirus", "ORGANISM", 172, 181], ["rotavirus", "SPECIES", 172, 181], ["vaccines", "TREATMENT", 40, 48], ["polio", "PROBLEM", 145, 150], ["measles", "PROBLEM", 152, 159], ["influenza", "PROBLEM", 161, 170], ["rotavirus", "PROBLEM", 172, 181]]], ["Scientific data reveal a dual mechanism for these heterologous properties of vaccines: crossprotective immunity (an old and well-known phenomenon described above) and immune training, a new and revolutionary concept referring to the innate immunological memory and its ability to be trained through vaccination.", [["Scientific data", "TEST", 0, 15], ["these heterologous properties of vaccines", "TREATMENT", 44, 85], ["known phenomenon", "PROBLEM", 129, 145], ["immune training", "TREATMENT", 167, 182]]], ["Immunological memory, or the ability to remember the encounter with a pathogen, used to be considered an exclusive virtue of the adaptive immune system.", [["immune system", "ANATOMICAL_SYSTEM", 138, 151], ["a pathogen", "PROBLEM", 68, 78]]], ["Immune training is the term applied to this recently described feature of innate immunity, and its demonstration in humans was first documented with BCG vaccination by Kleinnijenhuis et al.: they showed a BCG-induced trained immunity mechanism of nonspecific protection from infections through epigenetic reprogramming of innate immune cells as monocytes.", [["immune cells", "ANATOMY", 329, 341], ["monocytes", "ANATOMY", 345, 354], ["infections", "DISEASE", 275, 285], ["humans", "ORGANISM", 116, 122], ["innate immune cells", "CELL", 322, 341], ["monocytes", "CELL", 345, 354], ["innate immune cells", "CELL_TYPE", 322, 341], ["monocytes", "CELL_TYPE", 345, 354], ["humans", "SPECIES", 116, 122], ["humans", "SPECIES", 116, 122], ["Immune training", "TREATMENT", 0, 15], ["BCG vaccination", "TREATMENT", 149, 164], ["a BCG", "TREATMENT", 203, 208], ["nonspecific protection from infections", "PROBLEM", 247, 285], ["epigenetic reprogramming of innate immune cells", "TREATMENT", 294, 341], ["monocytes", "TEST", 345, 354], ["nonspecific", "OBSERVATION_MODIFIER", 247, 258], ["infections", "OBSERVATION", 275, 285]]], ["This revolutionary concept represents a plausible explanation for the rapid protective effects observed after BCG vaccination, unexplained by the cross-protective effect of the adaptive system -the latter, with long-term effects but slow to develop.Heterologous (Nonpecific) Effects of VaccinationAccording to this concept, vaccination would induce an enhanced innate immunity state mediated by natural killer or monocytes/macrophages, which would provide nonspecific protection against nonrelated infections.", [["natural killer", "ANATOMY", 395, 409], ["monocytes", "ANATOMY", 413, 422], ["macrophages", "ANATOMY", 423, 434], ["infections", "DISEASE", 498, 508], ["natural killer", "CELL", 395, 409], ["monocytes", "CELL", 413, 422], ["macrophages", "CELL", 423, 434], ["natural killer", "CELL_TYPE", 395, 409], ["monocytes", "CELL_TYPE", 413, 422], ["macrophages", "CELL_TYPE", 423, 434], ["the rapid protective effects", "PROBLEM", 66, 94], ["BCG vaccination", "TREATMENT", 110, 125], ["the adaptive system", "TREATMENT", 173, 192], ["long-term effects", "TREATMENT", 211, 228], ["VaccinationAccording", "TREATMENT", 286, 306], ["vaccination", "TREATMENT", 324, 335], ["macrophages", "PROBLEM", 423, 434], ["nonrelated infections", "PROBLEM", 487, 508], ["long-term effects", "OBSERVATION_MODIFIER", 211, 228], ["infections", "OBSERVATION", 498, 508]]], ["As a consequence of vaccination, innate immune cells become more efficient cells, and better responders against microbial aggressions.", [["immune cells", "ANATOMY", 40, 52], ["cells", "ANATOMY", 75, 80], ["aggressions", "DISEASE", 122, 133], ["immune cells", "CELL", 40, 52], ["cells", "CELL", 75, 80], ["innate immune cells", "CELL_TYPE", 33, 52], ["vaccination", "TREATMENT", 20, 31], ["innate immune cells", "TREATMENT", 33, 52]]], ["Epigenetic and metabolic modifications during innate cell development in the bone marrow would be responsible for the maintenance of these enhanced features to influence the functions of innate cells for longer periods.", [["cell", "ANATOMY", 53, 57], ["bone marrow", "ANATOMY", 77, 88], ["cells", "ANATOMY", 194, 199], ["cell", "CELL", 53, 57], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 77, 88], ["innate cells", "CELL", 187, 199], ["innate cells", "CELL_TYPE", 187, 199], ["Epigenetic and metabolic modifications", "PROBLEM", 0, 38], ["innate cells", "TREATMENT", 187, 199], ["metabolic modifications", "OBSERVATION", 15, 38], ["innate cell", "OBSERVATION", 46, 57], ["bone", "ANATOMY", 77, 81], ["marrow", "OBSERVATION", 82, 88]]], ["Epigenetic reprogramming of cells through tri-methylation of histones leads to a stronger gene transcription upon re-stimulation through the NOD2 receptor, an intracellular pattern recognition receptor (PRR).", [["cells", "ANATOMY", 28, 33], ["intracellular", "ANATOMY", 159, 172], ["cells", "CELL", 28, 33], ["histones", "CELLULAR_COMPONENT", 61, 69], ["NOD2 receptor", "GENE_OR_GENE_PRODUCT", 141, 154], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["pattern recognition receptor", "GENE_OR_GENE_PRODUCT", 173, 201], ["PRR", "GENE_OR_GENE_PRODUCT", 203, 206], ["histones", "PROTEIN", 61, 69], ["NOD2 receptor", "PROTEIN", 141, 154], ["intracellular pattern recognition receptor", "PROTEIN", 159, 201], ["PRR", "PROTEIN", 203, 206], ["Epigenetic reprogramming of cells", "PROBLEM", 0, 33], ["tri-methylation of histones", "TREATMENT", 42, 69]]], ["Metabolic processes would also be affected, with a cell metabolic shift toward an aerobic glycolytic (transformation of pyruvate to lactate) pathway, as opposed to the classic and less efficient aerobic oxidative phosphorylation of pyruvate.", [["cell", "ANATOMY", 51, 55], ["pyruvate", "CHEMICAL", 120, 128], ["lactate", "CHEMICAL", 132, 139], ["pyruvate", "CHEMICAL", 232, 240], ["pyruvate", "CHEMICAL", 120, 128], ["lactate", "CHEMICAL", 132, 139], ["pyruvate", "CHEMICAL", 232, 240], ["cell", "CELL", 51, 55], ["pyruvate", "SIMPLE_CHEMICAL", 120, 128], ["lactate", "SIMPLE_CHEMICAL", 132, 139], ["pyruvate", "SIMPLE_CHEMICAL", 232, 240], ["Metabolic processes", "PROBLEM", 0, 19], ["a cell metabolic shift", "PROBLEM", 49, 71], ["an aerobic glycolytic (transformation of pyruvate to lactate) pathway", "PROBLEM", 79, 148], ["the classic and less efficient aerobic oxidative phosphorylation of pyruvate", "PROBLEM", 164, 240], ["oxidative phosphorylation", "OBSERVATION", 203, 228]]], ["This shift of glucose metabolism is also known as the \"Warburg effect, \" and allows the rapid production of energy for the proliferation of cancer cells or activated lymphocytes.Heterologous (Nonpecific) Effects of VaccinationThis epigenetic and metabolic reprogramming is not the only mechanism involved in the immune training of innate cells.", [["cancer cells", "ANATOMY", 140, 152], ["lymphocytes", "ANATOMY", 166, 177], ["cells", "ANATOMY", 338, 343], ["glucose", "CHEMICAL", 14, 21], ["cancer", "DISEASE", 140, 146], ["glucose", "CHEMICAL", 14, 21], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["cancer cells", "CELL", 140, 152], ["lymphocytes", "CELL", 166, 177], ["innate cells", "CELL", 331, 343], ["cancer cells", "CELL_TYPE", 140, 152], ["activated lymphocytes", "CELL_TYPE", 156, 177], ["innate cells", "CELL_TYPE", 331, 343], ["glucose metabolism", "PROBLEM", 14, 32], ["cancer cells", "PROBLEM", 140, 152], ["activated lymphocytes", "PROBLEM", 156, 177], ["Heterologous (Nonpecific)", "PROBLEM", 178, 203], ["Vaccination", "TREATMENT", 215, 226], ["glucose metabolism", "OBSERVATION", 14, 32], ["cancer cells", "OBSERVATION", 140, 152], ["metabolic reprogramming", "OBSERVATION", 246, 269], ["innate cells", "OBSERVATION", 331, 343]]], ["Other mechanisms include an increased expression of recognition receptor pathogens (PRRs) on the cell surface following vaccination, and enhanced cytokine release, particularly inflammatory signals for a protective function.Heterologous (Nonpecific) Effects of VaccinationFuture research should seek a better understanding of innate immune training mechanisms induced by vaccines, including the impact of age, host genetics, geographical location, and sociological factors.", [["cell surface", "ANATOMY", 97, 109], ["PRRs", "GENE_OR_GENE_PRODUCT", 84, 88], ["cell surface", "CELLULAR_COMPONENT", 97, 109], ["recognition receptor pathogens", "PROTEIN", 52, 82], ["PRRs", "PROTEIN", 84, 88], ["cytokine", "PROTEIN", 146, 154], ["recognition receptor pathogens", "PROBLEM", 52, 82], ["the cell surface", "TREATMENT", 93, 109], ["vaccination", "TREATMENT", 120, 131], ["enhanced cytokine release", "TREATMENT", 137, 162], ["inflammatory signals", "PROBLEM", 177, 197], ["Vaccination", "TREATMENT", 261, 272], ["innate immune training mechanisms", "TREATMENT", 326, 359], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["It is also important to explore the timing and the combination of vaccines to avoid negative side effects and fully exploit their potential benefits.", [["vaccines", "TREATMENT", 66, 74], ["negative side effects", "PROBLEM", 84, 105]]], ["This will help us to improve the beneficial heterologous effects of vaccination.", [["the beneficial heterologous effects of vaccination", "TREATMENT", 29, 79]]], ["In addition, vaccines that were removed from the immunization schedule could now be re-considered in view of these beneficial nonspecific effects.Positive Heterologous EffectsThe paradigmatic case of vaccines providing heterologous benefits is that of bacillus Calmette-Gu\u00e9rin (BCG).", [["bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 252, 276], ["bacillus Calmette-Gu\u00e9rin", "ORGANISM", 252, 276], ["bacillus Calmette-Gu\u00e9rin", "SPECIES", 252, 276], ["vaccines", "TREATMENT", 13, 21], ["the immunization schedule", "TREATMENT", 45, 70], ["Positive Heterologous Effects", "PROBLEM", 146, 175], ["vaccines", "TREATMENT", 200, 208], ["heterologous benefits", "TREATMENT", 219, 240], ["bacillus Calmette", "TREATMENT", 252, 269], ["Heterologous Effects", "OBSERVATION", 155, 175]]], ["Several randomized controlled trials have indicated that BCG, a vaccine introduced in 1921 to fight against tuberculosis, has beneficial, heterologous, nonspecific effects in children from developing countries, reducing morbidity and mortality caused by unrelated pathogens.", [["tuberculosis", "DISEASE", 108, 120], ["children", "ORGANISM", 175, 183], ["children", "SPECIES", 175, 183], ["Several randomized controlled trials", "TREATMENT", 0, 36], ["BCG", "TREATMENT", 57, 60], ["a vaccine", "TREATMENT", 62, 71], ["tuberculosis", "PROBLEM", 108, 120], ["reducing morbidity", "PROBLEM", 211, 229], ["unrelated pathogens", "PROBLEM", 254, 273], ["pathogens", "OBSERVATION", 264, 273]]], ["Old epidemiological data had already pointed toward a protective nonspecific effect, without a mechanism that could explain it.", [["Old epidemiological data", "PROBLEM", 0, 24]]], ["More recently, it has been demonstrated that this beneficial effect was not restricted to developing countries, with reduced early childhood hospitalization and mortality rates also observed in highincome settings.Positive Heterologous EffectsApart from this heterologous effect on mortality and hospitalization of children, BCG has been revealed in recent years to be a potent immunomodulator, with potential applications in the treatment of immune-based disorders (type 1 diabetes and multiple sclerosis) and as immunotherapy for treating early-stage bladder cancer.1There are, however, reports describing heterologous effects for other vaccines, either live or attenuated.", [["early-stage bladder cancer", "ANATOMY", 541, 567], ["type 1 diabetes and multiple sclerosis", "DISEASE", 467, 505], ["bladder cancer", "DISEASE", 553, 567], ["children", "ORGANISM", 315, 323], ["early-stage bladder cancer", "CANCER", 541, 567], ["children", "SPECIES", 315, 323], ["mortality rates", "TEST", 161, 176], ["Positive Heterologous Effects", "PROBLEM", 214, 243], ["this heterologous effect", "PROBLEM", 254, 278], ["BCG", "PROBLEM", 325, 328], ["a potent immunomodulator", "TREATMENT", 369, 393], ["potential applications", "TREATMENT", 400, 422], ["the treatment", "TREATMENT", 426, 439], ["immune-based disorders", "PROBLEM", 443, 465], ["type 1 diabetes", "PROBLEM", 467, 482], ["multiple sclerosis)", "PROBLEM", 487, 506], ["immunotherapy", "TREATMENT", 514, 527], ["early-stage bladder cancer", "PROBLEM", 541, 567], ["heterologous effects", "PROBLEM", 608, 628], ["other vaccines", "TREATMENT", 633, 647], ["Heterologous Effects", "OBSERVATION", 223, 243], ["multiple", "OBSERVATION_MODIFIER", 487, 495], ["sclerosis", "OBSERVATION", 496, 505], ["stage", "OBSERVATION_MODIFIER", 547, 552], ["bladder", "ANATOMY", 553, 560], ["cancer", "OBSERVATION", 561, 567]]], ["Similar to the BCG vaccine, measlescontaining vaccines have been demonstrated to reduce mortality and hospital admissions from causes other than measles infection, in both lowand high-income countries.", [["measles infection", "DISEASE", 145, 162], ["the BCG vaccine", "TREATMENT", 11, 26], ["measlescontaining vaccines", "TREATMENT", 28, 54], ["measles infection", "PROBLEM", 145, 162], ["infection", "OBSERVATION", 153, 162]]], ["Incidence of infectious diseases other than measles has been found to correlate strongly with incidence of measles in different countries, in both pre-and post-vaccine periods.", [["infectious diseases", "DISEASE", 13, 32], ["measles", "DISEASE", 44, 51], ["measles", "DISEASE", 107, 114], ["measles", "SPECIES", 107, 114], ["infectious diseases", "PROBLEM", 13, 32], ["measles", "PROBLEM", 107, 114], ["infectious", "OBSERVATION", 13, 23]]], ["It has been recently described that the prevention of immunosuppressive effects of measles infection through vaccination might explain these long-term benefits of measles vaccination.1The effect of oral polio vaccine (OPV) on mortality has only been assessed in a few studies, which concluded that OPV is associated to lower infant mortality and morbidity through these non-specific effects.", [["oral", "ANATOMY", 198, 202], ["measles infection", "DISEASE", 83, 100], ["OPV", "CHEMICAL", 298, 301], ["measles", "ORGANISM", 83, 90], ["measles", "ORGANISM", 163, 170], ["oral", "ORGANISM_SUBDIVISION", 198, 202], ["OPV", "SPECIES", 218, 221], ["OPV", "SPECIES", 298, 301], ["immunosuppressive effects", "TREATMENT", 54, 79], ["measles infection", "PROBLEM", 83, 100], ["vaccination", "TREATMENT", 109, 120], ["measles vaccination", "TREATMENT", 163, 182], ["oral polio vaccine", "TREATMENT", 198, 216], ["a few studies", "TEST", 262, 275], ["lower infant mortality", "PROBLEM", 319, 341], ["morbidity", "PROBLEM", 346, 355], ["these non-specific effects", "PROBLEM", 364, 390]]], ["The observations of this beneficial effect of OPV have generated a controversial debate on the substitution of oral polio vaccine for the inactivated polio vaccine, and the possible consequences of this decision on the mortality increment.Negative Heterologous EffectsNegative heterologous effects are also possible.", [["oral", "ANATOMY", 111, 115], ["OPV", "CHEMICAL", 46, 49], ["OPV", "CHEMICAL", 46, 49], ["oral", "ORGANISM_SUBDIVISION", 111, 115], ["OPV", "TREATMENT", 46, 49], ["the substitution", "TREATMENT", 91, 107], ["oral polio vaccine", "TREATMENT", 111, 129], ["the inactivated polio vaccine", "TREATMENT", 134, 163], ["the mortality increment", "TREATMENT", 215, 238], ["Heterologous Effects", "PROBLEM", 248, 268], ["heterologous effects", "PROBLEM", 277, 297], ["Heterologous Effects", "OBSERVATION", 248, 268], ["heterologous effects", "OBSERVATION", 277, 297]]], ["An association between the AS03-adjuvanted influenza pandemic vaccine and the development of narcolepsy has been described in some children and infants due to cross-reactivity to host antigens.", [["AS03", "CHEMICAL", 27, 31], ["influenza pandemic", "DISEASE", 43, 61], ["narcolepsy", "DISEASE", 93, 103], ["AS03", "GENE_OR_GENE_PRODUCT", 27, 31], ["children", "ORGANISM", 131, 139], ["infants", "ORGANISM", 144, 151], ["host antigens", "PROTEIN", 179, 192], ["adjuvanted influenza pandemic vaccine", "SPECIES", 32, 69], ["children", "SPECIES", 131, 139], ["infants", "SPECIES", 144, 151], ["the AS03", "TREATMENT", 23, 31], ["adjuvanted influenza pandemic vaccine", "TREATMENT", 32, 69], ["narcolepsy", "PROBLEM", 93, 103]]], ["In this case, molecular mimicry between a fragment of one of the influenza antigens (nucleoprotein) and a portion of the human brain receptor that promotes wakefulness (hypocretin receptor 2) has been reported as an explanation for this heterologous effect.Negative Heterologous EffectsUnlike BCG, measles vaccine or OPV, the diphtheria-tetanus-pertussis (DTP) vaccine has not shown the same beneficial effect, and in fact some studies have suggested detrimental effects on children's survival.", [["brain", "ANATOMY", 127, 132], ["OPV", "CHEMICAL", 317, 320], ["diphtheria-tetanus-pertussis", "CHEMICAL", 326, 354], ["DTP", "CHEMICAL", 356, 359], ["human", "ORGANISM", 121, 126], ["brain", "ORGAN", 127, 132], ["hypocretin receptor 2", "GENE_OR_GENE_PRODUCT", 169, 190], ["diphtheria-tetanus-pertussis", "ORGANISM", 326, 354], ["DTP", "SIMPLE_CHEMICAL", 356, 359], ["children", "ORGANISM", 474, 482], ["influenza antigens", "PROTEIN", 65, 83], ["nucleoprotein", "PROTEIN", 85, 98], ["human brain receptor", "PROTEIN", 121, 141], ["hypocretin receptor 2", "PROTEIN", 169, 190], ["human", "SPECIES", 121, 126], ["diphtheria-tetanus-pertussis", "SPECIES", 326, 354], ["children", "SPECIES", 474, 482], ["human", "SPECIES", 121, 126], ["OPV", "SPECIES", 317, 320], ["diphtheria-tetanus-pertussis", "SPECIES", 326, 354], ["a fragment", "PROBLEM", 40, 50], ["the influenza antigens (nucleoprotein)", "PROBLEM", 61, 99], ["wakefulness (hypocretin receptor", "PROBLEM", 156, 188], ["this heterologous effect", "PROBLEM", 232, 256], ["Heterologous EffectsUnlike BCG", "TREATMENT", 266, 296], ["measles vaccine", "TREATMENT", 298, 313], ["OPV", "TREATMENT", 317, 320], ["the diphtheria", "TEST", 322, 336], ["tetanus-pertussis (DTP) vaccine", "TREATMENT", 337, 368], ["fragment", "OBSERVATION", 42, 50], ["influenza", "OBSERVATION", 65, 74], ["human brain", "ANATOMY", 121, 132]]], ["In 2013, a strategic advisory group of experts commissioned by the WHO reviewed all evidence concerning possible nonspecific effects of DTP-containing vaccines on survival and all-cause mortality in children under 5 years of age, concluding that findings on DTP vaccines were inconsistent.", [["DTP", "CHEMICAL", 136, 139], ["DTP", "CHEMICAL", 136, 139], ["DTP", "CHEMICAL", 258, 261], ["DTP", "SIMPLE_CHEMICAL", 136, 139], ["children", "ORGANISM", 199, 207], ["children", "SPECIES", 199, 207], ["DTP", "PROBLEM", 136, 139], ["vaccines", "TREATMENT", 151, 159], ["survival", "TREATMENT", 163, 171], ["DTP vaccines", "TREATMENT", 258, 270]]], ["Further research into the potential nonspecific effects of DTP vaccines is warranted.", [["DTP", "CHEMICAL", 59, 62], ["DTP", "CHEMICAL", 59, 62], ["DTP", "SIMPLE_CHEMICAL", 59, 62], ["DTP vaccines", "TREATMENT", 59, 71]]], ["Based on current knowledge, it is suggested that the order in the administration of DTP vaccines with other scheduled vaccines (especially BCG) is important in the generation of these nonspecific effects, as DTP seems to oppose the positive heterologous effects of live vaccines.Negative Heterologous EffectsIn summary, vaccine effectiveness and impact have exceeded expectations, often ahead of our actual understanding of all the mechanisms behind this success.", [["DTP", "CHEMICAL", 84, 87], ["DTP", "CHEMICAL", 208, 211], ["DTP", "CHEMICAL", 84, 87], ["DTP", "CHEMICAL", 208, 211], ["DTP", "SIMPLE_CHEMICAL", 208, 211], ["DTP vaccines", "TREATMENT", 84, 96], ["other scheduled vaccines", "TREATMENT", 102, 126], ["BCG", "TREATMENT", 139, 142], ["DTP", "PROBLEM", 208, 211], ["live vaccines", "TREATMENT", 265, 278], ["Heterologous Effects", "PROBLEM", 288, 308], ["vaccine effectiveness", "TREATMENT", 320, 341], ["Heterologous Effects", "OBSERVATION", 288, 308]]], ["We are now beginning to understand these mechanisms for the oldest vaccines, and are now applying this knowledge to the design of the next generation of vaccines.", [["the oldest vaccines", "TREATMENT", 56, 75], ["the next generation of vaccines", "TREATMENT", 130, 161]]]], "8a1af16e8d875de5f528a50b5ed889eebe34471b": [["IntroductionInformation revolution and wireless mobile technology growth have made a considerable contribution to the expansion and empowering of E-health services.", [["the expansion", "PROBLEM", 114, 127], ["E-health services", "TREATMENT", 146, 163]]], ["In fact, smart remote and mobile healthcare applications are making an enormous shift in the health and social care workforce efficiency as well as patients' wellbeing.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["mobile healthcare applications", "TREATMENT", 26, 56]]], ["The main target of such applications is leveraging IoT, ML and Semantic Web technologies to ensure opportunities that enable people to be and do what they value throughout their lives despite illness.", [["illness", "DISEASE", 192, 199], ["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["illness", "PROBLEM", 192, 199], ["main", "OBSERVATION_MODIFIER", 4, 8], ["target", "OBSERVATION_MODIFIER", 9, 15]]], ["[6] is one of the earliest studies that has highlighted the importance of the development of a powerful healthcare system.", [["the earliest studies", "TEST", 14, 34]]], ["The study conclude that an integrated multidisciplinary infrastructure allowing interoperability and scalability is crucial.", [["The study", "TEST", 0, 9], ["an integrated multidisciplinary infrastructure", "PROBLEM", 24, 70]]], ["The health sector is nowadays in its knowledge age: data, information, and knowledge are used in real time to support effective integration of prevention, treatment, and recovery services across healthcare services.", [["treatment", "TREATMENT", 155, 164]]], ["Therefore, healthcare applications are now exchanging and performing not only an enormous volume of data but also an important quantity of information and a large knowledge base Fig. 2 .", [["healthcare applications", "TREATMENT", 11, 34]]], ["Ontological models are becoming commonly used models in healthcare systems providing a flexible approach to integrate data and share meaning and able to assist inferring meaning [24, 33] .", [["a flexible approach", "TREATMENT", 85, 104]]], ["Often ontology-based systems are using rule-based decision support system in order to assure an active and assisted monitors of patients [33] .", [["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["active", "OBSERVATION", 96, 102]]], ["It is a dynamic rule-based system, which infers information and medical recommendations based on the interaction of IoT input captured data, subjective and objective knowledge and a dynamic rule base updates by a ML algorithm based rules generator.", [["IoT", "PROTEIN", 116, 119], ["a ML algorithm", "TREATMENT", 211, 225]]], ["The main contribution of this work is a combinations of semantic rules reasoning and ML reasoning to provide a new ubiquitous context awareness situation framework for healthcare monitoring systems.", [["healthcare monitoring systems", "TEST", 168, 197], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["8.Background and Related WorksAdoption of EHR 1 has increased almost 9 times since 2008 [12] .", [["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["This huge amount of data circling in clinical information systems has formed new challenges as: semantic interoperability, standardization, automatic medical discovery, knowledge reuse, preventive personalized health services, etc. Aligned with this list of challenges, our work is based on three key concepts: Ontologies, Semantic Rules and ML; presented in the sequel:Background and Related WorksOntologies Based Semantic Healthcare Modelling: The conceptual model ontology is encouraging knowledge reuse and simplify problem solving in various fields.", [["huge", "OBSERVATION_MODIFIER", 5, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["new", "OBSERVATION_MODIFIER", 77, 80]]], ["Healthcare applications are one of the systems that benefit from using ontologies: drug recommendations discovery [8] , clinical support decisions [31] , home personalized care to chronic patients [20] , healthcare monitoring [33] , etc. In Ontologies engineering, integration of ontologies is a useful process that consists on the combination of two or more standard validate ontologies from different disciplines in the aim to create a new multi-disciplinary ontology [23] .Background and Related WorksSemantic Rules Healthcare Reasoning: Semantic web and its technologies are providing efficient solutions in the information and system integration in any distributed information system environments including eHealth systems for which information integration and knowledge discovery are highly recommended [7] .", [["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["healthcare monitoring", "TEST", 204, 225], ["efficient solutions", "TREATMENT", 589, 608]]], ["The combination of Semantic Web Rules with Ontology are becoming a mature technology [14] .", [["Semantic Web", "OBSERVATION", 19, 31]]], ["A semantic rules are used in reasoning based approach for dieting and exercising management for diabetics [9] .", [["exercising management", "TREATMENT", 70, 91], ["diabetics", "PROBLEM", 96, 105]]], ["OWL ontologies and SWRL are combined to integrate reasoning for decision support in alerting system [21] .Background and Related WorksML Techniques for Healthcare: The high dimensional features and the availability of high quality software made the ML techniques widely used in all fields [4] .", [["the ML techniques", "TREATMENT", 245, 262]]], ["The use of ML algorithms in medicine is a hot research topic: disease progression [36, 37] , diagnosis prediction [5, 19, 35] , and so on.", [["ML algorithms", "TREATMENT", 11, 24], ["disease progression", "PROBLEM", 62, 81]]], ["One of the combination that appears successful and promising is the combination of ML techniques and ontologies [18, 26, 28] .Proposed MethodologyOur main goal is the integration of the ML Techniques in a combined ontology semantic modelling and semantic rules based reasoning healthcare framework for chronically ill and elderly patients.", [["chronically ill", "DISEASE", 302, 317], ["patients", "ORGANISM", 330, 338], ["patients", "SPECIES", 330, 338], ["the ML Techniques", "TREATMENT", 182, 199], ["successful", "OBSERVATION", 36, 46], ["main", "OBSERVATION_MODIFIER", 150, 154]]], ["Our framework is build up in three keys stage: ontology for semantic modelling and representation, semantic rules for reasoning and machine learning techniques for learning; detailed in the following:Semantic Representation and Ontological Modelling:The aim of this step is to find the best practices in semantic representation for holistic remote health monitoring system that is characterized by a large set of terminologies.", [["semantic modelling", "TEST", 60, 78]]], ["Ontology modelling is one of the best choices, and as discussed before, the combination of different standard and valid ontologies is one of the recommended practice to build up an integrated multidisciplinary ontology.Semantic Rules Reasoning Based Prediction:This step consists in the definition of primary knowledge base: a prediction based set of semantic rules.", [["semantic rules", "OBSERVATION", 351, 365]]], ["Subjective knowledge is defined about the patient profile and context such as prior medical history, genetic diseases, personal lifestyle, etc.Semantic Rules Reasoning Based Prediction:Machine Learning Based Healthcare Reasoning: The outcome of this step is the best ML algorithm able to give the efficient support to the risk assessment system by providing the best and accurate new medical rules, detailed later in the Algorithm 1.Information Life CycleIn this subsection, we explain the information life cycle in our system: from a data, to an information, then finally a knowledge.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["genetic diseases", "PROBLEM", 101, 117], ["the risk assessment system", "TEST", 318, 344]]], ["We have two main types of data sources: received data from smart devices and entered data by users (medical staff basically).", [["smart devices", "TREATMENT", 59, 72]]], ["All the data is collected and prepared to be analysed.", [["All the data", "TEST", 0, 12]]], ["The first step of the data preparation consists on highlighting the outliers and missing values: any abnormal value could be an alert.", [["any abnormal value", "PROBLEM", 97, 115]]], ["Then, in data selection, only contextual and health attributes are selected that are related to the environment or the health situation of a patient. un-selected data will be temporary removed from the data.", [["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148]]], ["Different transformations are required, viz, String to Nominal, Unify Date Format.", [["Different transformations", "PROBLEM", 0, 25]]], ["In a first step, the inferring meaning is used in real-time by the system to determinate the current health situation of the patient, instantaneous alert, healthcare risk assessment and anomalous detection.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["healthcare risk assessment", "TEST", 155, 181]]], ["ThisDetailed System DescriptionThe main functionalities of the system are summarized in the following: Electronic Health Record: is the basic functionality in our system since its the main way of the data collection.", [["main", "OBSERVATION_MODIFIER", 35, 39]]], ["It is a systematic recording of contextual and environmental signs adequate to a multimodal, continuous and real-time user interactions.Detailed System DescriptionAlerts for Instantaneous Rescue: is the main functionality of our system which consists in providing a help support system for elderly persons with chronic diseases.", [["chronic diseases", "DISEASE", 311, 327], ["persons", "ORGANISM", 298, 305], ["persons", "SPECIES", 298, 305], ["environmental signs", "TEST", 47, 66], ["chronic diseases", "PROBLEM", 311, 327], ["chronic", "OBSERVATION_MODIFIER", 311, 318], ["diseases", "OBSERVATION", 319, 327]]], ["It awareness users about risks and emergency situations for an early and preventive health care.Detailed System DescriptionReasoning for Clinical Decision Support: is the major contribution of our system providing all necessary techniques that ensure predictive analytic and preventive personalized health services for a better clinical support system.Ubiquitous Monitoring and Patient Tracking: is an optional functionalities provide an instantly monitoring and tracking that may be used for the already mentioned functionalities.Patient Reminder: is an optional but highly recommended functionality.", [["Patient", "SPECIES", 378, 385], ["Patient", "SPECIES", 531, 538], ["preventive health care", "TREATMENT", 73, 95], ["all necessary techniques", "TREATMENT", 214, 238], ["Ubiquitous Monitoring", "TEST", 352, 373], ["an instantly monitoring", "TEST", 435, 458]]], ["It is hard to imagine a healthcare system that is not providing a patient reminder about medical appointment, daily medical operations, etc. Aligned with the list of proposed functionalities, Fig. 2 is the generic architecture for a combined ML and ontology based situation awareness framework for clinical monitoring and healthcare decision supporting.", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["daily medical operations", "TREATMENT", 110, 134], ["a combined ML", "TREATMENT", 231, 244], ["clinical monitoring", "TEST", 298, 317]]], ["The main contribution in this architecture is the dynamic updates of its knowledge base in its objective and subjective parts.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Our system is a multi modal user interaction application, i.e. different smart devices are available in the patient's environment or in the patient's body.", [["body", "ANATOMY", 150, 154], ["patient", "ORGANISM", 108, 115], ["patient", "ORGANISM", 140, 147], ["body", "ORGANISM_SUBDIVISION", 150, 154], ["patient", "SPECIES", 108, 115], ["patient", "SPECIES", 140, 147], ["different smart devices", "TREATMENT", 63, 86]]], ["The data is collected from different devices like: body sensors worn by the user, ambient sensors surrounding the user or smart devices, as phone, tablet, etc. Body sensors are used to capture the health profile of the patient, viz, vital signs, motion, location, etc. Ambient sensor reflect an image of the patient's environment, viz, ambient temperature, lightness, existence of a caregiver, etc. Smart devices are basically used to allow the communication between the user and the system and between users, viz sending an alert to user about a patient's situation, monitoring a patient, etc. The architecture of the proposed system is layered and detailed in the following:Ubiquitous Monitoring and Patient Tracking: is an optional functionalities provide an instantly monitoring and tracking that may be used for the already mentioned functionalities.Active and Assisted Living Sensors Layer: contains all smart devices including the set of wearable and nearable sensors related directly to the user, his body and his environment.", [["body", "ANATOMY", 51, 55], ["Body", "ANATOMY", 160, 164], ["body", "ANATOMY", 1009, 1013], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["patient", "ORGANISM", 219, 226], ["patient", "ORGANISM", 308, 315], ["patient", "ORGANISM", 547, 554], ["patient", "ORGANISM", 581, 588], ["body", "ORGANISM_SUBDIVISION", 1009, 1013], ["patient", "SPECIES", 219, 226], ["patient", "SPECIES", 308, 315], ["patient", "SPECIES", 547, 554], ["patient", "SPECIES", 581, 588], ["The data", "TEST", 0, 8], ["body sensors worn", "TREATMENT", 51, 68], ["smart devices", "TREATMENT", 122, 135], ["Body sensors", "TEST", 160, 172], ["vital signs", "TEST", 233, 244], ["Ambient sensor", "TEST", 269, 283], ["Smart devices", "TREATMENT", 399, 412], ["Ubiquitous Monitoring", "TEST", 676, 697], ["an instantly monitoring", "TEST", 759, 782], ["all smart devices", "TREATMENT", 906, 923], ["layered", "OBSERVATION_MODIFIER", 638, 645]]], ["Its role is collecting data for a complete holistic health profile for each patient: health data, ambient data, location, motion, personal information, etc.Ubiquitous Monitoring and Patient Tracking: is an optional functionalities provide an instantly monitoring and tracking that may be used for the already mentioned functionalities.Networking and Communication Layer: a set of networking device allowing the communication between the different physical elements and the connection of those elements to the internet.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["Patient", "SPECIES", 182, 189], ["health data", "TEST", 85, 96], ["Ubiquitous Monitoring", "TEST", 156, 177], ["an instantly monitoring", "TEST", 239, 262], ["networking device", "TREATMENT", 380, 397]]], ["Ontological model based Data Layer: it contains the set of the collected (current and previous) data and the ontology used in this system.Multi-modal Interactions Application Layer:is the implementation of all the functionalities of the system providing all the services for ubiquitous and continuous medical monitoring and supporting the multi-modal interaction.Multi-modal Interactions Application Layer:Semantic Rules Based Knowledge Layer: it is composed by the objective and the subjective knowledge.", [["continuous medical monitoring", "TEST", 290, 319]]], ["It is playing a fundamental role in our system since it contains the prediction component, i.e. prevention and detection of emergency cases and alert management.ML Based Reasoning Layer:it is the layer performing the main contribution of our system which is the learning of new predictive and preventive medical or technical rules.Context and Situation Awareness ModellingOur ontology, Fig. 3 , is composed from different valid and standard ontologies: ICNP, SSN/SOAS and FOAF.", [["alert management", "TREATMENT", 144, 160], ["FOAF", "TREATMENT", 472, 476], ["Layer", "OBSERVATION_MODIFIER", 180, 185], ["layer", "OBSERVATION_MODIFIER", 196, 201], ["main", "OBSERVATION_MODIFIER", 217, 221], ["new", "OBSERVATION_MODIFIER", 274, 277]]], ["ICNP includes terminologies from the nurses' statements.", [["ICNP", "PROTEIN", 0, 4]]], ["And no doubt, nursing science has a significant contribution in healthcare services since nurses' statements are the early and important step in systematizing and prioritizing healthcare services [10] .", [["no doubt", "UNCERTAINTY", 4, 12]]], ["As One of the main classes in our application, we consider icnp : P atient representing the patient, icnp : V italSign representing its vital signs and icnp : Result representing all results of any diagnosis (measurement of vital sign, measurement from blood test, etc).", [["blood", "ANATOMY", 253, 258], ["patient", "ORGANISM", 92, 99], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["patient", "SPECIES", 92, 99], ["its vital signs", "TEST", 132, 147], ["vital sign", "TEST", 224, 234], ["blood test", "TEST", 253, 263], ["main", "OBSERVATION_MODIFIER", 14, 18]]], ["It describes the sensors capabilities, actuators observation and all the related concepts [3, 27] .", [["actuators observation", "TEST", 39, 60]]], ["FOAF declares the person profile in different fields such as health, finance, law, etc. [17] .", [["FOAF", "PROTEIN", 0, 4], ["person", "SPECIES", 18, 24]]], ["It has four main categories of information: basic, personal, online accounts and personal documents and images.", [["images", "TEST", 104, 110]]], ["The outcome of this operation a set of equivalent axioms defining equivalence between components having the same name as the entity Person.", [["this operation", "TREATMENT", 15, 29]]], ["Mapping: we are using FOAF to present the personal profile of users.", [["FOAF", "TREATMENT", 22, 26]]], ["However, the ontology ICNP has an entity called Individual presenting the health profile of a user as height, weight.", [["weight", "TEST", 110, 116]]], ["So, a merging operation has been performed between the entities FOAF: person and ICNP: individual.", [["person", "SPECIES", 70, 76], ["a merging operation", "TREATMENT", 4, 23]]], ["We created the property has Platform to link each user to his sensors.Knowledge and Reasoning EngineThe knowledge component is defining: general medicine domain and context data using a set of semantic rules SWRL [14] in an abstract manner.", [["context data", "TEST", 165, 177]]], ["However, the reasoning techniques will be able to learn dynamically from the previous facts, i.e. previous applied rules, and provide new SWRL rules.", [["new SWRL rules", "PROBLEM", 134, 148]]], ["Causes are the health situation represented by a set of signs and symptoms.", [["signs and symptoms", "PROBLEM", 56, 74]]], ["Effects are the medical situation of a patient, viz, emergency case, disease, diagnosis, etc.Semantic Rules KnowledgeReasoner Engine (RE) applies the knowledge into the collected data in the order to determinate new facts about the current patient's situation in real-time way.", [["patient", "ORGANISM", 39, 46], ["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 39, 46], ["patient", "SPECIES", 240, 247], ["disease", "PROBLEM", 69, 76]]], ["RE will be in continuous search of causes which are any changes in the medical situation (signs and symptoms of each patient).", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["any changes in the medical situation", "PROBLEM", 52, 88], ["symptoms", "PROBLEM", 100, 108]]], ["Our preliminary set of SWRL is only containing a basic set of medical rules allowing to detect few emergency cases as: less blood pressure, height temperature, etc. To resume any abnormal value for a vital sign, we define the following SWRL 2 rule (GM ): icnp :Learning and Prediction ReasoningML Engine (MLE) learns from previous patient's detected alarms to produce new reasoning rules in different steps from the Algorithm 1.", [["blood", "ANATOMY", 124, 129], ["GM", "CHEMICAL", 249, 251], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["patient", "ORGANISM", 331, 338], ["SWRL", "DNA", 23, 27], ["patient", "SPECIES", 331, 338], ["blood pressure", "TEST", 124, 138], ["height temperature", "PROBLEM", 140, 158], ["any abnormal value", "PROBLEM", 175, 193], ["a vital sign", "TEST", 198, 210]]], ["In addition, FDT is a well-known adapted version of DT that scales up well to large data sets with large number of attributes as a healthcare data set.Performance Evaluation and ResultsIn order to prove the feasibility of the proposed approach and to evaluate its performance, we have tested the general process previously proposed in Algorithm 1 to an electronic health recorded data set from [22, 30] .", [["Performance Evaluation", "TEST", 151, 173]]], ["This data is considered as preliminary data set.", [["This data", "TEST", 0, 9]]], ["An example of new rule is the detection of a low level of SpO2-Oxygen Saturation-that is used to continuously monitor the oxygenation status of critically ill patients.", [["critically ill", "DISEASE", 144, 158], ["SpO2", "CHEMICAL", 58, 62], ["Oxygen", "CHEMICAL", 63, 69], ["Oxygen", "SIMPLE_CHEMICAL", 63, 69], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["SpO2", "TEST", 58, 62], ["Oxygen Saturation", "TEST", 63, 80], ["new", "OBSERVATION_MODIFIER", 14, 17], ["low", "OBSERVATION_MODIFIER", 45, 48]]], ["Actually the SpO2 measurement provides: Pleth waveform (visual indication of patient's pulse), Oxygen saturation of arterial blood (SpO2) in percent, Pulse rate (derived from Pleth wave), Perfusion indicator (Perf)-numerical value for the pulsatile portion of the measured signal caused by arterial pulsation.", [["arterial blood", "ANATOMY", 116, 130], ["arterial", "ANATOMY", 290, 298], ["Oxygen", "CHEMICAL", 95, 101], ["patient", "ORGANISM", 77, 84], ["Oxygen", "SIMPLE_CHEMICAL", 95, 101], ["arterial", "MULTI-TISSUE_STRUCTURE", 116, 124], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["arterial", "MULTI-TISSUE_STRUCTURE", 290, 298], ["patient", "SPECIES", 77, 84], ["the SpO2 measurement", "TEST", 9, 29], ["Pleth waveform", "TEST", 40, 54], ["patient's pulse", "TEST", 77, 92], ["Oxygen saturation", "TEST", 95, 112], ["arterial blood", "TEST", 116, 130], ["SpO2", "TEST", 132, 136], ["Pulse rate", "TEST", 150, 160], ["Pleth wave", "TEST", 175, 185], ["Perfusion indicator", "TEST", 188, 207], ["numerical value", "TEST", 215, 230], ["arterial pulsation", "PROBLEM", 290, 308], ["arterial pulsation", "OBSERVATION", 290, 308]]], ["The result of Algorithm 1 applied to data from one patient allow the definition of the following new rule: Perf < 0.5 and AWV < 3749.05 and AWF < 10.4 and NBP (Sys) < 105 is an emergency case with alarm labelled SpO2 LOW PERF, Fig. 4 .", [["NBP", "CHEMICAL", 155, 158], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["Algorithm", "TEST", 14, 23], ["AWV", "TEST", 122, 125], ["AWF", "TEST", 140, 143], ["NBP", "TEST", 155, 158], ["alarm labelled SpO2", "TEST", 197, 216]]], ["Then, the different instances of non normal range of the following signs: Perf, AWV, AWF et NBP will be updated.", [["Perf", "PROBLEM", 74, 78], ["Perf", "OBSERVATION", 74, 78]]], ["For example, the following axioms will be defined (or update if it exists previously): Axiom 1 P erf AN SubClassOf P erf AbnoramlRange and Axiom 2 P erfAN EquivalentT o P erf AbnoramlRange and somexsd : real[< 0.5].", [["P erf", "DNA", 169, 174], ["Axiom", "TEST", 87, 92], ["erf AbnoramlRange", "TEST", 117, 134], ["Axiom", "TEST", 139, 144], ["erf", "TEST", 149, 152], ["erf AbnoramlRange", "TEST", 171, 188]]], ["Then, the rule GM will be applicable to determinate a new alert.ConclusionsThis paper presents a combined semantic rules reasoning and Fast Decision Tree Learner algorithm for a predictive, preventive and personalized medical framework.", [["GM", "CHEMICAL", 15, 17], ["new", "OBSERVATION_MODIFIER", 54, 57]]], ["The main idea consists in a knowledge and reasoning engine able to apply SWRL medical rules on collected data to generate alerts and able to create new general medicine rules based in previous detected alerts.", [["new general medicine", "TREATMENT", 148, 168], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["As a continuation of this work, we are aiming to develop a prototype of the proposed system and test it on a larger samples of data collected from an elderly population with chronic diseases.", [["chronic diseases", "DISEASE", 174, 190], ["chronic diseases", "PROBLEM", 174, 190], ["chronic", "OBSERVATION_MODIFIER", 174, 181], ["diseases", "OBSERVATION", 182, 190]]]], "ca5245364c2790950226a990a84196197a40e507": [["Introduction 52The emergence of a novel SARS-coronavirus in late 2019 (SARS-CoV-2; previously known 53 as 2019-nCoV), and the CoV disease (COVID)-19 it causes, has led to a devastating 54 pandemic of the 21 st century.", [["SARS-coronavirus", "DISEASE", 40, 56], ["CoV disease", "DISEASE", 126, 137], ["SARS-coronavirus", "ORGANISM", 40, 56], ["SARS-CoV-2", "ORGANISM", 71, 81], ["SARS-coronavirus", "SPECIES", 40, 56], ["SARS-CoV-2", "SPECIES", 71, 81], ["a novel SARS", "PROBLEM", 32, 44], ["coronavirus", "PROBLEM", 45, 56], ["SARS-CoV", "TEST", 71, 79], ["the CoV disease", "PROBLEM", 122, 137], ["CoV disease", "OBSERVATION", 126, 137]]], ["SARS-CoV-2 belongs to the beta-coronavirus genus with 55 approximately 79.5% sequence homology to the SARS-CoV that emerged in 2002 (Wang et 56 al., 2020b) .", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 102, 106], ["SARS-CoV-2", "ORGANISM", 0, 10], ["beta-coronavirus", "ORGANISM", 26, 42], ["SARS-CoV", "ORGANISM", 102, 110], ["SARS-CoV", "SPECIES", 0, 8], ["beta-coronavirus", "SPECIES", 26, 42], ["SARS-CoV", "SPECIES", 102, 110]]], ["Similar to SARS-CoV (2002) , this novel CoV also utilises angiotensin converting 57 enzyme (ACE)2 as its host receptor to mediate membrane fusion and virus entry and viral 58 replication (Zhou et al., 2020) .", [["membrane", "ANATOMY", 130, 138], ["SARS", "DISEASE", 11, 15], ["angiotensin", "CHEMICAL", 58, 69], ["SARS-CoV", "ORGANISM", 11, 19], ["CoV", "ORGANISM", 40, 43], ["angiotensin converting 57 enzyme (ACE)2", "GENE_OR_GENE_PRODUCT", 58, 97], ["membrane", "CELLULAR_COMPONENT", 130, 138], ["angiotensin converting 57 enzyme (ACE)2", "PROTEIN", 58, 97], ["SARS-CoV", "SPECIES", 11, 19], ["this novel CoV", "PROBLEM", 29, 43], ["angiotensin converting", "TREATMENT", 58, 80], ["enzyme (ACE)", "TREATMENT", 84, 96], ["its host receptor", "TREATMENT", 101, 118], ["membrane fusion", "TREATMENT", 130, 145], ["virus entry", "TREATMENT", 150, 161]]], ["SARS-CoV-2 spike protein contains two subunits, subunit 1 59 (S1) and S2, that mediates viral attachment to ACE2 and membrane fusion, respectively.", [["membrane", "ANATOMY", 117, 125], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["subunit 1 59", "GENE_OR_GENE_PRODUCT", 48, 60], ["S1", "GENE_OR_GENE_PRODUCT", 62, 64], ["S2", "GENE_OR_GENE_PRODUCT", 70, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["SARS-CoV-2 spike protein", "PROTEIN", 0, 24], ["subunit 1 59", "PROTEIN", 48, 60], ["S1", "PROTEIN", 62, 64], ["S2", "PROTEIN", 70, 72], ["ACE2", "PROTEIN", 108, 112], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["spike protein", "TEST", 11, 24], ["ACE2 and membrane fusion", "TREATMENT", 108, 132], ["S2", "ANATOMY", 70, 72], ["viral attachment", "OBSERVATION", 88, 104], ["membrane fusion", "OBSERVATION", 117, 132]]], ["The 60 receptor-binding domain (RBD) of S1 is the critical region of the spike protein for ACE2 61 binding.", [["S1", "GENE_OR_GENE_PRODUCT", 40, 42], ["ACE2 61", "GENE_OR_GENE_PRODUCT", 91, 98], ["60 receptor-binding domain", "PROTEIN", 4, 30], ["RBD", "PROTEIN", 32, 35], ["S1", "PROTEIN", 40, 42], ["spike protein", "PROTEIN", 73, 86], ["ACE2 61", "PROTEIN", 91, 98], ["ACE2", "TEST", 91, 95], ["S1", "ANATOMY", 40, 42]]], ["Currently there are no specific antiviral drugs available or anti-inflammatory drugs that have 80 been shown to influence clinical outcomes for people with COVID-19.", [["people", "ORGANISM", 144, 150], ["people", "SPECIES", 144, 150], ["specific antiviral drugs", "TREATMENT", 23, 47], ["anti-inflammatory drugs", "TREATMENT", 61, 84], ["COVID", "TEST", 156, 161], ["no", "UNCERTAINTY", 20, 22], ["antiviral drugs", "OBSERVATION", 32, 47]]], ["A broad-spectrum 81 antiviral drug remdesivir is currently being used for COVID-19 through compassionate use 82 requests as well as in clinical trials in the US and China.", [["remdesivir", "CHEMICAL", 35, 45], ["remdesivir", "CHEMICAL", 35, 45], ["remdesivir", "SIMPLE_CHEMICAL", 35, 45], ["A broad-spectrum 81 antiviral drug remdesivir", "TREATMENT", 0, 45], ["broad", "OBSERVATION_MODIFIER", 2, 7]]], ["The anti-malarial drug 83 hydroxychloroquine is also under several clinical trials, although preliminary reports have not 84 shown beneficial effects (Magagnoli et al., 2020; Mahevas et al., 2020) .", [["hydroxychloroquine", "CHEMICAL", 26, 44], ["hydroxychloroquine", "CHEMICAL", 26, 44], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 26, 44], ["The anti-malarial drug", "TREATMENT", 0, 22], ["hydroxychloroquine", "TREATMENT", 26, 44]]], ["85 6 using streptavidin diminished interactions between CoV2-S1 and ACE2 in AP-6 group and 147 not in the non-AP-6-treated group.", [["non-AP-6", "CHEMICAL", 106, 114], ["non-AP-6", "CHEMICAL", 106, 114], ["streptavidin", "GENE_OR_GENE_PRODUCT", 11, 23], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 56, 63], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["AP-6", "CELL", 76, 80], ["non-AP-6", "SIMPLE_CHEMICAL", 106, 114], ["CoV2", "PROTEIN", 56, 60], ["S1", "PROTEIN", 61, 63], ["ACE2", "PROTEIN", 68, 72], ["AP", "PROTEIN", 76, 78], ["non-AP-6-treated group", "CELL_LINE", 106, 128], ["streptavidin diminished interactions", "PROBLEM", 11, 47], ["CoV2", "TEST", 56, 60], ["ACE2", "TEST", 68, 72], ["AP", "TEST", 76, 78], ["S1", "ANATOMY", 61, 63]]], ["AP-6 also reduced CoV-S1 and ACE2 interaction, 148Introduction 52indicating the inhibition potentials of AP-6 across small differences in amino acid residue 149 sequences between CoV2-S1 and CoV-S1 RBM (Figure S1B -C).", [["amino acid", "CHEMICAL", 138, 148], ["amino acid", "CHEMICAL", 138, 148], ["AP-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 18, 24], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["AP-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["amino acid", "AMINO_ACID", 138, 148], ["residue 149", "AMINO_ACID", 149, 160], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 179, 186], ["S1B -C", "GENE_OR_GENE_PRODUCT", 210, 216], ["CoV", "PROTEIN", 18, 21], ["ACE2", "PROTEIN", 29, 33], ["AP", "PROTEIN", 105, 107], ["CoV2", "PROTEIN", 179, 183], ["CoV", "PROTEIN", 191, 194], ["RBM", "PROTEIN", 198, 201], ["Figure S1B -C", "PROTEIN", 203, 216], ["AP", "TEST", 0, 2], ["reduced CoV-S1 and ACE2 interaction", "PROBLEM", 10, 45], ["AP", "TEST", 105, 107], ["amino acid residue", "TEST", 138, 156], ["CoV2", "TEST", 179, 183], ["CoV", "TEST", 191, 194], ["S1", "ANATOMY", 22, 24], ["S1", "ANATOMY", 184, 186], ["CoV", "ANATOMY", 191, 194], ["S1 RBM", "ANATOMY", 195, 201]]], ["150 151 This indicates that CoV2-S1 elicits higher inflammatory responses than CoV-S1, and that the 152 CoV2-RBD alone is sufficient for inducing this response.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 28, 35], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 79, 85], ["CoV2-RBD", "GENE_OR_GENE_PRODUCT", 104, 112], ["CoV2", "PROTEIN", 28, 32], ["S1", "PROTEIN", 33, 35], ["CoV2", "PROTEIN", 104, 108], ["RBD", "PROTEIN", 109, 112], ["CoV2", "TEST", 28, 32], ["higher inflammatory responses", "PROBLEM", 44, 73], ["CoV", "TEST", 79, 82], ["higher", "OBSERVATION_MODIFIER", 44, 50], ["inflammatory", "OBSERVATION", 51, 63], ["S1", "ANATOMY", 83, 85]]], ["CoV2-S1-ACE2 interaction is 153 required for this heightened inflammatory response.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["CoV2", "PROTEIN", 0, 4], ["S1", "PROTEIN", 5, 7], ["ACE2", "PROTEIN", 8, 12], ["CoV2", "TEST", 0, 4], ["ACE2 interaction", "PROBLEM", 8, 24], ["this heightened inflammatory response", "PROBLEM", 45, 82], ["S1", "ANATOMY", 5, 7], ["inflammatory", "OBSERVATION", 61, 73]]], ["154 155 CoV2-S1-ACE2 facilitates NF-\u03baB activation via MAP kinase signalling.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 8, 15], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 33, 38], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 54, 64], ["CoV2", "PROTEIN", 8, 12], ["S1", "PROTEIN", 13, 15], ["ACE2", "PROTEIN", 16, 20], ["NF-\u03baB", "PROTEIN", 33, 38], ["MAP kinase", "PROTEIN", 54, 64], ["CoV2", "TEST", 8, 12], ["ACE2", "TEST", 16, 20], ["NF", "TEST", 33, 35], ["MAP kinase signalling", "TEST", 54, 75]]], ["156Introduction 52We investigated if S1-mediated production of pro-inflammatory cytokines requires common 157 adaptor proteins MyD88 or TRIF.", [["S1", "GENE_OR_GENE_PRODUCT", 37, 39], ["MyD88", "GENE_OR_GENE_PRODUCT", 127, 132], ["TRIF", "GENE_OR_GENE_PRODUCT", 136, 140], ["S1", "PROTEIN", 37, 39], ["pro-inflammatory cytokines", "PROTEIN", 63, 89], ["common 157 adaptor proteins", "PROTEIN", 99, 126], ["MyD88", "PROTEIN", 127, 132], ["TRIF", "PROTEIN", 136, 140], ["pro-inflammatory cytokines", "PROBLEM", 63, 89], ["TRIF", "PROBLEM", 136, 140]]], ["Knockdown of MyD88 or TRIF inhibited S1-mediated p65 158 phosphorylation ( Figure 3A) , indicating MyD88 and TRIF as important signalling adaptors in 159 S1-driven p65 activation.", [["MyD88", "GENE_OR_GENE_PRODUCT", 13, 18], ["TRIF", "GENE_OR_GENE_PRODUCT", 22, 26], ["S1", "GENE_OR_GENE_PRODUCT", 37, 39], ["p65", "GENE_OR_GENE_PRODUCT", 49, 52], ["Figure 3A", "GENE_OR_GENE_PRODUCT", 75, 84], ["MyD88", "GENE_OR_GENE_PRODUCT", 99, 104], ["TRIF", "GENE_OR_GENE_PRODUCT", 109, 113], ["159 S1", "GENE_OR_GENE_PRODUCT", 150, 156], ["p65", "GENE_OR_GENE_PRODUCT", 164, 167], ["MyD88", "PROTEIN", 13, 18], ["TRIF", "PROTEIN", 22, 26], ["S1", "PROTEIN", 37, 39], ["p65 158", "PROTEIN", 49, 56], ["MyD88", "PROTEIN", 99, 104], ["TRIF", "PROTEIN", 109, 113], ["signalling adaptors", "PROTEIN", 127, 146], ["159 S1", "PROTEIN", 150, 156], ["p65", "PROTEIN", 164, 167], ["phosphorylation", "TEST", 57, 72], ["MyD88", "PROBLEM", 99, 104], ["TRIF", "TREATMENT", 109, 113]]], ["However, immunoprecipitation using anti-His antibody did not pull 160 down MyD88 or TRIF ( Figure 3B) with the PCR array.", [["His", "CHEMICAL", 40, 43], ["MyD88", "GENE_OR_GENE_PRODUCT", 75, 80], ["TRIF", "GENE_OR_GENE_PRODUCT", 84, 88], ["anti-His antibody", "PROTEIN", 35, 52], ["MyD88", "PROTEIN", 75, 80], ["TRIF", "PROTEIN", 84, 88], ["Figure 3B", "PROTEIN", 91, 100], ["immunoprecipitation", "TEST", 9, 28], ["anti", "TREATMENT", 35, 39], ["His antibody", "TEST", 40, 52], ["the PCR array", "TEST", 107, 120]]], ["Here CoV2-S1 stimulation in BCi-NS1.1 cells also induced heightened 174 activation of MAP kinase p38 (12 -24hrs), Erk (2 and 24hrs), and Jnk (24hrs), compared to 175 inductions by CoV-S1 ( Figure 4A ).", [["BCi-NS1.1 cells", "ANATOMY", 28, 43], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 5, 12], ["BCi-NS1.1 cells", "CELL", 28, 43], ["MAP kinase p38", "GENE_OR_GENE_PRODUCT", 86, 100], ["Erk", "GENE_OR_GENE_PRODUCT", 114, 117], ["Jnk", "GENE_OR_GENE_PRODUCT", 137, 140], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 180, 186], ["CoV2", "PROTEIN", 5, 9], ["S1", "PROTEIN", 10, 12], ["BCi", "CELL_LINE", 28, 31], ["NS1.1 cells", "CELL_LINE", 32, 43], ["MAP kinase", "PROTEIN", 86, 96], ["p38", "PROTEIN", 97, 100], ["Erk", "PROTEIN", 114, 117], ["Jnk", "PROTEIN", 137, 140], ["CoV2", "TEST", 5, 9], ["BCi", "TEST", 28, 31], ["NS1.1 cells", "PROBLEM", 32, 43], ["MAP kinase p38", "TEST", 86, 100], ["Erk", "TEST", 114, 117], ["Jnk", "TEST", 137, 140], ["CoV", "TEST", 180, 183], ["S1", "ANATOMY", 184, 186]]], ["Knockdown of p38, Erk or Jnk expressions by siRNAs 176 all resulted in a significant reduction in phosphorylation of p65 following CoV2-S1 treatment 177 ( Figure 4B ), indicating that the MAP kinase is an important contributor to CoV2-S1-178 mediated NF-\u03baB activation.", [["p38", "GENE_OR_GENE_PRODUCT", 13, 16], ["Erk", "GENE_OR_GENE_PRODUCT", 18, 21], ["Jnk", "GENE_OR_GENE_PRODUCT", 25, 28], ["p65", "GENE_OR_GENE_PRODUCT", 117, 120], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 131, 138], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 188, 198], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 251, 256], ["p38", "PROTEIN", 13, 16], ["Erk", "PROTEIN", 18, 21], ["Jnk", "PROTEIN", 25, 28], ["p65", "PROTEIN", 117, 120], ["MAP kinase", "PROTEIN", 188, 198], ["CoV2", "PROTEIN", 230, 234], ["NF-\u03baB", "PROTEIN", 251, 256], ["p38", "TEST", 13, 16], ["Erk", "TEST", 18, 21], ["Jnk expressions", "TEST", 25, 40], ["siRNAs", "TEST", 44, 50], ["a significant reduction in phosphorylation of p65", "PROBLEM", 71, 120], ["CoV2", "TEST", 131, 135], ["S1 treatment", "TREATMENT", 136, 148], ["the MAP kinase", "TEST", 184, 198], ["CoV2", "TEST", 230, 234], ["S1", "TEST", 235, 237], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["reduction", "OBSERVATION_MODIFIER", 85, 94]]], ["179 7 CoV2-S1 stimulates rapid ER stress and UPR that activate NF-\u03baB via UPR-MAP kinase 181crosstalk.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 6, 13], ["ER", "GENE_OR_GENE_PRODUCT", 31, 33], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 63, 68], ["UPR-MAP kinase 181", "GENE_OR_GENE_PRODUCT", 73, 91], ["CoV2", "PROTEIN", 6, 10], ["S1", "PROTEIN", 11, 13], ["ER", "PROTEIN", 31, 33], ["UPR", "PROTEIN", 45, 48], ["NF-\u03baB", "PROTEIN", 63, 68], ["UPR", "PROTEIN", 73, 76], ["MAP kinase 181", "PROTEIN", 77, 91], ["CoV2", "TEST", 6, 10], ["rapid ER stress", "TEST", 25, 40], ["UPR", "TEST", 45, 48], ["NF", "TEST", 63, 65], ["MAP kinase", "TEST", 77, 87]]], ["182CoV2-S1 induced early activation of Erk, which is a kinase utilised by not only MAP kinase 183 but also ER stress and UPR.", [["182CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["Erk", "GENE_OR_GENE_PRODUCT", 39, 42], ["MAP kinase 183", "GENE_OR_GENE_PRODUCT", 83, 97], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["UPR", "GENE_OR_GENE_PRODUCT", 121, 124], ["182CoV2", "PROTEIN", 0, 7], ["S1", "PROTEIN", 8, 10], ["Erk", "PROTEIN", 39, 42], ["MAP kinase 183", "PROTEIN", 83, 97], ["ER", "PROTEIN", 107, 109], ["UPR", "PROTEIN", 121, 124], ["a kinase", "TEST", 53, 61], ["MAP kinase", "TEST", 83, 93], ["ER stress", "TEST", 107, 116]]], ["ER stress has been shown to be induced by the CoV spike 184 protein (Versteeg et al., 2007) .", [["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["ER", "PROTEIN", 0, 2], ["CoV spike 184 protein", "PROTEIN", 46, 67], ["ER stress", "PROBLEM", 0, 9], ["the CoV spike", "PROBLEM", 42, 55]]], ["ER-UPR features three main pathways, PERK-Erk-CHOP 185 pathway that modulates apoptosis, ATF6 that regulates protein folding, and the IRE1 -186 TRAF2 pathway that promotes NF-\u03baB and p38 activation (Pathinayake et al., 2018) .", [["ER", "GENE_OR_GENE_PRODUCT", 0, 2], ["PERK", "GENE_OR_GENE_PRODUCT", 37, 41], ["Erk-CHOP 185", "GENE_OR_GENE_PRODUCT", 42, 54], ["ATF6", "GENE_OR_GENE_PRODUCT", 89, 93], ["IRE1", "GENE_OR_GENE_PRODUCT", 134, 138], ["TRAF2", "GENE_OR_GENE_PRODUCT", 144, 149], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 172, 177], ["p38", "GENE_OR_GENE_PRODUCT", 182, 185], ["ER", "PROTEIN", 0, 2], ["UPR", "PROTEIN", 3, 6], ["PERK", "PROTEIN", 37, 41], ["Erk-CHOP 185", "PROTEIN", 42, 54], ["ATF6", "PROTEIN", 89, 93], ["IRE1", "PROTEIN", 134, 138], ["TRAF2", "PROTEIN", 144, 149], ["NF-\u03baB", "PROTEIN", 172, 177], ["p38", "PROTEIN", 182, 185], ["PERK", "TEST", 37, 41], ["modulates apoptosis", "PROBLEM", 68, 87], ["ATF6", "TEST", 89, 93], ["protein folding", "TEST", 109, 124], ["the IRE1", "TEST", 130, 138], ["TRAF2 pathway", "TEST", 144, 157]]], ["187crosstalk.", [["crosstalk", "OBSERVATION", 3, 12]]], ["182CoV2-S1 and -RBD resulted in an early increase of IRE1 and PERK activations at 2 and 188 6hrs, respectively, and this was sustained to 24hr post stimulation.", [["182CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["IRE1", "GENE_OR_GENE_PRODUCT", 53, 57], ["PERK", "GENE_OR_GENE_PRODUCT", 62, 66], ["182CoV2", "PROTEIN", 0, 7], ["S1", "PROTEIN", 8, 10], ["RBD", "PROTEIN", 16, 19], ["IRE1", "PROTEIN", 53, 57], ["PERK", "PROTEIN", 62, 66], ["RBD", "PROBLEM", 16, 19], ["PERK activations", "TEST", 62, 78], ["early", "OBSERVATION_MODIFIER", 35, 40], ["increase", "OBSERVATION_MODIFIER", 41, 49]]], ["Furthermore, IRE1 and 189 PERK activations were higher compared with CoV-S1 and -RBD ( Figure 5A ).", [["IRE1", "GENE_OR_GENE_PRODUCT", 13, 17], ["PERK", "GENE_OR_GENE_PRODUCT", 26, 30], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 69, 75], ["IRE1", "PROTEIN", 13, 17], ["PERK", "PROTEIN", 26, 30], ["CoV", "PROTEIN", 69, 72], ["S1", "PROTEIN", 73, 75], ["RBD", "PROTEIN", 81, 84], ["IRE1", "TEST", 13, 17], ["PERK activations", "TEST", 26, 42], ["CoV", "TEST", 69, 72], ["S1", "ANATOMY", 73, 75]]], ["ATF6 190 activation was equivalent for CoV2-S1 and CoV-S1.", [["ATF6 190", "GENE_OR_GENE_PRODUCT", 0, 8], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 39, 46], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 51, 57], ["ATF6 190", "PROTEIN", 0, 8], ["CoV2", "PROTEIN", 39, 43], ["S1", "PROTEIN", 44, 46], ["CoV", "PROTEIN", 51, 54], ["S1", "PROTEIN", 55, 57], ["CoV2", "TEST", 39, 43], ["S1", "ANATOMY", 44, 46], ["CoV", "ANATOMY", 51, 54], ["S1", "ANATOMY", 55, 57]]], ["As IRE1 activation was induced 191 earlier (2hrs) by CoV2-S1 than MAP kinases, we then investigated if increased ER-UPR by 192crosstalk.", [["IRE1", "GENE_OR_GENE_PRODUCT", 3, 7], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 53, 60], ["MAP kinases", "GENE_OR_GENE_PRODUCT", 66, 77], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["UPR", "GENE_OR_GENE_PRODUCT", 116, 119], ["IRE1", "PROTEIN", 3, 7], ["CoV2", "PROTEIN", 53, 57], ["S1", "PROTEIN", 58, 60], ["MAP kinases", "PROTEIN", 66, 77], ["ER", "PROTEIN", 113, 115], ["UPR", "PROTEIN", 116, 119], ["MAP kinases", "TEST", 66, 77]]], ["182CoV2-S1 leads to heightened MAP kinase activities by siRNAs.", [["182CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 31, 41], ["182CoV2", "PROTEIN", 0, 7], ["S1", "PROTEIN", 8, 10], ["MAP kinase", "PROTEIN", 31, 41], ["heightened MAP kinase activities", "TEST", 20, 52]]], ["193194Knockdown of PERK resulted in reduced phosphorylation levels of Erk, but had minimal 195 effect on p65, p38, and Jnk activation ( Figure 5B ).", [["PERK", "GENE_OR_GENE_PRODUCT", 19, 23], ["Erk", "GENE_OR_GENE_PRODUCT", 70, 73], ["p65", "GENE_OR_GENE_PRODUCT", 105, 108], ["p38", "GENE_OR_GENE_PRODUCT", 110, 113], ["Jnk", "GENE_OR_GENE_PRODUCT", 119, 122], ["PERK", "PROTEIN", 19, 23], ["Erk", "PROTEIN", 70, 73], ["p65", "PROTEIN", 105, 108], ["p38", "PROTEIN", 110, 113], ["Jnk", "PROTEIN", 119, 122], ["PERK", "TEST", 19, 23], ["reduced phosphorylation levels", "PROBLEM", 36, 66], ["Erk", "TEST", 70, 73], ["p65", "TEST", 105, 108], ["p38", "TEST", 110, 113], ["Jnk activation", "TEST", 119, 133]]], ["In contrast, reduction of IRE1 196 expression decreased p65, p38, and Erk phosphorylation/expression.", [["IRE1 196", "GENE_OR_GENE_PRODUCT", 26, 34], ["p65", "GENE_OR_GENE_PRODUCT", 56, 59], ["p38", "GENE_OR_GENE_PRODUCT", 61, 64], ["Erk", "GENE_OR_GENE_PRODUCT", 70, 73], ["IRE1 196", "PROTEIN", 26, 34], ["p65", "PROTEIN", 56, 59], ["p38", "PROTEIN", 61, 64], ["Erk", "PROTEIN", 70, 73], ["IRE1", "TEST", 26, 30], ["p38", "TEST", 61, 64], ["Erk phosphorylation", "TEST", 70, 89]]], ["This indicates that 197 IRE1 , and not PERK and ATF6 pathway, is involved in p65 activation.", [["IRE1", "GENE_OR_GENE_PRODUCT", 24, 28], ["PERK", "GENE_OR_GENE_PRODUCT", 39, 43], ["ATF6", "GENE_OR_GENE_PRODUCT", 48, 52], ["p65", "GENE_OR_GENE_PRODUCT", 77, 80], ["197 IRE1", "PROTEIN", 20, 28], ["PERK", "PROTEIN", 39, 43], ["ATF6", "PROTEIN", 48, 52], ["p65", "PROTEIN", 77, 80], ["IRE1", "TEST", 24, 28]]], ["198194We also assessed if MAP kinase modulates ER-UPR.", [["MAP kinase", "GENE_OR_GENE_PRODUCT", 26, 36], ["ER", "GENE_OR_GENE_PRODUCT", 47, 49], ["UPR", "GENE_OR_GENE_PRODUCT", 50, 53], ["MAP kinase", "PROTEIN", 26, 36], ["ER", "PROTEIN", 47, 49], ["UPR", "PROTEIN", 50, 53], ["MAP kinase", "TEST", 26, 36]]], ["While knockdown of either p38, Erk, 199 or Jnk decreased p65 phosphorylation ( Figure 4B ), reduction of p38 or Erk gene expression 200 led to decreased PERK phosphorylation but not IRE1 activation ( Figure 5C ).", [["p38", "GENE_OR_GENE_PRODUCT", 26, 29], ["Erk", "GENE_OR_GENE_PRODUCT", 31, 34], ["Jnk", "GENE_OR_GENE_PRODUCT", 43, 46], ["p65", "GENE_OR_GENE_PRODUCT", 57, 60], ["p38", "GENE_OR_GENE_PRODUCT", 105, 108], ["Erk", "GENE_OR_GENE_PRODUCT", 112, 115], ["PERK", "GENE_OR_GENE_PRODUCT", 153, 157], ["IRE1", "GENE_OR_GENE_PRODUCT", 182, 186], ["p38, Erk, 199 or Jnk", "PROTEIN", 26, 46], ["p65", "PROTEIN", 57, 60], ["p38", "PROTEIN", 105, 108], ["Erk", "PROTEIN", 112, 115], ["PERK", "PROTEIN", 153, 157], ["IRE1", "PROTEIN", 182, 186], ["p38", "TEST", 26, 29], ["Erk", "TEST", 31, 34], ["Jnk", "TEST", 43, 46], ["p65 phosphorylation", "TEST", 57, 76], ["Figure 4B", "TEST", 79, 88], ["reduction of p38", "TREATMENT", 92, 108], ["Erk gene expression", "TEST", 112, 131], ["decreased PERK phosphorylation", "PROBLEM", 143, 173]]], ["Jnk 201 knockdown led to reduced IRE1 phosphorylation and had no effect on PERK activation.", [["Jnk 201", "GENE_OR_GENE_PRODUCT", 0, 7], ["IRE1", "GENE_OR_GENE_PRODUCT", 33, 37], ["PERK", "GENE_OR_GENE_PRODUCT", 75, 79], ["Jnk 201", "PROTEIN", 0, 7], ["IRE1", "PROTEIN", 33, 37], ["PERK", "PROTEIN", 75, 79], ["Jnk", "TEST", 0, 3], ["reduced IRE1 phosphorylation", "PROBLEM", 25, 53], ["PERK activation", "PROBLEM", 75, 90], ["no", "UNCERTAINTY", 62, 64]]], ["202194This demonstrates CoV2-S1 promotes NF-\u03baB activation via the ER-UPR (IRE1 /PERK) and 203 MAP kinase pathway.", [["202194", "CHEMICAL", 0, 6], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 24, 31], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 41, 46], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["UPR", "GENE_OR_GENE_PRODUCT", 69, 72], ["IRE1", "GENE_OR_GENE_PRODUCT", 74, 78], ["PERK", "GENE_OR_GENE_PRODUCT", 80, 84], ["203 MAP kinase", "GENE_OR_GENE_PRODUCT", 90, 104], ["CoV2", "PROTEIN", 24, 28], ["NF-\u03baB", "PROTEIN", 41, 46], ["ER", "PROTEIN", 66, 68], ["UPR", "PROTEIN", 69, 72], ["IRE1", "PROTEIN", 74, 78], ["PERK", "PROTEIN", 80, 84], ["203 MAP kinase", "PROTEIN", 90, 104], ["CoV2", "TEST", 24, 28], ["MAP kinase pathway", "TEST", 94, 112]]], ["204 205CoV2-S1 induces markers of acute bronchial epithelial injury 206Acute lung injury is a feature observed with severe COVID-19 (Huang et al., 2020; Lai et al., 207 2017) , and markers associated with epithelial damage IL-1\u03b2, TNF , and CCL2 were all 208 markedly increased by CoV2-S1 in our targeted PCR array ( Figure 3C ), and at protein levels 209 ( Figure 1A ).", [["bronchial epithelial", "ANATOMY", 40, 60], ["lung", "ANATOMY", 77, 81], ["epithelial", "ANATOMY", 205, 215], ["lung injury", "DISEASE", 77, 88], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 7, 14], ["bronchial epithelial", "TISSUE", 40, 60], ["lung", "ORGAN", 77, 81], ["epithelial", "TISSUE", 205, 215], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 223, 228], ["TNF", "GENE_OR_GENE_PRODUCT", 230, 233], ["CCL2", "GENE_OR_GENE_PRODUCT", 240, 244], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 280, 287], ["epithelial damage IL-1\u03b2", "PROTEIN", 205, 228], ["TNF", "PROTEIN", 230, 233], ["CCL2", "PROTEIN", 240, 244], ["CoV2", "PROTEIN", 280, 284], ["CoV2", "TEST", 7, 11], ["acute bronchial epithelial injury", "PROBLEM", 34, 67], ["Acute lung injury", "PROBLEM", 71, 88], ["severe COVID", "PROBLEM", 116, 128], ["markers", "TEST", 181, 188], ["epithelial damage IL", "TEST", 205, 225], ["TNF", "TEST", 230, 233], ["CCL2", "TEST", 240, 244], ["CoV2", "TEST", 280, 284], ["Figure 3C", "TEST", 316, 325], ["protein levels", "TEST", 336, 350], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["bronchial", "ANATOMY", 40, 49], ["epithelial", "ANATOMY_MODIFIER", 50, 60], ["injury", "OBSERVATION", 61, 67], ["Acute", "OBSERVATION_MODIFIER", 71, 76], ["lung", "ANATOMY", 77, 81], ["injury", "OBSERVATION", 82, 88], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["epithelial", "ANATOMY_MODIFIER", 205, 215], ["CCL2", "ANATOMY", 240, 244], ["markedly", "OBSERVATION_MODIFIER", 258, 266], ["increased", "OBSERVATION_MODIFIER", 267, 276], ["S1", "ANATOMY", 285, 287]]], ["CoV2-S1 also significantly up-regulated protein productions of CCL2 in BCi-210 NS 1.1 cells ( Figure 6A ).", [["BCi-210 NS 1.1 cells", "ANATOMY", 71, 91], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["CCL2", "GENE_OR_GENE_PRODUCT", 63, 67], ["BCi-210 NS 1.1 cells", "CELL", 71, 91], ["CoV2", "PROTEIN", 0, 4], ["S1", "PROTEIN", 5, 7], ["CCL2", "PROTEIN", 63, 67], ["BCi-210 NS 1.1 cells", "CELL_LINE", 71, 91], ["CoV2", "TEST", 0, 4], ["CCL2", "TEST", 63, 67], ["BCi", "TEST", 71, 74], ["S1", "ANATOMY", 5, 7]]], ["To further investigate if CoV2-S1 induces epithelial damage, we 211 stimulated differentiated primary bronchial epithelial cells (pBECs) cultured at air-liquid 212 interface (ALI) with CoV2-S1 (50 and 100ng).", [["epithelial", "ANATOMY", 42, 52], ["primary bronchial epithelial cells", "ANATOMY", 94, 128], ["pBECs", "ANATOMY", 130, 135], ["epithelial damage", "DISEASE", 42, 59], ["ALI", "DISEASE", 175, 178], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 26, 33], ["epithelial", "TISSUE", 42, 52], ["bronchial epithelial cells", "CELL", 102, 128], ["pBECs", "CELL", 130, 135], ["CoV2", "PROTEIN", 26, 30], ["S1", "PROTEIN", 31, 33], ["primary bronchial epithelial cells", "CELL_TYPE", 94, 128], ["pBECs", "CELL_TYPE", 130, 135], ["CoV2", "TEST", 26, 30], ["epithelial damage", "PROBLEM", 42, 59], ["primary bronchial epithelial cells", "PROBLEM", 94, 128], ["pBECs", "TEST", 130, 135], ["CoV2", "TEST", 185, 189], ["S1", "ANATOMY", 31, 33], ["epithelial", "ANATOMY_MODIFIER", 42, 52], ["damage", "OBSERVATION", 53, 59], ["bronchial epithelial cells", "OBSERVATION", 102, 128]]], ["Stimulation resulted in a significant reduction 213 8 in transepithelial electrical resistance (TEER; Figure 6B ), demonstrating an increased 214 epithelial permeability and tight junction disruption caused by CoV2-S1.", [["transepithelial", "ANATOMY", 57, 72], ["epithelial", "ANATOMY", 146, 156], ["tight junction", "ANATOMY", 174, 188], ["epithelial", "TISSUE", 146, 156], ["tight junction", "CELLULAR_COMPONENT", 174, 188], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 210, 217], ["CoV2", "PROTEIN", 210, 214], ["S1", "PROTEIN", 215, 217], ["Stimulation", "TREATMENT", 0, 11], ["a significant reduction", "PROBLEM", 24, 47], ["transepithelial electrical resistance", "TEST", 57, 94], ["an increased 214 epithelial permeability", "PROBLEM", 129, 169], ["tight junction disruption", "PROBLEM", 174, 199], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["reduction", "OBSERVATION_MODIFIER", 38, 47], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["214", "OBSERVATION_MODIFIER", 142, 145], ["epithelial permeability", "OBSERVATION", 146, 169], ["tight junction disruption", "OBSERVATION", 174, 199], ["S1", "ANATOMY", 215, 217]]], ["This is 215 accompanied with increased protein production of epithelial damage factors IL-1\u03b2, TNF , 216 and CCL2, in a CoV2-S1 dose-dependent manner ( Figure 6C -E).", [["epithelial", "ANATOMY", 61, 71], ["epithelial", "TISSUE", 61, 71], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 87, 92], ["TNF", "GENE_OR_GENE_PRODUCT", 94, 97], ["216", "GENE_OR_GENE_PRODUCT", 100, 103], ["CCL2", "GENE_OR_GENE_PRODUCT", 108, 112], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 119, 126], ["epithelial damage factors", "PROTEIN", 61, 86], ["IL-1\u03b2", "PROTEIN", 87, 92], ["TNF", "PROTEIN", 94, 97], ["CCL2", "PROTEIN", 108, 112], ["CoV2", "PROTEIN", 119, 123], ["increased protein production", "PROBLEM", 29, 57], ["epithelial damage factors", "PROBLEM", 61, 86], ["IL", "TEST", 87, 89], ["TNF", "TEST", 94, 97], ["CCL2", "TEST", 108, 112], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["protein production", "OBSERVATION", 39, 57], ["epithelial damage", "OBSERVATION", 61, 78]]], ["217 Immunofluorescent staining of a tight junction protein zonula occludens-1 (ZO-1) showed 218 strong localisation at the cell borders in the non-stimulated controls, whereas CoV2-S1 led to 219 partial disappearance of ZO-1 at the cell borders ( Figure 6F ).", [["cell borders", "ANATOMY", 123, 135], ["cell", "ANATOMY", 232, 236], ["zonula occludens-1", "GENE_OR_GENE_PRODUCT", 59, 77], ["ZO-1", "GENE_OR_GENE_PRODUCT", 79, 83], ["cell", "CELL", 123, 127], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 176, 183], ["ZO-1", "GENE_OR_GENE_PRODUCT", 220, 224], ["cell", "CELL", 232, 236], ["tight junction protein", "PROTEIN", 36, 58], ["zonula occludens-1", "PROTEIN", 59, 77], ["ZO-1", "PROTEIN", 79, 83], ["CoV2", "PROTEIN", 176, 180], ["S1", "PROTEIN", 181, 183], ["ZO", "PROTEIN", 220, 222], ["Immunofluorescent staining", "TEST", 4, 30], ["a tight junction protein zonula occludens", "TEST", 34, 75], ["ZO", "TEST", 79, 81], ["CoV2", "TEST", 176, 180], ["ZO", "TEST", 220, 222], ["cell borders", "OBSERVATION", 123, 135], ["non-stimulated controls", "OBSERVATION", 143, 166]]], ["This indicates that CoV2-S1 220 may also disrupt epithelial barrier function.", [["epithelial barrier", "ANATOMY", 49, 67], ["CoV2-S1 220", "CHEMICAL", 20, 31], ["CoV2-S1 220", "GENE_OR_GENE_PRODUCT", 20, 31], ["epithelial barrier", "TISSUE", 49, 67], ["CoV2", "TEST", 20, 24], ["epithelial", "ANATOMY_MODIFIER", 49, 59], ["barrier function", "OBSERVATION", 60, 76]]], ["221 222 CoV2-S1-antagonistic AP-6 and FDA-approved ER stress and MAP kinase inhibitors 223 ameliorate CoV2-mediated inflammatory response.", [["CoV2", "CHEMICAL", 102, 106], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 8, 15], ["AP-6", "GENE_OR_GENE_PRODUCT", 29, 33], ["FDA", "SIMPLE_CHEMICAL", 38, 41], ["ER", "GENE_OR_GENE_PRODUCT", 51, 53], ["MAP kinase inhibitors 223", "SIMPLE_CHEMICAL", 65, 90], ["CoV2", "SIMPLE_CHEMICAL", 102, 106], ["ER", "PROTEIN", 51, 53], ["CoV2", "PROTEIN", 102, 106], ["CoV2", "TEST", 8, 12], ["antagonistic AP", "TEST", 16, 31], ["FDA", "TEST", 38, 41], ["ER stress", "TEST", 51, 60], ["MAP kinase inhibitors", "TEST", 65, 86], ["CoV2", "TEST", 102, 106], ["inflammatory response", "PROBLEM", 116, 137], ["inflammatory", "OBSERVATION_MODIFIER", 116, 128]]], ["224CoV2-S1 induces markers of acute bronchial epithelial injury 206CoV2-S1 induced NF-\u03baB activation and subsequent production of pro-inflammatory 225 cytokines was dependent on ACE2 interaction and early ER-UPR and MAP kinase activities.", [["bronchial epithelial", "ANATOMY", 36, 56], ["224CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["bronchial epithelial", "TISSUE", 36, 56], ["206CoV2-S1", "GENE_OR_GENE_PRODUCT", 64, 74], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 83, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 177, 181], ["ER", "GENE_OR_GENE_PRODUCT", 204, 206], ["UPR", "GENE_OR_GENE_PRODUCT", 207, 210], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 215, 225], ["224CoV2", "PROTEIN", 0, 7], ["S1", "PROTEIN", 8, 10], ["NF-\u03baB", "PROTEIN", 83, 88], ["pro-inflammatory 225 cytokines", "PROTEIN", 129, 159], ["ACE2", "PROTEIN", 177, 181], ["ER", "PROTEIN", 204, 206], ["UPR", "PROTEIN", 207, 210], ["acute bronchial epithelial injury", "PROBLEM", 30, 63], ["NF", "PROBLEM", 83, 85], ["B activation", "PROBLEM", 87, 99], ["pro-inflammatory 225 cytokines", "PROBLEM", 129, 159], ["ACE2 interaction", "TREATMENT", 177, 193], ["MAP kinase activities", "TEST", 215, 236], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["bronchial", "ANATOMY", 36, 45], ["epithelial", "ANATOMY_MODIFIER", 46, 56], ["injury", "OBSERVATION", 57, 63]]], ["226CoV2-S1 induces markers of acute bronchial epithelial injury 206We therefore assessed whether CoV2-S1-mediated inflammation could be reduced by our 227CoV2-S1 induces markers of acute bronchial epithelial injury 206CoV2-S1 inhibitory peptide AP-6, or with existing FDA-approved pharmacological 228 inhibitors, that target ER stress (4-PBA) or MAP kinase (trametinib and ulixertinib).", [["bronchial epithelial", "ANATOMY", 36, 56], ["bronchial epithelial", "ANATOMY", 187, 207], ["inflammation", "DISEASE", 114, 126], ["AP-6", "CHEMICAL", 245, 249], ["4-PBA", "CHEMICAL", 336, 341], ["trametinib", "CHEMICAL", 358, 368], ["ulixertinib", "CHEMICAL", 373, 384], ["4-PBA", "CHEMICAL", 336, 341], ["trametinib", "CHEMICAL", 358, 368], ["ulixertinib", "CHEMICAL", 373, 384], ["226CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["bronchial epithelial", "TISSUE", 36, 56], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 97, 104], ["227CoV2-S1", "GENE_OR_GENE_PRODUCT", 151, 161], ["bronchial epithelial", "TISSUE", 187, 207], ["206CoV2-S1", "GENE_OR_GENE_PRODUCT", 215, 225], ["AP-6", "GENE_OR_GENE_PRODUCT", 245, 249], ["ER", "GENE_OR_GENE_PRODUCT", 325, 327], ["4-PBA", "SIMPLE_CHEMICAL", 336, 341], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 346, 356], ["trametinib", "SIMPLE_CHEMICAL", 358, 368], ["ulixertinib", "SIMPLE_CHEMICAL", 373, 384], ["226CoV2", "PROTEIN", 0, 7], ["S1", "PROTEIN", 8, 10], ["CoV2", "PROTEIN", 97, 101], ["227CoV2", "PROTEIN", 151, 158], ["S1", "PROTEIN", 159, 161], ["ER", "PROTEIN", 325, 327], ["MAP kinase", "PROTEIN", 346, 356], ["acute bronchial epithelial injury", "PROBLEM", 30, 63], ["CoV2", "TEST", 97, 101], ["S1-mediated inflammation", "PROBLEM", 102, 126], ["acute bronchial epithelial injury", "PROBLEM", 181, 214], ["AP", "TEST", 245, 247], ["pharmacological 228 inhibitors", "TREATMENT", 281, 311], ["ER stress", "TEST", 325, 334], ["MAP kinase (trametinib and ulixertinib)", "TREATMENT", 346, 385], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["bronchial", "ANATOMY", 36, 45], ["epithelial injury", "OBSERVATION", 46, 63], ["inflammation", "OBSERVATION", 114, 126], ["acute", "OBSERVATION_MODIFIER", 181, 186], ["bronchial", "ANATOMY", 187, 196], ["epithelial", "ANATOMY_MODIFIER", 197, 207], ["injury", "OBSERVATION", 208, 214]]], ["229 230 Treatment with AP-6 led to a significant decrease in CoV2-S1-mediated phosphorylation of 231 p65 ( Figure 2C ) and production of IL-6, IL-1\u03b2, TNF , but not CCL2 ( Figure 7A -D) in a 232 dose-dependent manner.", [["AP-6", "CHEMICAL", 23, 27], ["AP-6", "CHEMICAL", 23, 27], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 61, 68], ["p65", "GENE_OR_GENE_PRODUCT", 101, 104], ["Figure 2C", "GENE_OR_GENE_PRODUCT", 107, 116], ["IL-6", "GENE_OR_GENE_PRODUCT", 137, 141], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 143, 148], ["TNF", "GENE_OR_GENE_PRODUCT", 150, 153], ["CCL2", "GENE_OR_GENE_PRODUCT", 164, 168], ["Figure 7A -D", "SIMPLE_CHEMICAL", 171, 183], ["CoV2", "PROTEIN", 61, 65], ["S1", "PROTEIN", 66, 68], ["231 p65", "PROTEIN", 97, 104], ["Figure 2C", "PROTEIN", 107, 116], ["IL-6", "PROTEIN", 137, 141], ["IL", "PROTEIN", 143, 145], ["TNF", "PROTEIN", 150, 153], ["CCL2", "PROTEIN", 164, 168], ["Figure 7A -D", "PROTEIN", 171, 183], ["AP", "TEST", 23, 25], ["a significant decrease in CoV2", "PROBLEM", 35, 65], ["Figure 2C", "TEST", 107, 116], ["IL", "TEST", 137, 139], ["IL", "TEST", 143, 145], ["TNF", "TEST", 150, 153], ["CCL2", "TEST", 164, 168], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["decrease", "OBSERVATION_MODIFIER", 49, 57]]], ["Similarly, the ER stress inhibitor 4-PBA and both MAP kinase 233 inhibitors led to decreased activation of p65 ( Figure S3 ) and expression of these pro-234 inflammatory and epithelial injury cytokines ( Figure 7E -L).", [["epithelial", "ANATOMY", 174, 184], ["4-PBA", "CHEMICAL", 35, 40], ["4-PBA", "CHEMICAL", 35, 40], ["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["4-PBA", "SIMPLE_CHEMICAL", 35, 40], ["MAP kinase 233", "GENE_OR_GENE_PRODUCT", 50, 64], ["p65", "GENE_OR_GENE_PRODUCT", 107, 110], ["Figure S3", "GENE_OR_GENE_PRODUCT", 113, 122], ["pro-234", "GENE_OR_GENE_PRODUCT", 149, 156], ["epithelial", "TISSUE", 174, 184], ["ER", "PROTEIN", 15, 17], ["p65", "PROTEIN", 107, 110], ["Figure S3", "PROTEIN", 113, 122], ["pro-234 inflammatory and epithelial injury cytokines", "PROTEIN", 149, 201], ["Figure 7E -L", "PROTEIN", 204, 216], ["the ER stress inhibitor", "TREATMENT", 11, 34], ["both MAP kinase", "TEST", 45, 60], ["decreased activation of p65", "PROBLEM", 83, 110], ["these pro-234 inflammatory", "PROBLEM", 143, 169], ["epithelial injury cytokines", "PROBLEM", 174, 201], ["inflammatory", "OBSERVATION_MODIFIER", 157, 169], ["epithelial", "ANATOMY", 174, 184], ["injury", "OBSERVATION", 185, 191]]], ["These drugs had no effect on 235 non-CoV2-S1-stimulated controls ( Figure S4 ).", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 37, 44], ["CoV2", "PROTEIN", 37, 41], ["S1", "PROTEIN", 42, 44], ["These drugs", "TREATMENT", 0, 11]]], ["CoV2-S1-induced reduction in barrier 236 integrity and ZO-1 was prevented via treatment with AP-6 and FDA-approved inhibitors, 237 suggesting maintained barrier function ( Figure S5A -B).", [["barrier", "ANATOMY", 153, 160], ["CoV2-S1", "CHEMICAL", 0, 7], ["AP-6", "CHEMICAL", 93, 97], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["barrier 236", "MULTI-TISSUE_STRUCTURE", 29, 40], ["ZO-1", "GENE_OR_GENE_PRODUCT", 55, 59], ["AP-6", "SIMPLE_CHEMICAL", 93, 97], ["FDA", "SIMPLE_CHEMICAL", 102, 105], ["barrier", "TISSUE", 153, 160], ["CoV2", "PROTEIN", 0, 4], ["S1", "PROTEIN", 5, 7], ["CoV2", "TEST", 0, 4], ["induced reduction", "PROBLEM", 8, 25], ["ZO", "TEST", 55, 57], ["AP", "TEST", 93, 95], ["FDA", "TEST", 102, 105], ["inhibitors", "TREATMENT", 115, 125], ["S1", "ANATOMY", 5, 7], ["reduction", "OBSERVATION_MODIFIER", 16, 25]]], ["This strongly indicates that AP-6 238 could serve as a proof-of-concept therapeutic peptides against SARS-CoV-2 and also that ER 239 stress / MAP kinase inhibitors could be used to reduce inflammation and lung injury caused 240 by CoV2-S1.", [["lung", "ANATOMY", 205, 209], ["AP-6 238", "CHEMICAL", 29, 37], ["SARS", "DISEASE", 101, 105], ["inflammation", "DISEASE", 188, 200], ["lung injury", "DISEASE", 205, 216], ["AP-6 238", "CHEMICAL", 29, 37], ["AP-6 238", "GENE_OR_GENE_PRODUCT", 29, 37], ["SARS-CoV-2", "ORGANISM", 101, 111], ["ER 239", "GENE_OR_GENE_PRODUCT", 126, 132], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 142, 152], ["lung", "ORGAN", 205, 209], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 231, 238], ["SARS-CoV", "SPECIES", 101, 109], ["AP", "TEST", 29, 31], ["therapeutic peptides", "TREATMENT", 72, 92], ["SARS", "PROBLEM", 101, 105], ["CoV", "TEST", 106, 109], ["stress / MAP kinase inhibitors", "TREATMENT", 133, 163], ["inflammation", "PROBLEM", 188, 200], ["lung injury", "PROBLEM", 205, 216], ["inflammation", "OBSERVATION", 188, 200], ["lung", "ANATOMY", 205, 209], ["injury", "OBSERVATION", 210, 216], ["S1", "ANATOMY", 236, 238]]], ["241 242 Discussion 243CoV2-S1 induces markers of acute bronchial epithelial injury 206CoV Spike protein and host ACE2 interaction is a critical first step to viral replication and 244CoV2-S1 induces markers of acute bronchial epithelial injury 206diseases.", [["bronchial epithelial", "ANATOMY", 55, 75], ["bronchial epithelial", "ANATOMY", 216, 236], ["243CoV2-S1", "GENE_OR_GENE_PRODUCT", 19, 29], ["bronchial epithelial", "TISSUE", 55, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 113, 117], ["244CoV2-S1", "GENE_OR_GENE_PRODUCT", 180, 190], ["bronchial epithelial", "TISSUE", 216, 236], ["206CoV Spike protein", "PROTEIN", 83, 103], ["ACE2", "PROTEIN", 113, 117], ["244CoV2", "PROTEIN", 180, 187], ["acute bronchial epithelial injury", "PROBLEM", 49, 82], ["Spike protein", "PROBLEM", 90, 103], ["host ACE2 interaction", "PROBLEM", 108, 129], ["viral replication", "TEST", 158, 175], ["acute bronchial epithelial injury 206diseases", "PROBLEM", 210, 255], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["bronchial", "ANATOMY", 55, 64], ["epithelial", "ANATOMY_MODIFIER", 65, 75], ["injury", "OBSERVATION", 76, 82], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["bronchial", "ANATOMY", 216, 225], ["epithelial injury", "OBSERVATION", 226, 243]]], ["Here we demonstrate that CoV2 S1 subunit and RBD induces early ER-UPR and 245 MAP kinase activations, leading to hyper-inflammatory responses.", [["CoV2 S1", "GENE_OR_GENE_PRODUCT", 25, 32], ["RBD", "GENE_OR_GENE_PRODUCT", 45, 48], ["ER", "GENE_OR_GENE_PRODUCT", 63, 65], ["UPR", "GENE_OR_GENE_PRODUCT", 66, 69], ["245 MAP kinase", "GENE_OR_GENE_PRODUCT", 74, 88], ["CoV2 S1 subunit", "PROTEIN", 25, 40], ["RBD", "PROTEIN", 45, 48], ["ER", "PROTEIN", 63, 65], ["MAP kinase activations", "TEST", 78, 100], ["hyper-inflammatory responses", "PROBLEM", 113, 141], ["inflammatory", "OBSERVATION", 119, 131]]], ["Our results indicate that 9 this inflammatory storm, and downstream consequences are inhibited by S1-inhibitory 247 peptides and existing FDA-approved ER stress and MAP kinase inhibitors ( .", [["ER", "GENE_OR_GENE_PRODUCT", 151, 153], ["MAP kinase inhibitors", "SIMPLE_CHEMICAL", 165, 186], ["ER", "PROTEIN", 151, 153], ["this inflammatory storm", "PROBLEM", 28, 51], ["existing FDA", "TEST", 129, 141], ["ER stress", "TEST", 151, 160], ["MAP kinase inhibitors", "TREATMENT", 165, 186]]], ["SARS-CoV-2 S1 and RBD alone induced heightened levels of IL-252 6, TNF and IL-1\u03b2, and the productions of which were higher compared with CoV-S1.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 0, 13], ["RBD", "GENE_OR_GENE_PRODUCT", 18, 21], ["IL-252 6", "GENE_OR_GENE_PRODUCT", 57, 65], ["TNF", "GENE_OR_GENE_PRODUCT", 67, 70], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 75, 80], ["CoV-S1", "ORGANISM", 137, 143], ["RBD", "PROTEIN", 18, 21], ["IL", "PROTEIN", 57, 59], ["TNF", "PROTEIN", 67, 70], ["IL-1\u03b2", "PROTEIN", 75, 80], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["IL", "TEST", 57, 59], ["TNF", "TEST", 67, 70], ["IL", "TEST", 75, 77], ["S1", "ANATOMY", 141, 143]]], ["This 253 induction occurs in an ACE2-dependent manner, and the higher affinity of CoV2-S1 towards 254 ACE2 may have contributed to this elevated inflammatory response (Wang et al., 2020a) .", [["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 82, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["ACE2", "PROTEIN", 32, 36], ["CoV2", "PROTEIN", 82, 86], ["S1", "PROTEIN", 87, 89], ["254 ACE2", "PROTEIN", 98, 106], ["this elevated inflammatory response", "PROBLEM", 131, 166], ["inflammatory", "OBSERVATION_MODIFIER", 145, 157]]], ["255CoV2-S1 induces markers of acute bronchial epithelial injury 206CoV2-S1-mediated NF-\u03baB activation is also dependent on common TLR adaptor proteins 256CoV2-S1 induces markers of acute bronchial epithelial injury 206MyD88 and TRIF, although we could not detect interactions between ACE2 and these 257 adaptor proteins.", [["bronchial epithelial", "ANATOMY", 36, 56], ["bronchial epithelial", "ANATOMY", 186, 206], ["255CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["bronchial epithelial", "TISSUE", 36, 56], ["206CoV2-S1", "GENE_OR_GENE_PRODUCT", 64, 74], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 84, 89], ["TLR", "GENE_OR_GENE_PRODUCT", 129, 132], ["256CoV2-S1", "GENE_OR_GENE_PRODUCT", 150, 160], ["bronchial epithelial", "TISSUE", 186, 206], ["TRIF", "GENE_OR_GENE_PRODUCT", 227, 231], ["ACE2", "GENE_OR_GENE_PRODUCT", 283, 287], ["255CoV2", "PROTEIN", 0, 7], ["S1", "PROTEIN", 8, 10], ["NF-\u03baB", "PROTEIN", 84, 89], ["TLR adaptor proteins", "PROTEIN", 129, 149], ["256CoV2", "PROTEIN", 150, 157], ["S1", "PROTEIN", 158, 160], ["TRIF", "PROTEIN", 227, 231], ["ACE2", "PROTEIN", 283, 287], ["257 adaptor proteins", "PROTEIN", 298, 318], ["acute bronchial epithelial injury", "PROBLEM", 30, 63], ["acute bronchial epithelial injury", "PROBLEM", 180, 213], ["TRIF", "TREATMENT", 227, 231], ["ACE2", "TEST", 283, 287], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["bronchial", "ANATOMY", 36, 45], ["epithelial", "ANATOMY_MODIFIER", 46, 56], ["injury", "OBSERVATION", 57, 63], ["acute", "OBSERVATION_MODIFIER", 180, 185], ["bronchial", "ANATOMY", 186, 195], ["epithelial", "ANATOMY_MODIFIER", 196, 206]]], ["It is possible that CoV2-S1-ACE2 interaction triggers MyD88 and TRIF 258 activations via other signalling factors that then result in NF-\u03baB activation.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 20, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["MyD88", "GENE_OR_GENE_PRODUCT", 54, 59], ["TRIF 258", "GENE_OR_GENE_PRODUCT", 64, 72], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["CoV2", "PROTEIN", 20, 24], ["S1", "PROTEIN", 25, 27], ["ACE2", "PROTEIN", 28, 32], ["MyD88", "PROTEIN", 54, 59], ["TRIF", "PROTEIN", 64, 68], ["signalling factors", "PROTEIN", 95, 113], ["NF-\u03baB", "PROTEIN", 134, 139], ["CoV2", "TEST", 20, 24], ["MyD88", "TEST", 54, 59], ["other signalling factors", "PROBLEM", 89, 113]]], ["259260Our data strong indicates that inflammation could be triggered by CoV2-S1 even before viral 261 replication occurs or in the absence of viral replication.", [["259260", "CHEMICAL", 0, 6], ["inflammation", "DISEASE", 37, 49], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 72, 79], ["CoV2", "PROTEIN", 72, 76], ["S1", "PROTEIN", 77, 79], ["259260", "SPECIES", 0, 6], ["Our data", "TEST", 6, 14], ["inflammation", "PROBLEM", 37, 49], ["viral 261 replication", "PROBLEM", 92, 113], ["viral replication", "PROBLEM", 142, 159], ["inflammation", "OBSERVATION", 37, 49], ["viral replication", "OBSERVATION", 142, 159]]], ["As CoV2-S1 is present throughout 262 viral replication cycles and infection, our data demonstrate that spike proteins are likely to be 263 a major contributor to inflammation.", [["infection", "DISEASE", 66, 75], ["inflammation", "DISEASE", 162, 174], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 3, 10], ["CoV2", "PROTEIN", 3, 7], ["S1", "PROTEIN", 8, 10], ["spike proteins", "PROTEIN", 103, 117], ["viral replication cycles", "TREATMENT", 37, 61], ["infection", "PROBLEM", 66, 75], ["our data", "TEST", 77, 85], ["spike proteins", "PROBLEM", 103, 117], ["inflammation", "PROBLEM", 162, 174], ["S1", "ANATOMY", 8, 10], ["viral replication", "OBSERVATION", 37, 54], ["infection", "OBSERVATION", 66, 75], ["inflammation", "OBSERVATION", 162, 174]]], ["The constant presence of S1 is consistent with the high 264 viral load and a long virus-shedding period observed in patients with severe COVID-19 (Liu 265 et al., 2020).", [["patients", "ORGANISM", 116, 124], ["S1", "PROTEIN", 25, 27], ["patients", "SPECIES", 116, 124], ["the high 264 viral load", "PROBLEM", 47, 70], ["a long virus-shedding period", "PROBLEM", 75, 103], ["severe COVID", "PROBLEM", 130, 142], ["S1", "ANATOMY", 25, 27], ["consistent with", "UNCERTAINTY", 31, 46], ["viral load", "OBSERVATION", 60, 70], ["severe", "OBSERVATION_MODIFIER", 130, 136]]], ["Furthermore, CoV2 spike protein has an estimated half-life of 30 hours in 266 mammalian systems (in silico analysis by ExPASy ProtParam) and consists of amino acid 267 residues with long half-lives (leucine (8%), threonine (7.6%), valine (7.6%), alanine (6.2%), 268 glycine (6.4%), and proline (4.6%)).", [["amino acid", "CHEMICAL", 153, 163], ["leucine", "CHEMICAL", 199, 206], ["threonine", "CHEMICAL", 213, 222], ["valine", "CHEMICAL", 231, 237], ["alanine", "CHEMICAL", 246, 253], ["glycine", "CHEMICAL", 266, 273], ["proline", "CHEMICAL", 286, 293], ["amino acid", "CHEMICAL", 153, 163], ["leucine", "CHEMICAL", 199, 206], ["threonine", "CHEMICAL", 213, 222], ["valine", "CHEMICAL", 231, 237], ["alanine", "CHEMICAL", 246, 253], ["glycine", "CHEMICAL", 266, 273], ["proline", "CHEMICAL", 286, 293], ["CoV2", "GENE_OR_GENE_PRODUCT", 13, 17], ["amino acid", "AMINO_ACID", 153, 163], ["leucine", "AMINO_ACID", 199, 206], ["threonine", "AMINO_ACID", 213, 222], ["valine", "AMINO_ACID", 231, 237], ["alanine", "AMINO_ACID", 246, 253], ["glycine", "AMINO_ACID", 266, 273], ["proline", "AMINO_ACID", 286, 293], ["CoV2 spike protein", "PROTEIN", 13, 31], ["CoV2 spike protein", "TEST", 13, 31], ["silico analysis", "TEST", 100, 115], ["amino acid", "TEST", 153, 163], ["threonine", "TEST", 213, 222], ["valine", "TREATMENT", 231, 237], ["alanine", "TEST", 246, 253], ["glycine", "TREATMENT", 266, 273], ["proline", "TREATMENT", 286, 293]]], ["This may suggest persistent presence of CoV2 spike 269 protein from live and dead viruses that plays major role in triggering the inflammatory storm 270 in COVID-19.", [["CoV2 spike 269", "GENE_OR_GENE_PRODUCT", 40, 54], ["CoV2 spike 269 protein", "PROTEIN", 40, 62], ["CoV2 spike", "PROBLEM", 40, 50], ["dead viruses", "PROBLEM", 77, 89], ["COVID", "TEST", 156, 161], ["may suggest", "UNCERTAINTY", 5, 16], ["persistent", "OBSERVATION_MODIFIER", 17, 27], ["viruses", "OBSERVATION", 82, 89], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142]]], ["Importantly, our antagonistic peptide inhibited this binding event and reduced 271 the production of pro-inflammatory cytokines.", [["pro-inflammatory cytokines", "PROTEIN", 101, 127], ["pro-inflammatory cytokines", "PROBLEM", 101, 127], ["pro-inflammatory cytokines", "OBSERVATION", 101, 127]]], ["While peptide sequence optimisations are 272 required to further increase effectiveness and stability, this highlights the potentials of using 273 S1 antagonistic peptides as neutralising molecules against SARS-CoV-2. that halts protein translation ; ATF6 that facilitates protein folding as 281 well as NF-\u03baB activation (Shen et al., 2005) ; and IRE1 promotes NF-\u03baB phosphorylation 282 and inflammation (Urano et al., 2000) .", [["inflammation", "DISEASE", 391, 403], ["SARS-CoV-2", "ORGANISM", 206, 216], ["ATF6", "GENE_OR_GENE_PRODUCT", 251, 255], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 304, 309], ["IRE1", "GENE_OR_GENE_PRODUCT", 347, 351], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 361, 366], ["ATF6", "PROTEIN", 251, 255], ["NF-\u03baB", "PROTEIN", 304, 309], ["IRE1", "PROTEIN", 347, 351], ["NF-\u03baB", "PROTEIN", 361, 366], ["SARS-CoV", "SPECIES", 206, 214], ["peptide sequence optimisations", "TEST", 6, 36], ["S1 antagonistic peptides", "TREATMENT", 147, 171], ["neutralising molecules", "TEST", 175, 197], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214], ["halts protein translation", "TREATMENT", 223, 248], ["inflammation", "PROBLEM", 391, 403], ["stability", "OBSERVATION_MODIFIER", 92, 101]]], ["Here we showed that both ER-UPR and MAP kinases 283 modulate CoV2-S1-induced NF-\u03baB activations.", [["ER", "GENE_OR_GENE_PRODUCT", 25, 27], ["UPR", "GENE_OR_GENE_PRODUCT", 28, 31], ["MAP kinases 283", "GENE_OR_GENE_PRODUCT", 36, 51], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 61, 68], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 77, 82], ["ER", "PROTEIN", 25, 27], ["UPR", "PROTEIN", 28, 31], ["MAP kinases 283", "PROTEIN", 36, 51], ["CoV2", "PROTEIN", 61, 65], ["S1", "PROTEIN", 66, 68], ["NF-\u03baB", "PROTEIN", 77, 82], ["UPR", "TEST", 28, 31], ["MAP kinases", "TEST", 36, 47], ["modulate", "TEST", 52, 60], ["CoV2", "TEST", 61, 65], ["S1", "TEST", 66, 68]]], ["284 285 CoV2-S1 caused early activation of ER-UPR IRE1 and PERK-Erk, leading to MAP kinases 286 phosphorylations, which then facilitated NF-\u03baB-mediated production of pro-inflammatory 287 cytokines.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 8, 15], ["ER", "GENE_OR_GENE_PRODUCT", 43, 45], ["IRE1", "GENE_OR_GENE_PRODUCT", 50, 54], ["PERK", "GENE_OR_GENE_PRODUCT", 59, 63], ["Erk", "GENE_OR_GENE_PRODUCT", 64, 67], ["MAP kinases 286", "GENE_OR_GENE_PRODUCT", 80, 95], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 137, 142], ["ER", "PROTEIN", 43, 45], ["UPR", "PROTEIN", 46, 49], ["IRE1", "PROTEIN", 50, 54], ["PERK", "PROTEIN", 59, 63], ["Erk", "PROTEIN", 64, 67], ["MAP kinases", "PROTEIN", 80, 91], ["NF-\u03baB", "PROTEIN", 137, 142], ["pro-inflammatory 287 cytokines", "PROTEIN", 166, 196], ["CoV2", "TEST", 8, 12], ["UPR IRE1", "TEST", 46, 54], ["PERK-Erk", "TEST", 59, 67], ["MAP kinases", "TEST", 80, 91], ["phosphorylations", "TEST", 96, 112], ["NF", "TEST", 137, 139], ["pro-inflammatory 287 cytokines", "PROBLEM", 166, 196]]], ["Although IRE1 activation occurred earlier than other ER-UPR and MAP kinase 288 factors, it is likely that CoV2-S1 can promote NF-\u03baB activation via ER-UPR and MAP comparison of IL-6, IL-1\u03b2 and TNF by CoV2-S1 and CoV-S1.", [["IRE1", "GENE_OR_GENE_PRODUCT", 9, 13], ["ER", "GENE_OR_GENE_PRODUCT", 53, 55], ["MAP kinase 288 factors", "GENE_OR_GENE_PRODUCT", 64, 86], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 106, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 126, 131], ["ER", "GENE_OR_GENE_PRODUCT", 147, 149], ["UPR", "GENE_OR_GENE_PRODUCT", 150, 153], ["IL-6", "GENE_OR_GENE_PRODUCT", 176, 180], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 182, 187], ["TNF", "GENE_OR_GENE_PRODUCT", 192, 195], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 199, 206], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 211, 217], ["IRE1", "PROTEIN", 9, 13], ["ER", "PROTEIN", 53, 55], ["UPR", "PROTEIN", 56, 59], ["MAP kinase 288 factors", "PROTEIN", 64, 86], ["CoV2", "PROTEIN", 106, 110], ["NF-\u03baB", "PROTEIN", 126, 131], ["ER", "PROTEIN", 147, 149], ["IL-6", "PROTEIN", 176, 180], ["IL-1\u03b2", "PROTEIN", 182, 187], ["TNF", "PROTEIN", 192, 195], ["CoV2", "PROTEIN", 199, 203], ["S1", "PROTEIN", 204, 206], ["CoV", "PROTEIN", 211, 214], ["IRE1 activation", "PROBLEM", 9, 24], ["MAP kinase", "TEST", 64, 74], ["CoV2", "TEST", 106, 110], ["NF", "TEST", 126, 128], ["IL", "TEST", 176, 178], ["IL", "TEST", 182, 184], ["TNF", "TEST", 192, 195], ["CoV2", "TEST", 199, 203], ["CoV", "TEST", 211, 214], ["TNF", "ANATOMY", 192, 195], ["S1", "ANATOMY", 204, 206], ["CoV", "ANATOMY", 211, 214], ["S1", "ANATOMY", 215, 217]]], ["G. Immunoblot (left) and 356 densitometry (right) of induction kinetics of phospho(p)-p65 at 2, 6, 12, and 24hr post 357 stimulation by CoV2-S1 and CoV-S1 compared with CoV2-S1 stimulated but untreated CoV2-S1/-RBD or CoV-2-S1/-RBD stimulation.", [["phospho", "CHEMICAL", 75, 82], ["phospho(p)-p65", "GENE_OR_GENE_PRODUCT", 75, 89], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 136, 143], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 148, 154], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 169, 176], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 202, 209], ["CoV", "ORGANISM", 218, 221], ["phospho(p)-p65", "PROTEIN", 75, 89], ["CoV2", "PROTEIN", 136, 140], ["CoV", "PROTEIN", 148, 151], ["CoV2", "PROTEIN", 169, 173], ["CoV2", "PROTEIN", 202, 206], ["S1", "PROTEIN", 207, 209], ["RBD", "PROTEIN", 211, 214], ["CoV-2", "PROTEIN", 218, 223], ["S1", "PROTEIN", 224, 226], ["RBD", "PROTEIN", 228, 231], ["356 densitometry", "TEST", 25, 41], ["phospho", "TEST", 75, 82], ["stimulation", "TEST", 121, 132], ["CoV2", "TEST", 136, 140], ["CoV", "TEST", 148, 151], ["CoV2", "TEST", 169, 173], ["CoV2", "TEST", 202, 206], ["RBD", "PROBLEM", 211, 214], ["CoV", "TEST", 218, 221], ["left", "ANATOMY_MODIFIER", 15, 19], ["right", "ANATOMY_MODIFIER", 43, 48], ["S1", "ANATOMY", 141, 143], ["S1", "ANATOMY", 152, 154]]], ["B. Schematic representation of CoV2-S1 366 protein and peptide design coverage.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 31, 38], ["CoV2", "PROTEIN", 31, 35], ["S1 366 protein", "PROTEIN", 36, 50], ["CoV2", "TEST", 31, 35], ["peptide design coverage", "TREATMENT", 55, 78]]], ["C. Immunoblot of p-p65 and p65 24hrs post CoV2-S1 367 stimulation and CoV2-S1 antagonistic peptides (AP-1 -6) compared with untreated control 368 (U).", [["AP-1 -6", "CHEMICAL", 101, 108], ["p-p65", "GENE_OR_GENE_PRODUCT", 17, 22], ["p65", "GENE_OR_GENE_PRODUCT", 27, 30], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 70, 77], ["p65", "PROTEIN", 19, 22], ["p65", "PROTEIN", 27, 30], ["CoV2", "PROTEIN", 42, 46], ["p", "TEST", 17, 18], ["CoV2", "TEST", 42, 46], ["S1", "TEST", 47, 49], ["stimulation", "TEST", 54, 65], ["CoV2", "TEST", 70, 74], ["S1 antagonistic peptides", "TEST", 75, 99], ["AP", "TEST", 101, 103]]], ["D. Immunoblot (left) and densitometry (right) of p-p65 and p65 at 24hrs post CoV2-S1 369 and AP-6 (10, 25\u00b5M) treatment compared with CoV2-S1 stimulated but untreated control 370 (U).", [["CoV2-S1 369", "CHEMICAL", 77, 88], ["AP-6", "CHEMICAL", 93, 97], ["AP-6", "CHEMICAL", 93, 97], ["p-p65", "GENE_OR_GENE_PRODUCT", 49, 54], ["p65", "GENE_OR_GENE_PRODUCT", 59, 62], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 133, 140], ["p65", "PROTEIN", 51, 54], ["p65", "PROTEIN", 59, 62], ["CoV2", "PROTEIN", 133, 137], ["densitometry", "TEST", 25, 37], ["p", "TEST", 49, 50], ["CoV2", "TEST", 77, 81], ["S1", "TEST", 82, 84], ["AP", "TEST", 93, 95], ["treatment", "TREATMENT", 109, 118], ["CoV2", "TEST", 133, 137], ["left", "ANATOMY_MODIFIER", 15, 19], ["right", "ANATOMY_MODIFIER", 39, 44]]], ["E. Immunoblot of ACE2 and His following immunoprecipitation using anti-His antibody 371 30 minutes post CoV2-S1/AP-6 treatment.", [["AP-6", "CHEMICAL", 112, 116], ["His", "CHEMICAL", 26, 29], ["His", "CHEMICAL", 71, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["AP-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["ACE2", "PROTEIN", 17, 21], ["His", "PROTEIN", 26, 29], ["anti-His antibody 371", "PROTEIN", 66, 87], ["AP", "PROTEIN", 112, 114], ["ACE2", "TEST", 17, 21], ["immunoprecipitation", "TEST", 40, 59], ["anti", "TEST", 66, 70], ["His antibody", "TEST", 71, 83], ["CoV2", "TEST", 104, 108], ["AP", "TEST", 112, 114], ["treatment", "TREATMENT", 117, 126]]], ["Immunoblot of His and ACE2 following 372 Erk, p-Jnk and Jnk at 2, 6, 12, and 24hr post stimulation by CoV2-S1 and CoV-S1 compared 390 with untreated control (U).", [["His", "GENE_OR_GENE_PRODUCT", 14, 17], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["Erk", "GENE_OR_GENE_PRODUCT", 41, 44], ["p-Jnk", "GENE_OR_GENE_PRODUCT", 46, 51], ["Jnk", "GENE_OR_GENE_PRODUCT", 56, 59], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 102, 109], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 114, 120], ["His", "PROTEIN", 14, 17], ["ACE2", "PROTEIN", 22, 26], ["Erk", "PROTEIN", 41, 44], ["p", "PROTEIN", 46, 47], ["Jnk", "PROTEIN", 48, 51], ["Jnk", "PROTEIN", 56, 59], ["CoV2", "PROTEIN", 102, 106], ["CoV", "PROTEIN", 114, 117], ["Immunoblot", "TEST", 0, 10], ["ACE2", "TEST", 22, 26], ["Erk", "TEST", 41, 44], ["p", "TEST", 46, 47], ["Jnk", "TEST", 48, 51], ["Jnk", "TEST", 56, 59], ["stimulation", "TEST", 87, 98], ["CoV2", "TEST", 102, 106], ["CoV", "TEST", 114, 117], ["S1", "ANATOMY", 107, 109], ["S1", "ANATOMY", 118, 120]]], ["B. Immunoblots of p-p65, p65, p-p38, p38, p-Erk, Erk, p-Jnk and 391260Jnk 24hrs post CoV2-S1 or -RBD stimulation in p38, Erk or Jnk silenced BCi-NS1.1.", [["p-p65", "GENE_OR_GENE_PRODUCT", 18, 23], ["p65", "GENE_OR_GENE_PRODUCT", 25, 28], ["p-p38", "GENE_OR_GENE_PRODUCT", 30, 35], ["p38", "GENE_OR_GENE_PRODUCT", 37, 40], ["p-Erk", "GENE_OR_GENE_PRODUCT", 42, 47], ["Erk", "GENE_OR_GENE_PRODUCT", 49, 52], ["p-Jnk", "GENE_OR_GENE_PRODUCT", 54, 59], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 85, 92], ["p38", "GENE_OR_GENE_PRODUCT", 116, 119], ["Erk", "GENE_OR_GENE_PRODUCT", 121, 124], ["Jnk", "GENE_OR_GENE_PRODUCT", 128, 131], ["BCi-NS1", "GENE_OR_GENE_PRODUCT", 141, 148], ["p", "PROTEIN", 18, 19], ["p65", "PROTEIN", 20, 23], ["p65", "PROTEIN", 25, 28], ["p", "PROTEIN", 30, 31], ["p38", "PROTEIN", 32, 35], ["p38", "PROTEIN", 37, 40], ["p", "PROTEIN", 42, 43], ["Erk", "PROTEIN", 44, 47], ["Erk", "PROTEIN", 49, 52], ["p", "PROTEIN", 54, 55], ["Jnk", "PROTEIN", 56, 59], ["Jnk", "PROTEIN", 70, 73], ["CoV2", "PROTEIN", 85, 89], ["S1", "PROTEIN", 90, 92], ["RBD", "PROTEIN", 97, 100], ["p38", "PROTEIN", 116, 119], ["Erk", "PROTEIN", 121, 124], ["Jnk", "PROTEIN", 128, 131], ["BCi", "PROTEIN", 141, 144], ["NS1", "PROTEIN", 145, 148], ["B. Immunoblots", "TEST", 0, 14], ["p", "TEST", 18, 19], ["p65", "TEST", 25, 28], ["p", "TEST", 30, 31], ["p38", "TEST", 32, 35], ["p38", "TEST", 37, 40], ["p", "TEST", 42, 43], ["Erk", "TEST", 44, 47], ["Erk", "TEST", 49, 52], ["p", "TEST", 54, 55], ["Jnk", "TEST", 56, 59], ["Jnk", "TEST", 70, 73], ["CoV2", "TEST", 85, 89], ["RBD stimulation", "TEST", 97, 112], ["p38", "TEST", 116, 119], ["Erk", "TEST", 121, 124], ["Jnk silenced BCi", "TEST", 128, 144], ["NS1", "PROBLEM", 145, 148]]], ["392260Immunoblots shown are representative of three independent experiments and \u03b2 -actin was 393 detected to show equal protein input (lower panel). * P \u2264 0.05 versus untreated control.", [["\u03b2 -actin", "GENE_OR_GENE_PRODUCT", 80, 88], ["\u03b2 -actin", "PROTEIN", 80, 88], ["Immunoblots", "TEST", 6, 17]]], ["CoV2-S1 induces rapid ER-UPR that activate NF-\u03baB via ER-MAP kinase 396crosstalk.", [["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["ER", "GENE_OR_GENE_PRODUCT", 22, 24], ["UPR", "GENE_OR_GENE_PRODUCT", 25, 28], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 43, 48], ["ER-MAP kinase 396", "GENE_OR_GENE_PRODUCT", 53, 70], ["CoV2", "PROTEIN", 0, 4], ["S1", "PROTEIN", 5, 7], ["ER", "PROTEIN", 22, 24], ["UPR", "PROTEIN", 25, 28], ["NF-\u03baB", "PROTEIN", 43, 48], ["ER", "PROTEIN", 53, 55], ["CoV2", "TEST", 0, 4], ["NF", "TEST", 43, 45], ["MAP kinase", "TEST", 56, 66], ["S1", "ANATOMY", 5, 7]]], ["Immunoblot (top) and densitometry (bottom) of induction kinetics of p-IRE1 , IRE1 , p-398 ATF6, ATF6, p-PERK and PERK at 2, 6, 12, and 24hr post stimulation by CoV2-S1 and 399crosstalk.", [["p-IRE1", "GENE_OR_GENE_PRODUCT", 68, 74], ["IRE1", "GENE_OR_GENE_PRODUCT", 77, 81], ["ATF6", "GENE_OR_GENE_PRODUCT", 90, 94], ["ATF6", "GENE_OR_GENE_PRODUCT", 96, 100], ["p-PERK", "GENE_OR_GENE_PRODUCT", 102, 108], ["PERK", "GENE_OR_GENE_PRODUCT", 113, 117], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 160, 167], ["IRE1", "PROTEIN", 70, 74], ["IRE1", "PROTEIN", 77, 81], ["p-398", "PROTEIN", 84, 89], ["ATF6", "PROTEIN", 90, 94], ["ATF6", "PROTEIN", 96, 100], ["p", "PROTEIN", 102, 103], ["PERK", "PROTEIN", 104, 108], ["PERK", "PROTEIN", 113, 117], ["CoV2", "PROTEIN", 160, 164], ["Immunoblot", "TEST", 0, 10], ["densitometry", "TEST", 21, 33], ["induction kinetics", "TEST", 46, 64], ["IRE1", "TEST", 77, 81], ["ATF6", "TEST", 90, 94], ["ATF6", "TEST", 96, 100], ["PERK", "TEST", 113, 117], ["S1", "ANATOMY", 165, 167]]], ["397CoV-S1 compared with untreated control (U).", [["397CoV-S1", "GENE_OR_GENE_PRODUCT", 0, 9], ["397CoV", "PROTEIN", 0, 6]]], ["B. Immunoblots of p-p65, p65, p-p38, p38, p-400 Erk, Erk, p-Jnk, Jnk, IRE1 and PERK 24hrs post CoV2-S1 or -RBD stimulation in PERK 401 and IRE1 silenced BCi-NS1.1.", [["p-p65", "GENE_OR_GENE_PRODUCT", 18, 23], ["p65", "GENE_OR_GENE_PRODUCT", 25, 28], ["p-p38", "GENE_OR_GENE_PRODUCT", 30, 35], ["p38", "GENE_OR_GENE_PRODUCT", 37, 40], ["p-400", "GENE_OR_GENE_PRODUCT", 42, 47], ["Erk", "GENE_OR_GENE_PRODUCT", 48, 51], ["Erk", "GENE_OR_GENE_PRODUCT", 53, 56], ["p-Jnk", "GENE_OR_GENE_PRODUCT", 58, 63], ["Jnk", "GENE_OR_GENE_PRODUCT", 65, 68], ["IRE1", "GENE_OR_GENE_PRODUCT", 70, 74], ["PERK", "GENE_OR_GENE_PRODUCT", 79, 83], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 95, 102], ["PERK 401", "GENE_OR_GENE_PRODUCT", 126, 134], ["IRE1", "GENE_OR_GENE_PRODUCT", 139, 143], ["BCi-NS1", "GENE_OR_GENE_PRODUCT", 153, 160], ["p", "PROTEIN", 18, 19], ["p65", "PROTEIN", 20, 23], ["p65", "PROTEIN", 25, 28], ["p", "PROTEIN", 30, 31], ["p38", "PROTEIN", 32, 35], ["p38", "PROTEIN", 37, 40], ["Erk", "PROTEIN", 48, 51], ["Erk", "PROTEIN", 53, 56], ["p", "PROTEIN", 58, 59], ["Jnk", "PROTEIN", 60, 63], ["Jnk", "PROTEIN", 65, 68], ["IRE1", "PROTEIN", 70, 74], ["PERK", "PROTEIN", 79, 83], ["CoV2", "PROTEIN", 95, 99], ["S1", "PROTEIN", 100, 102], ["RBD", "PROTEIN", 107, 110], ["PERK 401", "PROTEIN", 126, 134], ["IRE1", "PROTEIN", 139, 143], ["BCi", "PROTEIN", 153, 156], ["NS1", "PROTEIN", 157, 160], ["B. Immunoblots", "TEST", 0, 14], ["p", "TEST", 18, 19], ["p65", "TEST", 25, 28], ["p", "TEST", 30, 31], ["p38", "TEST", 32, 35], ["p38", "TEST", 37, 40], ["p", "TEST", 42, 43], ["Erk", "TEST", 48, 51], ["Erk", "TEST", 53, 56], ["p", "TEST", 58, 59], ["Jnk", "TEST", 60, 63], ["Jnk", "TEST", 65, 68], ["IRE1", "TEST", 70, 74], ["PERK", "TEST", 79, 83], ["CoV2", "TEST", 95, 99], ["RBD stimulation", "TEST", 107, 122], ["PERK", "TEST", 126, 130], ["IRE1 silenced BCi", "TEST", 139, 156], ["NS1", "PROBLEM", 157, 160]]], ["C. Immunoblots of p-PERK and p-IRE1 post CoV2-S1 or 402 were air-lifted by removing apical media and changing basal media into ALI final media (as 465 described above for ALI initial media but with 0.5ng/mL of rhEGF).", [["ALI", "DISEASE", 127, 130], ["ALI", "DISEASE", 171, 174], ["p-PERK", "GENE_OR_GENE_PRODUCT", 18, 24], ["p-IRE1", "GENE_OR_GENE_PRODUCT", 29, 35], ["rhEGF", "GENE_OR_GENE_PRODUCT", 210, 215], ["p-PERK", "PROTEIN", 18, 24], ["p", "PROTEIN", 29, 30], ["IRE1", "PROTEIN", 31, 35], ["CoV2", "PROTEIN", 41, 45], ["rhEGF", "PROTEIN", 210, 215], ["C. Immunoblots", "TEST", 0, 14], ["PERK", "TEST", 20, 24], ["p", "TEST", 29, 30], ["CoV2", "TEST", 41, 45], ["apical media", "TREATMENT", 84, 96], ["ALI initial media", "TREATMENT", 171, 188], ["apical", "ANATOMY_MODIFIER", 84, 90]]], ["Transepithelial 466 resistance (TEER) was measured every seven days using a EVOM2 Epithelial Voltohmmeter 467 (World Precision Instruments, USA).", [["Epithelial", "ANATOMY", 82, 92]]], ["The basal media was replaced with fresh ALI final 468 media every second day. pBECs were cultured at ALI for 25 days and then used for 469 experiments.", [["pBECs", "ANATOMY", 78, 83], ["ALI", "DISEASE", 101, 104], ["pBECs", "CELL", 78, 83], ["pBECs", "CELL_TYPE", 78, 83], ["The basal media", "TREATMENT", 0, 15], ["pBECs", "TEST", 78, 83], ["basal", "ANATOMY_MODIFIER", 4, 9], ["media", "ANATOMY", 10, 15], ["fresh ALI", "OBSERVATION", 34, 43]]], ["All cells were cultured and maintained at 37\u00b0C / 5% CO 2 .", [["cells", "ANATOMY", 4, 9], ["CO 2", "CHEMICAL", 52, 56], ["cells", "CELL", 4, 9], ["All cells", "TEST", 0, 9]]], ["470 471Method details 472Spike protein subunit 1 (S1) and receptor binding domain (RBD) stimulation 473Method details 472For cells cultured in submerged and at ALI conditions, his-tagged S1 and RBD (Sino 474 Biological Inc.) was diluted in BEBM minimal media (Lonza, Switzerland) and added to the 475 cells.", [["cells", "ANATOMY", 125, 130], ["cells", "ANATOMY", 301, 306], ["472Spike protein subunit 1", "GENE_OR_GENE_PRODUCT", 22, 48], ["S1", "GENE_OR_GENE_PRODUCT", 50, 52], ["cells", "CELL", 125, 130], ["cells", "CELL", 301, 306], ["472Spike protein subunit 1", "PROTEIN", 22, 48], ["S1", "PROTEIN", 50, 52], ["receptor binding domain", "PROTEIN", 58, 81], ["RBD", "PROTEIN", 83, 86], ["S1", "PROTEIN", 187, 189], ["RBD", "PROTEIN", 194, 197], ["475 cells", "CELL_LINE", 297, 306], ["Method details", "TEST", 7, 21], ["protein subunit", "TEST", 31, 46], ["receptor binding domain (RBD) stimulation", "TREATMENT", 58, 99], ["Method details", "TEST", 103, 117], ["cells cultured", "TEST", 125, 139], ["S1", "ANATOMY", 187, 189], ["RBD", "ANATOMY", 194, 197]]], ["For pBECs at ALI, S1 and RBD was added to the apical side.", [["pBECs", "ANATOMY", 4, 9], ["apical", "ANATOMY", 46, 52], ["ALI", "DISEASE", 13, 16], ["pBECs", "CANCER", 4, 9], ["pBECs", "CELL_TYPE", 4, 9], ["S1", "PROTEIN", 18, 20], ["RBD", "PROTEIN", 25, 28], ["pBECs at ALI", "PROBLEM", 4, 16], ["RBD", "PROBLEM", 25, 28], ["ALI", "ANATOMY", 13, 16], ["S1", "ANATOMY", 18, 20], ["RBD", "OBSERVATION", 25, 28], ["apical", "ANATOMY_MODIFIER", 46, 52]]], ["476 477 CoV2-S1 antagonistic peptides 1 1 7513Immunoblotting and immunoprecipitation 514 S1-stimulated cells were lysed in protease-inhibitor cocktail supplemented RIPA buffer 515 (Roche, UK).", [["cells", "ANATOMY", 103, 108], ["1 1 7513", "CHEMICAL", 38, 46], ["cells", "CELL", 103, 108], ["stimulated cells", "CELL_LINE", 92, 108], ["protease", "PROTEIN", 123, 131], ["CoV2", "TEST", 8, 12], ["Immunoblotting", "TEST", 46, 60], ["immunoprecipitation", "TEST", 65, 84], ["S1-stimulated cells", "TREATMENT", 89, 108], ["protease-inhibitor cocktail", "TREATMENT", 123, 150]]], ["Proteins were subjected to SDS-PAGE (Bio-Rad Laboratories, USA) and 516 transferred onto polyvinylidene fluoride membranes (Merck-Milipore, USA).", [["polyvinylidene fluoride", "CHEMICAL", 89, 112], ["polyvinylidene fluoride", "CHEMICAL", 89, 112], ["polyvinylidene fluoride membranes", "SIMPLE_CHEMICAL", 89, 122], ["SDS", "TEST", 27, 30], ["polyvinylidene fluoride membranes", "TREATMENT", 89, 122]]], ["Proteins were 517 detected using antibodies to His, MyD88, TRIF, p65, phospho-(p)-p65, p38, p-p38, Erk, p-518513Erk, Jnk, p-Jnk, PERK, p-PERK, IRE1 , and p-IRE1 antibodies (All from Abcam, UK).", [["His", "GENE_OR_GENE_PRODUCT", 47, 50], ["MyD88", "GENE_OR_GENE_PRODUCT", 52, 57], ["TRIF", "GENE_OR_GENE_PRODUCT", 59, 63], ["p65", "GENE_OR_GENE_PRODUCT", 65, 68], ["phospho-(p)-p65", "GENE_OR_GENE_PRODUCT", 70, 85], ["p38", "GENE_OR_GENE_PRODUCT", 87, 90], ["p-p38", "GENE_OR_GENE_PRODUCT", 92, 97], ["Erk", "GENE_OR_GENE_PRODUCT", 99, 102], ["p-518513", "GENE_OR_GENE_PRODUCT", 104, 112], ["Erk", "GENE_OR_GENE_PRODUCT", 112, 115], ["Jnk", "GENE_OR_GENE_PRODUCT", 117, 120], ["p-Jnk", "GENE_OR_GENE_PRODUCT", 122, 127], ["PERK", "GENE_OR_GENE_PRODUCT", 129, 133], ["p-PERK", "GENE_OR_GENE_PRODUCT", 135, 141], ["IRE1", "GENE_OR_GENE_PRODUCT", 143, 147], ["p-IRE1", "GENE_OR_GENE_PRODUCT", 154, 160], ["Abcam", "GENE_OR_GENE_PRODUCT", 182, 187], ["UK", "GENE_OR_GENE_PRODUCT", 189, 191], ["His", "PROTEIN", 47, 50], ["MyD88", "PROTEIN", 52, 57], ["TRIF", "PROTEIN", 59, 63], ["p65", "PROTEIN", 65, 68], ["phospho-(p)", "PROTEIN", 70, 81], ["p65", "PROTEIN", 82, 85], ["p38", "PROTEIN", 87, 90], ["p", "PROTEIN", 92, 93], ["p38", "PROTEIN", 94, 97], ["Erk", "PROTEIN", 99, 102], ["p-518513Erk", "PROTEIN", 104, 115], ["Jnk", "PROTEIN", 117, 120], ["p", "PROTEIN", 122, 123], ["Jnk", "PROTEIN", 124, 127], ["PERK", "PROTEIN", 129, 133], ["p", "PROTEIN", 135, 136], ["PERK", "PROTEIN", 137, 141], ["IRE1", "PROTEIN", 143, 147], ["p", "PROTEIN", 154, 155], ["IRE1 antibodies", "PROTEIN", 156, 171], ["Abcam", "PROTEIN", 182, 187], ["UK", "PROTEIN", 189, 191], ["Proteins", "TEST", 0, 8], ["antibodies", "TEST", 33, 43], ["His", "TEST", 47, 50], ["MyD88", "TEST", 52, 57], ["TRIF", "TEST", 59, 63], ["p65", "TEST", 65, 68], ["phospho", "TEST", 70, 77], ["p65", "TEST", 82, 85], ["p38", "TEST", 87, 90], ["p", "TEST", 92, 93], ["p38", "TEST", 94, 97], ["Erk", "TEST", 99, 102], ["p", "TEST", 104, 105], ["Erk", "TEST", 112, 115], ["Jnk", "TEST", 117, 120], ["p", "TEST", 122, 123], ["Jnk", "TEST", 124, 127], ["PERK", "TEST", 129, 133], ["p", "TEST", 135, 136], ["PERK", "TEST", 137, 141], ["IRE1", "TEST", 143, 147], ["p", "TEST", 154, 155], ["IRE1 antibodies", "TEST", 156, 171]]], ["519513Antibody to ACE2 was obtained from RnD Systems (USA).", [["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["ACE2", "PROTEIN", 18, 22]]], ["For immunoprecipitation, whole 520 cell lysates (1mg) were immunoprecipitated using anti-His antibody or isotytpe antibody 521 Data were analysed on GraphPad Prism 8.", [["whole 520 cell lysates", "ANATOMY", 25, 47], ["His", "CHEMICAL", 89, 92], ["cell lysates", "ORGANISM_SUBSTANCE", 35, 47], ["anti-His antibody", "PROTEIN", 84, 101], ["isotytpe antibody 521", "PROTEIN", 105, 126], ["immunoprecipitation", "TREATMENT", 4, 23], ["whole 520 cell lysates", "TREATMENT", 25, 47], ["anti", "TEST", 84, 88], ["His antibody", "TEST", 89, 101], ["isotytpe antibody", "TEST", 105, 122]]], ["Statistical significance of differences was assessed 544 using parametric Student's two tailed t test for normally distributed data and Mann-Whitney 545 U test for non-parametric data.", [["tailed t test", "TEST", 88, 101], ["U test", "TEST", 153, 159], ["non-parametric data", "TEST", 164, 183]]], ["AP-6 reduces CoV-S1 and ACE2 interaction.", [["AP-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["CoV-S1", "GENE_OR_GENE_PRODUCT", 13, 19], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["AP-6", "PROTEIN", 0, 4], ["CoV", "PROTEIN", 13, 16], ["ACE2", "PROTEIN", 24, 28], ["AP", "TEST", 0, 2], ["S1", "ANATOMY", 17, 19]]], ["548513A.", [["548513A", "CHEMICAL", 0, 7]]], ["Cell viability measured by annexin-V/7-AAD staining and flow cytometry.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["annexin-V", "GENE_OR_GENE_PRODUCT", 27, 36], ["Cell viability", "TEST", 0, 14], ["annexin", "TEST", 27, 34], ["flow cytometry", "TEST", 56, 70], ["flow cytometry", "OBSERVATION", 56, 70]]], ["B. 549513Immunoblot of ACE2 and His following immunoprecipitation using anti-His antibody 30 550 minutes post CoV2-S1/AP-6 treatment.", [["AP-6", "CHEMICAL", 118, 122], ["His", "CHEMICAL", 77, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["AP-6", "GENE_OR_GENE_PRODUCT", 118, 122], ["ACE2", "PROTEIN", 23, 27], ["His", "PROTEIN", 32, 35], ["anti-His antibody", "PROTEIN", 72, 89], ["AP", "PROTEIN", 118, 120], ["ACE2", "TEST", 23, 27], ["immunoprecipitation", "TEST", 46, 65], ["anti", "TEST", 72, 76], ["His antibody", "TEST", 77, 89], ["CoV2", "TEST", 110, 114], ["AP-6 treatment", "TREATMENT", 118, 132]]], ["Immunoblots shown are representative of 551 three independent experiments.", [["Immunoblots", "TEST", 0, 11]]], ["C. Amino acid residue sequence alignments of CoV2-S1 and 552513CoV-S1.", [["Amino acid", "CHEMICAL", 3, 13], ["Amino acid", "CHEMICAL", 3, 13], ["Amino acid", "AMINO_ACID", 3, 13], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 45, 52], ["552513CoV-S1", "GENE_OR_GENE_PRODUCT", 57, 69], ["CoV2-S1 and 552513CoV-S1", "DNA", 45, 69], ["Amino acid residue sequence alignments", "TEST", 3, 41], ["CoV2", "TEST", 45, 49], ["S1", "ANATOMY", 50, 52], ["S1", "ANATOMY", 67, 69]]], ["Blue = AP-6 contact region.", [["AP", "PROTEIN", 7, 9]]], ["Sequence alignment performed by Clustal Omega.", [["Sequence alignment", "TEST", 0, 18]]], ["CoV2-S1 up-regulates genes involved in inflammation, inflammasome and 555MAP kinase pathways.", [["inflammation", "DISEASE", 39, 51], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["555MAP kinase", "GENE_OR_GENE_PRODUCT", 70, 83], ["CoV2", "PROTEIN", 0, 4], ["S1", "PROTEIN", 5, 7], ["555MAP kinase", "PROTEIN", 70, 83], ["CoV2", "TEST", 0, 4], ["inflammation", "PROBLEM", 39, 51], ["inflammasome", "PROBLEM", 53, 65], ["MAP kinase pathways", "TEST", 73, 92], ["S1", "ANATOMY", 5, 7], ["inflammation", "OBSERVATION", 39, 51]]], ["556CoV2-S1-stimulated BCi-NS1.1 cells were subjected to RT 2 Profiler TM Human 557MAP kinase pathways.", [["BCi-NS1.1 cells", "ANATOMY", 22, 37], ["556CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["BCi-NS1.1 cells", "CELL", 22, 37], ["Human", "ORGANISM", 73, 78], ["556CoV2-S1-stimulated BCi-NS1.1 cells", "CELL_LINE", 0, 37], ["Human", "SPECIES", 73, 78], ["BCi", "TEST", 22, 25], ["NS1.1 cells", "PROBLEM", 26, 37], ["RT", "TEST", 56, 58], ["MAP kinase pathways", "TEST", 82, 101]]], ["556Inflammasone PCR array with highly up-regulated genes involved in NF-\u03baB, Inflammasome, 558 and MAP kinase pathways.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 69, 74], ["Inflammasome", "GENE_OR_GENE_PRODUCT", 76, 88], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 98, 108], ["556Inflammasone PCR array", "DNA", 0, 25], ["556Inflammasone PCR array", "TEST", 0, 25], ["Inflammasome", "TEST", 76, 88], ["MAP kinase pathways", "TEST", 98, 117]]], ["CoV2-S1 antagonistic peptides, Trametinib, and Ulixertinib had no effect on 561 IL-6, IL-1\u03b2, TNF , and CCL2 productions in non-CoV2-S1-treated cells.", [["cells", "ANATOMY", 143, 148], ["Trametinib", "CHEMICAL", 31, 41], ["Ulixertinib", "CHEMICAL", 47, 58], ["non-CoV2-S1", "CHEMICAL", 123, 134], ["Trametinib", "CHEMICAL", 31, 41], ["Ulixertinib", "CHEMICAL", 47, 58], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["Trametinib", "SIMPLE_CHEMICAL", 31, 41], ["Ulixertinib", "SIMPLE_CHEMICAL", 47, 58], ["IL-6", "GENE_OR_GENE_PRODUCT", 80, 84], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 86, 91], ["TNF", "GENE_OR_GENE_PRODUCT", 93, 96], ["CCL2", "GENE_OR_GENE_PRODUCT", 103, 107], ["non-CoV2-S1", "SIMPLE_CHEMICAL", 123, 134], ["cells", "CELL", 143, 148], ["CCL2", "PROTEIN", 103, 107], ["non-CoV2-S1-treated cells", "CELL_LINE", 123, 148], ["CoV2", "TEST", 0, 4], ["Trametinib", "TREATMENT", 31, 41], ["Ulixertinib", "TEST", 47, 58], ["IL", "TEST", 80, 82], ["IL", "TEST", 86, 88], ["TNF", "TEST", 93, 96], ["CCL2 productions", "TEST", 103, 119], ["TNF", "ANATOMY", 93, 96]]], ["CoV2-S1 stimulation and treatment with either AP-6, 4-PBA, trametinib, and ulixertinib.", [["AP-6, 4-PBA", "CHEMICAL", 46, 57], ["trametinib", "CHEMICAL", 59, 69], ["ulixertinib", "CHEMICAL", 75, 86], ["AP-6", "CHEMICAL", 46, 50], ["4-PBA", "CHEMICAL", 52, 57], ["trametinib", "CHEMICAL", 59, 69], ["ulixertinib", "CHEMICAL", 75, 86], ["CoV2-S1", "GENE_OR_GENE_PRODUCT", 0, 7], ["AP-6", "SIMPLE_CHEMICAL", 46, 50], ["4-PBA", "SIMPLE_CHEMICAL", 52, 57], ["trametinib", "SIMPLE_CHEMICAL", 59, 69], ["ulixertinib", "SIMPLE_CHEMICAL", 75, 86], ["CoV2", "PROTEIN", 0, 4], ["CoV2", "TEST", 0, 4], ["S1 stimulation", "TREATMENT", 5, 19], ["treatment", "TREATMENT", 24, 33], ["AP", "TEST", 46, 48], ["PBA", "TREATMENT", 54, 57], ["trametinib", "TREATMENT", 59, 69], ["ulixertinib", "TREATMENT", 75, 86]]], ["N = 576 3. * P \u2264 0.05 versus non-CoV2-S1-stimulated control, + versus CoV2-S1-stimulated group.", [["non-CoV2-S1", "GENE_OR_GENE_PRODUCT", 29, 40], ["CoV2-S1", "SIMPLE_CHEMICAL", 70, 77], ["CoV2", "PROTEIN", 70, 74], ["S1", "PROTEIN", 75, 77], ["non-CoV2", "TEST", 29, 37], ["stimulated control", "TREATMENT", 41, 59], ["CoV2", "TEST", 70, 74]]], ["B. 577MAP kinase pathways.", [["B. 577MAP kinase", "GENE_OR_GENE_PRODUCT", 0, 16], ["B. 577MAP kinase", "PROTEIN", 0, 16], ["MAP kinase pathways", "TEST", 6, 25]]], ["556Immunofluorescent images of ZO-1 staining.", [["ZO-1", "GENE_OR_GENE_PRODUCT", 31, 35]]]], "72bc3d51e1e171091a2f6d376556ebc0e8ee1727": [["IntroductionCombination antiretroviral therapy (cART) is now recommended for all pregnant women living with HIV, for maternal health and to prevent vertical HIV transmission (Money et al., 2014; Lundgren et al., 2015; WHO Guidelines, 2015) .", [["HIV", "DISEASE", 108, 111], ["vertical HIV transmission", "DISEASE", 148, 173], ["women", "ORGANISM", 90, 95], ["women", "SPECIES", 90, 95], ["HIV", "SPECIES", 108, 111], ["HIV", "SPECIES", 108, 111], ["HIV", "SPECIES", 157, 160], ["IntroductionCombination antiretroviral therapy (cART)", "TREATMENT", 0, 53]]], ["Current guidelines recommend early initiation of cART; therefore, the number of pregnancies exposed to cART at periconception is constantly rising.", [["cART", "TREATMENT", 49, 53], ["pregnancies", "PROBLEM", 80, 91], ["cART at periconception", "TREATMENT", 103, 125]]], ["However, many studies associate the use of cART in pregnancy with higher rates of adverse outcomes, including miscarriage, preterm birth (PTB), low birth weight (LBW) and small for gestational age (SGA) birth (Chen et al., 2012; Fowler et al., 2016; Li et al., 2016; Mofenson, 2016; Saleska et al., 2018) .", [["miscarriage", "DISEASE", 110, 121], ["preterm birth", "DISEASE", 123, 136], ["PTB", "DISEASE", 138, 141], ["low birth weight", "DISEASE", 144, 160], ["LBW", "DISEASE", 162, 165], ["cART in pregnancy", "TREATMENT", 43, 60], ["adverse outcomes", "PROBLEM", 82, 98], ["miscarriage", "PROBLEM", 110, 121], ["preterm birth", "PROBLEM", 123, 136], ["small", "OBSERVATION_MODIFIER", 171, 176]]], ["Adverse outcomes seem more frequent with protease inhibitor-based cART regimens (PI-cART) and with initiation of therapy prior to conception (Kourtis et al., 2007; Chen et al., 2012; Sibiude et al., 2012; Li et al., 2016; Van Dyke et al., 2016; Zash et al., 2017; Snijdewind et al., 2018; Wang et al., 2018) .", [["Adverse outcomes", "PROBLEM", 0, 16], ["protease inhibitor", "TREATMENT", 41, 59], ["cART regimens", "TREATMENT", 66, 79], ["PI-cART", "TREATMENT", 81, 88], ["therapy", "TREATMENT", 113, 120]]], ["A knowledge gap exists regarding the specific effects of PI-cART exposure on early gestational events including decidualization, implantation and placentation, which occur during periconception.IntroductionDecidualization is a dramatic morphological and functional transformation of the uterine endometrium to form the decidua-the maternal face of the placenta, in species with hemochorial (invasive) placentation.", [["uterine endometrium", "ANATOMY", 287, 306], ["decidua", "ANATOMY", 319, 326], ["face", "ANATOMY", 340, 344], ["placenta", "ANATOMY", 352, 360], ["hemochorial", "ANATOMY", 378, 389], ["PI-cART", "CHEMICAL", 57, 64], ["PI", "SIMPLE_CHEMICAL", 57, 59], ["uterine endometrium", "MULTI-TISSUE_STRUCTURE", 287, 306], ["decidua", "TISSUE", 319, 326], ["placenta", "ORGAN", 352, 360], ["A knowledge gap", "PROBLEM", 0, 15], ["early gestational events", "PROBLEM", 77, 101], ["decidualization", "PROBLEM", 112, 127], ["implantation", "TREATMENT", 129, 141], ["placentation", "PROBLEM", 146, 158], ["a dramatic morphological and functional transformation of the uterine endometrium", "PROBLEM", 225, 306], ["hemochorial (invasive) placentation", "TREATMENT", 378, 413], ["dramatic", "OBSERVATION_MODIFIER", 227, 235], ["functional transformation", "OBSERVATION", 254, 279], ["uterine endometrium", "ANATOMY", 287, 306], ["decidua", "OBSERVATION", 319, 326], ["placenta", "ANATOMY", 352, 360]]], ["In contrast to most of these species, decidualization of human endometrium does not require embryo implantatio but occurs in every menstrual cycle in response to stimulation by the ovarian hormones, progesterone and estrogen (Bhurke et al., 2016; Vinketova et al., 2016) .", [["endometrium", "ANATOMY", 63, 74], ["embryo", "ANATOMY", 92, 98], ["ovarian", "ANATOMY", 181, 188], ["progesterone", "CHEMICAL", 199, 211], ["estrogen", "CHEMICAL", 216, 224], ["progesterone", "CHEMICAL", 199, 211], ["estrogen", "CHEMICAL", 216, 224], ["human", "ORGANISM", 57, 62], ["endometrium", "MULTI-TISSUE_STRUCTURE", 63, 74], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 92, 98], ["ovarian", "ORGAN", 181, 188], ["progesterone", "SIMPLE_CHEMICAL", 199, 211], ["estrogen", "SIMPLE_CHEMICAL", 216, 224], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["these species", "PROBLEM", 23, 36], ["decidualization of human endometrium", "PROBLEM", 38, 74], ["embryo implantatio", "TREATMENT", 92, 110], ["progesterone", "TREATMENT", 199, 211], ["species", "OBSERVATION", 29, 36], ["human endometrium", "OBSERVATION", 57, 74], ["ovarian hormones", "ANATOMY", 181, 197]]], ["During decidualization, endometrial stromal cells (ESCs) differentiate into specialized secretory decidual stromal cells (DSCs).", [["endometrial stromal cells", "ANATOMY", 24, 49], ["ESCs", "ANATOMY", 51, 55], ["secretory decidual stromal cells", "ANATOMY", 88, 120], ["DSCs", "ANATOMY", 122, 126], ["endometrial stromal cells", "CELL", 24, 49], ["ESCs", "CELL", 51, 55], ["secretory decidual stromal cells", "CELL", 88, 120], ["DSCs", "CELL", 122, 126], ["endometrial stromal cells", "CELL_TYPE", 24, 49], ["ESCs", "CELL_TYPE", 51, 55], ["secretory decidual stromal cells", "CELL_TYPE", 88, 120], ["DSCs", "CELL_TYPE", 122, 126], ["endometrial stromal cells", "PROBLEM", 24, 49], ["specialized secretory decidual stromal cells", "PROBLEM", 76, 120], ["endometrial", "ANATOMY", 24, 35], ["stromal cells", "OBSERVATION", 36, 49], ["secretory decidual stromal cells", "OBSERVATION", 88, 120]]], ["If fertilization occurs, the process of decidualization continues facilitated by DSC-secreted hormonal factors that allow for blastocyst implantation (Gellersen and Brosens, 2014) .", [["blastocyst", "ANATOMY", 126, 136], ["blastocyst", "DEVELOPING_ANATOMICAL_STRUCTURE", 126, 136], ["hormonal factors", "PROTEIN", 94, 110], ["fertilization", "PROBLEM", 3, 16], ["decidualization", "PROBLEM", 40, 55], ["secreted hormonal factors", "PROBLEM", 85, 110], ["blastocyst implantation", "TREATMENT", 126, 149]]], ["Following successful implantation, decidual spiral arteries begin remodeling into highly dilated vessels to supply adequate maternal blood to the placenta and meet the increasing metabolic demands of the fetus (Whitley and Cartwright, 2010 ).", [["decidual spiral arteries", "ANATOMY", 35, 59], ["vessels", "ANATOMY", 97, 104], ["blood", "ANATOMY", 133, 138], ["placenta", "ANATOMY", 146, 154], ["fetus", "ANATOMY", 204, 209], ["decidual spiral arteries", "MULTI-TISSUE_STRUCTURE", 35, 59], ["vessels", "MULTI-TISSUE_STRUCTURE", 97, 104], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["placenta", "ORGAN", 146, 154], ["fetus", "ORGAN", 204, 209], ["successful implantation", "TREATMENT", 10, 33], ["decidual spiral arteries", "TREATMENT", 35, 59], ["highly dilated vessels", "PROBLEM", 82, 104], ["implantation", "OBSERVATION", 21, 33], ["arteries", "ANATOMY", 51, 59], ["highly", "OBSERVATION_MODIFIER", 82, 88], ["dilated", "OBSERVATION", 89, 96], ["vessels", "ANATOMY", 97, 104], ["placenta", "ANATOMY", 146, 154], ["increasing", "OBSERVATION_MODIFIER", 168, 178], ["metabolic demands", "OBSERVATION", 179, 196], ["fetus", "ANATOMY", 204, 209]]], ["In the early or 'trophoblast independent' stage, spiral artery remodeling is driven by uterine natural killer (uNK) cells, which account for $70% of all maternal leukocytes infiltrating the decidua (Smith et al., 2009; Hazan et al., 2010; Lima et al., 2014) . uNK cells surround the spiral arteries and are a rich source of cytokines and angiogenic factors that may prime the spiral arteries for trophoblast invasion (Dunk et al., 2008) .", [["trophoblast", "ANATOMY", 17, 28], ["spiral artery", "ANATOMY", 49, 62], ["uterine natural killer (uNK) cells", "ANATOMY", 87, 121], ["leukocytes", "ANATOMY", 162, 172], ["decidua", "ANATOMY", 190, 197], ["uNK cells", "ANATOMY", 260, 269], ["spiral arteries", "ANATOMY", 283, 298], ["spiral arteries", "ANATOMY", 376, 391], ["trophoblast", "ANATOMY", 396, 407], ["trophoblast", "CELL", 17, 28], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 49, 62], ["uterine natural killer (uNK) cells", "CELL", 87, 121], ["leukocytes", "CELL", 162, 172], ["decidua", "TISSUE", 190, 197], ["uNK cells", "CELL", 260, 269], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 283, 298], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 376, 391], ["trophoblast", "CELL", 396, 407], ["uterine natural killer (uNK) cells", "CELL_TYPE", 87, 121], ["maternal leukocytes", "CELL_TYPE", 153, 172], ["uNK cells", "CELL_TYPE", 260, 269], ["cytokines", "PROTEIN", 324, 333], ["angiogenic factors", "PROTEIN", 338, 356], ["spiral artery remodeling", "PROBLEM", 49, 73], ["uNK cells", "PROBLEM", 260, 269], ["cytokines", "PROBLEM", 324, 333], ["angiogenic factors", "PROBLEM", 338, 356], ["trophoblast invasion", "PROBLEM", 396, 416], ["spiral artery", "ANATOMY", 49, 62], ["uterine", "ANATOMY", 87, 94], ["natural killer", "OBSERVATION", 95, 109], ["spiral arteries", "ANATOMY", 283, 298], ["cytokines", "OBSERVATION", 324, 333], ["spiral arteries", "ANATOMY", 376, 391]]], ["In the advanced or 'trophoblast dependent' stage of spiral artery remodeling, extravillous trophoblasts (EVTs) migrate from trophoblast cell columns at the tips of the placental villi and invade the decidual spiral arteries (Kaufmann et al., 2003) .", [["trophoblast", "ANATOMY", 20, 31], ["spiral artery", "ANATOMY", 52, 65], ["extravillous trophoblasts", "ANATOMY", 78, 103], ["EVTs", "ANATOMY", 105, 109], ["trophoblast cell columns", "ANATOMY", 124, 148], ["placental villi", "ANATOMY", 168, 183], ["decidual spiral arteries", "ANATOMY", 199, 223], ["trophoblast", "CELL", 20, 31], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 52, 65], ["extravillous trophoblasts", "CELL", 78, 103], ["EVTs", "CELL", 105, 109], ["trophoblast cell", "CELL", 124, 140], ["placental villi", "TISSUE", 168, 183], ["decidual spiral arteries", "MULTI-TISSUE_STRUCTURE", 199, 223], ["extravillous trophoblasts", "CELL_TYPE", 78, 103], ["EVTs", "CELL_TYPE", 105, 109], ["spiral artery remodeling", "PROBLEM", 52, 76], ["extravillous trophoblasts (EVTs)", "PROBLEM", 78, 110], ["trophoblast cell columns", "PROBLEM", 124, 148], ["spiral artery", "ANATOMY", 52, 65], ["remodeling", "OBSERVATION", 66, 76], ["extravillous trophoblasts", "OBSERVATION", 78, 103], ["trophoblast cell columns", "OBSERVATION", 124, 148], ["tips", "ANATOMY_MODIFIER", 156, 160], ["placental villi", "ANATOMY", 168, 183], ["decidual", "ANATOMY_MODIFIER", 199, 207], ["spiral arteries", "ANATOMY", 208, 223]]], ["This results in degradation of endothelial and smooth muscle cells in spiral arteries and incorporation of EVTs within the vascular walls, thereby transforming the spiral arteries from narrow caliber, high resistance to large caliber, low . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . resistance vessels (Burton et al., 2009) .", [["endothelial", "ANATOMY", 31, 42], ["smooth muscle cells", "ANATOMY", 47, 66], ["spiral arteries", "ANATOMY", 70, 85], ["EVTs", "ANATOMY", 107, 111], ["vascular walls", "ANATOMY", 123, 137], ["spiral arteries", "ANATOMY", 164, 179], ["vessels", "ANATOMY", 596, 603], ["endothelial", "CELL", 31, 42], ["smooth muscle cells", "CELL", 47, 66], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 70, 85], ["EVTs", "GENE_OR_GENE_PRODUCT", 107, 111], ["vascular walls", "MULTI-TISSUE_STRUCTURE", 123, 137], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 164, 179], ["vessels", "MULTI-TISSUE_STRUCTURE", 596, 603], ["endothelial and smooth muscle cells", "CELL_TYPE", 31, 66], ["degradation of endothelial and smooth muscle cells", "PROBLEM", 16, 66], ["endothelial", "ANATOMY", 31, 42], ["smooth muscle cells", "OBSERVATION", 47, 66], ["spiral arteries", "ANATOMY", 70, 85], ["vascular walls", "ANATOMY", 123, 137], ["spiral arteries", "ANATOMY", 164, 179], ["narrow", "OBSERVATION_MODIFIER", 185, 191], ["caliber", "OBSERVATION_MODIFIER", 192, 199], ["high resistance", "OBSERVATION", 201, 216], ["large", "OBSERVATION_MODIFIER", 220, 225], ["caliber", "OBSERVATION_MODIFIER", 226, 233], ["low", "OBSERVATION_MODIFIER", 235, 238], ["vessels", "ANATOMY", 596, 603]]], ["The successful completion of decidualization and subsequent remodeling of spiral arteries is crucial to optimal placentation and fetal development, and therefore to overall pregnancy outcome.IntroductionBased on data from a clinical cohort of PI-cART exposed pregnant women living with HIV, we previously showed that exposure to PI-cART during pregnancy was associated with lower levels of progesterone that correlated with lower birth weight (Papp et al., 2015) .", [["spiral arteries", "ANATOMY", 74, 89], ["fetal", "ANATOMY", 129, 134], ["PI-cART", "CHEMICAL", 329, 336], ["progesterone", "CHEMICAL", 390, 402], ["progesterone", "CHEMICAL", 390, 402], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 74, 89], ["fetal", "ANATOMICAL_SYSTEM", 129, 134], ["women", "ORGANISM", 268, 273], ["PI", "SIMPLE_CHEMICAL", 329, 331], ["progesterone", "SIMPLE_CHEMICAL", 390, 402], ["women", "SPECIES", 268, 273], ["HIV", "SPECIES", 286, 289], ["HIV", "SPECIES", 286, 289], ["decidualization", "TREATMENT", 29, 44], ["subsequent remodeling of spiral arteries", "TREATMENT", 49, 89], ["overall pregnancy outcome", "PROBLEM", 165, 190], ["HIV", "PROBLEM", 286, 289], ["PI-cART", "TREATMENT", 329, 336], ["lower levels of progesterone", "PROBLEM", 374, 402], ["decidualization", "OBSERVATION", 29, 44], ["spiral arteries", "ANATOMY", 74, 89]]], ["This correlation was also observed in a mouse pregnancy model, where supplementation with progesterone partially reversed the PI-cART induced fetal growth restriction (Papp et al., 2015) .", [["fetal", "ANATOMY", 142, 147], ["progesterone", "CHEMICAL", 90, 102], ["PI", "CHEMICAL", 126, 128], ["progesterone", "CHEMICAL", 90, 102], ["mouse", "ORGANISM", 40, 45], ["progesterone", "SIMPLE_CHEMICAL", 90, 102], ["PI", "SIMPLE_CHEMICAL", 126, 128], ["fetal", "ORGAN", 142, 147], ["mouse", "SPECIES", 40, 45], ["mouse", "SPECIES", 40, 45], ["a mouse pregnancy model", "TREATMENT", 38, 61], ["supplementation with progesterone", "TREATMENT", 69, 102], ["the PI", "TREATMENT", 122, 128], ["fetal growth restriction", "PROBLEM", 142, 166]]], ["We also reported higher estradiol levels in maternal and cord plasma of PI-cART exposed pregnant women living with HIV, and found that cord estradiol levels were inversely correlated with birth weight centile (Balogun et al., 2018) .", [["cord plasma", "ANATOMY", 57, 68], ["cord", "ANATOMY", 135, 139], ["estradiol", "CHEMICAL", 24, 33], ["PI", "CHEMICAL", 72, 74], ["estradiol", "CHEMICAL", 140, 149], ["estradiol", "CHEMICAL", 24, 33], ["estradiol", "CHEMICAL", 140, 149], ["estradiol", "SIMPLE_CHEMICAL", 24, 33], ["cord plasma", "ORGANISM_SUBSTANCE", 57, 68], ["PI", "SIMPLE_CHEMICAL", 72, 74], ["women", "ORGANISM", 97, 102], ["HIV", "ORGANISM", 115, 118], ["cord", "ORGAN", 135, 139], ["estradiol", "SIMPLE_CHEMICAL", 140, 149], ["women", "SPECIES", 97, 102], ["HIV", "SPECIES", 115, 118], ["HIV", "SPECIES", 115, 118], ["higher estradiol levels", "PROBLEM", 17, 40], ["HIV", "PROBLEM", 115, 118], ["cord estradiol levels", "TEST", 135, 156], ["cord", "ANATOMY", 135, 139]]], ["The optimum balance between progesterone and estrogen is crucial for creating a suitable endometrial environment for implantation, and for uterine and placental angiogenesis.", [["endometrial", "ANATOMY", 89, 100], ["uterine", "ANATOMY", 139, 146], ["placental", "ANATOMY", 151, 160], ["progesterone", "CHEMICAL", 28, 40], ["estrogen", "CHEMICAL", 45, 53], ["progesterone", "CHEMICAL", 28, 40], ["estrogen", "CHEMICAL", 45, 53], ["progesterone", "SIMPLE_CHEMICAL", 28, 40], ["estrogen", "SIMPLE_CHEMICAL", 45, 53], ["endometrial", "MULTI-TISSUE_STRUCTURE", 89, 100], ["uterine", "MULTI-TISSUE_STRUCTURE", 139, 146], ["placental", "MULTI-TISSUE_STRUCTURE", 151, 160], ["progesterone and estrogen", "TREATMENT", 28, 53], ["implantation", "TREATMENT", 117, 129], ["uterine and placental angiogenesis", "PROBLEM", 139, 173], ["uterine", "ANATOMY", 139, 146], ["placental", "ANATOMY", 151, 160], ["angiogenesis", "OBSERVATION", 161, 173]]], ["While PI-cART exposure alters placental vasculature (Mohammadi et al., 2018) , it remains unknown whether or not uterine remodeling is affected by the initiation of periconceptional PI-cART.", [["placental vasculature", "ANATOMY", 30, 51], ["uterine", "ANATOMY", 113, 120], ["PI-cART", "CHEMICAL", 6, 13], ["PI", "CHEMICAL", 182, 184], ["PI-cART", "CHEMICAL", 6, 13], ["PI", "SIMPLE_CHEMICAL", 6, 8], ["placental vasculature", "MULTI-TISSUE_STRUCTURE", 30, 51], ["uterine", "MULTI-TISSUE_STRUCTURE", 113, 120], ["PI", "SIMPLE_CHEMICAL", 182, 184], ["uterine remodeling", "PROBLEM", 113, 131], ["periconceptional PI-cART", "TREATMENT", 165, 189], ["vasculature", "ANATOMY", 40, 51], ["uterine", "ANATOMY", 113, 120], ["remodeling", "OBSERVATION", 121, 131]]], ["This gap in knowledge needs to be addressed because current treatment guidelines advocate early initiation of cART, and growing evidence points to higher rates of adverse birth outcomes among women who initiated PI-cART before pregnancy or in first trimester (Kourtis et al., 2007; Chen et al., 2012; Sibiude et al., 2012; Li et al., 2016; Van Dyke et al., 2016; Zash et al., 2017; Snijdewind et al., 2018; Wang et al., 2018) .IntroductionHence, the objective of this study was to investigate whether PI-cART initiated at periconception affects decidualization and spiral artery remodeling in early pregnancy.", [["spiral artery", "ANATOMY", 565, 578], ["PI", "CHEMICAL", 212, 214], ["PI-cART", "CHEMICAL", 501, 508], ["women", "ORGANISM", 192, 197], ["PI", "SIMPLE_CHEMICAL", 212, 214], ["PI", "SIMPLE_CHEMICAL", 501, 503], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 565, 578], ["women", "SPECIES", 192, 197], ["current treatment guidelines", "TREATMENT", 52, 80], ["cART", "TREATMENT", 110, 114], ["PI-cART", "TREATMENT", 212, 219], ["this study", "TEST", 463, 473], ["PI", "PROBLEM", 501, 503], ["cART", "TREATMENT", 504, 508], ["decidualization", "PROBLEM", 545, 560], ["spiral artery remodeling in early pregnancy", "PROBLEM", 565, 608], ["spiral artery", "ANATOMY", 565, 578]]], ["Two PIs, lopinavir and darunavir, currently offered as cART options in human HIV-positive (HIV\u00fe) pregnancies, were evaluated in clinically relevant combinations using an ex vivo first-trimester human placenta-decidua explant model, an in vitro primary decidual cell culture system, and an in vivo mouse pregnancy model.", [["placenta", "ANATOMY", 200, 208], ["decidual cell culture system", "ANATOMY", 252, 280], ["lopinavir", "CHEMICAL", 9, 18], ["darunavir", "CHEMICAL", 23, 32], ["HIV-positive", "DISEASE", 77, 89], ["lopinavir", "CHEMICAL", 9, 18], ["darunavir", "CHEMICAL", 23, 32], ["lopinavir", "SIMPLE_CHEMICAL", 9, 18], ["darunavir", "SIMPLE_CHEMICAL", 23, 32], ["human", "ORGANISM", 71, 76], ["HIV-positive (HIV\u00fe", "ORGANISM", 77, 95], ["human", "ORGANISM", 194, 199], ["placenta-decidua explant", "TISSUE", 200, 224], ["decidual cell", "CELL", 252, 265], ["mouse", "ORGANISM", 297, 302], ["human", "SPECIES", 71, 76], ["HIV", "SPECIES", 77, 80], ["HIV", "SPECIES", 91, 94], ["human", "SPECIES", 194, 199], ["mouse", "SPECIES", 297, 302], ["human", "SPECIES", 71, 76], ["HIV", "SPECIES", 77, 80], ["HIV", "SPECIES", 91, 94], ["human", "SPECIES", 194, 199], ["mouse", "SPECIES", 297, 302], ["Two PIs", "TREATMENT", 0, 7], ["lopinavir", "TREATMENT", 9, 18], ["darunavir", "TREATMENT", 23, 32], ["cART options", "TREATMENT", 55, 67], ["pregnancies", "PROBLEM", 97, 108], ["an ex vivo first-trimester human placenta-decidua explant model", "TREATMENT", 167, 230], ["an in vivo mouse pregnancy model", "TREATMENT", 286, 318]]], ["As uterine remodeling is dependent on regulated levels of progesterone and estrogen, we hypothesized that the dysregulation of hormones by PI-cART will impair optimal decidualization and spiral artery remodeling, contributing to inefficient placentation and therefore poor birth outcomes.Drug regimensLopinavir, darunavir, ritonavir (r), zidovudine and lamivudine were obtained from the National Institutes of Health AIDS Reagent Program, dissolved in dimethyl sulphoxide (DMSO) to make 12 000\u00c2 stocks, aliquoted and stored at \u00c020 C until use.", [["uterine", "ANATOMY", 3, 10], ["spiral artery", "ANATOMY", 187, 200], ["progesterone", "CHEMICAL", 58, 70], ["estrogen", "CHEMICAL", 75, 83], ["PI-cART", "CHEMICAL", 139, 146], ["regimensLopinavir", "CHEMICAL", 293, 310], ["darunavir", "CHEMICAL", 312, 321], ["ritonavir", "CHEMICAL", 323, 332], ["zidovudine", "CHEMICAL", 338, 348], ["lamivudine", "CHEMICAL", 353, 363], ["AIDS", "DISEASE", 417, 421], ["dimethyl sulphoxide", "CHEMICAL", 452, 471], ["DMSO", "CHEMICAL", 473, 477], ["progesterone", "CHEMICAL", 58, 70], ["estrogen", "CHEMICAL", 75, 83], ["regimensLopinavir", "CHEMICAL", 293, 310], ["darunavir", "CHEMICAL", 312, 321], ["ritonavir", "CHEMICAL", 323, 332], ["zidovudine", "CHEMICAL", 338, 348], ["lamivudine", "CHEMICAL", 353, 363], ["dimethyl sulphoxide", "CHEMICAL", 452, 471], ["DMSO", "CHEMICAL", 473, 477], ["uterine", "MULTI-TISSUE_STRUCTURE", 3, 10], ["progesterone", "SIMPLE_CHEMICAL", 58, 70], ["estrogen", "SIMPLE_CHEMICAL", 75, 83], ["PI", "SIMPLE_CHEMICAL", 139, 141], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 187, 200], ["Drug regimensLopinavir", "SIMPLE_CHEMICAL", 288, 310], ["darunavir", "SIMPLE_CHEMICAL", 312, 321], ["ritonavir", "SIMPLE_CHEMICAL", 323, 332], ["r", "SIMPLE_CHEMICAL", 334, 335], ["zidovudine", "SIMPLE_CHEMICAL", 338, 348], ["lamivudine", "SIMPLE_CHEMICAL", 353, 363], ["dimethyl sulphoxide", "SIMPLE_CHEMICAL", 452, 471], ["DMSO", "SIMPLE_CHEMICAL", 473, 477], ["uterine remodeling", "PROBLEM", 3, 21], ["progesterone and estrogen", "TREATMENT", 58, 83], ["the dysregulation of hormones", "PROBLEM", 106, 135], ["PI-cART", "TREATMENT", 139, 146], ["optimal decidualization", "PROBLEM", 159, 182], ["spiral artery remodeling", "TREATMENT", 187, 211], ["inefficient placentation", "PROBLEM", 229, 253], ["poor birth outcomes", "PROBLEM", 268, 287], ["Drug regimensLopinavir", "TREATMENT", 288, 310], ["darunavir", "TREATMENT", 312, 321], ["ritonavir (r)", "TREATMENT", 323, 336], ["zidovudine", "TREATMENT", 338, 348], ["lamivudine", "TREATMENT", 353, 363], ["Reagent Program", "TREATMENT", 422, 437], ["dimethyl sulphoxide (DMSO", "TREATMENT", 452, 477], ["uterine", "ANATOMY", 3, 10], ["remodeling", "OBSERVATION", 11, 21], ["dependent", "OBSERVATION_MODIFIER", 25, 34], ["spiral artery", "ANATOMY", 187, 200]]], ["Drugs were thawed at room temperature and diluted to 200\u00c2 in culture medium (RPMI or DMEM) containing 1 mg/ml BSA to avoid precipitation, followed by further dilution to 1\u00c2 in the culture medium.", [["BSA", "CHEMICAL", 110, 113], ["BSA", "SIMPLE_CHEMICAL", 110, 113], ["Drugs", "TREATMENT", 0, 5], ["precipitation", "PROBLEM", 123, 136]]], ["1\u00c2 equals the C max concentration of the drug in human pregnancy (Kala et al., 2018 )-the concentrations have been listed in Supplementary Table SI .", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["the C max concentration", "TREATMENT", 10, 33]]], ["Tissues/ cells were incubated with the following drug combinations: ritonavir-boosted lopinavir (lopinavir/r)-cART \u00bc [lopinavir \u00fe ritonavir \u00fe zidovudine \u00fe lamivudine] or ritonavir-boosted darunavir (darunavir/ r)-cART\u00bc [darunavir \u00fe ritonavir \u00fe zidovudine \u00fe lamivudine].", [["Tissues", "ANATOMY", 0, 7], ["cells", "ANATOMY", 9, 14], ["ritonavir", "CHEMICAL", 68, 77], ["lopinavir", "CHEMICAL", 86, 95], ["lopinavir/r)-cART", "CHEMICAL", 97, 114], ["lopinavir \u00fe ritonavir", "CHEMICAL", 118, 139], ["zidovudine", "CHEMICAL", 142, 152], ["lamivudine", "CHEMICAL", 155, 165], ["ritonavir", "CHEMICAL", 170, 179], ["darunavir", "CHEMICAL", 188, 197], ["darunavir/ r)-cART", "CHEMICAL", 199, 217], ["darunavir \u00fe ritonavir", "CHEMICAL", 220, 241], ["zidovudine", "CHEMICAL", 244, 254], ["lamivudine", "CHEMICAL", 257, 267], ["ritonavir", "CHEMICAL", 68, 77], ["lopinavir", "CHEMICAL", 86, 95], ["lopinavir", "CHEMICAL", 97, 106], ["lopinavir", "CHEMICAL", 118, 127], ["ritonavir", "CHEMICAL", 130, 139], ["zidovudine", "CHEMICAL", 142, 152], ["lamivudine", "CHEMICAL", 155, 165], ["ritonavir", "CHEMICAL", 170, 179], ["darunavir", "CHEMICAL", 188, 197], ["darunavir", "CHEMICAL", 199, 208], ["darunavir", "CHEMICAL", 220, 229], ["ritonavir", "CHEMICAL", 232, 241], ["zidovudine", "CHEMICAL", 244, 254], ["lamivudine", "CHEMICAL", 257, 267], ["cells", "CELL", 9, 14], ["ritonavir", "SIMPLE_CHEMICAL", 68, 77], ["lopinavir", "SIMPLE_CHEMICAL", 86, 95], ["lopinavir", "SIMPLE_CHEMICAL", 97, 106], ["lopinavir", "SIMPLE_CHEMICAL", 118, 127], ["ritonavir", "SIMPLE_CHEMICAL", 130, 139], ["zidovudine", "SIMPLE_CHEMICAL", 142, 152], ["lamivudine", "SIMPLE_CHEMICAL", 155, 165], ["ritonavir", "SIMPLE_CHEMICAL", 170, 179], ["darunavir", "SIMPLE_CHEMICAL", 188, 197], ["darunavir/ r)-cART", "SIMPLE_CHEMICAL", 199, 217], ["darunavir", "SIMPLE_CHEMICAL", 220, 229], ["ritonavir", "SIMPLE_CHEMICAL", 232, 241], ["zidovudine", "SIMPLE_CHEMICAL", 244, 254], ["lamivudine", "SIMPLE_CHEMICAL", 257, 267], ["ritonavir", "TREATMENT", 68, 77], ["lopinavir (lopinavir/r)", "TREATMENT", 86, 109], ["cART \u00bc", "TREATMENT", 110, 116], ["lopinavir", "TREATMENT", 118, 127], ["ritonavir", "TREATMENT", 130, 139], ["zidovudine", "TREATMENT", 142, 152], ["lamivudine", "TREATMENT", 155, 165], ["ritonavir", "TREATMENT", 170, 179], ["darunavir (darunavir/ r)", "TREATMENT", 188, 212], ["cART\u00bc", "TREATMENT", 213, 218], ["darunavir", "TREATMENT", 220, 229], ["ritonavir", "TREATMENT", 232, 241], ["zidovudine", "TREATMENT", 244, 254], ["lamivudine", "TREATMENT", 257, 267]]], ["The final concentration of DMSO in the culture medium was 0.025% (v/v).Drug regimensDrugs administered to the mice were purchased as prescription drugs.", [["DMSO", "CHEMICAL", 27, 31], ["DMSO", "CHEMICAL", 27, 31], ["DMSO", "SIMPLE_CHEMICAL", 27, 31], ["mice", "ORGANISM", 110, 114], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["DMSO", "TREATMENT", 27, 31], ["the culture medium", "TEST", 35, 53], ["Drug regimensDrugs", "TREATMENT", 71, 89], ["prescription drugs", "TREATMENT", 133, 151], ["concentration", "OBSERVATION_MODIFIER", 10, 23], ["DMSO", "OBSERVATION_MODIFIER", 27, 31]]], ["Drug doses yielding human therapeutic plasma concentrations were used (Kala et al., 2018) .", [["plasma", "ANATOMY", 38, 44], ["Drug", "SIMPLE_CHEMICAL", 0, 4], ["human", "ORGANISM", 20, 25], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["Drug doses", "TREATMENT", 0, 10], ["human therapeutic plasma concentrations", "TREATMENT", 20, 59]]], ["Animals were administered either lopinavir/r-cART\u00bc [lopinavir/r (133/33.3 mg/kg/day) with zidovudine \u00fe lamivudine (100 \u00fe 50 mg/kg/day)], darunavir/r-cART \u00bc [darunavir/r (40/5 mg/kg/day) with zidovudine \u00fe lamivudine (100 \u00fe 50 mg/kg/ day)] or water as a control.", [["lopinavir", "CHEMICAL", 33, 42], ["lopinavir", "CHEMICAL", 52, 61], ["zidovudine", "CHEMICAL", 90, 100], ["lamivudine", "CHEMICAL", 103, 113], ["darunavir/r-cART", "CHEMICAL", 137, 153], ["darunavir", "CHEMICAL", 157, 166], ["zidovudine", "CHEMICAL", 191, 201], ["lamivudine", "CHEMICAL", 204, 214], ["lopinavir", "CHEMICAL", 33, 42], ["r-cART", "CHEMICAL", 43, 49], ["lopinavir", "CHEMICAL", 52, 61], ["zidovudine", "CHEMICAL", 90, 100], ["lamivudine", "CHEMICAL", 103, 113], ["darunavir", "CHEMICAL", 137, 146], ["r-cART", "CHEMICAL", 147, 153], ["darunavir", "CHEMICAL", 157, 166], ["zidovudine", "CHEMICAL", 191, 201], ["lamivudine", "CHEMICAL", 204, 214], ["Animals", "ORGANISM", 0, 7], ["lopinavir", "SIMPLE_CHEMICAL", 33, 42], ["lopinavir", "SIMPLE_CHEMICAL", 52, 61], ["zidovudine", "SIMPLE_CHEMICAL", 90, 100], ["lamivudine", "SIMPLE_CHEMICAL", 103, 113], ["darunavir", "SIMPLE_CHEMICAL", 137, 146], ["r-cART", "SIMPLE_CHEMICAL", 147, 153], ["darunavir", "SIMPLE_CHEMICAL", 157, 166], ["zidovudine", "SIMPLE_CHEMICAL", 191, 201], ["lamivudine", "SIMPLE_CHEMICAL", 204, 214], ["lopinavir", "TREATMENT", 33, 42], ["lopinavir", "TREATMENT", 52, 61], ["zidovudine", "TREATMENT", 90, 100], ["lamivudine", "TREATMENT", 103, 113], ["darunavir", "TREATMENT", 137, 146], ["darunavir", "TREATMENT", 157, 166], ["zidovudine", "TREATMENT", 191, 201], ["lamivudine", "TREATMENT", 204, 214]]], ["Pulverized tablets were dissolved in sterile water and administered by oral gavage.Tissue collection and preparationHuman.Tissue collection and preparationFirst-trimester placentae and/or decidua parietalis samples were obtained from healthy women undergoing elective terminations of pregnancy between 6 and 9 weeks of gestation.", [["oral", "ANATOMY", 71, 75], ["Tissue", "ANATOMY", 83, 89], ["Tissue", "ANATOMY", 122, 128], ["placentae", "ANATOMY", 171, 180], ["decidua parietalis samples", "ANATOMY", 188, 214], ["oral", "ORGANISM_SUBDIVISION", 71, 75], ["Tissue", "TISSUE", 83, 89], ["Tissue", "TISSUE", 122, 128], ["placentae", "ORGANISM", 171, 180], ["decidua parietalis samples", "ORGANISM_SUBSTANCE", 188, 214], ["women", "ORGANISM", 242, 247], ["women", "SPECIES", 242, 247], ["Pulverized tablets", "TREATMENT", 0, 18], ["Tissue collection", "TEST", 83, 100], ["preparationHuman", "TREATMENT", 105, 121], ["Tissue collection", "TEST", 122, 139], ["preparationFirst-trimester placentae", "TREATMENT", 144, 180], ["decidua parietalis samples", "PROBLEM", 188, 214], ["elective terminations of pregnancy", "TREATMENT", 259, 293], ["collection", "OBSERVATION", 90, 100], ["collection", "OBSERVATION", 129, 139]]], ["Fresh tissue was collected in ice-cold PBS and processed within 2 h of collection.Mouse.Housing conditions, breeding and drug treatment of mice have been described previously (Papp et al., 2015) .", [["Fresh tissue", "ANATOMY", 0, 12], ["Fresh tissue", "TISSUE", 0, 12], ["Mouse", "ORGANISM", 82, 87], ["mice", "ORGANISM", 139, 143], ["Mouse", "SPECIES", 82, 87], ["mice", "SPECIES", 139, 143], ["Mouse", "SPECIES", 82, 87], ["mice", "SPECIES", 139, 143], ["Fresh tissue", "PROBLEM", 0, 12], ["ice-cold PBS", "TREATMENT", 30, 42], ["collection", "PROBLEM", 71, 81], ["drug treatment", "TREATMENT", 121, 135], ["tissue", "OBSERVATION", 6, 12], ["collection", "OBSERVATION", 71, 81]]], ["Eight to 10 weeks old, plugged C57Bl/6 females were randomly assigned into a treatment arm, and administered either lopinavir/r-cART, darunavir/r-cART or water by oral gavage once daily starting on the day of plug detection (gestational day (GD) 0.5) until sacrifice.", [["oral", "ANATOMY", 163, 167], ["lopinavir/r-cART", "CHEMICAL", 116, 132], ["darunavir/r-cART", "CHEMICAL", 134, 150], ["lopinavir", "CHEMICAL", 116, 125], ["r-cART", "CHEMICAL", 126, 132], ["darunavir", "CHEMICAL", 134, 143], ["r-cART", "CHEMICAL", 144, 150], ["lopinavir", "SIMPLE_CHEMICAL", 116, 125], ["r-cART", "SIMPLE_CHEMICAL", 126, 132], ["darunavir", "SIMPLE_CHEMICAL", 134, 143], ["r-cART", "SIMPLE_CHEMICAL", 144, 150], ["water", "SIMPLE_CHEMICAL", 154, 159], ["oral", "ORGANISM_SUBDIVISION", 163, 167], ["a treatment arm", "TREATMENT", 75, 90], ["lopinavir", "TREATMENT", 116, 125], ["cART", "TREATMENT", 128, 132], ["darunavir", "TREATMENT", 134, 143], ["plug detection (gestational day (GD)", "TREATMENT", 209, 245]]], ["On GD 6.5, pregnant dams (n \u00bc 4/treatment group) were sacrificed by CO 2 inhalation.", [["CO 2", "CHEMICAL", 68, 72], ["dams", "ORGANISM", 20, 24]]], ["The uterine horn was dissected and the number of implantation sites counted.", [["uterine horn", "ANATOMY", 4, 16], ["sites", "ANATOMY", 62, 67], ["uterine horn", "MULTI-TISSUE_STRUCTURE", 4, 16], ["implantation sites", "TREATMENT", 49, 67], ["uterine horn", "ANATOMY", 4, 16], ["dissected", "OBSERVATION", 21, 30], ["number", "OBSERVATION_MODIFIER", 39, 45], ["implantation", "OBSERVATION", 49, 61]]], ["Individual implantation sites were collected and immersed in 4% (v/v) paraformaldehyde for 1 h at room temperature for fixation, and then stored in 70% (v/v) ethanol at 4 C until processing.", [["ethanol", "CHEMICAL", 158, 165], ["paraformaldehyde", "CHEMICAL", 70, 86], ["ethanol", "CHEMICAL", 158, 165], ["paraformaldehyde", "SIMPLE_CHEMICAL", 70, 86], ["ethanol", "SIMPLE_CHEMICAL", 158, 165], ["Individual implantation sites", "TREATMENT", 0, 29], ["paraformaldehyde", "TREATMENT", 70, 86], ["fixation", "TREATMENT", 119, 127], ["ethanol", "TREATMENT", 158, 165], ["implantation", "OBSERVATION", 11, 23]]], ["On GD 9.5, pregnant dams (n \u00bc 4/treatment group) were sacrificed by cervical dislocation.", [["cervical", "ANATOMY", 68, 76], ["cervical dislocation", "DISEASE", 68, 88], ["dams", "ORGANISM", 20, 24], ["cervical", "ORGAN", 68, 76], ["pregnant dams (n \u00bc 4/treatment group", "TREATMENT", 11, 47], ["cervical dislocation", "PROBLEM", 68, 88], ["cervical", "ANATOMY", 68, 76], ["dislocation", "OBSERVATION", 77, 88]]], ["Euthanasia by CO 2 asphyxiation was avoided to prevent vasodilation of uterine arteries.", [["uterine arteries", "ANATOMY", 71, 87], ["CO 2", "CHEMICAL", 14, 18], ["CO 2", "SIMPLE_CHEMICAL", 14, 18], ["uterine arteries", "MULTI-TISSUE_STRUCTURE", 71, 87], ["Euthanasia", "PROBLEM", 0, 10], ["vasodilation of uterine arteries", "PROBLEM", 55, 87], ["uterine arteries", "ANATOMY", 71, 87]]], ["Prior to uteri removal, dental floss was tied around the cervix and the distal end of each uterine horn, proximal to the ovaries, to ligate the uterine artery and prevent arterial collapse (Kieckbusch et al., 2015) .", [["uteri", "ANATOMY", 9, 14], ["dental", "ANATOMY", 24, 30], ["cervix", "ANATOMY", 57, 63], ["uterine horn", "ANATOMY", 91, 103], ["ovaries", "ANATOMY", 121, 128], ["uterine artery", "ANATOMY", 144, 158], ["arterial", "ANATOMY", 171, 179], ["arterial collapse", "DISEASE", 171, 188], ["uteri", "ORGAN", 9, 14], ["cervix", "ORGAN", 57, 63], ["uterine horn", "MULTI-TISSUE_STRUCTURE", 91, 103], ["ovaries", "ORGAN", 121, 128], ["uterine artery", "MULTI-TISSUE_STRUCTURE", 144, 158], ["arterial", "MULTI-TISSUE_STRUCTURE", 171, 179], ["uteri removal", "TREATMENT", 9, 22], ["dental floss", "TREATMENT", 24, 36], ["arterial collapse", "PROBLEM", 171, 188], ["uteri", "ANATOMY", 9, 14], ["removal", "OBSERVATION", 15, 22], ["floss", "OBSERVATION", 31, 36], ["cervix", "ANATOMY", 57, 63], ["distal", "ANATOMY_MODIFIER", 72, 78], ["uterine horn", "ANATOMY", 91, 103], ["ovaries", "ANATOMY", 121, 128], ["uterine artery", "ANATOMY", 144, 158], ["arterial", "ANATOMY", 171, 179], ["collapse", "OBSERVATION", 180, 188]]], ["Intact uteri were excised distally to the three ligation points and the number of implantation sites counted.", [["uteri", "ANATOMY", 7, 12], ["sites", "ANATOMY", 95, 100], ["uteri", "ORGAN", 7, 12], ["implantation sites", "TREATMENT", 82, 100], ["uteri", "ANATOMY", 7, 12], ["distally", "OBSERVATION_MODIFIER", 26, 34], ["three", "OBSERVATION_MODIFIER", 42, 47], ["ligation", "OBSERVATION", 48, 56], ["number", "OBSERVATION_MODIFIER", 72, 78], ["implantation", "OBSERVATION", 82, 94]]], ["To preserve the original size and shape of utero-placental vasculature, whole uteri were stretched along the same long-axis and secured to a polystyrene block, then immersed in 10% (v/v) formalin overnight at 4 C. Excess uterine adipose tissue was trimmed and individual implantation sites were collected from the uterine membrane, then stored in 70% (v/v) ethanol at 4 C until processing into paraffin using a Shandon Excelsior ES (Thermo Scientific) automated tissue processor.", [["-placental vasculature", "ANATOMY", 48, 70], ["whole uteri", "ANATOMY", 72, 83], ["uterine adipose tissue", "ANATOMY", 221, 243], ["sites", "ANATOMY", 284, 289], ["uterine membrane", "ANATOMY", 314, 330], ["tissue", "ANATOMY", 462, 468], ["ethanol", "CHEMICAL", 357, 364], ["polystyrene", "CHEMICAL", 141, 152], ["formalin", "CHEMICAL", 187, 195], ["ethanol", "CHEMICAL", 357, 364], ["paraffin", "CHEMICAL", 394, 402], ["-placental vasculature", "MULTI-TISSUE_STRUCTURE", 48, 70], ["uteri", "ORGAN", 78, 83], ["uterine adipose tissue", "TISSUE", 221, 243], ["uterine membrane", "MULTI-TISSUE_STRUCTURE", 314, 330], ["ethanol", "SIMPLE_CHEMICAL", 357, 364], ["tissue", "TISSUE", 462, 468], ["a polystyrene block", "TREATMENT", 139, 158], ["v/v) formalin", "TREATMENT", 182, 195], ["Excess uterine adipose tissue", "PROBLEM", 214, 243], ["individual implantation sites", "TREATMENT", 260, 289], ["ethanol", "TREATMENT", 357, 364], ["size", "OBSERVATION_MODIFIER", 25, 29], ["shape", "OBSERVATION_MODIFIER", 34, 39], ["utero", "ANATOMY_MODIFIER", 43, 48], ["-placental", "ANATOMY_MODIFIER", 48, 58], ["vasculature", "ANATOMY", 59, 70], ["polystyrene block", "OBSERVATION", 141, 158], ["uterine", "ANATOMY", 221, 228], ["adipose tissue", "ANATOMY", 229, 243], ["uterine membrane", "ANATOMY", 314, 330]]], ["Processed implantation sites were carefully sliced in the plane perpendicular to the long-axis of the uterus, and embedded in paraffin, cut side facing down.", [["sites", "ANATOMY", 23, 28], ["uterus", "ANATOMY", 102, 108], ["paraffin", "CHEMICAL", 126, 134], ["uterus", "ORGAN", 102, 108], ["Processed implantation sites", "TREATMENT", 0, 28], ["implantation", "OBSERVATION", 10, 22], ["long", "ANATOMY_MODIFIER", 85, 89], ["-axis", "ANATOMY_MODIFIER", 89, 94], ["uterus", "ANATOMY", 102, 108], ["paraffin", "OBSERVATION_MODIFIER", 126, 134]]], ["Serial sections of 5 mm thickness were cut at the midsagittal point and stained with hematoxylin-eosin (H&E) to evaluate morphology.Mouse.First-trimester human placenta-decidua explant co-culture Placenta-decidua co-culture was performed as described previously (Dunk et al., 2003) .", [["sections", "ANATOMY", 7, 15], ["placenta", "ANATOMY", 160, 168], ["Placenta-decidua", "ANATOMY", 196, 212], ["hematoxylin-eosin", "CHEMICAL", 85, 102], ["hematoxylin", "CHEMICAL", 85, 96], ["eosin", "CHEMICAL", 97, 102], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 85, 102], ["Mouse", "ORGANISM", 132, 137], ["human", "ORGANISM", 154, 159], ["placenta-decidua explant", "CELL", 160, 184], ["Placenta-decidua", "CELL", 196, 212], ["Mouse", "SPECIES", 132, 137], ["human", "SPECIES", 154, 159], ["Mouse", "SPECIES", 132, 137], ["human", "SPECIES", 154, 159], ["Serial sections of 5 mm thickness", "TEST", 0, 33], ["hematoxylin", "TEST", 85, 96], ["First-trimester human placenta", "TREATMENT", 138, 168], ["decidua co-culture", "TEST", 205, 223], ["placenta", "ANATOMY", 160, 168]]], ["Briefly, fresh tissues were collected and assessed for quality.", [["tissues", "ANATOMY", 15, 22], ["tissues", "TISSUE", 15, 22], ["fresh tissues", "OBSERVATION", 9, 22]]], ["Small sections of decidua parietalis with a solid structure and intact luminal epithelium were dissected.", [["sections", "ANATOMY", 6, 14], ["decidua parietalis", "ANATOMY", 18, 36], ["solid structure", "ANATOMY", 44, 59], ["luminal epithelium", "ANATOMY", 71, 89], ["luminal", "CHEMICAL", 71, 78], ["sections", "MULTI-TISSUE_STRUCTURE", 6, 14], ["decidua parietalis", "CANCER", 18, 36], ["luminal epithelium", "TISSUE", 71, 89], ["Small sections of decidua parietalis", "PROBLEM", 0, 36], ["a solid structure", "PROBLEM", 42, 59], ["decidua parietalis", "OBSERVATION", 18, 36], ["solid structure", "OBSERVATION", 44, 59], ["intact", "OBSERVATION", 64, 70], ["luminal", "ANATOMY_MODIFIER", 71, 78], ["epithelium", "ANATOMY_MODIFIER", 79, 89]]], ["Intact villi with EVT columns were carefully dissected from the matched placenta (same donor).", [["villi", "ANATOMY", 7, 12], ["EVT columns", "ANATOMY", 18, 29], ["placenta", "ANATOMY", 72, 80], ["villi", "MULTI-TISSUE_STRUCTURE", 7, 12], ["placenta", "ORGAN", 72, 80], ["EVT columns", "TREATMENT", 18, 29], ["villi", "ANATOMY", 7, 12], ["placenta", "ANATOMY", 72, 80]]], ["Decidua pieces were incubated in serum-free media (DMEM-F12, phenol red free, Gibco) containing drugs or DMSO (0.025% (v/v) final concentration) for 2 h at 37 C. These were then placed at a 45 degree angle, epithelial side facing up, on cell culture inserts (0.4 mm, 12 mm diameter, EMD Millipore) pre-coated with 120 ml matrigel (undiluted, high concentration, phenol red-free, Corning), and placed in a 24-well plate.", [["serum", "ANATOMY", 33, 38], ["epithelial", "ANATOMY", 207, 217], ["cell", "ANATOMY", 237, 241], ["DMEM-F12, phenol red", "CHEMICAL", 51, 71], ["DMSO", "CHEMICAL", 105, 109], ["phenol", "CHEMICAL", 362, 368], ["phenol red", "CHEMICAL", 61, 71], ["DMSO", "CHEMICAL", 105, 109], ["phenol", "CHEMICAL", 362, 368], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["phenol red free", "SIMPLE_CHEMICAL", 61, 76], ["DMSO", "SIMPLE_CHEMICAL", 105, 109], ["cell", "CELL", 237, 241], ["Decidua pieces", "TREATMENT", 0, 14], ["serum", "TEST", 33, 38], ["phenol red free, Gibco)", "TREATMENT", 61, 84], ["drugs", "TREATMENT", 96, 101], ["DMSO", "TREATMENT", 105, 109], ["cell culture", "TEST", 237, 249], ["120 ml matrigel", "TREATMENT", 314, 329]]], ["The matrigel was allowed to solidify, followed by careful placement of placental villous explants on the decidual epithelial surface.", [["matrigel", "ANATOMY", 4, 12], ["placental villous explants", "ANATOMY", 71, 97], ["decidual epithelial surface", "ANATOMY", 105, 132], ["placental villous explants", "TISSUE", 71, 97], ["decidual epithelial surface", "TISSUE", 105, 132], ["careful placement of placental villous explants on the decidual epithelial surface", "TREATMENT", 50, 132], ["placental villous explants", "OBSERVATION", 71, 97], ["decidual", "ANATOMY_MODIFIER", 105, 113], ["epithelial", "ANATOMY_MODIFIER", 114, 124], ["surface", "OBSERVATION_MODIFIER", 125, 132]]], ["Four hundred microliters of serum-free DMEM-F12 medium supplemented with normocin, progesterone (20 ng/ml) and estradiol (0.3 ng/ml) (N\u00feP4\u00feE2) was placed outside the insert and tissues were incubated overnight at 37 C with 3% O 2 , 5% CO 2 and balanced N 2 .", [["serum", "ANATOMY", 28, 33], ["tissues", "ANATOMY", 177, 184], ["normocin", "CHEMICAL", 73, 81], ["progesterone", "CHEMICAL", 83, 95], ["estradiol", "CHEMICAL", 111, 120], ["N\u00feP4\u00feE2", "CHEMICAL", 134, 141], ["normocin", "CHEMICAL", 73, 81], ["progesterone", "CHEMICAL", 83, 95], ["estradiol", "CHEMICAL", 111, 120], ["O 2", "CHEMICAL", 226, 229], ["CO", "CHEMICAL", 235, 237], ["N 2", "CHEMICAL", 253, 256], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["DMEM-F12", "CELL", 39, 47], ["normocin", "SIMPLE_CHEMICAL", 73, 81], ["progesterone", "SIMPLE_CHEMICAL", 83, 95], ["estradiol", "SIMPLE_CHEMICAL", 111, 120], ["tissues", "TISSUE", 177, 184], ["serum-free DMEM", "TREATMENT", 28, 43], ["normocin", "TREATMENT", 73, 81], ["progesterone", "TREATMENT", 83, 95], ["estradiol", "TREATMENT", 111, 120], ["N\u00feP4\u00feE2)", "TREATMENT", 134, 142], ["tissues", "ANATOMY", 177, 184]]], ["Next morning, the placental explants were further anchored with 30 ml of matrigel.", [["placental explants", "ANATOMY", 18, 36], ["matrigel", "ANATOMY", 73, 81], ["placental explants", "TISSUE", 18, 36], ["the placental explants", "TREATMENT", 14, 36]]], ["Tissues were then covered with 200 ml of supplemented (N\u00feP4\u00feE2) serum-free DMEM-F12 medium containing drugs or DMSO and allowed to incubate for an additional 5 days, during which the media inside and outside the insert was changed once.", [["Tissues", "ANATOMY", 0, 7], ["serum", "ANATOMY", 64, 69], ["N\u00feP4\u00feE2", "CHEMICAL", 55, 62], ["DMSO", "CHEMICAL", 111, 115], ["DMSO", "CHEMICAL", 111, 115], ["Tissues", "CANCER", 0, 7], ["N\u00feP4\u00feE2", "SIMPLE_CHEMICAL", 55, 62], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["DMSO", "SIMPLE_CHEMICAL", 111, 115], ["supplemented (N\u00feP4\u00feE2", "TREATMENT", 41, 62], ["serum-free DMEM", "TREATMENT", 64, 79], ["F12 medium containing drugs", "TREATMENT", 80, 107], ["DMSO", "TREATMENT", 111, 115]]], ["The tissues were fixed in 4% (v/v) paraformaldehyde for 1 h, washed with PBS, dehydrated in ascending concentrations of ethanol, cleared in xylene and embedded in paraffin.", [["tissues", "ANATOMY", 4, 11], ["ethanol", "CHEMICAL", 120, 127], ["paraformaldehyde", "CHEMICAL", 35, 51], ["ethanol", "CHEMICAL", 120, 127], ["xylene", "CHEMICAL", 140, 146], ["paraffin", "CHEMICAL", 163, 171], ["tissues", "TISSUE", 4, 11], ["paraformaldehyde", "SIMPLE_CHEMICAL", 35, 51], ["ethanol", "SIMPLE_CHEMICAL", 120, 127], ["xylene", "SIMPLE_CHEMICAL", 140, 146], ["paraformaldehyde", "TREATMENT", 35, 51], ["PBS", "TREATMENT", 73, 76], ["ethanol", "TREATMENT", 120, 127], ["tissues", "ANATOMY", 4, 11], ["dehydrated", "OBSERVATION", 78, 88], ["ascending concentrations", "OBSERVATION_MODIFIER", 92, 116]]], ["Blocks were sectioned to 5 mm thickness and every 10th serial section was histologically assessed by standard H&E staining.", [["Blocks", "TREATMENT", 0, 6], ["serial section", "TEST", 55, 69]]], ["Explants from each donor were cultured in triplicate for each treatment group.", [["Explants", "ANATOMY", 0, 8], ["Explants", "DEVELOPING_ANATOMICAL_STRUCTURE", 0, 8], ["each treatment group", "TREATMENT", 57, 77]]], ["The experiment was repeated with placenta-decidua matched tissues from five different donors.", [["placenta-decidua", "ANATOMY", 33, 49], ["tissues", "ANATOMY", 58, 65], ["placenta-decidua", "TISSUE", 33, 49], ["tissues", "TISSUE", 58, 65], ["donors", "ORGANISM", 86, 92], ["placenta-decidua matched tissues", "TREATMENT", 33, 65]]], ["Decidua-alone samples served as a control to ensure that there was no trophoblast invasion prior to setting up the co-culture.Mouse.To quantify the depth of remodeling, co-culture sections immunostained for CK-7, SMA and CD31 were imaged and signs of progressive remodeling were tracked along the depth of the decidua as previously described (Hazan et al., 2010) .", [["samples", "ANATOMY", 14, 21], ["trophoblast", "ANATOMY", 70, 81], ["sections", "ANATOMY", 180, 188], ["decidua", "ANATOMY", 310, 317], ["Decidua", "SIMPLE_CHEMICAL", 0, 7], ["trophoblast", "CELL", 70, 81], ["Mouse", "ORGANISM", 126, 131], ["CK-7", "GENE_OR_GENE_PRODUCT", 207, 211], ["SMA", "GENE_OR_GENE_PRODUCT", 213, 216], ["CD31", "GENE_OR_GENE_PRODUCT", 221, 225], ["decidua", "MULTI-TISSUE_STRUCTURE", 310, 317], ["CK-7", "PROTEIN", 207, 211], ["SMA", "PROTEIN", 213, 216], ["CD31", "PROTEIN", 221, 225], ["Mouse", "SPECIES", 126, 131], ["Mouse", "SPECIES", 126, 131], ["trophoblast invasion", "PROBLEM", 70, 90], ["the co-culture", "TEST", 111, 125], ["co-culture sections", "TEST", 169, 188], ["CK", "TEST", 207, 209], ["SMA", "TEST", 213, 216], ["progressive remodeling", "PROBLEM", 251, 273], ["no", "UNCERTAINTY", 67, 69], ["trophoblast", "ANATOMY", 70, 81], ["invasion", "OBSERVATION", 82, 90], ["depth", "OBSERVATION_MODIFIER", 148, 153], ["remodeling", "OBSERVATION", 157, 167], ["SMA", "ANATOMY", 213, 216], ["CD31", "ANATOMY", 221, 225], ["progressive", "OBSERVATION_MODIFIER", 251, 262], ["remodeling", "OBSERVATION", 263, 273], ["depth", "OBSERVATION_MODIFIER", 297, 302], ["decidua", "ANATOMY", 310, 317]]], ["Measurements were made from the epithelial surface up to the midsegment of the decidua (0-1000 mm) showing advanced or early stages of vascular transformation.", [["epithelial surface", "ANATOMY", 32, 50], ["midsegment", "ANATOMY", 61, 71], ["decidua", "ANATOMY", 79, 86], ["vascular", "ANATOMY", 135, 143], ["vascular transformation", "DISEASE", 135, 158], ["epithelial surface", "TISSUE", 32, 50], ["decidua", "TISSUE", 79, 86], ["vascular", "MULTI-TISSUE_STRUCTURE", 135, 143], ["Measurements", "TEST", 0, 12], ["vascular transformation", "PROBLEM", 135, 158], ["epithelial", "ANATOMY_MODIFIER", 32, 42], ["surface", "ANATOMY_MODIFIER", 43, 50], ["midsegment", "ANATOMY_MODIFIER", 61, 71], ["decidua", "ANATOMY", 79, 86], ["advanced", "OBSERVATION_MODIFIER", 107, 115], ["early", "OBSERVATION_MODIFIER", 119, 124], ["stages", "OBSERVATION_MODIFIER", 125, 131], ["vascular transformation", "OBSERVATION", 135, 158]]], ["CK-7 positive enEVTs were scored as present (within the vessel lumen) or absent.", [["enEVTs", "ANATOMY", 14, 20], ["vessel lumen", "ANATOMY", 56, 68], ["CK-7", "GENE_OR_GENE_PRODUCT", 0, 4], ["vessel lumen", "MULTI-TISSUE_STRUCTURE", 56, 68], ["CK-7 positive enEVTs", "DNA", 0, 20], ["CK", "TEST", 0, 2], ["positive enEVTs", "PROBLEM", 5, 20], ["vessel", "ANATOMY", 56, 62], ["lumen", "ANATOMY_MODIFIER", 63, 68], ["absent", "OBSERVATION", 73, 79]]], ["Five independent experiments from five different donors, each with two to three explants per treatment group, were quantified.First-trimester human placental villous explant cultureEVT-containing villi were dissected from placenta tissue, positioned on cell culture inserts pre-coated with 200 ml matrigel, and placed in a 24-well plate.", [["explants", "ANATOMY", 80, 88], ["placental villous explant", "ANATOMY", 148, 173], ["villi", "ANATOMY", 196, 201], ["placenta tissue", "ANATOMY", 222, 237], ["cell", "ANATOMY", 253, 257], ["matrigel", "ANATOMY", 297, 305], ["donors", "ORGANISM", 49, 55], ["human", "ORGANISM", 142, 147], ["placental villous explant cultureEVT", "TISSUE", 148, 184], ["villi", "MULTI-TISSUE_STRUCTURE", 196, 201], ["placenta tissue", "TISSUE", 222, 237], ["cell", "CELL", 253, 257], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["treatment group", "TREATMENT", 93, 108], ["First-trimester human placental villous explant cultureEVT", "TREATMENT", 126, 184], ["villi", "PROBLEM", 196, 201], ["placenta tissue", "PROBLEM", 222, 237], ["cell culture inserts", "TREATMENT", 253, 273], ["villous explant", "OBSERVATION", 158, 173], ["villi", "ANATOMY", 196, 201], ["placenta tissue", "OBSERVATION", 222, 237]]], ["Four hundred microliters of serum-free media (DMEM-F12, phenol red free) supplemented with normocin was placed outside the insert and the explants were incubated overnight at 37 C with 3% O 2 and 5% CO 2 .", [["serum", "ANATOMY", 28, 33], ["explants", "ANATOMY", 138, 146], ["DMEM-F12, phenol red", "CHEMICAL", 46, 66], ["normocin", "CHEMICAL", 91, 99], ["phenol red", "CHEMICAL", 56, 66], ["normocin", "CHEMICAL", 91, 99], ["O 2", "CHEMICAL", 188, 191], ["CO 2", "CHEMICAL", 199, 203], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["phenol", "SIMPLE_CHEMICAL", 56, 62], ["normocin", "SIMPLE_CHEMICAL", 91, 99], ["serum-free media (DMEM", "TREATMENT", 28, 50], ["phenol red free)", "TREATMENT", 56, 72], ["normocin", "TREATMENT", 91, 99]]], ["Next morning, all successfully attached explants were randomly assigned to a treatment group.", [["explants", "ANATOMY", 40, 48], ["explants", "CELL", 40, 48], ["a treatment group", "TREATMENT", 75, 92]]], ["The villous explants were either treated with media containing drugs (or DMSO) in the absence or presence of decidua-conditioned medium (DCM).", [["villous explants", "ANATOMY", 4, 20], ["DMSO", "CHEMICAL", 73, 77], ["DMSO", "CHEMICAL", 73, 77], ["villous explants", "TISSUE", 4, 20], ["DMSO", "SIMPLE_CHEMICAL", 73, 77], ["The villous explants", "PROBLEM", 0, 20], ["media containing drugs", "TREATMENT", 46, 68], ["DMSO", "TREATMENT", 73, 77], ["villous explants", "OBSERVATION", 4, 20]]], ["The DCM was a pool of (filtered) culture supernatants obtained from several individual primary decidual cell cultures, treated with either lopinavir/ r-cART, or darunavir/r-cART, or DMSO.", [["supernatants", "ANATOMY", 41, 53], ["decidual cell cultures", "ANATOMY", 95, 117], ["DCM", "DISEASE", 4, 7], ["lopinavir/ r-cART", "CHEMICAL", 139, 156], ["darunavir/r-cART", "CHEMICAL", 161, 177], ["DMSO", "CHEMICAL", 182, 186], ["lopinavir", "CHEMICAL", 139, 148], ["r-cART", "CHEMICAL", 150, 156], ["darunavir", "CHEMICAL", 161, 170], ["r-cART", "CHEMICAL", 171, 177], ["DMSO", "CHEMICAL", 182, 186], ["decidual cell cultures", "CELL", 95, 117], ["lopinavir", "SIMPLE_CHEMICAL", 139, 148], ["r-cART", "SIMPLE_CHEMICAL", 150, 156], ["darunavir", "SIMPLE_CHEMICAL", 161, 170], ["r-cART", "SIMPLE_CHEMICAL", 171, 177], ["DMSO", "SIMPLE_CHEMICAL", 182, 186], ["primary decidual cell cultures", "CELL_LINE", 87, 117], ["culture supernatants", "TEST", 33, 53], ["several individual primary decidual cell cultures", "PROBLEM", 68, 117], ["lopinavir", "TREATMENT", 139, 148], ["cART", "TREATMENT", 152, 156], ["darunavir", "TREATMENT", 161, 170], ["cART", "TREATMENT", 173, 177], ["DMSO", "TREATMENT", 182, 186], ["DCM", "OBSERVATION", 4, 7], ["primary decidual cell cultures", "OBSERVATION", 87, 117]]], ["The explants were photographed after 48 h of drug treatment, using a Leica DFC400 camera attached to a dissecting microscope.", [["explants", "ANATOMY", 4, 12], ["Leica DFC400 camera", "DNA", 69, 88], ["drug treatment", "TREATMENT", 45, 59], ["a Leica DFC400 camera", "TREATMENT", 67, 88], ["a dissecting microscope", "TREATMENT", 101, 124]]], ["ImageJ software (NIH, USA) was used to measure the area of EVT outgrowth.", [["EVT", "ANATOMY", 59, 62], ["EVT", "CELL", 59, 62], ["ImageJ software", "TEST", 0, 15], ["EVT outgrowth", "PROBLEM", 59, 72], ["EVT", "OBSERVATION", 59, 62], ["outgrowth", "OBSERVATION_MODIFIER", 63, 72]]], ["Seven independent experiments, each with three to four villous explants per treatment group, were quantified by a reviewer blinded to treatment allocation.First-trimester human decidual cell cultureDecidual tissue was processed as described previously, with modifications (Wright et al., 2006) .", [["villous explants", "ANATOMY", 55, 71], ["decidual cell cultureDecidual tissue", "ANATOMY", 177, 213], ["villous explants", "TISSUE", 55, 71], ["human", "ORGANISM", 171, 176], ["decidual cell", "CELL", 177, 190], ["cultureDecidual tissue", "TISSUE", 191, 213], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["First-trimester human decidual cell cultureDecidual tissue", "TREATMENT", 155, 213], ["decidual cell", "OBSERVATION", 177, 190]]], ["Tissue was thoroughly washed in PBS to remove blood clots and finely minced with scalpels in a small volume of RPMI 1640 medium (serum and phenol red free) containing 50 mg/ml gentamicin.", [["Tissue", "ANATOMY", 0, 6], ["blood clots", "ANATOMY", 46, 57], ["serum", "ANATOMY", 129, 134], ["phenol", "CHEMICAL", 139, 145], ["gentamicin", "CHEMICAL", 176, 186], ["phenol red", "CHEMICAL", 139, 149], ["gentamicin", "CHEMICAL", 176, 186], ["Tissue", "TISSUE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["clots", "ORGANISM_SUBSTANCE", 52, 57], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["phenol", "SIMPLE_CHEMICAL", 139, 145], ["gentamicin", "SIMPLE_CHEMICAL", 176, 186], ["PBS", "TREATMENT", 32, 35], ["blood clots", "PROBLEM", 46, 57], ["scalpels", "TREATMENT", 81, 89], ["a small volume of RPMI", "TREATMENT", 93, 115], ["serum", "TEST", 129, 134], ["phenol red free)", "TREATMENT", 139, 155], ["gentamicin", "TREATMENT", 176, 186], ["clots", "OBSERVATION", 52, 57], ["small", "OBSERVATION_MODIFIER", 95, 100]]], ["Tissue fragments were digested in a cocktail of 1 mg/ml collagenase (type IV, Worthington), 0.1 mg/ml trypsin inhibitor, 0.15 mg/ml DNaseI and 1 mg/ml BSA for 45 min at 37 C. At the end of the incubation, cells were chilled on ice and the enzymes were inactivated with 10% (v/v) fetal bovine serum (FBS).", [["Tissue fragments", "ANATOMY", 0, 16], ["cells", "ANATOMY", 205, 210], ["fetal bovine serum", "ANATOMY", 279, 297], ["FBS", "ANATOMY", 299, 302], ["DNaseI", "CHEMICAL", 132, 138], ["Tissue", "ORGANISM_SUBSTANCE", 0, 6], ["collagenase", "GENE_OR_GENE_PRODUCT", 56, 67], ["trypsin", "GENE_OR_GENE_PRODUCT", 102, 109], ["DNaseI", "SIMPLE_CHEMICAL", 132, 138], ["BSA", "SIMPLE_CHEMICAL", 151, 154], ["cells", "CELL", 205, 210], ["bovine", "ORGANISM", 285, 291], ["serum", "ORGANISM_SUBSTANCE", 292, 297], ["FBS", "ORGANISM_SUBSTANCE", 299, 302], ["collagenase", "PROTEIN", 56, 67], ["DNaseI", "PROTEIN", 132, 138], ["bovine", "SPECIES", 285, 291], ["bovine", "SPECIES", 285, 291], ["Tissue fragments", "PROBLEM", 0, 16], ["a cocktail", "TREATMENT", 34, 44], ["collagenase (type IV, Worthington)", "TREATMENT", 56, 90], ["trypsin inhibitor", "TREATMENT", 102, 119], ["DNaseI", "TREATMENT", 132, 138], ["the enzymes", "TEST", 235, 246], ["fetal bovine serum", "TEST", 279, 297], ["fragments", "OBSERVATION", 7, 16]]], ["Decidual cells were collected via filtration through a 70 lm cell strainer and centrifugation at 500g for 10 min at 4 C. The supernatant was discarded, the cell pellet was washed once with serum-free medium and finally resuspended in serum-free RPMI 1640 medium (phenol red free) supplemented with 1\u00c2 MEM non-essential amino acids (Gibco), 1\u00c2 glutamax (Gibco), 10 mM HEPES, 1 mM sodium pyruvate and 50 mg/ml gentamycin.", [["Decidual cells", "ANATOMY", 0, 14], ["cell", "ANATOMY", 61, 65], ["supernatant", "ANATOMY", 125, 136], ["cell pellet", "ANATOMY", 156, 167], ["serum", "ANATOMY", 189, 194], ["serum", "ANATOMY", 234, 239], ["phenol red", "CHEMICAL", 263, 273], ["amino acids", "CHEMICAL", 319, 330], ["glutamax", "CHEMICAL", 343, 351], ["sodium pyruvate", "CHEMICAL", 379, 394], ["gentamycin", "CHEMICAL", 408, 418], ["phenol red", "CHEMICAL", 263, 273], ["amino acids", "CHEMICAL", 319, 330], ["glutamax", "CHEMICAL", 343, 351], ["HEPES", "CHEMICAL", 367, 372], ["sodium pyruvate", "CHEMICAL", 379, 394], ["gentamycin", "CHEMICAL", 408, 418], ["Decidual cells", "CELL", 0, 14], ["cell", "CELL", 156, 160], ["serum", "ORGANISM_SUBSTANCE", 189, 194], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["phenol", "SIMPLE_CHEMICAL", 263, 269], ["amino acids", "AMINO_ACID", 319, 330], ["glutamax", "SIMPLE_CHEMICAL", 343, 351], ["sodium pyruvate", "SIMPLE_CHEMICAL", 379, 394], ["gentamycin", "SIMPLE_CHEMICAL", 408, 418], ["Decidual cells", "CELL_TYPE", 0, 14], ["Decidual cells", "PROBLEM", 0, 14], ["a 70 lm cell strainer", "TREATMENT", 53, 74], ["centrifugation", "TREATMENT", 79, 93], ["the cell pellet", "TREATMENT", 152, 167], ["serum", "TEST", 189, 194], ["serum", "TEST", 234, 239], ["1\u00c2 MEM non-essential amino acids", "TREATMENT", 298, 330], ["10 mM HEPES", "TREATMENT", 361, 372], ["1 mM sodium pyruvate", "TREATMENT", 374, 394], ["gentamycin", "TREATMENT", 408, 418], ["cell pellet", "OBSERVATION", 156, 167]]], ["Cells were plated on a 24-well plate at a density of 1 \u00c2 10 6 cells/well, in the presence of progesterone (100 nM), estradiol (10 nM) and cAMP (20 lM).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 62, 67], ["progesterone", "CHEMICAL", 93, 105], ["estradiol", "CHEMICAL", 116, 125], ["cAMP", "CHEMICAL", 138, 142], ["progesterone", "CHEMICAL", 93, 105], ["estradiol", "CHEMICAL", 116, 125], ["cAMP", "CHEMICAL", 138, 142], ["Cells", "CELL", 0, 5], ["cells", "CELL", 62, 67], ["progesterone", "SIMPLE_CHEMICAL", 93, 105], ["estradiol", "SIMPLE_CHEMICAL", 116, 125], ["cAMP", "SIMPLE_CHEMICAL", 138, 142], ["Cells", "TEST", 0, 5], ["progesterone", "TREATMENT", 93, 105], ["estradiol", "TREATMENT", 116, 125], ["cAMP", "TEST", 138, 142]]], ["Cells were exposed to DMSO (control) or drugs at C max concentration (as described above) for 48 h at 37 C in a 5% CO 2 incubator; following which, the cells were harvested and used for flow cytometric analysis and aliquots of the culture supernatant were stored at \u00c020 C until tested by ELISA or multiplex assays.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 152, 157], ["supernatant", "ANATOMY", 239, 250], ["DMSO", "CHEMICAL", 22, 26], ["DMSO", "CHEMICAL", 22, 26], ["CO 2", "CHEMICAL", 115, 119], ["Cells", "CELL", 0, 5], ["DMSO", "SIMPLE_CHEMICAL", 22, 26], ["C max", "SIMPLE_CHEMICAL", 49, 54], ["cells", "CELL", 152, 157], ["DMSO", "TREATMENT", 22, 26], ["drugs at C max concentration", "TREATMENT", 40, 68], ["a 5% CO 2 incubator", "TREATMENT", 110, 129], ["flow cytometric analysis", "TEST", 186, 210], ["the culture supernatant", "TEST", 227, 250], ["multiplex assays", "TEST", 297, 313]]], ["Alamar Blue (Life Technologies) was used as per the manufacturer's instructions to determine cellular viability to control for differences in the number of live cells.", [["cellular", "ANATOMY", 93, 101], ["cells", "ANATOMY", 161, 166], ["Alamar Blue", "CHEMICAL", 0, 11], ["cellular", "CELL", 93, 101], ["cells", "CELL", 161, 166], ["live cells", "CELL_TYPE", 156, 166], ["cellular viability", "PROBLEM", 93, 111]]], ["Experiments were performed in triplicate and repeated 13-15 times.Flow cytometryOne million cells from each treatment group of the human decidual cell culture were washed with PBS and incubated for 30 min on ice with Live Dead dye (fixable viability dye eFluor780, Invitrogen) followed by a wash in stain buffer (with FBS, BD Pharmingen).", [["cells", "ANATOMY", 92, 97], ["decidual cell culture", "ANATOMY", 137, 158], ["FBS", "ANATOMY", 318, 321], ["eFluor780", "CHEMICAL", 254, 263], ["eFluor780", "CHEMICAL", 254, 263], ["cells", "CELL", 92, 97], ["human", "ORGANISM", 131, 136], ["decidual cell culture", "CELL", 137, 158], ["Live Dead dye", "SIMPLE_CHEMICAL", 217, 230], ["FBS", "ORGANISM_SUBSTANCE", 318, 321], ["human decidual cell culture", "CELL_LINE", 131, 158], ["BD Pharmingen", "PROTEIN", 323, 336], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["Flow cytometry", "TEST", 66, 80], ["One million cells", "TREATMENT", 80, 97], ["each treatment", "TREATMENT", 103, 117], ["the human decidual cell culture", "TEST", 127, 158], ["PBS", "TREATMENT", 176, 179], ["Live Dead dye", "TREATMENT", 217, 230], ["fixable viability dye eFluor", "TREATMENT", 232, 260], ["Invitrogen", "TREATMENT", 265, 275], ["a wash in stain buffer", "TREATMENT", 289, 311], ["FBS", "TEST", 318, 321], ["million cells", "OBSERVATION", 84, 97], ["human", "ANATOMY", 131, 136], ["decidual cell", "OBSERVATION", 137, 150]]], ["Cells were incubated with 10% (v/v) human serum for 15 min on ice to block non-specific antibody binding sites, followed by incubation with fluorochrome-conjugated mouse monoclonal antibodies for 30 min on ice.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 42, 47], ["Cells", "CELL", 0, 5], ["human", "ORGANISM", 36, 41], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["fluorochrome", "SIMPLE_CHEMICAL", 140, 152], ["mouse", "ORGANISM", 164, 169], ["fluorochrome-conjugated mouse monoclonal antibodies", "PROTEIN", 140, 191], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 164, 169], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 164, 169], ["Cells", "TEST", 0, 5], ["human serum", "TEST", 36, 47], ["ice", "TREATMENT", 62, 65], ["block non-specific antibody binding sites", "PROBLEM", 69, 110], ["fluorochrome", "TREATMENT", 140, 152], ["conjugated mouse monoclonal antibodies", "TREATMENT", 153, 191]]], ["Cells were washed in stain buffer and fixed in 2% (v/v) paraformaldehyde for 30 min on ice, followed by an additional wash.", [["Cells", "ANATOMY", 0, 5], ["paraformaldehyde", "CHEMICAL", 56, 72], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 56, 72], ["paraformaldehyde", "TREATMENT", 56, 72], ["ice", "TREATMENT", 87, 90], ["an additional wash", "TREATMENT", 104, 122]]], ["Cells were then analyzed using a BD LSRII flow cytometer and data analysis was performed using FlowJo V10.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["a BD LSRII flow cytometer", "TEST", 31, 56], ["data analysis", "TEST", 61, 74]]], ["Cell debris and aggregates were excluded by gating on forward versus side scatter, then by height versus area of forward scatter plots prior to population discrimination.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell debris", "PROBLEM", 0, 11], ["aggregates", "PROBLEM", 16, 26], ["forward scatter plots", "PROBLEM", 113, 134], ["debris", "OBSERVATION", 5, 11], ["scatter plots", "OBSERVATION", 121, 134]]], ["Live cells were gated using a viability dye that marks all dead cells.", [["Live cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 64, 69], ["Live cells", "CELL", 0, 10], ["cells", "CELL", 64, 69], ["dead cells", "CELL_TYPE", 59, 69], ["a viability dye", "TREATMENT", 28, 43], ["dead cells", "OBSERVATION", 59, 69]]], ["The gates for leukocyte sub-populations were set within CD45-expressing cells as follows: uNK cells (CD45 and CD56 positive, CD16 negative), macrophages (CD45 and CD14 positive) and T cells (CD45 and CD3 positive).", [["leukocyte", "ANATOMY", 14, 23], ["CD45-expressing cells", "ANATOMY", 56, 77], ["uNK cells", "ANATOMY", 90, 99], ["CD45", "ANATOMY", 101, 105], ["macrophages", "ANATOMY", 141, 152], ["CD45", "ANATOMY", 154, 158], ["T cells", "ANATOMY", 182, 189], ["leukocyte", "CELL", 14, 23], ["CD45", "GENE_OR_GENE_PRODUCT", 56, 60], ["cells", "CELL", 72, 77], ["uNK cells", "CELL", 90, 99], ["CD45", "GENE_OR_GENE_PRODUCT", 101, 105], ["CD56", "GENE_OR_GENE_PRODUCT", 110, 114], ["CD16", "GENE_OR_GENE_PRODUCT", 125, 129], ["macrophages", "CELL", 141, 152], ["CD45", "GENE_OR_GENE_PRODUCT", 154, 158], ["CD14", "GENE_OR_GENE_PRODUCT", 163, 167], ["T cells", "CELL", 182, 189], ["CD45", "GENE_OR_GENE_PRODUCT", 191, 195], ["CD3", "GENE_OR_GENE_PRODUCT", 200, 203], ["CD45", "PROTEIN", 56, 60], ["expressing cells", "CELL_TYPE", 61, 77], ["uNK cells", "CELL_TYPE", 90, 99], ["CD45", "PROTEIN", 101, 105], ["CD56", "PROTEIN", 110, 114], ["CD16", "PROTEIN", 125, 129], ["macrophages", "CELL_TYPE", 141, 152], ["CD45", "PROTEIN", 154, 158], ["CD14", "PROTEIN", 163, 167], ["T cells", "CELL_TYPE", 182, 189], ["CD45", "PROTEIN", 191, 195], ["CD3", "PROTEIN", 200, 203], ["The gates", "TEST", 0, 9], ["leukocyte sub", "TEST", 14, 27], ["CD45", "TEST", 56, 60], ["uNK cells", "PROBLEM", 90, 99], ["CD45", "TEST", 101, 105], ["CD56", "TEST", 110, 114], ["CD16", "TEST", 125, 129], ["macrophages", "TEST", 141, 152], ["CD45", "TEST", 154, 158], ["CD14", "TEST", 163, 167], ["T cells", "TEST", 182, 189], ["CD45", "TEST", 191, 195], ["CD3", "TEST", 200, 203], ["macrophages", "ANATOMY", 141, 152]]], ["The gate for DSCs was set within CD45 negative cells, positive for CD90.", [["DSCs", "ANATOMY", 13, 17], ["CD45 negative cells", "ANATOMY", 33, 52], ["DSCs", "CANCER", 13, 17], ["CD45", "GENE_OR_GENE_PRODUCT", 33, 37], ["cells", "CELL", 47, 52], ["CD90", "GENE_OR_GENE_PRODUCT", 67, 71], ["DSCs", "CELL_TYPE", 13, 17], ["CD45", "PROTEIN", 33, 37], ["CD90", "PROTEIN", 67, 71], ["DSCs", "TEST", 13, 17], ["CD90", "TEST", 67, 71]]], ["Fluorescence minus one controls were used to set appropriate gates during analysis.", [["Fluorescence minus one controls", "TREATMENT", 0, 31], ["analysis", "TEST", 74, 82]]], ["Antibodies used are listed in Supplementary Table SII .Luminex assayReagents for Luminex V R assay were custom developed by R&D Systems.", [["Luminex V R", "GENE_OR_GENE_PRODUCT", 81, 92], ["Luminex assayReagents", "TEST", 55, 76], ["Luminex V R assay", "TEST", 81, 98]]], ["Human decidual cell culture supernatants (n \u00bc 15) were screened to measure 17 analytes which were divided into two panels. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", [["decidual cell culture supernatants", "ANATOMY", 6, 40], ["Human", "ORGANISM", 0, 5], ["decidual cell", "CELL", 6, 19], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human decidual cell culture supernatants", "TEST", 0, 40]]], ["Panel 1 included the following nine analytes: Endoglin, VEGF, MMP-8, prolactin, IGFBP-1, CXCL16, GM-CSF, IL-15 and PlGF.", [["Endoglin", "GENE_OR_GENE_PRODUCT", 46, 54], ["VEGF", "GENE_OR_GENE_PRODUCT", 56, 60], ["MMP-8", "GENE_OR_GENE_PRODUCT", 62, 67], ["prolactin", "GENE_OR_GENE_PRODUCT", 69, 78], ["IGFBP-1", "GENE_OR_GENE_PRODUCT", 80, 87], ["CXCL16", "GENE_OR_GENE_PRODUCT", 89, 95], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 97, 103], ["IL-15", "GENE_OR_GENE_PRODUCT", 105, 110], ["PlGF", "GENE_OR_GENE_PRODUCT", 115, 119], ["Endoglin", "PROTEIN", 46, 54], ["VEGF", "PROTEIN", 56, 60], ["MMP-8", "PROTEIN", 62, 67], ["prolactin", "PROTEIN", 69, 78], ["IGFBP-1", "PROTEIN", 80, 87], ["CXCL16", "PROTEIN", 89, 95], ["GM", "PROTEIN", 97, 99], ["CSF", "PROTEIN", 100, 103], ["IL-15", "PROTEIN", 105, 110], ["PlGF", "PROTEIN", 115, 119], ["Panel", "TEST", 0, 5], ["Endoglin", "TEST", 46, 54], ["VEGF", "TEST", 56, 60], ["MMP", "TEST", 62, 65], ["prolactin", "TEST", 69, 78], ["IGFBP", "TEST", 80, 85], ["CXCL16", "TEST", 89, 95], ["GM", "TEST", 97, 99], ["CSF", "TEST", 100, 103], ["IL", "TEST", 105, 107], ["PlGF", "TEST", 115, 119], ["VEGF", "ANATOMY", 56, 60]]], ["Panel 2 included the following eight analytes: MMP-9, CXCL12, CXCL10, CCL2, angiopoietin-2, IFN-c, CCL3 and IL-11.", [["MMP-9", "GENE_OR_GENE_PRODUCT", 47, 52], ["CXCL12", "GENE_OR_GENE_PRODUCT", 54, 60], ["CXCL10", "GENE_OR_GENE_PRODUCT", 62, 68], ["CCL2", "GENE_OR_GENE_PRODUCT", 70, 74], ["angiopoietin-2", "GENE_OR_GENE_PRODUCT", 76, 90], ["IFN-c", "GENE_OR_GENE_PRODUCT", 92, 97], ["CCL3", "GENE_OR_GENE_PRODUCT", 99, 103], ["IL-11", "GENE_OR_GENE_PRODUCT", 108, 113], ["MMP", "PROTEIN", 47, 50], ["CXCL12", "PROTEIN", 54, 60], ["CXCL10", "PROTEIN", 62, 68], ["CCL2", "PROTEIN", 70, 74], ["angiopoietin", "PROTEIN", 76, 88], ["IFN", "PROTEIN", 92, 95], ["CCL3", "PROTEIN", 99, 103], ["IL", "PROTEIN", 108, 110], ["Panel", "TEST", 0, 5], ["analytes", "TEST", 37, 45], ["MMP", "TEST", 47, 50], ["CXCL12", "TEST", 54, 60], ["CXCL10", "TEST", 62, 68], ["CCL2", "TEST", 70, 74], ["angiopoietin", "TEST", 76, 88], ["IFN", "TEST", 92, 95], ["CCL3", "TEST", 99, 103], ["IL", "TEST", 108, 110]]], ["Undiluted culture supernatants were used to perform the assay according to the manufacturer's instructions.", [["supernatants", "ANATOMY", 18, 30], ["Undiluted culture supernatants", "TEST", 0, 30], ["the assay", "TEST", 52, 61]]], ["Standards and samples were run in duplicates and serum-free medium was assayed as blank control.", [["samples", "ANATOMY", 14, 21], ["serum", "ANATOMY", 49, 54], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["serum", "TEST", 49, 54]]], ["Plates were read immediately on the MAGPIX instrument and raw data were analyzed using the xPONENT software.", [["the MAGPIX instrument", "TEST", 32, 53]]], ["The % CV between the duplicates was <5%.", [["The % CV between the duplicates", "TEST", 0, 31]]], ["Values outside the lower limit of quantification were assigned a value of one-third of the lower limit of the standard curve.", [["lower limit", "OBSERVATION_MODIFIER", 19, 30], ["lower limit", "OBSERVATION_MODIFIER", 91, 102]]], ["The concentration of each analyte per decidual sample was calculated in picogram per milliliter and corrected for the number of live cells per treatment group.", [["decidual sample", "ANATOMY", 38, 53], ["cells", "ANATOMY", 133, 138], ["cells", "CELL", 133, 138], ["live cells", "CELL_TYPE", 128, 138], ["decidual sample", "TEST", 38, 53]]], ["ELISA Activin-A was measured in undiluted decidual culture supernatants (n \u00bc 11) using the human activin-A duoset ELISA kit (R&D Systems) as per the manufacturer's protocol.", [["decidual culture supernatants", "ANATOMY", 42, 71], ["Activin-A", "GENE_OR_GENE_PRODUCT", 6, 15], ["human", "ORGANISM", 91, 96], ["activin", "GENE_OR_GENE_PRODUCT", 97, 104], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["undiluted decidual culture supernatants", "TREATMENT", 32, 71], ["the human activin", "TREATMENT", 87, 104], ["A duoset ELISA kit (R&D Systems", "TREATMENT", 105, 136], ["the manufacturer's protocol", "TREATMENT", 145, 172]]], ["The concentrations were calculated in picogram per milliliter and corrected for the number of live cells per treatment group.", [["cells", "ANATOMY", 99, 104], ["cells", "CELL", 99, 104], ["live cells", "CELL_TYPE", 94, 104]]], ["Total STAT3 was measured in decidual cell lysates (n \u00bc 8) using the human STAT3 ELISA kit (Abcam ab176666) as per the manufacturer's protocol.", [["decidual cell lysates", "ANATOMY", 28, 49], ["STAT3", "GENE_OR_GENE_PRODUCT", 6, 11], ["decidual cell lysates", "ORGANISM_SUBSTANCE", 28, 49], ["human", "ORGANISM", 68, 73], ["STAT3", "GENE_OR_GENE_PRODUCT", 74, 79], ["STAT3", "PROTEIN", 6, 11], ["STAT3", "PROTEIN", 74, 79], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["Total STAT3", "TREATMENT", 0, 11], ["decidual cell lysates", "TREATMENT", 28, 49], ["the manufacturer's protocol", "TREATMENT", 114, 141], ["decidual cell lysates", "OBSERVATION", 28, 49]]], ["Cell lysates were prepared from 2 \u00c2 10 6 cells per treatment group and were in the range of 100-500 mg/ml of total protein.", [["Cell lysates", "ANATOMY", 0, 12], ["cells", "ANATOMY", 41, 46], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["cells", "CELL", 41, 46], ["Cell lysates", "TEST", 0, 12], ["total protein", "TREATMENT", 109, 122]]], ["Lysates were aliquoted and stored at \u00c080 C and assayed within a month.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Lysates", "TEST", 0, 7]]], ["Total STAT3 concentrations were calculated in microgram per milliliter, corrected for total protein concentration per treatment group, and normalized to the control, which was set at 100%.Immunohistochemical analysisImmunohistochemical analysis was performed on 5 mm sections using the streptavidin peroxidase method as described previously (Hazan et al., 2010) .", [["sections", "ANATOMY", 267, 275], ["STAT3", "GENE_OR_GENE_PRODUCT", 6, 11], ["streptavidin", "GENE_OR_GENE_PRODUCT", 286, 298], ["peroxidase", "GENE_OR_GENE_PRODUCT", 299, 309], ["STAT3", "PROTEIN", 6, 11], ["streptavidin peroxidase", "PROTEIN", 286, 309], ["Total STAT3 concentrations", "TREATMENT", 0, 26], ["total protein concentration", "TREATMENT", 86, 113], ["Immunohistochemical analysisImmunohistochemical analysis", "TEST", 188, 244], ["the streptavidin peroxidase method", "TREATMENT", 282, 316]]], ["Antigen retrieval was performed by microwaving the slides in 10 mM sodium citrate (pH 6) or 1 mM EDTA (pH 9).", [["sodium citrate", "CHEMICAL", 67, 81], ["sodium citrate", "CHEMICAL", 67, 81], ["EDTA", "CHEMICAL", 97, 101], ["sodium citrate", "SIMPLE_CHEMICAL", 67, 81], ["EDTA", "SIMPLE_CHEMICAL", 97, 101], ["Antigen retrieval", "TREATMENT", 0, 17], ["10 mM sodium citrate", "TREATMENT", 61, 81], ["pH", "TEST", 83, 85], ["pH", "TEST", 103, 105]]], ["Slides were blocked using serum-free protein blocking solution (Dako) for 1 h at room temperature, followed by overnight incubation at 4 C in primary antibody (Supplementary Table SII) .", [["serum", "ANATOMY", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["primary antibody", "PROTEIN", 142, 158], ["serum-free protein blocking solution", "TREATMENT", 26, 62]]], ["Subsequent incubations with anti-mouse (1:300, Dako) or anti-rabbit (1:1000, Abcam) biotinylated secondary antibody and streptavidin-horseradish peroxidase-conjugated tertiary reagent (Invitrogen) were carried out for 1 h each at room temperature.", [["Abcam", "GENE_OR_GENE_PRODUCT", 77, 82], ["streptavidin", "SIMPLE_CHEMICAL", 120, 132], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 133, 155], ["conjugated tertiary reagent", "SIMPLE_CHEMICAL", 156, 183], ["Invitrogen", "SIMPLE_CHEMICAL", 185, 195], ["anti-mouse (1:300, Dako", "PROTEIN", 28, 51], ["anti-rabbit (1:1000, Abcam) biotinylated secondary antibody", "PROTEIN", 56, 115], ["horseradish peroxidase", "PROTEIN", 133, 155], ["anti-mouse", "SPECIES", 28, 38], ["anti-rabbit", "SPECIES", 56, 67], ["horseradish", "SPECIES", 133, 144], ["anti-rabbit", "SPECIES", 56, 67], ["anti-mouse", "TREATMENT", 28, 38], ["anti-rabbit", "TREATMENT", 56, 67], ["Abcam", "TREATMENT", 77, 82], ["biotinylated secondary antibody", "TREATMENT", 84, 115], ["streptavidin", "TEST", 120, 132], ["horseradish peroxidase", "TREATMENT", 133, 155], ["conjugated tertiary reagent (Invitrogen)", "TREATMENT", 156, 196]]], ["Incubation with mouse IgG (Dako) or rabbit IgG (Abcam) in place of primary antibody served as a negative control.", [["mouse", "ORGANISM", 16, 21], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["Dako", "GENE_OR_GENE_PRODUCT", 27, 31], ["rabbit", "ORGANISM", 36, 42], ["IgG", "GENE_OR_GENE_PRODUCT", 43, 46], ["Abcam", "GENE_OR_GENE_PRODUCT", 48, 53], ["mouse IgG", "PROTEIN", 16, 25], ["Dako", "PROTEIN", 27, 31], ["rabbit IgG", "PROTEIN", 36, 46], ["Abcam", "PROTEIN", 48, 53], ["primary antibody", "PROTEIN", 67, 83], ["mouse", "SPECIES", 16, 21], ["rabbit", "SPECIES", 36, 42], ["mouse", "SPECIES", 16, 21], ["rabbit", "SPECIES", 36, 42], ["Incubation", "TREATMENT", 0, 10], ["mouse IgG (Dako)", "TREATMENT", 16, 32], ["rabbit IgG (Abcam)", "TREATMENT", 36, 54], ["primary antibody", "TREATMENT", 67, 83]]], ["Specific signals were detected using a Liquid DAB\u00fe (3,3-diaminobenzidine) Chromogen System (Dako).", [["3,3-diaminobenzidine", "CHEMICAL", 52, 72], ["DAB", "CHEMICAL", 46, 49], ["(3,3-diaminobenzidine)", "CHEMICAL", 51, 73], ["3,3-diaminobenzidine", "SIMPLE_CHEMICAL", 52, 72]]], ["Slides were counterstained using Gill's No.1 hematoxylin (Sigma-Aldrich), dehydrated in ascending series of ethanol, cleared in xylene and mounted with Cytoseal (Thermo Fisher Scientific).", [["ethanol", "CHEMICAL", 108, 115], ["hematoxylin", "CHEMICAL", 45, 56], ["ethanol", "CHEMICAL", 108, 115], ["xylene", "CHEMICAL", 128, 134], ["hematoxylin", "SIMPLE_CHEMICAL", 45, 56], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 58, 71], ["ethanol", "SIMPLE_CHEMICAL", 108, 115], ["xylene", "SIMPLE_CHEMICAL", 128, 134], ["ethanol", "TREATMENT", 108, 115], ["ascending", "ANATOMY_MODIFIER", 88, 97]]], ["Photographs were taken with an Olympus DP72 camera mounted on a BX61 Olympus microscope using the CellSens Standard program or the slides were scanned at 20\u00c2 magnification with Aperio AT2 brightfield scanner.Immunohistochemical analysisThe images were quantified by either the newCAST software (Visiopharm) or by digital imaging analysis software; HALO (Indica Labs).", [["Olympus DP72 camera", "DNA", 31, 50], ["AT2", "PROTEIN", 184, 187], ["Photographs", "TEST", 0, 11], ["an Olympus", "TEST", 28, 38], ["the slides", "TEST", 127, 137], ["Immunohistochemical analysis", "TEST", 208, 236], ["The images", "TEST", 236, 246], ["digital imaging analysis software", "TEST", 313, 346]]], ["Quantification of CD56 positive uNK cells and pSTAT3 staining in human decidua samples was performed by Visiopharm.", [["CD56 positive uNK cells", "ANATOMY", 18, 41], ["decidua samples", "ANATOMY", 71, 86], ["CD56", "GENE_OR_GENE_PRODUCT", 18, 22], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 46, 52], ["human", "ORGANISM", 65, 70], ["decidua samples", "CANCER", 71, 86], ["CD56 positive uNK cells", "CELL_TYPE", 18, 41], ["pSTAT3", "PROTEIN", 46, 52], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["CD56 positive uNK cells", "PROBLEM", 18, 41], ["pSTAT3 staining", "TEST", 46, 61], ["human decidua samples", "TEST", 65, 86], ["CD56 positive uNK cells", "OBSERVATION", 18, 41]]], ["The region of interest was identified using a masking tool and the total area was recorded in two replicates for the same biological sample.", [["a masking tool", "TEST", 44, 58]]], ["Counts were performed using a standard protocol that assigned random counting frames covering 5% of each total masked tissue area.", [["tissue area", "ANATOMY", 118, 129], ["tissue", "TISSUE", 118, 124], ["Counts", "TEST", 0, 6], ["a standard protocol", "TREATMENT", 28, 47]]], ["Brown cells (positively staining) and blue cells (negatively staining) were counted at 10\u00c2 magnification.", [["Brown cells", "ANATOMY", 0, 11], ["blue cells", "ANATOMY", 38, 48], ["Brown cells", "CELL", 0, 11], ["blue cells", "CELL", 38, 48], ["Brown cells", "CELL_TYPE", 0, 11], ["blue cells", "CELL_TYPE", 38, 48], ["Brown cells", "TEST", 0, 11], ["staining", "TEST", 24, 32], ["blue cells", "TEST", 38, 48], ["cells", "ANATOMY", 6, 11], ["blue cells", "OBSERVATION", 38, 48]]], ["A positively stained ratio was generated by dividing the total numbers of positively staining cells by the total number of cells counted in the tissue area.Immunohistochemical analysisQuantification of mouse immunostained tissues was performed by using the Cytonuclear IHC module of HALO software.", [["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 123, 128], ["tissue area", "ANATOMY", 144, 155], ["tissues", "ANATOMY", 222, 229], ["cells", "CELL", 94, 99], ["cells", "CELL", 123, 128], ["tissue", "TISSUE", 144, 150], ["mouse", "ORGANISM", 202, 207], ["tissues", "TISSUE", 222, 229], ["positively staining cells", "CELL_TYPE", 74, 99], ["mouse", "SPECIES", 202, 207], ["mouse", "SPECIES", 202, 207], ["A positively stained ratio", "TEST", 0, 26], ["positively staining cells", "PROBLEM", 74, 99], ["staining cells", "OBSERVATION", 85, 99], ["tissue", "ANATOMY", 144, 150], ["area", "ANATOMY_MODIFIER", 151, 155]]], ["The region of interest was identified in each image and the settings were set to include the full range of staining intensity (weak to strong).", [["staining intensity", "TEST", 107, 125]]], ["Cells stained with an intensity exceeding the settings threshold were counted as positive.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["an intensity", "TEST", 19, 31], ["intensity", "OBSERVATION_MODIFIER", 22, 31]]], ["Data were collected as the number of positive cells divided by the tissue area scanned.ImmunofluorescenceSections were dewaxed and rehydrated followed by antigen retrieval.", [["cells", "ANATOMY", 46, 51], ["tissue area", "ANATOMY", 67, 78], ["cells", "CELL", 46, 51], ["tissue", "TISSUE", 67, 73], ["positive cells", "CELL_TYPE", 37, 51], ["positive cells", "PROBLEM", 37, 51], ["ImmunofluorescenceSections", "TEST", 87, 113], ["positive cells", "OBSERVATION", 37, 51]]], ["Autofluorescence was blocked using 1% (w/v) Sudan black in 70% (v/ v) ethanol for 1 min.", [["ethanol", "CHEMICAL", 70, 77], ["ethanol", "CHEMICAL", 70, 77], ["ethanol", "SIMPLE_CHEMICAL", 70, 77], ["Autofluorescence", "TEST", 0, 16]]], ["Non-immune block (10% (v/v) goat serum) was applied for 1 h at room temperature followed by overnight incubation with pan-keratin mouse monoclonal antibody at 4 C (Supplementary Table SII) .", [["serum", "ANATOMY", 33, 38], ["goat", "ORGANISM", 28, 32], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["mouse", "ORGANISM", 130, 135], ["pan-keratin mouse monoclonal antibody", "PROTEIN", 118, 155], ["goat", "SPECIES", 28, 32], ["mouse", "SPECIES", 130, 135], ["goat", "SPECIES", 28, 32], ["mouse", "SPECIES", 130, 135], ["Non-immune block", "PROBLEM", 0, 16], ["v/v) goat serum)", "TREATMENT", 23, 39], ["overnight incubation", "TREATMENT", 92, 112], ["pan-keratin mouse monoclonal antibody", "TREATMENT", 118, 155]]], ["Goat anti-mouse Alexa Fluor-488 conjugated secondary antibody (Invitrogen) was applied at 1:200 dilution, together with DAPI nuclear counterstain for 1 h at room temperature.", [["nuclear", "ANATOMY", 125, 132], ["Alexa Fluor-488", "CHEMICAL", 16, 31], ["Alexa Fluor-488", "CHEMICAL", 16, 31], ["DAPI", "CHEMICAL", 120, 124], ["Fluor-488", "SIMPLE_CHEMICAL", 22, 31], ["Invitrogen", "SIMPLE_CHEMICAL", 63, 73], ["DAPI", "SIMPLE_CHEMICAL", 120, 124], ["Goat anti-mouse Alexa Fluor-488 conjugated secondary antibody", "PROTEIN", 0, 61], ["Goat", "SPECIES", 0, 4], ["anti-mouse", "SPECIES", 5, 15], ["Goat", "SPECIES", 0, 4], ["Alexa Fluor-488", "SPECIES", 16, 31], ["Goat anti-mouse Alexa Fluor", "TREATMENT", 0, 27], ["conjugated secondary antibody (Invitrogen)", "TREATMENT", 32, 74]]], ["Negative control included omission of primary antibody to control for autofluorescence.", [["primary antibody", "PROTEIN", 38, 54], ["primary antibody", "TREATMENT", 38, 54], ["autofluorescence", "PROBLEM", 70, 86]]], ["Slides were stored at 4 C in dark until scanned.Statistical analysisGraphing and statistical analyses were conducted using GraphPad Prism 7.0 (GraphPad Software Inc. ) .", [["Statistical analysisGraphing", "TEST", 48, 76], ["statistical analyses", "TEST", 81, 101], ["GraphPad Prism", "TEST", 123, 137]]], ["Normality of all data was assessed using the Shapiro-Wilk normality test, and all data were normally distributed.", [["the Shapiro-Wilk normality test", "TEST", 41, 72]]], ["Comparisons of multiple groups were evaluated using oneway ANOVA, without matching or pairing followed by Tukey's post-test.", [["Tukey's post-test", "TEST", 106, 123]]], ["For multiplex data analysis of secreted decidual proteins, differences between multiple groups were evaluated using repeated measures one-way ANOVA with Tukey's post-test.", [["decidual", "ANATOMY", 40, 48], ["secreted decidual proteins", "PROTEIN", 31, 57], ["multiplex data analysis", "TEST", 4, 27], ["secreted decidual proteins", "PROBLEM", 31, 57], ["repeated measures", "TREATMENT", 116, 133], ["Tukey's post-test", "TEST", 153, 170]]], ["Results were deemed statistically significant when P < 0.05.Study approvalThis study was carried out in accordance with the recommendations of Mount Sinai Hospital Research Ethics Board, Sinai Health System.", [["P", "TEST", 51, 52], ["Study approval", "TEST", 60, 74], ["This study", "TEST", 74, 84]]], ["The protocol was approved by the Mount Sinai Hospital Research Ethics Board, Sinai Health System REB# 02-0061A and University Health Network Research Ethics Board REB# 15-9661.", [["REB# 15-9661", "CHEMICAL", 163, 175]]], ["Informed consent was obtained through the BioBank program at the Research Centre for Women's and Infants' Health at Mount Sinai Hospital using the above mentioned REB approved protocol.", [["Women", "SPECIES", 85, 90], ["Infants", "SPECIES", 97, 104]]], ["All research using human tissues was performed in a class II certified laboratory by qualified staff trained in biological and chemical safety protocols, and in accordance with Health Canada guidelines and regulations.Study approvalAnimal experiments were approved by the University Health Network Animal Use Committee (REB approval number 2575.25) and performed according to the policies and guidelines of the Canadian Council on Animal Care.ResultsLopinavir treatment impairs spiral artery remodeling in a human placenta-decidua explant co-culture systemResultsTo investigate the effect of PIs on decidual spiral artery remodeling, we employed a human placenta-decidua explant co-culture system previously shown to emulate uterine vascular adaptations during the first trimester (Dunk et al., 2003) (Fig. 1) .", [["tissues", "ANATOMY", 25, 32], ["spiral artery", "ANATOMY", 478, 491], ["placenta", "ANATOMY", 514, 522], ["decidual spiral artery", "ANATOMY", 599, 621], ["placenta", "ANATOMY", 654, 662], ["uterine vascular", "ANATOMY", 725, 741], ["ResultsLopinavir", "CHEMICAL", 443, 459], ["ResultsLopinavir", "CHEMICAL", 443, 459], ["human", "ORGANISM", 19, 24], ["tissues", "TISSUE", 25, 32], ["ResultsLopinavir", "SIMPLE_CHEMICAL", 443, 459], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 478, 491], ["human", "ORGANISM", 508, 513], ["placenta", "DEVELOPING_ANATOMICAL_STRUCTURE", 514, 522], ["decidual spiral artery", "MULTI-TISSUE_STRUCTURE", 599, 621], ["human", "ORGANISM", 648, 653], ["placenta-decidua explant", "CELL", 654, 678], ["uterine vascular", "MULTI-TISSUE_STRUCTURE", 725, 741], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 508, 513], ["human", "SPECIES", 648, 653], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 508, 513], ["human", "SPECIES", 648, 653], ["Study approval", "TEST", 218, 232], ["Animal Care", "TREATMENT", 431, 442], ["ResultsLopinavir treatment", "TREATMENT", 443, 469], ["spiral artery remodeling", "PROBLEM", 478, 502], ["a human placenta", "PROBLEM", 506, 522], ["PIs on decidual spiral artery remodeling", "TREATMENT", 592, 632], ["a human placenta-decidua explant co-culture system", "TREATMENT", 646, 696], ["artery", "ANATOMY", 485, 491], ["artery", "ANATOMY", 615, 621], ["vascular", "ANATOMY", 733, 741]]], ["Placental-decidual co-cultures were treated with either lopinavir boosted with ritonavir (lopinavir/r) (abbreviated as LPV/r in figures), or darunavir boosted with ritonavir (darunavir/r) (abbreviated as DRV/r in figures), or DMSO (final concentration 0.025% (v/v)) as a control.", [["Placental-decidual co-cultures", "ANATOMY", 0, 30], ["lopinavir", "CHEMICAL", 56, 65], ["ritonavir", "CHEMICAL", 79, 88], ["lopinavir", "CHEMICAL", 90, 99], ["darunavir", "CHEMICAL", 141, 150], ["ritonavir", "CHEMICAL", 164, 173], ["darunavir", "CHEMICAL", 175, 184], ["DMSO", "CHEMICAL", 226, 230], ["lopinavir", "CHEMICAL", 56, 65], ["ritonavir", "CHEMICAL", 79, 88], ["lopinavir", "CHEMICAL", 90, 99], ["darunavir", "CHEMICAL", 141, 150], ["ritonavir", "CHEMICAL", 164, 173], ["darunavir", "CHEMICAL", 175, 184], ["DMSO", "CHEMICAL", 226, 230], ["Placental-decidual co-cultures", "CELL", 0, 30], ["lopinavir", "SIMPLE_CHEMICAL", 56, 65], ["ritonavir", "SIMPLE_CHEMICAL", 79, 88], ["lopinavir", "SIMPLE_CHEMICAL", 90, 99], ["darunavir", "SIMPLE_CHEMICAL", 141, 150], ["ritonavir", "SIMPLE_CHEMICAL", 164, 173], ["darunavir", "SIMPLE_CHEMICAL", 175, 184], ["DMSO", "SIMPLE_CHEMICAL", 226, 230], ["Placental-decidual co-cultures", "CELL_TYPE", 0, 30], ["decidual co-cultures", "PROBLEM", 10, 30], ["lopinavir", "TREATMENT", 56, 65], ["ritonavir", "TREATMENT", 79, 88], ["lopinavir", "TREATMENT", 90, 99], ["LPV/r in figures", "TREATMENT", 119, 135], ["darunavir", "TREATMENT", 141, 150], ["ritonavir", "TREATMENT", 164, 173], ["darunavir", "TREATMENT", 175, 184], ["DRV/r in figures", "TREATMENT", 204, 220], ["DMSO", "TREATMENT", 226, 230]]], ["Tissue sections were stained with cytokeratin-7 (CK-7) to assess trophoblast invasion, CD31 or smooth muscle actin (SMA) to assess presence or loss of endothelial cells and smooth muscle cells, respectively, around vessels, or CD45 to assess leukocyte location around vessels.ResultsIn both the darunavir/r and control co-cultures, trophoblast invasion of spiral arteries could be observed.", [["Tissue sections", "ANATOMY", 0, 15], ["trophoblast", "ANATOMY", 65, 76], ["smooth muscle", "ANATOMY", 95, 108], ["endothelial cells", "ANATOMY", 151, 168], ["smooth muscle cells", "ANATOMY", 173, 192], ["vessels", "ANATOMY", 215, 222], ["leukocyte", "ANATOMY", 242, 251], ["vessels", "ANATOMY", 268, 275], ["trophoblast", "ANATOMY", 332, 343], ["spiral arteries", "ANATOMY", 356, 371], ["darunavir", "CHEMICAL", 295, 304], ["darunavir", "CHEMICAL", 295, 304], ["Tissue sections", "CANCER", 0, 15], ["cytokeratin-7", "GENE_OR_GENE_PRODUCT", 34, 47], ["CK-7", "GENE_OR_GENE_PRODUCT", 49, 53], ["trophoblast", "CELL", 65, 76], ["CD31", "GENE_OR_GENE_PRODUCT", 87, 91], ["smooth muscle actin", "GENE_OR_GENE_PRODUCT", 95, 114], ["SMA", "GENE_OR_GENE_PRODUCT", 116, 119], ["endothelial cells", "CELL", 151, 168], ["smooth muscle cells", "CELL", 173, 192], ["vessels", "MULTI-TISSUE_STRUCTURE", 215, 222], ["CD45", "GENE_OR_GENE_PRODUCT", 227, 231], ["leukocyte", "CELL", 242, 251], ["vessels", "MULTI-TISSUE_STRUCTURE", 268, 275], ["trophoblast", "CELL", 332, 343], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 356, 371], ["cytokeratin-7", "PROTEIN", 34, 47], ["CK-7", "PROTEIN", 49, 53], ["CD31", "PROTEIN", 87, 91], ["smooth muscle actin", "PROTEIN", 95, 114], ["SMA", "PROTEIN", 116, 119], ["endothelial cells", "CELL_TYPE", 151, 168], ["smooth muscle cells", "CELL_TYPE", 173, 192], ["CD45", "PROTEIN", 227, 231], ["Tissue sections", "TEST", 0, 15], ["cytokeratin", "TEST", 34, 45], ["CK", "TEST", 49, 51], ["trophoblast invasion", "PROBLEM", 65, 85], ["CD31", "TEST", 87, 91], ["loss of endothelial cells", "PROBLEM", 143, 168], ["smooth muscle cells", "PROBLEM", 173, 192], ["the darunavir/r and control co-cultures", "TREATMENT", 291, 330], ["trophoblast", "ANATOMY", 65, 76], ["invasion", "OBSERVATION", 77, 85], ["smooth muscle", "ANATOMY", 95, 108], ["SMA", "ANATOMY", 116, 119], ["loss", "OBSERVATION", 143, 147], ["endothelial cells", "OBSERVATION", 151, 168], ["smooth muscle cells", "OBSERVATION", 173, 192], ["vessels", "ANATOMY", 215, 222], ["vessels", "ANATOMY", 268, 275], ["spiral arteries", "ANATOMY", 356, 371]]], ["CK-7 \u00fe endovascular EVTs (enEVTs) could be seen invading the lumen of arteries traversing the region of decidua in close proximity to the placenta (see arrows in Fig. 1A and I).", [["enEVTs", "ANATOMY", 26, 32], ["lumen", "ANATOMY", 61, 66], ["arteries", "ANATOMY", 70, 78], ["decidua", "ANATOMY", 104, 111], ["placenta", "ANATOMY", 138, 146], ["CK-7", "GENE_OR_GENE_PRODUCT", 0, 4], ["enEVTs", "CANCER", 26, 32], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 66], ["arteries", "MULTI-TISSUE_STRUCTURE", 70, 78], ["decidua", "MULTI-TISSUE_STRUCTURE", 104, 111], ["placenta", "ORGAN", 138, 146], ["CK", "TEST", 0, 2], ["endovascular EVTs", "TREATMENT", 7, 24], ["lumen", "ANATOMY_MODIFIER", 61, 66], ["arteries", "ANATOMY", 70, 78], ["decidua", "OBSERVATION", 104, 111], ["placenta", "ANATOMY", 138, 146]]], ["The invaded arteries in both the control and darunavir/r co-cultures displayed advanced stages of remodeling, evident by a complete loss of endothelial (lack of CD31 staining) (see arrows in Fig. 1B and J) and smooth muscle cells (lack of SMA staining) (see arrows in Fig. 1C and K) lining the vessel walls.", [["arteries", "ANATOMY", 12, 20], ["endothelial", "ANATOMY", 140, 151], ["smooth muscle cells", "ANATOMY", 210, 229], ["vessel walls", "ANATOMY", 294, 306], ["darunavir", "CHEMICAL", 45, 54], ["darunavir", "CHEMICAL", 45, 54], ["arteries", "MULTI-TISSUE_STRUCTURE", 12, 20], ["endothelial", "CELL", 140, 151], ["CD31", "GENE_OR_GENE_PRODUCT", 161, 165], ["1B", "GENE_OR_GENE_PRODUCT", 196, 198], ["smooth muscle cells", "CELL", 210, 229], ["SMA", "GENE_OR_GENE_PRODUCT", 239, 242], ["vessel walls", "MULTI-TISSUE_STRUCTURE", 294, 306], ["darunavir/r co-cultures", "CELL_LINE", 45, 68], ["CD31", "PROTEIN", 161, 165], ["smooth muscle cells", "CELL_TYPE", 210, 229], ["SMA", "PROTEIN", 239, 242], ["darunavir/r co-cultures", "TEST", 45, 68], ["advanced stages of remodeling", "PROBLEM", 79, 108], ["a complete loss of endothelial", "PROBLEM", 121, 151], ["CD31 staining", "PROBLEM", 161, 174], ["smooth muscle cells", "PROBLEM", 210, 229], ["SMA staining", "PROBLEM", 239, 251], ["1C", "TEST", 273, 275], ["invaded", "OBSERVATION", 4, 11], ["arteries", "ANATOMY", 12, 20], ["advanced", "OBSERVATION_MODIFIER", 79, 87], ["remodeling", "OBSERVATION", 98, 108], ["complete", "OBSERVATION_MODIFIER", 123, 131], ["loss", "OBSERVATION", 132, 136], ["endothelial", "ANATOMY", 140, 151], ["smooth muscle", "ANATOMY", 210, 223], ["cells", "OBSERVATION", 224, 229], ["SMA", "ANATOMY", 239, 242], ["vessel", "ANATOMY", 294, 300], ["walls", "ANATOMY_MODIFIER", 301, 306]]], ["The expected leukocyte recruitment to the site of vascular remodeling could also be seen ( Fig. 1D and L).ResultsIn contrast, in the lopinavir/r treated co-cultures vessel remodeling was impaired.", [["leukocyte", "ANATOMY", 13, 22], ["site", "ANATOMY", 42, 46], ["vascular", "ANATOMY", 50, 58], ["vessel", "ANATOMY", 165, 171], ["lopinavir", "CHEMICAL", 133, 142], ["lopinavir", "CHEMICAL", 133, 142], ["leukocyte", "CELL", 13, 22], ["vascular", "MULTI-TISSUE_STRUCTURE", 50, 58], ["lopinavir", "SIMPLE_CHEMICAL", 133, 142], ["vessel", "MULTI-TISSUE_STRUCTURE", 165, 171], ["The expected leukocyte recruitment", "TREATMENT", 0, 34], ["vascular remodeling", "PROBLEM", 50, 69], ["the lopinavir/r treated co-cultures vessel remodeling", "TREATMENT", 129, 182], ["leukocyte recruitment", "OBSERVATION", 13, 34], ["vascular", "ANATOMY", 50, 58], ["remodeling", "OBSERVATION", 59, 69], ["could also be seen", "UNCERTAINTY", 70, 88], ["L", "ANATOMY_MODIFIER", 103, 104], ["vessel", "ANATOMY", 165, 171], ["impaired", "OBSERVATION", 187, 195]]], ["Although EVTs were released from the placenta, enEVT invasion of spiral arteries was not seen, as evident from absence of CK-7 staining inside the vessel lumen (see arrows in Fig. 1E ).", [["EVTs", "ANATOMY", 9, 13], ["placenta", "ANATOMY", 37, 45], ["enEVT", "ANATOMY", 47, 52], ["spiral arteries", "ANATOMY", 65, 80], ["vessel lumen", "ANATOMY", 147, 159], ["EVTs", "CANCER", 9, 13], ["placenta", "ORGAN", 37, 45], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 65, 80], ["CK-7", "GENE_OR_GENE_PRODUCT", 122, 126], ["vessel lumen", "MULTI-TISSUE_STRUCTURE", 147, 159], ["EVTs", "PROTEIN", 9, 13], ["CK", "PROTEIN", 122, 124], ["EVTs", "TEST", 9, 13], ["CK", "TEST", 122, 124], ["placenta", "ANATOMY", 37, 45], ["invasion", "OBSERVATION_MODIFIER", 53, 61], ["spiral arteries", "ANATOMY", 65, 80], ["not seen", "UNCERTAINTY", 85, 93], ["vessel", "ANATOMY", 147, 153], ["lumen", "ANATOMY_MODIFIER", 154, 159]]], ["Robust CD31 (see arrows in Fig. 1F ) and SMA staining (see arrows in Fig. 1G) were seen around the vessel walls, indicating un-remodeled vessels with intact endothelial and smooth muscle cells.", [["vessel walls", "ANATOMY", 99, 111], ["vessels", "ANATOMY", 137, 144], ["endothelial", "ANATOMY", 157, 168], ["smooth muscle cells", "ANATOMY", 173, 192], ["CD31", "GENE_OR_GENE_PRODUCT", 7, 11], ["SMA", "GENE_OR_GENE_PRODUCT", 41, 44], ["vessel walls", "MULTI-TISSUE_STRUCTURE", 99, 111], ["vessels", "MULTI-TISSUE_STRUCTURE", 137, 144], ["endothelial", "CELL", 157, 168], ["smooth muscle cells", "CELL", 173, 192], ["CD31", "PROTEIN", 7, 11], ["SMA", "PROTEIN", 41, 44], ["endothelial and smooth muscle cells", "CELL_TYPE", 157, 192], ["Robust CD31", "TEST", 0, 11], ["SMA staining", "PROBLEM", 41, 53], ["SMA", "ANATOMY", 41, 44], ["vessel", "ANATOMY", 99, 105], ["walls", "ANATOMY_MODIFIER", 106, 111], ["un", "OBSERVATION", 124, 126], ["remodeled", "ANATOMY_MODIFIER", 127, 136], ["vessels", "ANATOMY", 137, 144], ["intact endothelial", "OBSERVATION", 150, 168], ["smooth muscle cells", "OBSERVATION", 173, 192]]], ["Although leukocytes were present, their accumulation around the vessels was impaired in the lopinavir/r treated co-cultures (see arrows in Fig. 1H) .ResultsA decidua-alone culture (in the absence of placental explants) was used to rule out any sign of spiral artery remodeling before the setup of co-culture ( Fig. 1M-P) .", [["leukocytes", "ANATOMY", 9, 19], ["vessels", "ANATOMY", 64, 71], ["placental explants", "ANATOMY", 199, 217], ["spiral artery", "ANATOMY", 252, 265], ["lopinavir", "CHEMICAL", 92, 101], ["lopinavir", "CHEMICAL", 92, 101], ["1H", "CHEMICAL", 144, 146], ["leukocytes", "CELL", 9, 19], ["vessels", "MULTI-TISSUE_STRUCTURE", 64, 71], ["lopinavir", "SIMPLE_CHEMICAL", 92, 101], ["placental explants", "TISSUE", 199, 217], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 252, 265], ["leukocytes", "CELL_TYPE", 9, 19], ["lopinavir/r treated co-cultures", "CELL_LINE", 92, 123], ["leukocytes", "PROBLEM", 9, 19], ["the lopinavir/r treated co-cultures", "TREATMENT", 88, 123], ["culture", "TEST", 172, 179], ["placental explants", "TREATMENT", 199, 217], ["spiral artery remodeling", "PROBLEM", 252, 276], ["co-culture", "TEST", 297, 307], ["leukocytes", "OBSERVATION", 9, 19], ["vessels", "ANATOMY", 64, 71], ["spiral artery", "ANATOMY", 252, 265], ["remodeling", "OBSERVATION", 266, 276]]], ["The control decidua was negative for CK-7, and non-invaded vessels stained positive for SMA and CD31.ResultsSimilar results were obtained from five independent co-culture experiments, each using matched placenta-decidua tissue from different donors.", [["decidua", "ANATOMY", 12, 19], ["vessels", "ANATOMY", 59, 66], ["placenta-decidua tissue", "ANATOMY", 203, 226], ["decidua", "CELL", 12, 19], ["CK-7", "GENE_OR_GENE_PRODUCT", 37, 41], ["vessels", "MULTI-TISSUE_STRUCTURE", 59, 66], ["SMA", "GENE_OR_GENE_PRODUCT", 88, 91], ["CD31", "GENE_OR_GENE_PRODUCT", 96, 100], ["placenta-decidua tissue", "TISSUE", 203, 226], ["donors", "ORGANISM", 242, 248], ["CK", "PROTEIN", 37, 39], ["SMA", "PROTEIN", 88, 91], ["CD31", "PROTEIN", 96, 100], ["CK", "TEST", 37, 39], ["decidua tissue", "PROBLEM", 212, 226], ["vessels", "ANATOMY", 59, 66], ["SMA", "ANATOMY", 88, 91], ["CD31", "OBSERVATION", 96, 100], ["placenta", "ANATOMY", 203, 211], ["decidua tissue", "OBSERVATION", 212, 226]]], ["Summed data from all the co-culture experiments indicate that in the proximal part of the decidua, close to the site of placentaldecidual contact, 80% of the arteries in the control group and 73% in the darunavir/r group were fully remodeled and showed trophoblast invasion.", [["decidua", "ANATOMY", 90, 97], ["arteries", "ANATOMY", 158, 166], ["trophoblast", "ANATOMY", 253, 264], ["darunavir", "CHEMICAL", 203, 212], ["darunavir", "CHEMICAL", 203, 212], ["decidua", "TISSUE", 90, 97], ["arteries", "MULTI-TISSUE_STRUCTURE", 158, 166], ["trophoblast", "CELL", 253, 264], ["the co-culture experiments", "TEST", 21, 47], ["the darunavir/r group", "TEST", 199, 220], ["trophoblast invasion", "PROBLEM", 253, 273], ["proximal", "ANATOMY_MODIFIER", 69, 77], ["decidua", "OBSERVATION", 90, 97], ["arteries", "ANATOMY", 158, 166], ["trophoblast invasion", "OBSERVATION", 253, 273]]], ["In contrast, none of the arteries in the lopinavir/r group were fully remodeled, and only 26% of the arteries showed signs of the early stages of vascular transformation, i.e. partial loss of smooth muscle cells and endothelium, and absence of trophoblast invasion.", [["arteries", "ANATOMY", 25, 33], ["arteries", "ANATOMY", 101, 109], ["vascular", "ANATOMY", 146, 154], ["smooth muscle cells", "ANATOMY", 192, 211], ["endothelium", "ANATOMY", 216, 227], ["trophoblast", "ANATOMY", 244, 255], ["lopinavir", "CHEMICAL", 41, 50], ["vascular transformation", "DISEASE", 146, 169], ["lopinavir", "CHEMICAL", 41, 50], ["arteries", "MULTI-TISSUE_STRUCTURE", 25, 33], ["lopinavir", "SIMPLE_CHEMICAL", 41, 50], ["arteries", "MULTI-TISSUE_STRUCTURE", 101, 109], ["vascular", "MULTI-TISSUE_STRUCTURE", 146, 154], ["smooth muscle cells", "CELL", 192, 211], ["endothelium", "TISSUE", 216, 227], ["trophoblast", "CELL", 244, 255], ["smooth muscle cells", "CELL_TYPE", 192, 211], ["the lopinavir/r group", "TEST", 37, 58], ["vascular transformation", "PROBLEM", 146, 169], ["partial loss of smooth muscle cells", "PROBLEM", 176, 211], ["trophoblast invasion", "PROBLEM", 244, 264], ["arteries", "ANATOMY", 25, 33], ["arteries", "ANATOMY", 101, 109], ["early", "OBSERVATION_MODIFIER", 130, 135], ["vascular", "ANATOMY", 146, 154], ["transformation", "OBSERVATION", 155, 169], ["partial", "OBSERVATION_MODIFIER", 176, 183], ["loss", "OBSERVATION_MODIFIER", 184, 188], ["smooth muscle cells", "OBSERVATION", 192, 211], ["endothelium", "OBSERVATION_MODIFIER", 216, 227], ["trophoblast invasion", "OBSERVATION", 244, 264]]], ["On the basis of these criteria, the depth of remodeling from the decidual epithelial surface up to the midsegment of the decidua was calculated and found to be significantly lower in the lopinavir/r group, compared to control and darunavir/r (Fig. 1Q ).Lopinavir treatment inhibits trophoblast migration in a human placental explant cultureSince EVTs play an important role in decidual vascular remodeling, especially in the advanced stages of remodeling, the effects of PI-cART on EVT outgrowth were investigated using human villous explants with EVT cell columns dissected from first-trimester placentas.", [["decidual epithelial surface", "ANATOMY", 65, 92], ["midsegment", "ANATOMY", 103, 113], ["decidua", "ANATOMY", 121, 128], ["trophoblast", "ANATOMY", 282, 293], ["placental explant", "ANATOMY", 315, 332], ["EVTs", "ANATOMY", 346, 350], ["decidual vascular", "ANATOMY", 377, 394], ["EVT", "ANATOMY", 482, 485], ["villous explants", "ANATOMY", 526, 542], ["EVT cell columns", "ANATOMY", 548, 564], ["placentas", "ANATOMY", 596, 605], ["lopinavir", "CHEMICAL", 187, 196], ["darunavir", "CHEMICAL", 230, 239], ["Lopinavir", "CHEMICAL", 253, 262], ["PI-cART", "CHEMICAL", 471, 478], ["lopinavir", "CHEMICAL", 187, 196], ["darunavir", "CHEMICAL", 230, 239], ["Lopinavir", "CHEMICAL", 253, 262], ["decidual epithelial surface", "TISSUE", 65, 92], ["decidua", "TISSUE", 121, 128], ["lopinavir", "SIMPLE_CHEMICAL", 187, 196], ["Fig. 1Q", "SIMPLE_CHEMICAL", 243, 250], ["Lopinavir", "SIMPLE_CHEMICAL", 253, 262], ["trophoblast", "CELL", 282, 293], ["human", "ORGANISM", 309, 314], ["EVTs", "GENE_OR_GENE_PRODUCT", 346, 350], ["decidual vascular", "MULTI-TISSUE_STRUCTURE", 377, 394], ["PI-cART", "SIMPLE_CHEMICAL", 471, 478], ["EVT", "CELL", 482, 485], ["human", "ORGANISM", 520, 525], ["villous explants", "TISSUE", 526, 542], ["EVT cell", "CELL", 548, 556], ["placentas", "MULTI-TISSUE_STRUCTURE", 596, 605], ["human placental explant culture", "CELL_LINE", 309, 340], ["EVTs", "PROTEIN", 346, 350], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 520, 525], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 520, 525], ["darunavir", "TREATMENT", 230, 239], ["Lopinavir treatment", "TREATMENT", 253, 272], ["trophoblast migration", "TREATMENT", 282, 303], ["a human placental explant culture", "TEST", 307, 340], ["decidual vascular remodeling", "PROBLEM", 377, 405], ["PI-cART", "TREATMENT", 471, 478], ["EVT outgrowth", "TREATMENT", 482, 495], ["human villous explants", "TREATMENT", 520, 542], ["EVT cell columns", "TREATMENT", 548, 564], ["first-trimester placentas", "TREATMENT", 580, 605], ["depth", "OBSERVATION_MODIFIER", 36, 41], ["remodeling", "OBSERVATION", 45, 55], ["decidual", "OBSERVATION_MODIFIER", 65, 73], ["epithelial", "OBSERVATION_MODIFIER", 74, 84], ["surface", "OBSERVATION_MODIFIER", 85, 92], ["decidua", "OBSERVATION", 121, 128], ["significantly", "OBSERVATION_MODIFIER", 160, 173], ["lower", "OBSERVATION_MODIFIER", 174, 179], ["vascular", "ANATOMY", 386, 394], ["remodeling", "OBSERVATION", 395, 405], ["remodeling", "OBSERVATION", 444, 454], ["EVT cell columns", "OBSERVATION", 548, 564]]], ["No pronounced differences in EVT outgrowth were observed between treatment groups when villi were treated with lopinavir/r, lopinavir/ r-cART, darunavir/r-cART or DMSO (Supplementary Fig. S1 ).Lopinavir treatment inhibits trophoblast migration in a human placental explant cultureEVT migration relies in part on chemo-attractant signals provided by the decidua.", [["EVT", "ANATOMY", 29, 32], ["villi", "ANATOMY", 87, 92], ["trophoblast", "ANATOMY", 222, 233], ["placental explant", "ANATOMY", 255, 272], ["decidua", "ANATOMY", 353, 360], ["lopinavir", "CHEMICAL", 111, 120], ["lopinavir/ r-cART", "CHEMICAL", 124, 141], ["darunavir/r-cART", "CHEMICAL", 143, 159], ["DMSO", "CHEMICAL", 163, 167], ["Lopinavir", "CHEMICAL", 193, 202], ["lopinavir", "CHEMICAL", 111, 120], ["lopinavir", "CHEMICAL", 124, 133], ["r-cART", "CHEMICAL", 135, 141], ["darunavir", "CHEMICAL", 143, 152], ["r-cART", "CHEMICAL", 153, 159], ["DMSO", "CHEMICAL", 163, 167], ["Lopinavir", "CHEMICAL", 193, 202], ["EVT", "CELL", 29, 32], ["villi", "MULTI-TISSUE_STRUCTURE", 87, 92], ["lopinavir", "SIMPLE_CHEMICAL", 111, 120], ["lopinavir", "SIMPLE_CHEMICAL", 124, 133], ["r-cART", "SIMPLE_CHEMICAL", 135, 141], ["darunavir", "SIMPLE_CHEMICAL", 143, 152], ["r-cART", "SIMPLE_CHEMICAL", 153, 159], ["DMSO", "SIMPLE_CHEMICAL", 163, 167], ["S1", "GENE_OR_GENE_PRODUCT", 188, 190], ["Lopinavir", "SIMPLE_CHEMICAL", 193, 202], ["trophoblast", "CELL", 222, 233], ["human", "ORGANISM", 249, 254], ["decidua", "TISSUE", 353, 360], ["S1", "PROTEIN", 188, 190], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["pronounced differences in EVT outgrowth", "PROBLEM", 3, 42], ["lopinavir", "TREATMENT", 111, 120], ["lopinavir", "TREATMENT", 124, 133], ["cART", "TREATMENT", 137, 141], ["darunavir", "TREATMENT", 143, 152], ["DMSO", "TREATMENT", 163, 167], ["Supplementary Fig", "TREATMENT", 169, 186], ["Lopinavir treatment", "TREATMENT", 193, 212], ["trophoblast migration", "TREATMENT", 222, 243], ["a human placental explant cultureEVT migration", "TREATMENT", 247, 293], ["pronounced", "OBSERVATION_MODIFIER", 3, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["EVT", "OBSERVATION", 29, 32], ["trophoblast migration", "OBSERVATION", 222, 243]]], ["We repeated the EVT migration experiments in the presence of DCM obtained from primary decidual cell cultures treated with the same drugs (or DMSO).", [["decidual cell cultures", "ANATOMY", 87, 109], ["DCM", "CHEMICAL", 61, 64], ["DMSO", "CHEMICAL", 142, 146], ["DMSO", "CHEMICAL", 142, 146], ["decidual cell cultures", "CELL", 87, 109], ["DMSO", "SIMPLE_CHEMICAL", 142, 146], ["primary decidual cell cultures", "CELL_LINE", 79, 109], ["the EVT migration experiments", "TREATMENT", 12, 41], ["DCM", "PROBLEM", 61, 64], ["primary decidual cell cultures", "PROBLEM", 79, 109], ["the same drugs", "TREATMENT", 123, 137], ["DMSO", "TREATMENT", 142, 146], ["DCM", "OBSERVATION", 61, 64], ["primary decidual cell cultures", "OBSERVATION", 79, 109]]], ["While a healthy EVT outgrowth was seen upon exposure to DCM from DMSO or darunavir/r-cARTtreated cultures, EVT outgrowth was impeded upon exposure to DCM from lopinavir/r-cART or lopinavir/r alone treated cultures (Fig. 2) .Lopinavir treatment inhibits trophoblast migration in a human placental explant cultureIn summary, EVT migration was impaired in the presence of lopinavir/r-DCM.", [["EVT", "ANATOMY", 16, 19], ["EVT", "ANATOMY", 107, 110], ["cultures", "ANATOMY", 205, 213], ["trophoblast", "ANATOMY", 253, 264], ["placental explant", "ANATOMY", 286, 303], ["EVT", "ANATOMY", 323, 326], ["DCM", "CHEMICAL", 56, 59], ["DMSO", "CHEMICAL", 65, 69], ["darunavir/r-cARTtreated", "CHEMICAL", 73, 96], ["DCM", "CHEMICAL", 150, 153], ["lopinavir/r-cART", "CHEMICAL", 159, 175], ["lopinavir", "CHEMICAL", 179, 188], ["Lopinavir", "CHEMICAL", 224, 233], ["lopinavir/r-DCM", "CHEMICAL", 369, 384], ["DMSO", "CHEMICAL", 65, 69], ["darunavir", "CHEMICAL", 73, 82], ["r-cARTtreated", "CHEMICAL", 83, 96], ["lopinavir", "CHEMICAL", 159, 168], ["r-cART", "CHEMICAL", 169, 175], ["lopinavir", "CHEMICAL", 179, 188], ["Lopinavir", "CHEMICAL", 224, 233], ["lopinavir", "CHEMICAL", 369, 378], ["r-DCM", "CHEMICAL", 379, 384], ["EVT", "CELL", 16, 19], ["DMSO", "SIMPLE_CHEMICAL", 65, 69], ["darunavir", "SIMPLE_CHEMICAL", 73, 82], ["EVT", "CELL", 107, 110], ["lopinavir", "SIMPLE_CHEMICAL", 159, 168], ["r-cART", "SIMPLE_CHEMICAL", 169, 175], ["lopinavir", "SIMPLE_CHEMICAL", 179, 188], ["Lopinavir", "SIMPLE_CHEMICAL", 224, 233], ["trophoblast", "CELL", 253, 264], ["human", "ORGANISM", 280, 285], ["EVT", "CELL", 323, 326], ["lopinavir", "SIMPLE_CHEMICAL", 369, 378], ["r-DCM", "SIMPLE_CHEMICAL", 379, 384], ["darunavir/r-cARTtreated cultures", "CELL_LINE", 73, 105], ["human placental explant culture", "CELL_LINE", 280, 311], ["human", "SPECIES", 280, 285], ["human", "SPECIES", 280, 285], ["DCM", "PROBLEM", 56, 59], ["DMSO", "TREATMENT", 65, 69], ["darunavir", "TREATMENT", 73, 82], ["r-cARTtreated cultures", "TREATMENT", 83, 105], ["EVT outgrowth", "PROBLEM", 107, 120], ["DCM", "PROBLEM", 150, 153], ["lopinavir", "TREATMENT", 159, 168], ["cART", "TREATMENT", 171, 175], ["lopinavir", "TREATMENT", 179, 188], ["cultures", "TEST", 205, 213], ["Lopinavir treatment", "TREATMENT", 224, 243], ["trophoblast migration", "TREATMENT", 253, 274], ["a human placental explant culture", "TEST", 278, 311], ["EVT migration", "PROBLEM", 323, 336], ["lopinavir", "TREATMENT", 369, 378], ["DCM", "PROBLEM", 381, 384], ["DCM", "OBSERVATION", 381, 384]]], ["EVT outgrowth was unaffected by drug treatment in the absence of DCM, suggesting that lopinavir's impact on EVT migration is likely due to effects on decidua-secreted factors rather than direct effects on EVTs.Lopinavir treatment inhibits trophoblast migration in a human placental explant cultureLopinavir treatment leads to depletion of uNK cells in a primary culture of human decidual cells Decidua immune cells, comprised of uNK cells, T cells, dendritic cells and macrophages, also play an important role in the early stages of decidual vascular remodeling.", [["EVT", "ANATOMY", 0, 3], ["EVT", "ANATOMY", 108, 111], ["decidua", "ANATOMY", 150, 157], ["EVTs", "ANATOMY", 205, 209], ["trophoblast", "ANATOMY", 239, 250], ["placental explant", "ANATOMY", 272, 289], ["uNK cells", "ANATOMY", 339, 348], ["decidual cells", "ANATOMY", 379, 393], ["immune cells", "ANATOMY", 402, 414], ["uNK cells", "ANATOMY", 429, 438], ["T cells", "ANATOMY", 440, 447], ["dendritic cells", "ANATOMY", 449, 464], ["macrophages", "ANATOMY", 469, 480], ["decidual vascular", "ANATOMY", 533, 550], ["DCM", "DISEASE", 65, 68], ["lopinavir", "CHEMICAL", 86, 95], ["Lopinavir", "CHEMICAL", 210, 219], ["cultureLopinavir", "CHEMICAL", 290, 306], ["lopinavir", "CHEMICAL", 86, 95], ["Lopinavir", "CHEMICAL", 210, 219], ["cultureLopinavir", "CHEMICAL", 290, 306], ["EVT", "CELL", 0, 3], ["lopinavir", "SIMPLE_CHEMICAL", 86, 95], ["EVT", "CELL", 108, 111], ["decidua", "MULTI-TISSUE_STRUCTURE", 150, 157], ["EVTs", "PATHOLOGICAL_FORMATION", 205, 209], ["Lopinavir", "SIMPLE_CHEMICAL", 210, 219], ["trophoblast", "CELL", 239, 250], ["human", "ORGANISM", 266, 271], ["placental explant", "MULTI-TISSUE_STRUCTURE", 272, 289], ["cultureLopinavir", "SIMPLE_CHEMICAL", 290, 306], ["uNK cells", "CELL", 339, 348], ["human", "ORGANISM", 373, 378], ["decidual cells", "CELL", 379, 393], ["Decidua immune cells", "CELL", 394, 414], ["uNK cells", "CELL", 429, 438], ["T cells", "CELL", 440, 447], ["dendritic cells", "CELL", 449, 464], ["macrophages", "CELL", 469, 480], ["decidual vascular", "MULTI-TISSUE_STRUCTURE", 533, 550], ["secreted factors", "PROTEIN", 158, 174], ["uNK cells", "CELL_TYPE", 339, 348], ["human decidual cells", "CELL_TYPE", 373, 393], ["immune cells", "CELL_TYPE", 402, 414], ["uNK cells", "CELL_TYPE", 429, 438], ["T cells", "CELL_TYPE", 440, 447], ["dendritic cells", "CELL_TYPE", 449, 464], ["macrophages", "CELL_TYPE", 469, 480], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 373, 378], ["EVT outgrowth", "PROBLEM", 0, 13], ["drug treatment", "TREATMENT", 32, 46], ["DCM", "PROBLEM", 65, 68], ["lopinavir", "TREATMENT", 86, 95], ["EVT migration", "TREATMENT", 108, 121], ["decidua", "PROBLEM", 150, 157], ["secreted factors", "PROBLEM", 158, 174], ["direct effects on EVTs", "PROBLEM", 187, 209], ["Lopinavir treatment", "TREATMENT", 210, 229], ["trophoblast migration", "TREATMENT", 239, 260], ["a human placental explant cultureLopinavir treatment", "TREATMENT", 264, 316], ["uNK cells", "PROBLEM", 339, 348], ["a primary culture", "TEST", 352, 369], ["human decidual cells", "PROBLEM", 373, 393], ["Decidua immune cells", "PROBLEM", 394, 414], ["uNK cells", "PROBLEM", 429, 438], ["T cells", "PROBLEM", 440, 447], ["dendritic cells and macrophages", "PROBLEM", 449, 480], ["decidual vascular remodeling", "PROBLEM", 533, 561], ["DCM", "OBSERVATION", 65, 68], ["uNK cells", "OBSERVATION", 339, 348], ["human decidual cells Decidua immune cells", "OBSERVATION", 373, 414], ["uNK cells", "OBSERVATION", 429, 438], ["dendritic cells", "OBSERVATION", 449, 464], ["macrophages", "ANATOMY", 469, 480], ["early stages", "OBSERVATION_MODIFIER", 517, 529], ["decidual", "OBSERVATION", 533, 541], ["vascular", "ANATOMY", 542, 550], ["remodeling", "OBSERVATION", 551, 561]]], ["We next investigated the effects of PI-cART on total decidual cell cultures.", [["decidual cell cultures", "ANATOMY", 53, 75], ["PI-cART", "CHEMICAL", 36, 43], ["PI", "SIMPLE_CHEMICAL", 36, 38], ["decidual cell cultures", "CELL", 53, 75], ["total decidual cell cultures", "CELL_LINE", 47, 75], ["PI-cART", "TREATMENT", 36, 43], ["total decidual cell cultures", "TEST", 47, 75]]], ["Total cells were isolated from human first-trimester decidua samples and cultured in the presence of drugs, or DMSO as a control, for 48 h followed by flow cytometric analysis.", [["Total cells", "ANATOMY", 0, 11], ["decidua samples", "ANATOMY", 53, 68], ["DMSO", "CHEMICAL", 111, 115], ["DMSO", "CHEMICAL", 111, 115], ["Total cells", "CELL", 0, 11], ["human", "ORGANISM", 31, 36], ["decidua samples", "TISSUE", 53, 68], ["DMSO", "SIMPLE_CHEMICAL", 111, 115], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["Total cells", "PROBLEM", 0, 11], ["human first-trimester decidua samples", "TREATMENT", 31, 68], ["drugs", "TREATMENT", 101, 106], ["DMSO", "TREATMENT", 111, 115], ["flow cytometric analysis", "TEST", 151, 175]]], ["The gating strategy is shown ( Supplementary Fig. S2 ).", [["S2", "PROTEIN", 50, 52]]], ["The percentage of total viable cells was reduced upon lopinavir/r and lopinavir/r-cART treatment, but was similar to the control upon darunavir/r-cART treatment, indicating that lopinavir was associated with loss of cellular viability (Fig. 3A) .", [["cells", "ANATOMY", 31, 36], ["cellular", "ANATOMY", 216, 224], ["lopinavir", "CHEMICAL", 54, 63], ["lopinavir/r-cART", "CHEMICAL", 70, 86], ["darunavir/r-cART", "CHEMICAL", 134, 150], ["lopinavir", "CHEMICAL", 178, 187], ["lopinavir", "CHEMICAL", 54, 63], ["lopinavir", "CHEMICAL", 70, 79], ["r-cART", "CHEMICAL", 80, 86], ["darunavir", "CHEMICAL", 134, 143], ["r-cART", "CHEMICAL", 144, 150], ["lopinavir", "CHEMICAL", 178, 187], ["cells", "CELL", 31, 36], ["lopinavir", "SIMPLE_CHEMICAL", 54, 63], ["lopinavir", "SIMPLE_CHEMICAL", 70, 79], ["r-cART", "SIMPLE_CHEMICAL", 80, 86], ["darunavir", "SIMPLE_CHEMICAL", 134, 143], ["r-cART", "SIMPLE_CHEMICAL", 144, 150], ["lopinavir", "SIMPLE_CHEMICAL", 178, 187], ["cellular", "CELL", 216, 224], ["total viable cells", "PROBLEM", 18, 36], ["lopinavir", "TREATMENT", 54, 63], ["lopinavir", "TREATMENT", 70, 79], ["r-cART treatment", "TREATMENT", 80, 96], ["darunavir", "TREATMENT", 134, 143], ["r-cART treatment", "TREATMENT", 144, 160], ["lopinavir", "TREATMENT", 178, 187], ["loss of cellular viability", "PROBLEM", 208, 234], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["total", "OBSERVATION_MODIFIER", 18, 23], ["viable cells", "OBSERVATION", 24, 36], ["cellular viability", "OBSERVATION", 216, 234]]], ["Further analysis of decidual subpopulations revealed that the viability of stroma cells, macrophages and T cells did not differ between treatments.", [["decidual subpopulations", "ANATOMY", 20, 43], ["stroma cells", "ANATOMY", 75, 87], ["macrophages", "ANATOMY", 89, 100], ["T cells", "ANATOMY", 105, 112], ["decidual subpopulations", "CELL", 20, 43], ["stroma cells", "CELL", 75, 87], ["macrophages", "CELL", 89, 100], ["T cells", "CELL", 105, 112], ["decidual subpopulations", "CELL_TYPE", 20, 43], ["stroma cells", "CELL_TYPE", 75, 87], ["macrophages", "CELL_TYPE", 89, 100], ["T cells", "CELL_TYPE", 105, 112], ["Further analysis", "TEST", 0, 16], ["decidual subpopulations", "PROBLEM", 20, 43], ["stroma cells", "PROBLEM", 75, 87], ["macrophages and T cells", "PROBLEM", 89, 112], ["stroma cells", "OBSERVATION", 75, 87]]], ["However, the viability of uNK cells was significantly lower in the lopinavir/r and lopinavir/r-cART groups, as compared to control and darunavir/r-cART (Fig. 3A) .", [["uNK cells", "ANATOMY", 26, 35], ["lopinavir", "CHEMICAL", 67, 76], ["lopinavir", "CHEMICAL", 83, 92], ["darunavir", "CHEMICAL", 135, 144], ["lopinavir", "CHEMICAL", 67, 76], ["lopinavir", "CHEMICAL", 83, 92], ["r-cART", "CHEMICAL", 93, 99], ["darunavir", "CHEMICAL", 135, 144], ["uNK cells", "CELL", 26, 35], ["lopinavir", "SIMPLE_CHEMICAL", 67, 76], ["lopinavir", "SIMPLE_CHEMICAL", 83, 92], ["r-cART", "SIMPLE_CHEMICAL", 93, 99], ["darunavir/r-cART", "SIMPLE_CHEMICAL", 135, 151], ["uNK cells", "CELL_TYPE", 26, 35], ["uNK cells", "PROBLEM", 26, 35], ["the lopinavir", "TEST", 63, 76], ["lopinavir/r-cART groups", "TREATMENT", 83, 106], ["darunavir", "TREATMENT", 135, 144], ["uNK cells", "OBSERVATION", 26, 35]]], ["Thus, exposure of primary decidual cell cultures to lopinavir resulted in selective depletion of uNK cells.", [["decidual cell cultures", "ANATOMY", 26, 48], ["uNK cells", "ANATOMY", 97, 106], ["lopinavir", "CHEMICAL", 52, 61], ["lopinavir", "CHEMICAL", 52, 61], ["decidual cell cultures", "CELL", 26, 48], ["lopinavir", "SIMPLE_CHEMICAL", 52, 61], ["uNK cells", "CELL", 97, 106], ["primary decidual cell cultures", "CELL_LINE", 18, 48], ["uNK cells", "CELL_TYPE", 97, 106], ["primary decidual cell cultures", "PROBLEM", 18, 48], ["lopinavir", "TREATMENT", 52, 61], ["selective depletion of uNK cells", "PROBLEM", 74, 106], ["primary decidual cell", "OBSERVATION", 18, 39], ["selective depletion", "OBSERVATION", 74, 93], ["uNK cells", "OBSERVATION", 97, 106]]], ["Macrophages are also known to influence vascular remodeling, but no significant differences were observed in CD14\u00fe macrophage populations across treatments.", [["Macrophages", "ANATOMY", 0, 11], ["vascular", "ANATOMY", 40, 48], ["Macrophages", "CELL", 0, 11], ["vascular", "MULTI-TISSUE_STRUCTURE", 40, 48], ["CD14", "GENE_OR_GENE_PRODUCT", 109, 113], ["Macrophages", "CELL_TYPE", 0, 11], ["CD14", "PROTEIN", 109, 113], ["significant differences", "PROBLEM", 68, 91], ["vascular", "ANATOMY", 40, 48], ["remodeling", "OBSERVATION", 49, 59], ["no", "UNCERTAINTY", 65, 67], ["significant", "OBSERVATION_MODIFIER", 68, 79]]], ["Macrophage subset analysis was not performed, but may be merited for future studies.Lopinavir treatment inhibits trophoblast migration in a human placental explant cultureTo confirm the flow cytometry data, we also stained placentaldecidual co-cultures with CD56 to detect uNK cells (Fig. 3B) .", [["Macrophage", "ANATOMY", 0, 10], ["trophoblast", "ANATOMY", 113, 124], ["placental explant", "ANATOMY", 146, 163], ["uNK cells", "ANATOMY", 273, 282], ["Lopinavir", "CHEMICAL", 84, 93], ["Lopinavir", "CHEMICAL", 84, 93], ["Macrophage", "CELL", 0, 10], ["Lopinavir", "SIMPLE_CHEMICAL", 84, 93], ["trophoblast", "CELL", 113, 124], ["human", "ORGANISM", 140, 145], ["CD56", "GENE_OR_GENE_PRODUCT", 258, 262], ["uNK cells", "CELL", 273, 282], ["Fig. 3B", "CELL", 284, 291], ["human placental explant culture", "CELL_LINE", 140, 171], ["placentaldecidual co-cultures", "CELL_LINE", 223, 252], ["CD56", "PROTEIN", 258, 262], ["uNK cells", "CELL_TYPE", 273, 282], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["Macrophage subset analysis", "TEST", 0, 26], ["future studies", "TEST", 69, 83], ["Lopinavir treatment", "TREATMENT", 84, 103], ["trophoblast migration", "TREATMENT", 113, 134], ["a human placental explant culture", "TEST", 138, 171], ["the flow cytometry data", "TEST", 182, 205], ["CD56", "TEST", 258, 262], ["uNK cells", "PROBLEM", 273, 282], ["uNK cells", "OBSERVATION", 273, 282]]], ["Fewer uNK cells were detected in co-cultures treated with lopinavir/rLopinavir treatment inhibits trophoblast migration in a human placental explant culturecompared to control or darunavir/r treated co-cultures (Fig. 3C ).", [["uNK cells", "ANATOMY", 6, 15], ["trophoblast", "ANATOMY", 98, 109], ["placental explant", "ANATOMY", 131, 148], ["lopinavir", "CHEMICAL", 58, 67], ["rLopinavir", "CHEMICAL", 68, 78], ["darunavir", "CHEMICAL", 179, 188], ["lopinavir", "CHEMICAL", 58, 67], ["rLopinavir", "CHEMICAL", 68, 78], ["darunavir", "CHEMICAL", 179, 188], ["uNK cells", "CELL", 6, 15], ["lopinavir", "SIMPLE_CHEMICAL", 58, 67], ["rLopinavir", "SIMPLE_CHEMICAL", 68, 78], ["trophoblast", "CELL", 98, 109], ["human", "ORGANISM", 125, 130], ["placental explant", "TISSUE", 131, 148], ["uNK cells", "CELL_TYPE", 6, 15], ["darunavir/r treated co-cultures", "CELL_LINE", 179, 210], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["Fewer uNK cells", "PROBLEM", 0, 15], ["co-cultures", "TEST", 33, 44], ["lopinavir", "TREATMENT", 58, 67], ["rLopinavir treatment", "TREATMENT", 68, 88], ["trophoblast migration", "TREATMENT", 98, 119], ["a human placental explant culturecompared", "TREATMENT", 123, 164], ["darunavir/r treated co-cultures", "TREATMENT", 179, 210], ["uNK cells", "OBSERVATION", 6, 15]]], ["In addition, uNK cells in the lopinavir/r treated co-cultures showed a condensed appearance, characteristic of apoptotic cells (see arrows in Fig. 3B , middle panel).Lopinavir treatment of human decidual cell cultures results in a decline in the levels of biomarkers of decidualization, chemokines and angiogenic factorsOur data so far suggested that lopinavir/r treatment impacts both decidual immune cell composition, i.e. uNK cells, and decidual soluble factors that affect EVT migration.", [["uNK cells", "ANATOMY", 13, 22], ["cells", "ANATOMY", 121, 126], ["decidual cell cultures", "ANATOMY", 195, 217], ["decidual immune cell", "ANATOMY", 386, 406], ["uNK cells", "ANATOMY", 425, 434], ["decidual", "ANATOMY", 440, 448], ["EVT", "ANATOMY", 477, 480], ["lopinavir", "CHEMICAL", 30, 39], ["Lopinavir", "CHEMICAL", 166, 175], ["lopinavir", "CHEMICAL", 351, 360], ["lopinavir", "CHEMICAL", 30, 39], ["Lopinavir", "CHEMICAL", 166, 175], ["lopinavir", "CHEMICAL", 351, 360], ["uNK cells", "CELL", 13, 22], ["lopinavir", "SIMPLE_CHEMICAL", 30, 39], ["co-cultures", "CELL", 50, 61], ["cells", "CELL", 121, 126], ["Lopinavir", "SIMPLE_CHEMICAL", 166, 175], ["human", "ORGANISM", 189, 194], ["decidual cell cultures", "CELL", 195, 217], ["lopinavir", "SIMPLE_CHEMICAL", 351, 360], ["decidual immune cell", "CELL", 386, 406], ["uNK cells", "CELL", 425, 434], ["EVT", "CELL", 477, 480], ["uNK cells", "CELL_TYPE", 13, 22], ["lopinavir/r treated co-cultures", "CELL_LINE", 30, 61], ["apoptotic cells", "CELL_TYPE", 111, 126], ["human decidual cell cultures", "CELL_LINE", 189, 217], ["chemokines", "PROTEIN", 287, 297], ["angiogenic factors", "PROTEIN", 302, 320], ["uNK cells", "CELL_TYPE", 425, 434], ["decidual soluble factors", "PROTEIN", 440, 464], ["human", "SPECIES", 189, 194], ["human", "SPECIES", 189, 194], ["uNK cells", "PROBLEM", 13, 22], ["the lopinavir/r treated co-cultures", "TEST", 26, 61], ["a condensed appearance", "PROBLEM", 69, 91], ["apoptotic cells", "PROBLEM", 111, 126], ["Lopinavir treatment", "TREATMENT", 166, 185], ["human decidual cell cultures", "TEST", 189, 217], ["a decline", "PROBLEM", 229, 238], ["decidualization", "PROBLEM", 270, 285], ["angiogenic factors", "PROBLEM", 302, 320], ["Our data", "TEST", 320, 328], ["lopinavir/r treatment impacts", "TREATMENT", 351, 380], ["decidual immune cell composition", "TREATMENT", 386, 418], ["uNK cells", "PROBLEM", 425, 434], ["decidual soluble factors", "TREATMENT", 440, 464], ["EVT migration", "PROBLEM", 477, 490], ["uNK cells", "OBSERVATION", 13, 22], ["apoptotic cells", "OBSERVATION", 111, 126], ["middle", "ANATOMY_MODIFIER", 152, 158], ["decidual immune cell", "OBSERVATION", 386, 406], ["uNK cells", "OBSERVATION", 425, 434]]], ["To further examine the impact of PI-cART on decidua function, we quantified soluble factors in DCM.", [["decidua", "ANATOMY", 44, 51], ["PI", "CHEMICAL", 33, 35], ["DCM", "DISEASE", 95, 98], ["PI", "SIMPLE_CHEMICAL", 33, 35], ["decidua", "MULTI-TISSUE_STRUCTURE", 44, 51], ["soluble factors", "PROTEIN", 76, 91], ["PI-cART on decidua function", "TREATMENT", 33, 60], ["DCM", "PROBLEM", 95, 98]]], ["Primary human decidual cells (total) were cultured in the presence of progesterone, estradiol and cAMP to maintain the decidual phenotype in vitro and treated with drugs or DMSO as a control.Lopinavir treatment of human decidual cell cultures results in a decline in the levels of biomarkers of decidualization, chemokines and angiogenic factorsLevels of the classic biomarkers of decidualization, including prolactin, IGFBP-1, IL-11, IL-15 and activin-A were significantly lower in the supernatants of decidual cell cultures treated with lopinavir/r or lopinavir/r-cART compared to control ( Table I) , suggesting that lopinavir exposure leads to a loss of the decidual phenotype.", [["decidual cells", "ANATOMY", 14, 28], ["decidual", "ANATOMY", 119, 127], ["decidual cell cultures", "ANATOMY", 220, 242], ["supernatants", "ANATOMY", 487, 499], ["decidual cell cultures", "ANATOMY", 503, 525], ["decidual", "ANATOMY", 662, 670], ["progesterone", "CHEMICAL", 70, 82], ["estradiol", "CHEMICAL", 84, 93], ["cAMP", "CHEMICAL", 98, 102], ["DMSO", "CHEMICAL", 173, 177], ["Lopinavir", "CHEMICAL", 191, 200], ["lopinavir", "CHEMICAL", 539, 548], ["lopinavir/r-cART", "CHEMICAL", 554, 570], ["lopinavir", "CHEMICAL", 620, 629], ["loss of the decidual phenotype", "DISEASE", 650, 680], ["progesterone", "CHEMICAL", 70, 82], ["estradiol", "CHEMICAL", 84, 93], ["cAMP", "CHEMICAL", 98, 102], ["DMSO", "CHEMICAL", 173, 177], ["Lopinavir", "CHEMICAL", 191, 200], ["lopinavir", "CHEMICAL", 539, 548], ["lopinavir", "CHEMICAL", 554, 563], ["r-cART", "CHEMICAL", 564, 570], ["lopinavir", "CHEMICAL", 620, 629], ["human", "ORGANISM", 8, 13], ["decidual cells", "CELL", 14, 28], ["progesterone", "SIMPLE_CHEMICAL", 70, 82], ["estradiol", "SIMPLE_CHEMICAL", 84, 93], ["cAMP", "SIMPLE_CHEMICAL", 98, 102], ["DMSO", "SIMPLE_CHEMICAL", 173, 177], ["Lopinavir", "SIMPLE_CHEMICAL", 191, 200], ["human", "ORGANISM", 214, 219], ["decidual cell cultures", "CELL", 220, 242], ["prolactin", "GENE_OR_GENE_PRODUCT", 408, 417], ["IGFBP-1", "GENE_OR_GENE_PRODUCT", 419, 426], ["IL-11", "GENE_OR_GENE_PRODUCT", 428, 433], ["IL-15", "GENE_OR_GENE_PRODUCT", 435, 440], ["activin-A", "GENE_OR_GENE_PRODUCT", 445, 454], ["decidual cell cultures", "CELL", 503, 525], ["lopinavir", "SIMPLE_CHEMICAL", 539, 548], ["lopinavir", "SIMPLE_CHEMICAL", 554, 563], ["r-cART", "SIMPLE_CHEMICAL", 564, 570], ["lopinavir", "SIMPLE_CHEMICAL", 620, 629], ["human decidual cells", "CELL_TYPE", 8, 28], ["human decidual cell cultures", "CELL_LINE", 214, 242], ["chemokines", "PROTEIN", 312, 322], ["angiogenic factors", "PROTEIN", 327, 345], ["IL-15", "PROTEIN", 435, 440], ["activin-A", "PROTEIN", 445, 454], ["decidual cell cultures", "CELL_LINE", 503, 525], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 214, 219], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 214, 219], ["Primary human decidual cells", "TREATMENT", 0, 28], ["progesterone", "TREATMENT", 70, 82], ["estradiol", "TREATMENT", 84, 93], ["cAMP", "TREATMENT", 98, 102], ["the decidual phenotype in vitro", "TREATMENT", 115, 146], ["drugs", "TREATMENT", 164, 169], ["DMSO", "TREATMENT", 173, 177], ["Lopinavir treatment", "TREATMENT", 191, 210], ["human decidual cell cultures", "TEST", 214, 242], ["a decline", "PROBLEM", 254, 263], ["decidualization", "PROBLEM", 295, 310], ["chemokines", "TEST", 312, 322], ["angiogenic factorsLevels", "TEST", 327, 351], ["the classic biomarkers", "TEST", 355, 377], ["decidualization", "PROBLEM", 381, 396], ["prolactin", "TEST", 408, 417], ["IGFBP", "TEST", 419, 424], ["IL", "TEST", 428, 430], ["IL", "TEST", 435, 437], ["activin", "TEST", 445, 452], ["decidual cell cultures", "PROBLEM", 503, 525], ["lopinavir", "TREATMENT", 539, 548], ["lopinavir", "TREATMENT", 554, 563], ["r-cART", "TREATMENT", 564, 570], ["lopinavir exposure", "PROBLEM", 620, 638], ["a loss of the decidual phenotype", "PROBLEM", 648, 680], ["decidual cells", "OBSERVATION", 14, 28], ["decidual cell", "OBSERVATION", 503, 516], ["decidual phenotype", "OBSERVATION", 662, 680]]], ["Levels of these factors in cultures treated with darunavir/r-cART were similar to control.Lopinavir treatment of human decidual cell cultures results in a decline in the levels of biomarkers of decidualization, chemokines and angiogenic factorsLevels of CXCL10, CXCL12, CXCL16, CCL2 and CCL3 chemokines that play a role in immune cell recruitment and trophoblast chemotaxis were also significantly lower in decidual cell cultures treated with lopinavir/r or lopinavir/r-cART, but were similar to control in cultures treated with darunavir/r-cART (Table I) .Lopinavir treatment of human decidual cell cultures results in a decline in the levels of biomarkers of decidualization, chemokines and angiogenic factorsLevels of the angiogenic factors VEGF, PlGF, angiopoietin-2, GM-CSF, IFN-c and MMP-9 were significantly lower with lopinavir/r or lopinavir/r-cART, but not with darunavir/r-cART treatment, compared to control (Table I) .", [["cultures", "ANATOMY", 27, 35], ["decidual cell cultures", "ANATOMY", 119, 141], ["immune cell", "ANATOMY", 323, 334], ["trophoblast", "ANATOMY", 351, 362], ["decidual cell cultures", "ANATOMY", 407, 429], ["cultures", "ANATOMY", 507, 515], ["decidual cell cultures", "ANATOMY", 586, 608], ["darunavir", "CHEMICAL", 49, 58], ["Lopinavir", "CHEMICAL", 90, 99], ["lopinavir", "CHEMICAL", 443, 452], ["lopinavir/r-cART", "CHEMICAL", 458, 474], ["darunavir", "CHEMICAL", 529, 538], ["Lopinavir", "CHEMICAL", 557, 566], ["lopinavir", "CHEMICAL", 826, 835], ["lopinavir", "CHEMICAL", 841, 850], ["darunavir/r-cART", "CHEMICAL", 872, 888], ["darunavir", "CHEMICAL", 49, 58], ["r-cART", "CHEMICAL", 59, 65], ["Lopinavir", "CHEMICAL", 90, 99], ["lopinavir", "CHEMICAL", 443, 452], ["lopinavir", "CHEMICAL", 458, 467], ["r-cART", "CHEMICAL", 468, 474], ["darunavir", "CHEMICAL", 529, 538], ["Lopinavir", "CHEMICAL", 557, 566], ["lopinavir", "CHEMICAL", 826, 835], ["lopinavir", "CHEMICAL", 841, 850], ["r-cART", "CHEMICAL", 851, 857], ["darunavir", "CHEMICAL", 872, 881], ["r-cART", "CHEMICAL", 882, 888], ["darunavir", "SIMPLE_CHEMICAL", 49, 58], ["r-cART", "SIMPLE_CHEMICAL", 59, 65], ["Lopinavir", "SIMPLE_CHEMICAL", 90, 99], ["human", "ORGANISM", 113, 118], ["decidual cell cultures", "CELL", 119, 141], ["CXCL10", "GENE_OR_GENE_PRODUCT", 254, 260], ["CXCL12", "GENE_OR_GENE_PRODUCT", 262, 268], ["CXCL16", "GENE_OR_GENE_PRODUCT", 270, 276], ["CCL2", "GENE_OR_GENE_PRODUCT", 278, 282], ["CCL3", "GENE_OR_GENE_PRODUCT", 287, 291], ["immune cell", "CELL", 323, 334], ["trophoblast", "CELL", 351, 362], ["decidual cell cultures", "CELL", 407, 429], ["lopinavir", "SIMPLE_CHEMICAL", 443, 452], ["lopinavir", "SIMPLE_CHEMICAL", 458, 467], ["r-cART", "SIMPLE_CHEMICAL", 468, 474], ["darunavir", "SIMPLE_CHEMICAL", 529, 538], ["r-cART", "SIMPLE_CHEMICAL", 539, 545], ["Lopinavir", "SIMPLE_CHEMICAL", 557, 566], ["human", "ORGANISM", 580, 585], ["decidual cell cultures", "CELL", 586, 608], ["VEGF", "GENE_OR_GENE_PRODUCT", 744, 748], ["PlGF", "GENE_OR_GENE_PRODUCT", 750, 754], ["angiopoietin-2", "GENE_OR_GENE_PRODUCT", 756, 770], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 772, 778], ["IFN-c", "GENE_OR_GENE_PRODUCT", 780, 785], ["MMP-9", "GENE_OR_GENE_PRODUCT", 790, 795], ["lopinavir", "SIMPLE_CHEMICAL", 826, 835], ["lopinavir", "SIMPLE_CHEMICAL", 841, 850], ["r-cART", "SIMPLE_CHEMICAL", 851, 857], ["darunavir", "SIMPLE_CHEMICAL", 872, 881], ["r-cART", "SIMPLE_CHEMICAL", 882, 888], ["human decidual cell cultures", "CELL_LINE", 113, 141], ["chemokines", "PROTEIN", 211, 221], ["angiogenic factors", "PROTEIN", 226, 244], ["CXCL10", "PROTEIN", 254, 260], ["CXCL12", "PROTEIN", 262, 268], ["CXCL16", "PROTEIN", 270, 276], ["CCL2", "PROTEIN", 278, 282], ["CCL3", "PROTEIN", 287, 291], ["chemokines", "PROTEIN", 292, 302], ["decidual cell cultures", "CELL_LINE", 407, 429], ["human decidual cell cultures", "CELL_LINE", 580, 608], ["chemokines", "PROTEIN", 678, 688], ["angiogenic factors", "PROTEIN", 693, 711], ["angiogenic factors", "PROTEIN", 725, 743], ["VEGF", "PROTEIN", 744, 748], ["PlGF", "PROTEIN", 750, 754], ["angiopoietin-2", "PROTEIN", 756, 770], ["GM", "PROTEIN", 772, 774], ["CSF", "PROTEIN", 775, 778], ["IFN", "PROTEIN", 780, 783], ["MMP", "PROTEIN", 790, 793], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 580, 585], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 580, 585], ["these factors", "PROBLEM", 10, 23], ["cultures", "TEST", 27, 35], ["darunavir", "TREATMENT", 49, 58], ["r-cART", "TREATMENT", 59, 65], ["Lopinavir treatment", "TREATMENT", 90, 109], ["human decidual cell cultures", "TEST", 113, 141], ["a decline", "PROBLEM", 153, 162], ["decidualization", "PROBLEM", 194, 209], ["angiogenic factors", "PROBLEM", 226, 244], ["Levels", "TEST", 244, 250], ["CXCL10", "TEST", 254, 260], ["CXCL12", "TEST", 262, 268], ["CXCL16", "TEST", 270, 276], ["CCL2", "TEST", 278, 282], ["CCL3 chemokines", "TREATMENT", 287, 302], ["immune cell recruitment", "TREATMENT", 323, 346], ["trophoblast chemotaxis", "PROBLEM", 351, 373], ["decidual cell cultures", "PROBLEM", 407, 429], ["lopinavir", "TREATMENT", 443, 452], ["lopinavir", "TREATMENT", 458, 467], ["r-cART", "TREATMENT", 468, 474], ["cultures", "TEST", 507, 515], ["darunavir", "TREATMENT", 529, 538], ["Lopinavir treatment", "TREATMENT", 557, 576], ["human decidual cell cultures", "TEST", 580, 608], ["a decline", "PROBLEM", 620, 629], ["decidualization", "PROBLEM", 661, 676], ["chemokines", "TEST", 678, 688], ["angiogenic factorsLevels", "TEST", 693, 717], ["the angiogenic factors", "TEST", 721, 743], ["VEGF", "TEST", 744, 748], ["PlGF", "TEST", 750, 754], ["angiopoietin", "TEST", 756, 768], ["GM", "TEST", 772, 774], ["CSF", "TEST", 775, 778], ["IFN", "TEST", 780, 783], ["MMP", "TEST", 790, 793], ["lopinavir", "TREATMENT", 826, 835], ["lopinavir", "TREATMENT", 841, 850], ["cART", "TREATMENT", 853, 857], ["darunavir", "TREATMENT", 872, 881], ["r-cART treatment", "TREATMENT", 882, 898], ["immune cell recruitment", "OBSERVATION", 323, 346], ["decidual cell", "OBSERVATION", 407, 420]]], ["Levels of endoglin and MMP-8 were similar in all treatment groups.Lopinavir treatment of human decidual cell cultures results in a decline in the levels of biomarkers of decidualization, chemokines and angiogenic factorsCollectively these data show that lopinavir treatment of human decidual cells results in a reduction in secretion of factors involved in decidualization, chemotaxis and angiogenesis, suggesting altered decidua cell function and a loss of the decidual phenotype with lopinavir exposure.Lopinavir treatment is associated with impaired decidualization and spiral artery remodeling, and lower uNK cells in a mouse pregnancy modelWe next sought to confirm our findings of impairments in decidualization, decidual function and spiral artery remodeling in the context of lopinavir/r treatment in an in vivo system using a murine model.Decidualization.To test the effect of PI-cART on the process of decidualization, we collected GD 6.5 implantation sites from mice treated once daily orally with PI-cART (yielding plasma drug levels approximating human minimal effective concentrations), or water as a control.", [["decidual cell cultures", "ANATOMY", 95, 117], ["decidual cells", "ANATOMY", 283, 297], ["decidua cell", "ANATOMY", 422, 434], ["decidual", "ANATOMY", 462, 470], ["spiral artery", "ANATOMY", 573, 586], ["uNK cells", "ANATOMY", 609, 618], ["decidual", "ANATOMY", 719, 727], ["spiral artery", "ANATOMY", 741, 754], ["plasma", "ANATOMY", 1027, 1033], ["Lopinavir", "CHEMICAL", 66, 75], ["lopinavir", "CHEMICAL", 254, 263], ["lopinavir", "CHEMICAL", 486, 495], ["Lopinavir", "CHEMICAL", 505, 514], ["lopinavir", "CHEMICAL", 784, 793], ["PI", "CHEMICAL", 886, 888], ["PI-cART", "CHEMICAL", 1009, 1016], ["Lopinavir", "CHEMICAL", 66, 75], ["lopinavir", "CHEMICAL", 254, 263], ["lopinavir", "CHEMICAL", 486, 495], ["Lopinavir", "CHEMICAL", 505, 514], ["lopinavir", "CHEMICAL", 784, 793], ["endoglin", "GENE_OR_GENE_PRODUCT", 10, 18], ["MMP-8", "GENE_OR_GENE_PRODUCT", 23, 28], ["Lopinavir", "SIMPLE_CHEMICAL", 66, 75], ["human", "ORGANISM", 89, 94], ["decidual cell cultures", "CELL", 95, 117], ["lopinavir", "SIMPLE_CHEMICAL", 254, 263], ["human", "ORGANISM", 277, 282], ["decidual cells", "CELL", 283, 297], ["decidua cell", "CELL", 422, 434], ["lopinavir", "SIMPLE_CHEMICAL", 486, 495], ["Lopinavir", "SIMPLE_CHEMICAL", 505, 514], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 573, 586], ["uNK cells", "CELL", 609, 618], ["mouse", "ORGANISM", 624, 629], ["decidual", "TISSUE", 719, 727], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 741, 754], ["lopinavir", "SIMPLE_CHEMICAL", 784, 793], ["murine", "ORGANISM", 835, 841], ["PI", "SIMPLE_CHEMICAL", 886, 888], ["mice", "ORGANISM", 973, 977], ["PI", "SIMPLE_CHEMICAL", 1009, 1011], ["plasma", "ORGANISM_SUBSTANCE", 1027, 1033], ["human", "ORGANISM", 1060, 1065], ["endoglin", "PROTEIN", 10, 18], ["MMP-8", "PROTEIN", 23, 28], ["human decidual cell cultures", "CELL_LINE", 89, 117], ["chemokines", "PROTEIN", 187, 197], ["angiogenic factors", "PROTEIN", 202, 220], ["human decidual cells", "CELL_TYPE", 277, 297], ["uNK cells", "CELL_TYPE", 609, 618], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 277, 282], ["mouse", "SPECIES", 624, 629], ["murine", "SPECIES", 835, 841], ["mice", "SPECIES", 973, 977], ["human", "SPECIES", 1060, 1065], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 277, 282], ["mouse", "SPECIES", 624, 629], ["mice", "SPECIES", 973, 977], ["human", "SPECIES", 1060, 1065], ["Levels", "TEST", 0, 6], ["endoglin", "TEST", 10, 18], ["MMP", "TEST", 23, 26], ["Lopinavir treatment", "TREATMENT", 66, 85], ["human decidual cell cultures", "TEST", 89, 117], ["a decline", "PROBLEM", 129, 138], ["decidualization", "PROBLEM", 170, 185], ["angiogenic factors", "PROBLEM", 202, 220], ["lopinavir treatment of human decidual cells", "TREATMENT", 254, 297], ["a reduction in secretion of factors", "PROBLEM", 309, 344], ["chemotaxis", "PROBLEM", 374, 384], ["angiogenesis", "PROBLEM", 389, 401], ["altered decidua cell function", "PROBLEM", 414, 443], ["a loss of the decidual phenotype", "PROBLEM", 448, 480], ["lopinavir exposure", "TREATMENT", 486, 504], ["Lopinavir treatment", "TREATMENT", 505, 524], ["impaired decidualization", "PROBLEM", 544, 568], ["spiral artery remodeling", "PROBLEM", 573, 597], ["lower uNK cells", "PROBLEM", 603, 618], ["a mouse pregnancy model", "TREATMENT", 622, 645], ["impairments in decidualization", "PROBLEM", 687, 717], ["decidual function", "PROBLEM", 719, 736], ["spiral artery remodeling", "TREATMENT", 741, 765], ["lopinavir/r treatment", "TREATMENT", 784, 805], ["a murine model", "TREATMENT", 833, 847], ["PI-cART", "TREATMENT", 886, 893], ["decidualization", "PROBLEM", 912, 927], ["GD 6.5 implantation sites", "TREATMENT", 942, 967], ["PI-cART", "TREATMENT", 1009, 1016], ["plasma drug levels", "TREATMENT", 1027, 1045], ["human minimal effective concentrations)", "TREATMENT", 1060, 1099], ["reduction", "OBSERVATION_MODIFIER", 311, 320], ["suggesting", "UNCERTAINTY", 403, 413], ["altered", "OBSERVATION_MODIFIER", 414, 421], ["decidua cell function", "OBSERVATION", 422, 443], ["decidual phenotype", "OBSERVATION", 462, 480], ["impaired", "OBSERVATION_MODIFIER", 544, 552], ["decidualization", "OBSERVATION", 553, 568], ["spiral artery", "ANATOMY", 573, 586], ["lower uNK cells", "OBSERVATION", 603, 618], ["spiral artery", "ANATOMY", 741, 754]]], ["GD6 .5 implantation sites were slightly smaller (not significant) in the lopinavir/r-cART group as compared to darunavir/r-cART and control groups.", [["lopinavir", "CHEMICAL", 73, 82], ["darunavir", "CHEMICAL", 111, 120], ["lopinavir", "CHEMICAL", 73, 82], ["r-cART", "CHEMICAL", 83, 89], ["darunavir", "CHEMICAL", 111, 120], ["r-cART", "CHEMICAL", 121, 127], ["lopinavir", "SIMPLE_CHEMICAL", 73, 82], ["darunavir", "SIMPLE_CHEMICAL", 111, 120], ["r-cART", "SIMPLE_CHEMICAL", 121, 127], ["GD6", "PROTEIN", 0, 3], ["GD6 .5 implantation", "TREATMENT", 0, 19], ["slightly smaller", "PROBLEM", 31, 47], ["the lopinavir/r-cART group", "TREATMENT", 69, 95], ["darunavir", "TREATMENT", 111, 120], ["slightly", "OBSERVATION_MODIFIER", 31, 39], ["smaller", "OBSERVATION_MODIFIER", 40, 47]]], ["H&E staining indicated that implantation site morphology was similar, with successful embryo implantation observed in all the treatment groups, although uterine lumen closure seemed to be delayed in the lopinavir/ r-cART group ( Supplementary Fig. S3) .Decidualization.To evaluate the extent of decidualization, GD6.5 implantation sites were immunostained with anti-Ki67 antibody, a marker for cellular proliferation (Fig. 4A) .", [["site", "ANATOMY", 41, 45], ["embryo", "ANATOMY", 86, 92], ["uterine lumen", "ANATOMY", 153, 166], ["cellular", "ANATOMY", 394, 402], ["lopinavir/ r-cART", "CHEMICAL", 203, 220], ["lopinavir", "CHEMICAL", 203, 212], ["r-cART", "CHEMICAL", 214, 220], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 86, 92], ["uterine lumen", "MULTI-TISSUE_STRUCTURE", 153, 166], ["lopinavir", "SIMPLE_CHEMICAL", 203, 212], ["anti-Ki67", "GENE_OR_GENE_PRODUCT", 361, 370], ["cellular", "CELL", 394, 402], ["anti-Ki67 antibody", "PROTEIN", 361, 379], ["implantation site morphology", "PROBLEM", 28, 56], ["successful embryo implantation", "TREATMENT", 75, 105], ["all the treatment groups", "TREATMENT", 118, 142], ["uterine lumen closure", "TREATMENT", 153, 174], ["the lopinavir/ r-cART group", "TREATMENT", 199, 226], ["Supplementary Fig", "TREATMENT", 229, 246], ["decidualization", "PROBLEM", 295, 310], ["GD6.5 implantation sites", "TREATMENT", 312, 336], ["anti-Ki67 antibody", "TEST", 361, 379], ["implantation", "OBSERVATION", 28, 40], ["embryo implantation", "OBSERVATION", 86, 105], ["uterine", "ANATOMY", 153, 160], ["lumen", "ANATOMY_MODIFIER", 161, 166], ["closure", "OBSERVATION", 167, 174], ["decidualization", "OBSERVATION", 295, 310], ["cellular proliferation", "OBSERVATION", 394, 416]]], ["A robust decidual response was observed in the implantation sites of control and darunavir/r-cART-treated mice, marked by intense Ki67 staining in the secondary decidual zone (SDZ) and the mesometrial decidua, indicative of extensive stromal cell proliferation ( Fig. 4A and B) .", [["decidual", "ANATOMY", 9, 17], ["sites", "ANATOMY", 60, 65], ["decidual zone", "ANATOMY", 161, 174], ["SDZ", "ANATOMY", 176, 179], ["mesometrial decidua", "ANATOMY", 189, 208], ["stromal cell", "ANATOMY", 234, 246], ["darunavir/r-cART", "CHEMICAL", 81, 97], ["SDZ", "CHEMICAL", 176, 179], ["darunavir", "CHEMICAL", 81, 90], ["r-cART", "CHEMICAL", 91, 97], ["decidual", "CELL", 9, 17], ["r-cART", "SIMPLE_CHEMICAL", 91, 97], ["mice", "ORGANISM", 106, 110], ["Ki67", "GENE_OR_GENE_PRODUCT", 130, 134], ["decidual zone", "TISSUE", 161, 174], ["SDZ", "CANCER", 176, 179], ["mesometrial decidua", "TISSUE", 189, 208], ["stromal cell", "CELL", 234, 246], ["B", "GENE_OR_GENE_PRODUCT", 275, 276], ["Ki67", "PROTEIN", 130, 134], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["the implantation sites", "TREATMENT", 43, 65], ["darunavir", "TREATMENT", 81, 90], ["the mesometrial decidua", "PROBLEM", 185, 208], ["extensive stromal cell proliferation", "PROBLEM", 224, 260], ["robust", "OBSERVATION_MODIFIER", 2, 8], ["decidual response", "OBSERVATION", 9, 26], ["implantation", "OBSERVATION", 47, 59], ["intense", "OBSERVATION_MODIFIER", 122, 129], ["Ki67 staining", "OBSERVATION", 130, 143], ["secondary decidual", "OBSERVATION", 151, 169], ["zone", "OBSERVATION_MODIFIER", 170, 174], ["SDZ", "OBSERVATION_MODIFIER", 176, 179], ["mesometrial decidua", "ANATOMY", 189, 208], ["indicative of", "UNCERTAINTY", 210, 223], ["extensive", "OBSERVATION_MODIFIER", 224, 233], ["stromal cell proliferation", "OBSERVATION", 234, 260]]], ["In lopinavir/r-cART-treated mice, Ki67\u00fe cells in the mesometrial decidua were dramatically reduced, while only weakly Ki67\u00fe cells were observed in the SDZ ( Fig. 4A and B) .", [["Ki67\u00fe cells", "ANATOMY", 34, 45], ["mesometrial decidua", "ANATOMY", 53, 72], ["Ki67\u00fe cells", "ANATOMY", 118, 129], ["lopinavir/r-cART", "CHEMICAL", 3, 19], ["SDZ", "CHEMICAL", 151, 154], ["lopinavir", "CHEMICAL", 3, 12], ["r-cART", "CHEMICAL", 13, 19], ["SDZ", "CHEMICAL", 151, 154], ["lopinavir", "SIMPLE_CHEMICAL", 3, 12], ["r-cART", "SIMPLE_CHEMICAL", 13, 19], ["mice", "ORGANISM", 28, 32], ["Ki67", "GENE_OR_GENE_PRODUCT", 34, 38], ["mesometrial decidua", "TISSUE", 53, 72], ["Ki67", "GENE_OR_GENE_PRODUCT", 118, 122], ["cells", "CELL", 124, 129], ["SDZ", "SIMPLE_CHEMICAL", 151, 154], ["B", "CELL", 169, 170], ["Ki67\u00fe cells", "CELL_LINE", 34, 45], ["Ki67", "PROTEIN", 118, 122], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["lopinavir", "TREATMENT", 3, 12], ["cART", "TREATMENT", 15, 19], ["the SDZ", "TEST", 147, 154], ["mesometrial decidua", "ANATOMY", 53, 72], ["dramatically", "OBSERVATION_MODIFIER", 78, 90], ["reduced", "OBSERVATION_MODIFIER", 91, 98]]], ["Ki67 staining was not observed in the primary decidual zone (PDZ) across all treatments.", [["primary decidual zone", "ANATOMY", 38, 59], ["Ki67", "GENE_OR_GENE_PRODUCT", 0, 4], ["decidual zone", "TISSUE", 46, 59], ["Ki67", "PROTEIN", 0, 4], ["Ki67 staining", "TEST", 0, 13], ["all treatments", "TREATMENT", 73, 87], ["not observed", "UNCERTAINTY", 18, 30], ["primary decidual", "OBSERVATION", 38, 54], ["zone", "OBSERVATION_MODIFIER", 55, 59]]], ["These data show that lopinavir treatment is associated with less proliferation in the stromal compartments, indicative of impaired decidualization.Spiral artery remodeling.To investigate the effect of PI-cART on spiral artery remodeling, we collected GD9.5 implantation sites (Fig. 4C, upper panels) .", [["stromal compartments", "ANATOMY", 86, 106], ["Spiral artery", "ANATOMY", 147, 160], ["spiral artery", "ANATOMY", 212, 225], ["lopinavir", "CHEMICAL", 21, 30], ["impaired decidualization", "DISEASE", 122, 146], ["PI-cART", "CHEMICAL", 201, 208], ["lopinavir", "CHEMICAL", 21, 30], ["lopinavir", "SIMPLE_CHEMICAL", 21, 30], ["stromal compartments", "MULTI-TISSUE_STRUCTURE", 86, 106], ["Spiral artery", "MULTI-TISSUE_STRUCTURE", 147, 160], ["PI", "SIMPLE_CHEMICAL", 201, 203], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 212, 225], ["These data", "TEST", 0, 10], ["lopinavir treatment", "TREATMENT", 21, 40], ["less proliferation in the stromal compartments", "PROBLEM", 60, 106], ["impaired decidualization", "PROBLEM", 122, 146], ["Spiral artery remodeling", "PROBLEM", 147, 171], ["PI", "TREATMENT", 201, 203], ["spiral artery remodeling", "TREATMENT", 212, 236], ["implantation sites", "TREATMENT", 257, 275], ["lopinavir treatment", "OBSERVATION", 21, 40], ["less", "OBSERVATION_MODIFIER", 60, 64], ["proliferation", "OBSERVATION", 65, 78], ["stromal compartments", "OBSERVATION", 86, 106], ["indicative of", "UNCERTAINTY", 108, 121], ["impaired", "OBSERVATION_MODIFIER", 122, 130], ["decidualization", "OBSERVATION", 131, 146], ["artery", "ANATOMY", 154, 160], ["remodeling", "OBSERVATION", 161, 171], ["spiral artery", "ANATOMY", 212, 225]]], ["Number of implantation sites (9 \u00a7 1) did not differ between treatment groups at this gestational stage; however, implantation sites were slightly smaller (not significant) and more frequently displayed signs of resorption (dark spots) in the lopinavir/r-cART group.", [["lopinavir/r-cART", "CHEMICAL", 242, 258], ["lopinavir", "CHEMICAL", 242, 251], ["r-cART", "CHEMICAL", 252, 258], ["lopinavir", "SIMPLE_CHEMICAL", 242, 251], ["implantation sites", "TREATMENT", 10, 28], ["treatment groups", "TREATMENT", 60, 76], ["implantation sites", "PROBLEM", 113, 131], ["slightly smaller", "PROBLEM", 137, 153], ["resorption (dark spots", "PROBLEM", 211, 233], ["the lopinavir/r-cART group", "TREATMENT", 238, 264], ["implantation", "OBSERVATION", 10, 22], ["slightly", "OBSERVATION_MODIFIER", 137, 145], ["smaller", "OBSERVATION_MODIFIER", 146, 153], ["resorption", "OBSERVATION", 211, 221]]], ["To quantify degree of spiral artery remodeling, spiral artery lumen area in the decidua basalis was assessed by stereology (Fig. 4C, lower panels) .", [["spiral artery", "ANATOMY", 22, 35], ["spiral artery lumen area", "ANATOMY", 48, 72], ["decidua basalis", "ANATOMY", 80, 95], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 22, 35], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 48, 61], ["decidua basalis", "TISSUE", 80, 95], ["spiral artery remodeling", "PROBLEM", 22, 46], ["spiral artery lumen area", "TREATMENT", 48, 72], ["spiral artery", "ANATOMY", 22, 35], ["remodeling", "OBSERVATION", 36, 46], ["spiral", "ANATOMY_MODIFIER", 48, 54], ["artery", "ANATOMY", 55, 61], ["lumen", "ANATOMY_MODIFIER", 62, 67], ["decidua basalis", "ANATOMY", 80, 95]]], ["Mean vessel lumen area was significantly lower in the lopinavir/r-cART group compared to control or darunavir/r-cART, indicative of reduced spiral artery Quantification of flow cytometry data showing total live cells and leukocyte subsets from the primary human decidual cell cultures treated with DMSO (control) or protease inhibitors (PIs) as indicated.", [["vessel lumen area", "ANATOMY", 5, 22], ["spiral artery", "ANATOMY", 140, 153], ["live cells", "ANATOMY", 206, 216], ["leukocyte", "ANATOMY", 221, 230], ["decidual cell cultures", "ANATOMY", 262, 284], ["lopinavir/r-cART", "CHEMICAL", 54, 70], ["darunavir", "CHEMICAL", 100, 109], ["DMSO", "CHEMICAL", 298, 302], ["lopinavir", "CHEMICAL", 54, 63], ["r-cART", "CHEMICAL", 64, 70], ["darunavir", "CHEMICAL", 100, 109], ["r-cART", "CHEMICAL", 110, 116], ["DMSO", "CHEMICAL", 298, 302], ["vessel lumen", "MULTI-TISSUE_STRUCTURE", 5, 17], ["lopinavir", "SIMPLE_CHEMICAL", 54, 63], ["darunavir", "SIMPLE_CHEMICAL", 100, 109], ["r-cART", "SIMPLE_CHEMICAL", 110, 116], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 140, 153], ["cells", "CELL", 211, 216], ["leukocyte", "CELL", 221, 230], ["human", "ORGANISM", 256, 261], ["decidual cell cultures", "CELL", 262, 284], ["DMSO", "SIMPLE_CHEMICAL", 298, 302], ["protease inhibitors", "SIMPLE_CHEMICAL", 316, 335], ["leukocyte subsets", "CELL_TYPE", 221, 238], ["primary human decidual cell cultures", "CELL_LINE", 248, 284], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["Mean vessel lumen area", "TEST", 0, 22], ["the lopinavir", "TEST", 50, 63], ["darunavir", "TEST", 100, 109], ["reduced spiral artery", "PROBLEM", 132, 153], ["flow cytometry data", "TEST", 172, 191], ["total live cells", "PROBLEM", 200, 216], ["leukocyte subsets", "PROBLEM", 221, 238], ["the primary human decidual cell cultures", "TREATMENT", 244, 284], ["DMSO (control", "TREATMENT", 298, 311], ["protease inhibitors", "TREATMENT", 316, 335], ["vessel", "ANATOMY", 5, 11], ["lumen", "ANATOMY_MODIFIER", 12, 17], ["significantly", "OBSERVATION_MODIFIER", 27, 40], ["lower", "OBSERVATION", 41, 46], ["indicative of", "UNCERTAINTY", 118, 131], ["reduced", "OBSERVATION", 132, 139], ["spiral artery", "ANATOMY", 140, 153], ["flow cytometry", "OBSERVATION", 172, 186], ["leukocyte subsets", "OBSERVATION", 221, 238], ["primary human decidual cell", "OBSERVATION", 248, 275]]], ["Results are the mean \u00a7 SD. *** indicates P-value < 0.0001, calculated using ANOVA with Tukey's post hoc analysis.", [["P-value", "TEST", 41, 48], ["Tukey's post hoc analysis", "TEST", 87, 112]]], ["For T cells, macrophages and stroma cells, P-value was not significant between the treatment groups.", [["T cells", "ANATOMY", 4, 11], ["macrophages", "ANATOMY", 13, 24], ["stroma cells", "ANATOMY", 29, 41], ["T cells", "CELL", 4, 11], ["macrophages", "CELL", 13, 24], ["stroma cells", "CELL", 29, 41], ["T cells", "CELL_TYPE", 4, 11], ["macrophages", "CELL_TYPE", 13, 24], ["stroma cells", "CELL_TYPE", 29, 41], ["T cells", "PROBLEM", 4, 11], ["macrophages", "PROBLEM", 13, 24], ["stroma cells", "TEST", 29, 41], ["P-value", "TEST", 43, 50], ["stroma cells", "OBSERVATION", 29, 41]]], ["(B) Representative images of CD56 immunostaining of uterine NK (uNK) cells in first-trimester decidua treated with DMSO (control) or PIs as indicated.", [["uterine NK (uNK) cells", "ANATOMY", 52, 74], ["decidua", "ANATOMY", 94, 101], ["DMSO", "CHEMICAL", 115, 119], ["DMSO", "CHEMICAL", 115, 119], ["CD56", "GENE_OR_GENE_PRODUCT", 29, 33], ["uterine NK (uNK) cells", "CELL", 52, 74], ["decidua", "CELL", 94, 101], ["DMSO", "SIMPLE_CHEMICAL", 115, 119], ["CD56", "PROTEIN", 29, 33], ["uterine NK (uNK) cells", "CELL_TYPE", 52, 74], ["Representative images", "TEST", 4, 25], ["CD56 immunostaining", "TEST", 29, 48], ["uterine NK (uNK) cells", "TREATMENT", 52, 74], ["first-trimester decidua", "TREATMENT", 78, 101], ["DMSO (control", "TREATMENT", 115, 128], ["PIs", "TREATMENT", 133, 136], ["uterine NK", "ANATOMY", 52, 62]]], ["In the ritonavir-boosted lopinavir (LPV/r) treatment group, uNK cells display a condensed appearance (arrows), characteristic of apoptotic cells.", [["uNK cells", "ANATOMY", 60, 69], ["cells", "ANATOMY", 139, 144], ["ritonavir", "CHEMICAL", 7, 16], ["lopinavir", "CHEMICAL", 25, 34], ["LPV", "CHEMICAL", 36, 39], ["ritonavir", "CHEMICAL", 7, 16], ["lopinavir", "CHEMICAL", 25, 34], ["LPV", "CHEMICAL", 36, 39], ["ritonavir", "SIMPLE_CHEMICAL", 7, 16], ["lopinavir", "SIMPLE_CHEMICAL", 25, 34], ["uNK cells", "CELL", 60, 69], ["cells", "CELL", 139, 144], ["uNK cells", "CELL_TYPE", 60, 69], ["apoptotic cells", "CELL_TYPE", 129, 144], ["the ritonavir-boosted lopinavir (LPV/r) treatment group", "TREATMENT", 3, 58], ["uNK cells", "PROBLEM", 60, 69], ["a condensed appearance", "PROBLEM", 78, 100], ["apoptotic cells", "PROBLEM", 129, 144], ["apoptotic cells", "OBSERVATION", 129, 144]]], ["Scale bar, 20 mm.", [["20 mm", "OBSERVATION_MODIFIER", 11, 16]]], ["(C) Stereological quantification of CD56 positive uNK cells.", [["CD56 positive uNK cells", "ANATOMY", 36, 59], ["CD56", "GENE_OR_GENE_PRODUCT", 36, 40], ["CD56 positive uNK cells", "CELL_TYPE", 36, 59], ["Stereological quantification", "TEST", 4, 32], ["CD56 positive uNK cells", "PROBLEM", 36, 59], ["CD56 positive uNK cells", "OBSERVATION", 36, 59]]], ["Results are the mean \u00a7 SD. *** indicates P < 0.0001, calculated using ANOVA with Tukey's post hoc analysis.", [["hoc analysis", "TEST", 94, 106]]], ["Each data point represents the average of two to three replicates per experiment; n \u00bc 6 independent experiments. cART, combination antiretroviral therapy; DRV/r, ritonavir-boosted darunavir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . remodeling (Fig. 4D) .", [["cART", "CHEMICAL", 113, 117], ["DRV", "CHEMICAL", 155, 158], ["ritonavir", "CHEMICAL", 162, 171], ["darunavir", "CHEMICAL", 180, 189], ["ritonavir", "CHEMICAL", 162, 171], ["darunavir", "CHEMICAL", 180, 189], ["DRV", "SIMPLE_CHEMICAL", 155, 158], ["ritonavir", "SIMPLE_CHEMICAL", 162, 171], ["darunavir", "SIMPLE_CHEMICAL", 180, 189], ["cART", "TREATMENT", 113, 117], ["combination antiretroviral therapy", "TREATMENT", 119, 153], ["DRV", "TREATMENT", 155, 158], ["ritonavir", "TREATMENT", 162, 171], ["darunavir", "TREATMENT", 180, 189]]], ["Consistent with the findings of smaller vessel lumen areas in the lopinavir/r-cART group, SMA staining demonstrated the presence of entire rings of smooth muscle cells around spiral arteries ( Fig. 4E and F) , indicative of un-remodeled vessels.", [["vessel lumen", "ANATOMY", 40, 52], ["smooth muscle cells", "ANATOMY", 148, 167], ["spiral arteries", "ANATOMY", 175, 190], ["vessels", "ANATOMY", 237, 244], ["lopinavir/r-cART", "CHEMICAL", 66, 82], ["lopinavir", "CHEMICAL", 66, 75], ["r-cART", "CHEMICAL", 76, 82], ["vessel lumen", "MULTI-TISSUE_STRUCTURE", 40, 52], ["lopinavir", "SIMPLE_CHEMICAL", 66, 75], ["SMA", "GENE_OR_GENE_PRODUCT", 90, 93], ["smooth muscle cells", "CELL", 148, 167], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 175, 190], ["vessels", "MULTI-TISSUE_STRUCTURE", 237, 244], ["SMA", "PROTEIN", 90, 93], ["smooth muscle cells", "CELL_TYPE", 148, 167], ["smaller vessel lumen areas", "PROBLEM", 32, 58], ["the lopinavir/r-cART group", "TREATMENT", 62, 88], ["SMA staining", "TEST", 90, 102], ["entire rings of smooth muscle cells", "PROBLEM", 132, 167], ["smaller", "OBSERVATION_MODIFIER", 32, 39], ["vessel", "ANATOMY", 40, 46], ["lumen", "ANATOMY_MODIFIER", 47, 52], ["lopinavir", "ANATOMY", 66, 75], ["SMA", "ANATOMY", 90, 93], ["entire", "OBSERVATION_MODIFIER", 132, 138], ["rings", "OBSERVATION_MODIFIER", 139, 144], ["smooth muscle cells", "OBSERVATION", 148, 167], ["spiral arteries", "ANATOMY", 175, 190], ["indicative of", "UNCERTAINTY", 210, 223], ["un", "OBSERVATION", 224, 226], ["remodeled", "OBSERVATION", 227, 236], ["vessels", "ANATOMY", 237, 244]]], ["In contrast, intensity of SMA staining was significantly reduced, with only specks of SMA remaining in spiral arteries of control and darunavir/r-cART groups ( Fig. 4E and F) , suggestive of a successful remodeling process.uNK cell.To assess the impact of PI-cART on the early contributions of uNK cells to decidual remodeling, GD9.5 implantation sites were stained with DBA-lectin, a marker for murine uNK cells.", [["spiral arteries", "ANATOMY", 103, 118], ["cell", "ANATOMY", 227, 231], ["uNK cells", "ANATOMY", 294, 303], ["decidual", "ANATOMY", 307, 315], ["sites", "ANATOMY", 347, 352], ["uNK cells", "ANATOMY", 403, 412], ["darunavir", "CHEMICAL", 134, 143], ["PI", "CHEMICAL", 256, 258], ["darunavir", "CHEMICAL", 134, 143], ["r-cART", "CHEMICAL", 144, 150], ["SMA", "GENE_OR_GENE_PRODUCT", 26, 29], ["SMA", "GENE_OR_GENE_PRODUCT", 86, 89], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 103, 118], ["darunavir", "SIMPLE_CHEMICAL", 134, 143], ["process.uNK cell", "CELL", 215, 231], ["PI", "SIMPLE_CHEMICAL", 256, 258], ["uNK cells", "CELL", 294, 303], ["decidual", "CELL", 307, 315], ["DBA-lectin", "GENE_OR_GENE_PRODUCT", 371, 381], ["murine", "ORGANISM", 396, 402], ["uNK cells", "CELL", 403, 412], ["SMA", "PROTEIN", 26, 29], ["SMA", "PROTEIN", 86, 89], ["process.uNK cell", "CELL_LINE", 215, 231], ["uNK cells", "CELL_TYPE", 294, 303], ["DBA", "PROTEIN", 371, 374], ["lectin", "PROTEIN", 375, 381], ["murine uNK cells", "CELL_TYPE", 396, 412], ["murine", "SPECIES", 396, 402], ["SMA staining", "PROBLEM", 26, 38], ["darunavir", "TEST", 134, 143], ["a successful remodeling process.uNK cell", "PROBLEM", 191, 231], ["PI", "TREATMENT", 256, 258], ["uNK cells", "TREATMENT", 294, 303], ["decidual remodeling", "PROBLEM", 307, 326], ["GD9.5 implantation sites", "TREATMENT", 328, 352], ["DBA", "TEST", 371, 374], ["murine uNK cells", "PROBLEM", 396, 412], ["intensity", "OBSERVATION_MODIFIER", 13, 22], ["SMA", "ANATOMY", 26, 29], ["staining", "OBSERVATION", 30, 38], ["significantly", "OBSERVATION_MODIFIER", 43, 56], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["SMA", "ANATOMY", 86, 89], ["spiral arteries", "ANATOMY", 103, 118], ["suggestive of", "UNCERTAINTY", 177, 190], ["successful", "OBSERVATION_MODIFIER", 193, 203], ["remodeling", "OBSERVATION", 204, 214], ["process.uNK cell", "OBSERVATION", 215, 231], ["uNK cells", "OBSERVATION", 294, 303], ["uNK cells", "OBSERVATION", 403, 412]]], ["As expected in midgestation, uNK cells were abundant in the decidua basalis of both control and darunavir/r-cART-treated mice ( Fig. 5A-C) , with uNK cells surrounding the spiral arteries and frequently invading their lumen (Fig. 5A, lower panels) .", [["uNK cells", "ANATOMY", 29, 38], ["decidua basalis", "ANATOMY", 60, 75], ["uNK cells", "ANATOMY", 146, 155], ["spiral arteries", "ANATOMY", 172, 187], ["lumen", "ANATOMY", 218, 223], ["darunavir/r-cART", "CHEMICAL", 96, 112], ["darunavir", "CHEMICAL", 96, 105], ["r-cART", "CHEMICAL", 106, 112], ["uNK cells", "CELL", 29, 38], ["decidua basalis", "TISSUE", 60, 75], ["r-cART", "SIMPLE_CHEMICAL", 106, 112], ["mice", "ORGANISM", 121, 125], ["Fig. 5A-C", "CELL", 128, 137], ["uNK cells", "CELL", 146, 155], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 172, 187], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 218, 223], ["uNK cells", "CELL_TYPE", 29, 38], ["uNK cells", "CELL_TYPE", 146, 155], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 121, 125], ["uNK cells", "PROBLEM", 29, 38], ["darunavir/r-cART", "TREATMENT", 96, 112], ["uNK cells", "PROBLEM", 146, 155], ["uNK cells", "OBSERVATION", 29, 38], ["uNK cells", "OBSERVATION", 146, 155], ["spiral arteries", "ANATOMY", 172, 187], ["lumen", "ANATOMY_MODIFIER", 218, 223]]], ["In contrast, the number of uNK cells was significantly reduced in the decidua basalis of lopinavir/r-cART-treated mice ( Fig. 5A-C) and vascular infiltration by the uNK cells was reduced (see arrows in Fig. 5A, lower panels) .", [["uNK cells", "ANATOMY", 27, 36], ["decidua basalis", "ANATOMY", 70, 85], ["vascular", "ANATOMY", 136, 144], ["uNK cells", "ANATOMY", 165, 174], ["lopinavir/r-cART", "CHEMICAL", 89, 105], ["lopinavir", "CHEMICAL", 89, 98], ["r-cART", "CHEMICAL", 99, 105], ["uNK cells", "CELL", 27, 36], ["decidua basalis", "TISSUE", 70, 85], ["lopinavir", "SIMPLE_CHEMICAL", 89, 98], ["r-cART", "SIMPLE_CHEMICAL", 99, 105], ["mice", "ORGANISM", 114, 118], ["Fig. 5A-C", "CELL", 121, 130], ["vascular", "MULTI-TISSUE_STRUCTURE", 136, 144], ["uNK cells", "CELL", 165, 174], ["uNK cells", "CELL_TYPE", 27, 36], ["uNK cells", "CELL_TYPE", 165, 174], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 114, 118], ["uNK cells", "PROBLEM", 27, 36], ["lopinavir", "TREATMENT", 89, 98], ["r-cART", "TREATMENT", 99, 105], ["vascular infiltration", "PROBLEM", 136, 157], ["the uNK cells", "TEST", 161, 174], ["uNK cells", "OBSERVATION", 27, 36], ["reduced", "OBSERVATION_MODIFIER", 55, 62], ["vascular", "ANATOMY", 136, 144], ["infiltration", "OBSERVATION", 145, 157], ["uNK cells", "OBSERVATION", 165, 174]]], ["The apoptotic-cell like condensed appearance seen in the uNK cells in the human co-cultures was also noticeable in the mouse (indicated by * in Fig. 5A , lower panel).Lopinavir treatment is associated with defective placentation and developmental retardation in a mouse pregnancy modelGiven the observed impact of lopinavir on the decidua, we explored whether this would influence placenta and fetal development.", [["cell", "ANATOMY", 14, 18], ["uNK cells", "ANATOMY", 57, 66], ["decidua", "ANATOMY", 331, 338], ["placenta", "ANATOMY", 381, 389], ["fetal", "ANATOMY", 394, 399], ["Lopinavir", "CHEMICAL", 167, 176], ["developmental retardation", "DISEASE", 233, 258], ["lopinavir", "CHEMICAL", 314, 323], ["Lopinavir", "CHEMICAL", 167, 176], ["lopinavir", "CHEMICAL", 314, 323], ["cell", "CELL", 14, 18], ["uNK cells", "CELL", 57, 66], ["human", "ORGANISM", 74, 79], ["co-cultures", "CELL", 80, 91], ["mouse", "ORGANISM", 119, 124], ["Lopinavir", "SIMPLE_CHEMICAL", 167, 176], ["mouse", "ORGANISM", 264, 269], ["lopinavir", "SIMPLE_CHEMICAL", 314, 323], ["decidua", "ORGANISM_SUBSTANCE", 331, 338], ["placenta", "TISSUE", 381, 389], ["fetal", "ANATOMICAL_SYSTEM", 394, 399], ["uNK cells", "CELL_TYPE", 57, 66], ["human", "SPECIES", 74, 79], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 264, 269], ["human", "SPECIES", 74, 79], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 264, 269], ["condensed appearance", "PROBLEM", 24, 44], ["the human co-cultures", "TEST", 70, 91], ["Lopinavir treatment", "TREATMENT", 167, 186], ["defective placentation", "PROBLEM", 206, 228], ["developmental retardation", "PROBLEM", 233, 258], ["a mouse pregnancy model", "TREATMENT", 262, 285], ["lopinavir", "TREATMENT", 314, 323], ["apoptotic", "OBSERVATION_MODIFIER", 4, 13], ["-cell", "OBSERVATION_MODIFIER", 13, 18], ["like condensed", "OBSERVATION_MODIFIER", 19, 33], ["uNK cells", "OBSERVATION", 57, 66], ["human", "ANATOMY", 74, 79], ["defective placentation", "OBSERVATION", 206, 228]]], ["By midgestation, the structure of the early placenta begins to form, and the three distinct placental layers namely, the labyrinthine trophoblast, spongiotrophoblast and giant cell layers, can be readily identified.", [["placenta", "ANATOMY", 44, 52], ["placental layers", "ANATOMY", 92, 108], ["labyrinthine trophoblast", "ANATOMY", 121, 145], ["spongiotrophoblast", "ANATOMY", 147, 165], ["giant cell layers", "ANATOMY", 170, 187], ["placenta", "ORGAN", 44, 52], ["placental layers", "TISSUE", 92, 108], ["labyrinthine trophoblast", "CELL", 121, 145], ["spongiotrophoblast", "CELL", 147, 165], ["giant cell layers", "TISSUE", 170, 187], ["labyrinthine trophoblast", "CELL_TYPE", 121, 145], ["spongiotrophoblast and giant cell layers", "CELL_TYPE", 147, 187], ["the labyrinthine trophoblast", "TEST", 117, 145], ["giant cell layers", "PROBLEM", 170, 187], ["early", "OBSERVATION_MODIFIER", 38, 43], ["placenta", "OBSERVATION", 44, 52], ["distinct", "OBSERVATION_MODIFIER", 83, 91], ["placental", "OBSERVATION", 92, 101], ["layers", "OBSERVATION_MODIFIER", 102, 108], ["labyrinthine trophoblast", "OBSERVATION", 121, 145], ["giant cell layers", "OBSERVATION", 170, 187]]], ["Immunostaining of implantation sites with the pan trophoblast cell marker cytokeratin revealed that placental morphology differed in the lopinavir/r-cART treated mice compared to the other groups (Fig. 6) .", [["sites", "ANATOMY", 31, 36], ["trophoblast cell", "ANATOMY", 50, 66], ["placental", "ANATOMY", 100, 109], ["lopinavir/r-cART", "CHEMICAL", 137, 153], ["lopinavir", "CHEMICAL", 137, 146], ["r-cART", "CHEMICAL", 147, 153], ["trophoblast cell", "CELL", 50, 66], ["cytokeratin", "GENE_OR_GENE_PRODUCT", 74, 85], ["placental", "ORGAN", 100, 109], ["lopinavir", "SIMPLE_CHEMICAL", 137, 146], ["mice", "ORGANISM", 162, 166], ["pan trophoblast cell marker cytokeratin", "PROTEIN", 46, 85], ["mice", "SPECIES", 162, 166], ["mice", "SPECIES", 162, 166], ["Immunostaining of implantation sites", "PROBLEM", 0, 36], ["the pan trophoblast cell marker cytokeratin", "TEST", 42, 85], ["placental morphology", "PROBLEM", 100, 120], ["the lopinavir/r-cART", "TREATMENT", 133, 153], ["implantation", "OBSERVATION", 18, 30], ["placental morphology", "OBSERVATION_MODIFIER", 100, 120]]], ["In the placentae of control and darunavir/r-cART-treated mice, trophoblasts migrated centrally into the decidua and only one or two layers of parietal trophoblast giant cells (P-TGCs) were visible.", [["placentae", "ANATOMY", 7, 16], ["trophoblasts", "ANATOMY", 63, 75], ["decidua", "ANATOMY", 104, 111], ["parietal trophoblast giant cells", "ANATOMY", 142, 174], ["P-TGCs", "ANATOMY", 176, 182], ["darunavir/r-cART", "CHEMICAL", 32, 48], ["darunavir", "CHEMICAL", 32, 41], ["r-cART", "CHEMICAL", 42, 48], ["placentae", "ORGANISM", 7, 16], ["darunavir", "SIMPLE_CHEMICAL", 32, 41], ["r-cART", "SIMPLE_CHEMICAL", 42, 48], ["mice", "ORGANISM", 57, 61], ["trophoblasts", "CELL", 63, 75], ["decidua", "TISSUE", 104, 111], ["parietal trophoblast giant cells", "CELL", 142, 174], ["P-TGCs", "CELL", 176, 182], ["trophoblasts", "CELL_TYPE", 63, 75], ["parietal trophoblast giant cells", "CELL_TYPE", 142, 174], ["TGCs", "CELL_TYPE", 178, 182], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["darunavir", "TREATMENT", 32, 41], ["r-cART-treated mice", "TREATMENT", 42, 61], ["trophoblasts", "PROBLEM", 63, 75], ["parietal trophoblast giant cells", "PROBLEM", 142, 174], ["P-TGCs", "TEST", 176, 182], ["decidua", "ANATOMY", 104, 111], ["layers", "OBSERVATION_MODIFIER", 132, 138], ["parietal trophoblast", "ANATOMY", 142, 162], ["giant cells", "OBSERVATION", 163, 174]]], ["In contrast, the placentae of lopinavir/r-cART-treated mice did not exhibit a centrally directed invasive front and displayed an increased number of P-TGC layers (Fig. 6, middle panel) .", [["placentae", "ANATOMY", 17, 26], ["lopinavir/r-cART", "CHEMICAL", 30, 46], ["lopinavir", "CHEMICAL", 30, 39], ["r-cART", "CHEMICAL", 40, 46], ["placentae", "ORGANISM", 17, 26], ["lopinavir", "SIMPLE_CHEMICAL", 30, 39], ["r-cART", "SIMPLE_CHEMICAL", 40, 46], ["mice", "ORGANISM", 55, 59], ["P", "DNA", 149, 150], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["lopinavir/r-cART", "TREATMENT", 30, 46], ["a centrally directed invasive front", "PROBLEM", 76, 111], ["middle panel", "TEST", 171, 183], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["number", "OBSERVATION_MODIFIER", 139, 145]]], ["Prospective spongiotrophoblast and labyrinth layers were diminished, and fewer fetal blood vessels were seen in the developing labyrinth of lopinavir/r-cART compared to control or darunavir/r-cART-treated mice ( Supplementary Fig. S4) .", [["spongiotrophoblast", "ANATOMY", 12, 30], ["labyrinth layers", "ANATOMY", 35, 51], ["fetal blood vessels", "ANATOMY", 79, 98], ["labyrinth", "ANATOMY", 127, 136], ["lopinavir/r-cART", "CHEMICAL", 140, 156], ["darunavir/r-cART", "CHEMICAL", 180, 196], ["lopinavir", "CHEMICAL", 140, 149], ["darunavir", "CHEMICAL", 180, 189], ["r-cART", "CHEMICAL", 190, 196], ["spongiotrophoblast", "CANCER", 12, 30], ["labyrinth layers", "TISSUE", 35, 51], ["fetal blood vessels", "MULTI-TISSUE_STRUCTURE", 79, 98], ["labyrinth", "ORGAN", 127, 136], ["lopinavir", "SIMPLE_CHEMICAL", 140, 149], ["darunavir", "SIMPLE_CHEMICAL", 180, 189], ["r-cART", "SIMPLE_CHEMICAL", 190, 196], ["mice", "ORGANISM", 205, 209], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 205, 209], ["Prospective spongiotrophoblast and labyrinth layers", "TEST", 0, 51], ["diminished", "PROBLEM", 57, 67], ["fewer fetal blood vessels", "PROBLEM", 73, 98], ["lopinavir", "TREATMENT", 140, 149], ["r-cART", "TREATMENT", 150, 156], ["darunavir", "TREATMENT", 180, 189], ["r-cART", "TREATMENT", 190, 196], ["Supplementary Fig", "TREATMENT", 212, 229], ["labyrinth", "ANATOMY_MODIFIER", 35, 44], ["layers", "ANATOMY_MODIFIER", 45, 51], ["diminished", "OBSERVATION_MODIFIER", 57, 67], ["blood vessels", "ANATOMY", 85, 98]]], ["It was also noted that in a minority of lopinavir/r-cART-treated mice, chorioallantoic fusion had failed to occur.", [["chorioallantoic", "ANATOMY", 71, 86], ["lopinavir/r-cART", "CHEMICAL", 40, 56], ["lopinavir", "CHEMICAL", 40, 49], ["r-cART", "CHEMICAL", 50, 56], ["lopinavir", "SIMPLE_CHEMICAL", 40, 49], ["r-cART", "SIMPLE_CHEMICAL", 50, 56], ["mice", "ORGANISM", 65, 69], ["chorioallantoic", "ORGAN", 71, 86], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["lopinavir/r-cART", "TREATMENT", 40, 56], ["chorioallantoic fusion", "TREATMENT", 71, 93]]], ["Additionally, H&E-stained midsagittal sections of the GD9.5 implantation sites revealed an abnormal ............................................................................................................................................................................................................................", [["sections", "ANATOMY", 38, 46], ["H&E", "TEST", 14, 17], ["the GD9.5 implantation", "TREATMENT", 50, 72], ["an abnormal", "PROBLEM", 88, 99], ["abnormal", "OBSERVATION", 91, 99]]], ["Table I Multiplex analysis of secreted proteins of human decidual cell culture treated with ritonavir-boosted lopinavir (lopinavir/r), lopinavir/r-combined antiretroviral therapy (cART), ritonavir-boosted darunavir (darunavir/r)-cART, or DMSO (control) as indicated.", [["decidual cell culture", "ANATOMY", 57, 78], ["ritonavir", "CHEMICAL", 92, 101], ["lopinavir", "CHEMICAL", 110, 119], ["lopinavir", "CHEMICAL", 121, 130], ["lopinavir", "CHEMICAL", 135, 144], ["ritonavir", "CHEMICAL", 187, 196], ["darunavir", "CHEMICAL", 205, 214], ["darunavir", "CHEMICAL", 216, 225], ["DMSO", "CHEMICAL", 238, 242], ["ritonavir", "CHEMICAL", 92, 101], ["lopinavir", "CHEMICAL", 110, 119], ["lopinavir", "CHEMICAL", 121, 130], ["lopinavir", "CHEMICAL", 135, 144], ["ritonavir", "CHEMICAL", 187, 196], ["darunavir", "CHEMICAL", 205, 214], ["darunavir", "CHEMICAL", 216, 225], ["DMSO", "CHEMICAL", 238, 242], ["human", "ORGANISM", 51, 56], ["decidual cell culture", "CELL", 57, 78], ["ritonavir", "SIMPLE_CHEMICAL", 92, 101], ["lopinavir", "SIMPLE_CHEMICAL", 110, 119], ["lopinavir", "SIMPLE_CHEMICAL", 121, 130], ["lopinavir", "SIMPLE_CHEMICAL", 135, 144], ["ritonavir", "SIMPLE_CHEMICAL", 187, 196], ["darunavir", "SIMPLE_CHEMICAL", 205, 214], ["darunavir/r)-cART", "SIMPLE_CHEMICAL", 216, 233], ["DMSO", "SIMPLE_CHEMICAL", 238, 242], ["secreted proteins", "PROTEIN", 30, 47], ["human decidual cell culture", "CELL_LINE", 51, 78], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["human decidual cell culture", "TREATMENT", 51, 78], ["ritonavir", "TREATMENT", 92, 101], ["lopinavir", "TREATMENT", 110, 119], ["lopinavir/r)", "TREATMENT", 121, 133], ["lopinavir", "TREATMENT", 135, 144], ["combined antiretroviral therapy", "TREATMENT", 147, 178], ["cART)", "TREATMENT", 180, 185], ["ritonavir", "TREATMENT", 187, 196], ["darunavir", "TREATMENT", 205, 214], ["darunavir", "TREATMENT", 216, 225], ["cART", "TREATMENT", 229, 233], ["DMSO (control", "TREATMENT", 238, 251]]], ["(28) All protein concentrations are in pg/ml.", [["All protein concentrations", "TREATMENT", 5, 31]]], ["Differences between groups were evaluated using repeated measures one-way ANOVA with Tukey's post-test. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . progression of fetal development in the lopinavir/r-cART group, likely indicating developmental retardation (Fig. 4C , upper panels).Lopinavir treatment inhibits the transcription factor STAT3Our data, thus far, strongly support that lopinavir exposure in early pregnancy has a negative impact on decidualization and spiral artery remodeling both in a human first-trimester decidua-placenta explant model and in a murine model.", [["fetal", "ANATOMY", 255, 260], ["spiral artery", "ANATOMY", 557, 570], ["placenta explant", "ANATOMY", 622, 638], ["lopinavir/r-cART", "CHEMICAL", 280, 296], ["Lopinavir", "CHEMICAL", 373, 382], ["lopinavir", "CHEMICAL", 474, 483], ["lopinavir", "CHEMICAL", 280, 289], ["Lopinavir", "CHEMICAL", 373, 382], ["lopinavir", "CHEMICAL", 474, 483], ["fetal", "ANATOMICAL_SYSTEM", 255, 260], ["lopinavir", "SIMPLE_CHEMICAL", 280, 289], ["Lopinavir", "SIMPLE_CHEMICAL", 373, 382], ["STAT3Our", "GENE_OR_GENE_PRODUCT", 427, 435], ["lopinavir", "SIMPLE_CHEMICAL", 474, 483], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 557, 570], ["human", "ORGANISM", 592, 597], ["placenta explant", "MULTI-TISSUE_STRUCTURE", 622, 638], ["murine", "ORGANISM", 654, 660], ["transcription factor", "PROTEIN", 406, 426], ["STAT3Our", "PROTEIN", 427, 435], ["human", "SPECIES", 592, 597], ["murine", "SPECIES", 654, 660], ["human", "SPECIES", 592, 597], ["repeated measures", "TREATMENT", 48, 65], ["Tukey's post-test", "TEST", 85, 102], ["fetal development", "PROBLEM", 255, 272], ["the lopinavir/r-cART group", "TREATMENT", 276, 302], ["developmental retardation", "PROBLEM", 322, 347], ["Lopinavir treatment", "TREATMENT", 373, 392], ["lopinavir exposure", "TREATMENT", 474, 492], ["spiral artery remodeling", "PROBLEM", 557, 581], ["a human first-trimester decidua-placenta explant model", "TREATMENT", 590, 644], ["a murine model", "TREATMENT", 652, 666], ["fetal development", "OBSERVATION", 255, 272], ["likely indicating", "UNCERTAINTY", 304, 321], ["developmental retardation", "OBSERVATION", 322, 347], ["spiral artery", "ANATOMY", 557, 570]]], ["Progesterone-dependent decidualization of uterine endometrium is mediated by cyclic AMP (cAMP), which induces the expression or activation of the core decidual transcription factors, including signal transducer and activator of transcription (STAT)-3 (Gellersen and Brosens, 2014) .", [["uterine endometrium", "ANATOMY", 42, 61], ["Progesterone", "CHEMICAL", 0, 12], ["cyclic AMP", "CHEMICAL", 77, 87], ["cAMP", "CHEMICAL", 89, 93], ["Progesterone", "CHEMICAL", 0, 12], ["cyclic AMP", "CHEMICAL", 77, 87], ["cAMP", "CHEMICAL", 89, 93], ["Progesterone", "SIMPLE_CHEMICAL", 0, 12], ["uterine endometrium", "MULTI-TISSUE_STRUCTURE", 42, 61], ["cyclic AMP", "GENE_OR_GENE_PRODUCT", 77, 87], ["cAMP", "SIMPLE_CHEMICAL", 89, 93], ["signal transducer and activator of transcription (STAT)-3", "GENE_OR_GENE_PRODUCT", 193, 250], ["core decidual transcription factors", "PROTEIN", 146, 181], ["signal transducer and activator of transcription (STAT)-3", "PROTEIN", 193, 250], ["Progesterone-dependent decidualization of uterine endometrium", "TREATMENT", 0, 61], ["cyclic AMP (cAMP)", "TREATMENT", 77, 94], ["the core decidual transcription factors", "TREATMENT", 142, 181], ["signal transducer and activator of transcription", "TREATMENT", 193, 241], ["uterine endometrium", "ANATOMY", 42, 61]]], ["In decidual stroma cells, STAT3 is activated by phosphorylation and phosphorylated STAT3 (pSTAT3) is transported from the cytoplasm into the nucleus, where it activates the expression of target genes such as prolactin and igfbp-1, the classic biomarkers of decidualization (Vinketova et al., 2016) .Lopinavir treatment inhibits the transcription factor STAT3Silencing of STAT3 in human ESCs retards decidualization (Jiang et al., 2015) , emphasizing the critical role of STAT3 signaling in this process (Zhang et al., 2015) .", [["decidual stroma cells", "ANATOMY", 3, 24], ["cytoplasm", "ANATOMY", 122, 131], ["nucleus", "ANATOMY", 141, 148], ["ESCs", "ANATOMY", 386, 390], ["Lopinavir", "CHEMICAL", 299, 308], ["Lopinavir", "CHEMICAL", 299, 308], ["decidual stroma cells", "CELL", 3, 24], ["STAT3", "GENE_OR_GENE_PRODUCT", 26, 31], ["STAT3", "GENE_OR_GENE_PRODUCT", 83, 88], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 90, 96], ["cytoplasm", "ORGANISM_SUBSTANCE", 122, 131], ["nucleus", "CELLULAR_COMPONENT", 141, 148], ["prolactin", "GENE_OR_GENE_PRODUCT", 208, 217], ["igfbp-1", "GENE_OR_GENE_PRODUCT", 222, 229], ["Lopinavir", "SIMPLE_CHEMICAL", 299, 308], ["STAT3Silencing", "GENE_OR_GENE_PRODUCT", 353, 367], ["STAT3", "GENE_OR_GENE_PRODUCT", 371, 376], ["human", "ORGANISM", 380, 385], ["ESCs", "CELL", 386, 390], ["STAT3", "GENE_OR_GENE_PRODUCT", 471, 476], ["decidual stroma cells", "CELL_TYPE", 3, 24], ["STAT3", "PROTEIN", 26, 31], ["STAT3", "PROTEIN", 83, 88], ["pSTAT3", "PROTEIN", 90, 96], ["target genes", "DNA", 187, 199], ["igfbp", "DNA", 222, 227], ["transcription factor", "PROTEIN", 332, 352], ["STAT3", "PROTEIN", 371, 376], ["human ESCs", "CELL_TYPE", 380, 390], ["STAT3", "PROTEIN", 471, 476], ["human", "SPECIES", 380, 385], ["human", "SPECIES", 380, 385], ["prolactin", "TEST", 208, 217], ["igfbp", "TEST", 222, 227], ["Lopinavir treatment", "TREATMENT", 299, 318], ["STAT3 in human ESCs retards decidualization", "TREATMENT", 371, 414], ["STAT3 signaling", "PROBLEM", 471, 486], ["decidual", "OBSERVATION", 3, 11], ["stroma cells", "OBSERVATION", 12, 24], ["nucleus", "ANATOMY", 141, 148]]], ["We hypothesized that lopinavir may influence decidualization by impairing STAT3 signaling.Lopinavir treatment inhibits the transcription factor STAT3Lysates from first-trimester human decidual cell cultures treated with lopinavir/r or lopinavir/r-cART showed lower levels of total STAT3 protein as compared to lysates from cultures treated with darunavir/r-cART or DMSO ( Supplementary Fig. S5 ).", [["decidual cell cultures", "ANATOMY", 184, 206], ["lysates", "ANATOMY", 310, 317], ["cultures", "ANATOMY", 323, 331], ["lopinavir", "CHEMICAL", 21, 30], ["Lopinavir", "CHEMICAL", 90, 99], ["lopinavir", "CHEMICAL", 220, 229], ["lopinavir", "CHEMICAL", 235, 244], ["darunavir", "CHEMICAL", 345, 354], ["DMSO", "CHEMICAL", 365, 369], ["lopinavir", "CHEMICAL", 21, 30], ["Lopinavir", "CHEMICAL", 90, 99], ["lopinavir", "CHEMICAL", 220, 229], ["lopinavir", "CHEMICAL", 235, 244], ["r-cART", "CHEMICAL", 245, 251], ["darunavir", "CHEMICAL", 345, 354], ["-cART", "CHEMICAL", 356, 361], ["DMSO", "CHEMICAL", 365, 369], ["lopinavir", "SIMPLE_CHEMICAL", 21, 30], ["STAT3", "GENE_OR_GENE_PRODUCT", 74, 79], ["Lopinavir", "SIMPLE_CHEMICAL", 90, 99], ["STAT3Lysates", "GENE_OR_GENE_PRODUCT", 144, 156], ["human", "ORGANISM", 178, 183], ["decidual cell cultures", "CELL", 184, 206], ["lopinavir", "SIMPLE_CHEMICAL", 220, 229], ["lopinavir", "SIMPLE_CHEMICAL", 235, 244], ["r-cART", "SIMPLE_CHEMICAL", 245, 251], ["STAT3", "GENE_OR_GENE_PRODUCT", 281, 286], ["lysates", "ORGANISM_SUBSTANCE", 310, 317], ["darunavir", "SIMPLE_CHEMICAL", 345, 354], ["r-cART", "SIMPLE_CHEMICAL", 355, 361], ["DMSO", "SIMPLE_CHEMICAL", 365, 369], ["STAT3", "PROTEIN", 74, 79], ["transcription factor", "PROTEIN", 123, 143], ["STAT3Lysates", "PROTEIN", 144, 156], ["first-trimester human decidual cell cultures", "CELL_LINE", 162, 206], ["STAT3 protein", "PROTEIN", 281, 294], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["lopinavir", "TREATMENT", 21, 30], ["impairing STAT3 signaling", "PROBLEM", 64, 89], ["Lopinavir treatment", "TREATMENT", 90, 109], ["the transcription factor STAT3Lysates", "TREATMENT", 119, 156], ["first-trimester human decidual cell cultures", "TREATMENT", 162, 206], ["lopinavir", "TREATMENT", 220, 229], ["lopinavir", "TREATMENT", 235, 244], ["cART", "TREATMENT", 247, 251], ["lower levels", "PROBLEM", 259, 271], ["total STAT3 protein", "TREATMENT", 275, 294], ["lysates", "TEST", 310, 317], ["cultures", "TEST", 323, 331], ["darunavir", "TREATMENT", 345, 354], ["r-cART", "TREATMENT", 355, 361], ["DMSO", "TREATMENT", 365, 369]]], ["As the transcriptional function of STAT3 is activated upon its phosphorylation, we examined the effect of drug treatment on the level of pSTAT3 in decidual tissue of both human and mouse.", [["decidual tissue", "ANATOMY", 147, 162], ["STAT3", "GENE_OR_GENE_PRODUCT", 35, 40], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 137, 143], ["decidual tissue", "TISSUE", 147, 162], ["human", "ORGANISM", 171, 176], ["mouse", "ORGANISM", 181, 186], ["STAT3", "PROTEIN", 35, 40], ["pSTAT3", "PROTEIN", 137, 143], ["human", "SPECIES", 171, 176], ["mouse", "SPECIES", 181, 186], ["human", "SPECIES", 171, 176], ["mouse", "SPECIES", 181, 186], ["drug treatment", "TREATMENT", 106, 120]]], ["First-trimester human decidua tissue treated with lopinavir/r-cART showed weaker pSTAT3 immunostaining in the nuclei of stromal cells as compared to decidua samples treated with darunavir/r-cART or DMSO ( Fig. 7A and B) .", [["decidua tissue", "ANATOMY", 22, 36], ["nuclei", "ANATOMY", 110, 116], ["stromal cells", "ANATOMY", 120, 133], ["decidua samples", "ANATOMY", 149, 164], ["lopinavir", "CHEMICAL", 50, 59], ["darunavir/r-cART", "CHEMICAL", 178, 194], ["DMSO", "CHEMICAL", 198, 202], ["lopinavir", "CHEMICAL", 50, 59], ["r-cART", "CHEMICAL", 60, 66], ["darunavir", "CHEMICAL", 178, 187], ["DMSO", "CHEMICAL", 198, 202], ["human", "ORGANISM", 16, 21], ["decidua tissue", "TISSUE", 22, 36], ["lopinavir", "SIMPLE_CHEMICAL", 50, 59], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 81, 87], ["nuclei", "CELLULAR_COMPONENT", 110, 116], ["stromal cells", "CELL", 120, 133], ["decidua samples", "TISSUE", 149, 164], ["darunavir", "SIMPLE_CHEMICAL", 178, 187], ["r-cART", "SIMPLE_CHEMICAL", 188, 194], ["DMSO", "SIMPLE_CHEMICAL", 198, 202], ["B", "CELL", 217, 218], ["pSTAT3", "PROTEIN", 81, 87], ["stromal cells", "CELL_TYPE", 120, 133], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["First-trimester human decidua tissue", "TREATMENT", 0, 36], ["lopinavir", "TREATMENT", 50, 59], ["cART", "TREATMENT", 62, 66], ["weaker pSTAT3 immunostaining", "PROBLEM", 74, 102], ["stromal cells", "PROBLEM", 120, 133], ["decidua samples", "TEST", 149, 164], ["darunavir", "TREATMENT", 178, 187], ["r-cART", "TREATMENT", 188, 194], ["DMSO", "TREATMENT", 198, 202], ["stromal cells", "OBSERVATION", 120, 133]]], ["Consistent with these observations, mouse GD6.5 implantation sites stained with pSTAT3, also revealed significantly lower levels of pSTAT3 in the lopinavir/r-cART treatment group as compared to darunavir/r-cART and control ( Fig. 7C and D) .", [["lopinavir/r-cART", "CHEMICAL", 146, 162], ["darunavir", "CHEMICAL", 194, 203], ["lopinavir", "CHEMICAL", 146, 155], ["r-cART", "CHEMICAL", 156, 162], ["darunavir", "CHEMICAL", 194, 203], ["mouse", "ORGANISM", 36, 41], ["GD6.5", "GENE_OR_GENE_PRODUCT", 42, 47], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 80, 86], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 132, 138], ["lopinavir", "SIMPLE_CHEMICAL", 146, 155], ["darunavir", "SIMPLE_CHEMICAL", 194, 203], ["mouse GD6.5 implantation sites", "DNA", 36, 66], ["pSTAT3", "PROTEIN", 80, 86], ["pSTAT3", "PROTEIN", 132, 138], ["mouse", "SPECIES", 36, 41], ["mouse", "SPECIES", 36, 41], ["mouse GD6.5 implantation sites", "TREATMENT", 36, 66], ["pSTAT3", "TEST", 80, 86], ["significantly lower levels of pSTAT3", "PROBLEM", 102, 138], ["the lopinavir", "TREATMENT", 142, 155], ["cART treatment group", "TREATMENT", 158, 178], ["darunavir", "TREATMENT", 194, 203], ["significantly", "OBSERVATION_MODIFIER", 102, 115], ["lower levels", "OBSERVATION_MODIFIER", 116, 128], ["pSTAT3", "OBSERVATION", 132, 138]]], ["The pattern of pSTAT3 staining was similar to that of Ki67 staining, indicating an overlap between proliferating and decidualizing stromal compartments.", [["stromal compartments", "ANATOMY", 131, 151], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 15, 21], ["Ki67", "GENE_OR_GENE_PRODUCT", 54, 58], ["stromal compartments", "TISSUE", 131, 151], ["pSTAT3", "PROTEIN", 15, 21], ["Ki67", "PROTEIN", 54, 58], ["pSTAT3 staining", "PROBLEM", 15, 30], ["Ki67 staining", "TEST", 54, 67], ["an overlap between proliferating and decidualizing stromal compartments", "PROBLEM", 80, 151], ["pSTAT3 staining", "OBSERVATION", 15, 30], ["proliferating", "OBSERVATION_MODIFIER", 99, 112], ["stromal compartments", "OBSERVATION", 131, 151]]], ["The lopinavir/r-cART-treated mice displayed a significant reduction in the number of cells stained positively for pSTAT3 in the mesometrial decidua and SDZ of the implantation sites ( Fig. 7C and D) .", [["cells", "ANATOMY", 85, 90], ["mesometrial decidua", "ANATOMY", 128, 147], ["lopinavir/r-cART", "CHEMICAL", 4, 20], ["SDZ", "CHEMICAL", 152, 155], ["lopinavir", "CHEMICAL", 4, 13], ["r-cART", "CHEMICAL", 14, 20], ["SDZ", "CHEMICAL", 152, 155], ["lopinavir", "SIMPLE_CHEMICAL", 4, 13], ["r-cART", "SIMPLE_CHEMICAL", 14, 20], ["mice", "ORGANISM", 29, 33], ["cells", "CELL", 85, 90], ["pSTAT3", "GENE_OR_GENE_PRODUCT", 114, 120], ["mesometrial decidua", "TISSUE", 128, 147], ["SDZ", "SIMPLE_CHEMICAL", 152, 155], ["pSTAT3", "PROTEIN", 114, 120], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["The lopinavir/r-cART", "TREATMENT", 0, 20], ["a significant reduction", "PROBLEM", 44, 67], ["pSTAT3", "PROBLEM", 114, 120], ["the mesometrial decidua", "TREATMENT", 124, 147], ["SDZ of the implantation sites", "TREATMENT", 152, 181], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["reduction", "OBSERVATION_MODIFIER", 58, 67], ["mesometrial decidua", "ANATOMY", 128, 147], ["implantation", "OBSERVATION", 163, 175]]], ["Our data suggest that lopinavir treatment may cause decidual defects by interfering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . with STAT3 signaling which regulates stromal proliferation and differentiation.DiscussionPericonception and first-trimester use of lopinavir-based cART has been linked to a higher incidence of adverse birth outcomes (Kourtis et al., 2007; Chen et al., 2012; Sibiude et al., 2012; Li et al., 2016; Van Dyke et al., 2016; Zash et al., 2017; Snijdewind et al., 2018; Wang et al., 2018) .", [["decidual", "ANATOMY", 52, 60], ["stromal", "ANATOMY", 245, 252], ["lopinavir", "CHEMICAL", 22, 31], ["decidual defects", "DISEASE", 52, 68], ["lopinavir", "CHEMICAL", 339, 348], ["lopinavir", "CHEMICAL", 22, 31], ["lopinavir", "CHEMICAL", 339, 348], ["lopinavir", "SIMPLE_CHEMICAL", 22, 31], ["STAT3", "GENE_OR_GENE_PRODUCT", 213, 218], ["stromal", "CELL", 245, 252], ["lopinavir", "SIMPLE_CHEMICAL", 339, 348], ["STAT3", "PROTEIN", 213, 218], ["Our data", "TEST", 0, 8], ["lopinavir treatment", "TREATMENT", 22, 41], ["decidual defects", "PROBLEM", 52, 68], ["STAT3 signaling", "PROBLEM", 213, 228], ["stromal proliferation", "PROBLEM", 245, 266], ["lopinavir", "TREATMENT", 339, 348], ["stromal proliferation", "OBSERVATION", 245, 266], ["differentiation", "OBSERVATION_MODIFIER", 271, 286]]], ["We investigated the effects of PI-cART on uterine remodeling during early pregnancy using established models of firsttrimester human placenta-decidua co-culture and mouse pregnancy.DiscussionHere we present data, which demonstrate that initiation of lopinavir/ r-based, but not darunavir/r-based cART from conception causes insufficient or defective maturation of the decidua during early pregnancy, leading to inadequate placentation that likely contribute to poor birth outcomes.DiscussionOur data from both human tissue and mouse studies are mutually supportive, and demonstrate that use of lopinavir/r-cART, but not darunavir/r-cART, impaired spiral artery remodeling and uterine decidualization.", [["uterine", "ANATOMY", 42, 49], ["placenta", "ANATOMY", 133, 141], ["decidua", "ANATOMY", 142, 149], ["decidua", "ANATOMY", 368, 375], ["tissue", "ANATOMY", 516, 522], ["spiral artery", "ANATOMY", 647, 660], ["uterine", "ANATOMY", 676, 683], ["PI-cART", "CHEMICAL", 31, 38], ["lopinavir", "CHEMICAL", 250, 259], ["darunavir", "CHEMICAL", 278, 287], ["lopinavir/r-cART", "CHEMICAL", 594, 610], ["darunavir", "CHEMICAL", 620, 629], ["lopinavir", "CHEMICAL", 250, 259], ["darunavir", "CHEMICAL", 278, 287], ["lopinavir", "CHEMICAL", 594, 603], ["r-cART", "CHEMICAL", 604, 610], ["darunavir", "CHEMICAL", 620, 629], ["r-cART", "CHEMICAL", 630, 636], ["PI", "SIMPLE_CHEMICAL", 31, 33], ["uterine", "MULTI-TISSUE_STRUCTURE", 42, 49], ["human", "ORGANISM", 127, 132], ["placenta-decidua", "CELL", 133, 149], ["mouse", "ORGANISM", 165, 170], ["lopinavir", "SIMPLE_CHEMICAL", 250, 259], ["darunavir", "SIMPLE_CHEMICAL", 278, 287], ["decidua", "MULTI-TISSUE_STRUCTURE", 368, 375], ["human", "ORGANISM", 510, 515], ["tissue", "TISSUE", 516, 522], ["mouse", "ORGANISM", 527, 532], ["lopinavir", "SIMPLE_CHEMICAL", 594, 603], ["r-cART", "SIMPLE_CHEMICAL", 604, 610], ["darunavir", "SIMPLE_CHEMICAL", 620, 629], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 647, 660], ["uterine", "MULTI-TISSUE_STRUCTURE", 676, 683], ["human", "SPECIES", 127, 132], ["mouse", "SPECIES", 165, 170], ["human", "SPECIES", 510, 515], ["mouse", "SPECIES", 527, 532], ["human", "SPECIES", 127, 132], ["mouse", "SPECIES", 165, 170], ["human", "SPECIES", 510, 515], ["mouse", "SPECIES", 527, 532], ["PI-cART", "TREATMENT", 31, 38], ["uterine remodeling", "TREATMENT", 42, 60], ["early pregnancy", "PROBLEM", 68, 83], ["firsttrimester human placenta", "TREATMENT", 112, 141], ["decidua co-culture", "PROBLEM", 142, 160], ["mouse pregnancy", "PROBLEM", 165, 180], ["lopinavir", "TREATMENT", 250, 259], ["darunavir", "TREATMENT", 278, 287], ["defective maturation", "PROBLEM", 340, 360], ["the decidua", "PROBLEM", 364, 375], ["inadequate placentation", "PROBLEM", 411, 434], ["poor birth outcomes", "PROBLEM", 461, 480], ["mouse studies", "TEST", 527, 540], ["lopinavir", "TREATMENT", 594, 603], ["cART", "TREATMENT", 606, 610], ["darunavir", "TREATMENT", 620, 629], ["impaired spiral artery remodeling", "PROBLEM", 638, 671], ["uterine decidualization", "PROBLEM", 676, 699], ["uterine", "ANATOMY", 42, 49], ["spiral artery", "ANATOMY", 647, 660], ["uterine", "ANATOMY", 676, 683], ["decidualization", "OBSERVATION", 684, 699]]], ["We observed the presence of un-remodeled vessels marked by intact SMA and endothelium, and a lack of EVT invasion in human placenta-decidua co-cultures treated with lopinavir/r.", [["vessels", "ANATOMY", 41, 48], ["SMA", "ANATOMY", 66, 69], ["endothelium", "ANATOMY", 74, 85], ["EVT", "ANATOMY", 101, 104], ["placenta-decidua co-cultures", "ANATOMY", 123, 151], ["lopinavir/r.", "CHEMICAL", 165, 177], ["lopinavir", "CHEMICAL", 165, 174], ["vessels", "MULTI-TISSUE_STRUCTURE", 41, 48], ["SMA", "MULTI-TISSUE_STRUCTURE", 66, 69], ["endothelium", "TISSUE", 74, 85], ["EVT", "CELL", 101, 104], ["human", "ORGANISM", 117, 122], ["placenta-decidua co-cultures", "CELL", 123, 151], ["lopinavir", "SIMPLE_CHEMICAL", 165, 174], ["SMA", "PROTEIN", 66, 69], ["human placenta-decidua co-cultures", "CELL_LINE", 117, 151], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["un-remodeled vessels", "PROBLEM", 28, 48], ["EVT invasion in human placenta", "PROBLEM", 101, 131], ["decidua co-cultures", "PROBLEM", 132, 151], ["lopinavir", "TREATMENT", 165, 174], ["vessels", "ANATOMY", 41, 48], ["intact", "OBSERVATION", 59, 65], ["SMA", "ANATOMY", 66, 69], ["endothelium", "ANATOMY", 74, 85], ["EVT", "OBSERVATION_MODIFIER", 101, 104], ["invasion", "OBSERVATION", 105, 113], ["placenta", "ANATOMY", 123, 131]]], ["In the mouse model, we found that the lopinavir/r-cART group displayed spiral arteries with significantly smaller lumens and intact rings of SMA at GD9.5, indicative of impaired remodeling.", [["spiral arteries", "ANATOMY", 71, 86], ["lumens", "ANATOMY", 114, 120], ["lopinavir", "CHEMICAL", 38, 47], ["lopinavir", "CHEMICAL", 38, 47], ["r-cART", "CHEMICAL", 48, 54], ["mouse", "ORGANISM", 7, 12], ["lopinavir", "SIMPLE_CHEMICAL", 38, 47], ["spiral arteries", "MULTI-TISSUE_STRUCTURE", 71, 86], ["lumens", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 120], ["SMA", "GENE_OR_GENE_PRODUCT", 141, 144], ["SMA", "PROTEIN", 141, 144], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 7, 12], ["the lopinavir", "TREATMENT", 34, 47], ["spiral arteries", "PROBLEM", 71, 86], ["significantly smaller lumens", "PROBLEM", 92, 120], ["intact rings of SMA", "TREATMENT", 125, 144], ["impaired remodeling", "PROBLEM", 169, 188], ["spiral arteries", "ANATOMY", 71, 86], ["significantly", "OBSERVATION_MODIFIER", 92, 105], ["smaller lumens", "OBSERVATION", 106, 120], ["intact", "OBSERVATION", 125, 131], ["rings", "OBSERVATION_MODIFIER", 132, 137], ["SMA", "ANATOMY", 141, 144], ["indicative of", "UNCERTAINTY", 155, 168], ["impaired", "OBSERVATION_MODIFIER", 169, 177], ["remodeling", "OBSERVATION", 178, 188]]], ["Lopinavir treatment caused dysregulation of decidualization, as the secreted levels of the classic biomarkers of decidualization, prolactin, IGFBP-1, IL-11, IL-15 and activin-A, were significantly lower in the supernatants of primary decidual cell cultures treated with lopinavir/r-cART.", [["supernatants", "ANATOMY", 210, 222], ["decidual cell cultures", "ANATOMY", 234, 256], ["Lopinavir", "CHEMICAL", 0, 9], ["lopinavir/r-cART", "CHEMICAL", 270, 286], ["Lopinavir", "CHEMICAL", 0, 9], ["lopinavir", "CHEMICAL", 270, 279], ["r-cART", "CHEMICAL", 280, 286], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["prolactin", "GENE_OR_GENE_PRODUCT", 130, 139], ["IGFBP-1", "GENE_OR_GENE_PRODUCT", 141, 148], ["IL-11", "GENE_OR_GENE_PRODUCT", 150, 155], ["IL-15", "GENE_OR_GENE_PRODUCT", 157, 162], ["activin-A", "GENE_OR_GENE_PRODUCT", 167, 176], ["decidual cell cultures", "CELL", 234, 256], ["lopinavir", "SIMPLE_CHEMICAL", 270, 279], ["r-cART", "SIMPLE_CHEMICAL", 280, 286], ["IL-15", "PROTEIN", 157, 162], ["activin-A", "PROTEIN", 167, 176], ["primary decidual cell cultures", "CELL_LINE", 226, 256], ["Lopinavir treatment", "TREATMENT", 0, 19], ["dysregulation of decidualization", "PROBLEM", 27, 59], ["the secreted levels", "TEST", 64, 83], ["decidualization", "PROBLEM", 113, 128], ["prolactin", "TEST", 130, 139], ["IGFBP", "TEST", 141, 146], ["IL", "TEST", 150, 152], ["IL", "TEST", 157, 159], ["activin", "TEST", 167, 174], ["primary decidual cell cultures", "PROBLEM", 226, 256], ["lopinavir", "TREATMENT", 270, 279], ["r-cART", "TREATMENT", 280, 286], ["primary decidual cell", "OBSERVATION", 226, 247]]], ["Data from the mouse model further confirmed the defect in decidualization, as indicated by loss of proliferative Ki67\u00fe cells in the stromal compartments of GD6.5 implantation sites of mice treated with lopinavir/r-cART.", [["Ki67\u00fe cells", "ANATOMY", 113, 124], ["stromal compartments", "ANATOMY", 132, 152], ["GD6.5 implantation sites", "ANATOMY", 156, 180], ["lopinavir/r-cART", "CHEMICAL", 202, 218], ["lopinavir", "CHEMICAL", 202, 211], ["r-cART", "CHEMICAL", 212, 218], ["mouse", "ORGANISM", 14, 19], ["Ki67", "GENE_OR_GENE_PRODUCT", 113, 117], ["stromal compartments", "MULTI-TISSUE_STRUCTURE", 132, 152], ["mice", "ORGANISM", 184, 188], ["lopinavir", "SIMPLE_CHEMICAL", 202, 211], ["proliferative Ki67\u00fe cells", "CELL_TYPE", 99, 124], ["mouse", "SPECIES", 14, 19], ["mice", "SPECIES", 184, 188], ["mouse", "SPECIES", 14, 19], ["mice", "SPECIES", 184, 188], ["the defect in decidualization", "PROBLEM", 44, 73], ["proliferative Ki67\u00fe cells", "PROBLEM", 99, 124], ["GD6.5 implantation sites", "TREATMENT", 156, 180], ["lopinavir", "TREATMENT", 202, 211], ["r-cART", "TREATMENT", 212, 218], ["defect", "OBSERVATION", 48, 54], ["decidualization", "OBSERVATION", 58, 73], ["proliferative", "OBSERVATION_MODIFIER", 99, 112], ["Ki67\u00fe cells", "OBSERVATION", 113, 124], ["stromal compartments", "OBSERVATION", 132, 152]]], ["Lopinavir/r-cART was also associated with lower decidual levels of total and phosphorylated STAT3, a transcription factor known to regulate decidualization.", [["decidual", "ANATOMY", 48, 56], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["STAT3", "GENE_OR_GENE_PRODUCT", 92, 97], ["STAT3", "PROTEIN", 92, 97], ["transcription factor", "PROTEIN", 101, 121], ["Lopinavir/r-cART", "TREATMENT", 0, 16], ["lower decidual levels", "PROBLEM", 42, 63], ["total and phosphorylated STAT3", "TREATMENT", 67, 97]]], ["This could possibly explain the association between lopinavir/r exposure and failure to maintain the decidual phenotype.DiscussionDuring decidualization, differentiating stromal cells stimulated by progesterone produce a variety of chemokines and cytokines that trigger the recruitment of uNK cells and support their proliferation and survival in the decidua (Keskin et al., 2007; Carlino et al., 2008) .", [["decidual", "ANATOMY", 101, 109], ["stromal cells", "ANATOMY", 170, 183], ["uNK cells", "ANATOMY", 289, 298], ["decidua", "ANATOMY", 351, 358], ["lopinavir", "CHEMICAL", 52, 61], ["progesterone", "CHEMICAL", 198, 210], ["lopinavir", "CHEMICAL", 52, 61], ["progesterone", "CHEMICAL", 198, 210], ["lopinavir", "SIMPLE_CHEMICAL", 52, 61], ["stromal cells", "CELL", 170, 183], ["progesterone", "SIMPLE_CHEMICAL", 198, 210], ["uNK cells", "CELL", 289, 298], ["decidua", "TISSUE", 351, 358], ["differentiating stromal cells", "CELL_TYPE", 154, 183], ["chemokines", "PROTEIN", 232, 242], ["cytokines", "PROTEIN", 247, 256], ["uNK cells", "CELL_TYPE", 289, 298], ["lopinavir/r exposure", "TREATMENT", 52, 72], ["failure", "PROBLEM", 77, 84], ["the decidual phenotype", "PROBLEM", 97, 119], ["decidualization", "PROBLEM", 137, 152], ["stromal cells", "PROBLEM", 170, 183], ["progesterone", "TREATMENT", 198, 210], ["chemokines and cytokines", "TREATMENT", 232, 256], ["uNK cells", "PROBLEM", 289, 298], ["their proliferation", "PROBLEM", 311, 330], ["could possibly explain", "UNCERTAINTY", 5, 27], ["failure", "OBSERVATION", 77, 84], ["decidual phenotype", "OBSERVATION", 101, 119], ["stromal cells", "OBSERVATION", 170, 183], ["uNK cells", "OBSERVATION", 289, 298]]], ["In turn, uNK cells play a role in maintaining the decidual reaction in the stromal cells (Croy et al., 2002) .", [["uNK cells", "ANATOMY", 9, 18], ["decidual", "ANATOMY", 50, 58], ["stromal cells", "ANATOMY", 75, 88], ["uNK cells", "CELL", 9, 18], ["stromal cells", "CELL", 75, 88], ["uNK cells", "CELL_TYPE", 9, 18], ["stromal cells", "CELL_TYPE", 75, 88], ["uNK cells", "TREATMENT", 9, 18], ["the decidual reaction", "PROBLEM", 46, 67], ["uNK cells", "OBSERVATION", 9, 18], ["stromal cells", "ANATOMY", 75, 88]]], ["We found that the decidualization defects induced by lopinavir treatment were concomitant with lower levels of secreted chemokines (CXCL10, CXCL12, CXCL16, CCL2 and CCL3) in the primary decidual cell cultures, indicative of dysfunctional stromal cells.", [["primary decidual cell cultures", "ANATOMY", 178, 208], ["stromal cells", "ANATOMY", 238, 251], ["decidualization defects", "DISEASE", 18, 41], ["lopinavir", "CHEMICAL", 53, 62], ["lopinavir", "CHEMICAL", 53, 62], ["lopinavir", "SIMPLE_CHEMICAL", 53, 62], ["CXCL10", "GENE_OR_GENE_PRODUCT", 132, 138], ["CXCL12", "GENE_OR_GENE_PRODUCT", 140, 146], ["CXCL16", "GENE_OR_GENE_PRODUCT", 148, 154], ["CCL2", "GENE_OR_GENE_PRODUCT", 156, 160], ["CCL3", "GENE_OR_GENE_PRODUCT", 165, 169], ["decidual cell cultures", "CELL", 186, 208], ["stromal cells", "CELL", 238, 251], ["secreted chemokines", "PROTEIN", 111, 130], ["CXCL10", "PROTEIN", 132, 138], ["CXCL12", "PROTEIN", 140, 146], ["CXCL16", "PROTEIN", 148, 154], ["CCL2", "PROTEIN", 156, 160], ["CCL3", "PROTEIN", 165, 169], ["primary decidual cell cultures", "CELL_LINE", 178, 208], ["dysfunctional stromal cells", "CELL_TYPE", 224, 251], ["the decidualization defects", "PROBLEM", 14, 41], ["lopinavir treatment", "TREATMENT", 53, 72], ["secreted chemokines", "TEST", 111, 130], ["CXCL10", "TEST", 132, 138], ["CXCL12", "TEST", 140, 146], ["CXCL16", "TEST", 148, 154], ["CCL2", "TEST", 156, 160], ["the primary decidual cell cultures", "TEST", 174, 208], ["dysfunctional stromal cells", "PROBLEM", 224, 251], ["decidualization defects", "OBSERVATION", 18, 41], ["lopinavir treatment", "OBSERVATION", 53, 72], ["primary decidual cell cultures", "OBSERVATION", 178, 208], ["indicative of", "UNCERTAINTY", 210, 223], ["dysfunctional stromal cells", "OBSERVATION", 224, 251]]], ["Lopinavir treatment was also associated with lower levels of IL-15, a key cytokine required for uNK proliferation and survival.", [["uNK", "ANATOMY", 96, 99], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["IL-15", "GENE_OR_GENE_PRODUCT", 61, 66], ["uNK", "CELL", 96, 99], ["IL-15", "PROTEIN", 61, 66], ["Lopinavir treatment", "TREATMENT", 0, 19], ["IL", "TEST", 61, 63], ["uNK proliferation", "PROBLEM", 96, 113]]], ["Thus, the lower number of uNK cells and their frequent apoptotic-like phenotype observed in both decidual cultures and in mice treated with lopinavir/r-cART could be the result of defective decidua stromal cell function that led to both poor chemo-attraction of NK cells to the decidua, and poor support of their proliferation and survival.DiscussionuNK cells secrete various growth and angiogenic factors which are not only beneficial to decidua stromal cells but also play critical roles in remodeling of the decidual spiral arteries (Robson et al., 2012) .", [["uNK cells", "ANATOMY", 26, 35], ["decidual cultures", "ANATOMY", 97, 114], ["decidua stromal cell", "ANATOMY", 190, 210], ["NK cells", "ANATOMY", 262, 270], ["decidua", "ANATOMY", 278, 285], ["DiscussionuNK cells", "ANATOMY", 340, 359], ["decidua stromal cells", "ANATOMY", 439, 460], ["decidual spiral arteries", "ANATOMY", 511, 535], ["lopinavir/r-cART", "CHEMICAL", 140, 156], ["lopinavir", "CHEMICAL", 140, 149], ["r-cART", "CHEMICAL", 150, 156], ["uNK cells", "CELL", 26, 35], ["decidual cultures", "CELL", 97, 114], ["mice", "ORGANISM", 122, 126], ["lopinavir", "SIMPLE_CHEMICAL", 140, 149], ["decidua stromal cell", "CELL", 190, 210], ["NK cells", "CELL", 262, 270], ["decidua", "MULTI-TISSUE_STRUCTURE", 278, 285], ["DiscussionuNK cells", "CELL", 340, 359], ["decidua stromal cells", "CELL", 439, 460], ["decidual spiral arteries", "MULTI-TISSUE_STRUCTURE", 511, 535], ["uNK cells", "CELL_TYPE", 26, 35], ["decidual cultures", "CELL_LINE", 97, 114], ["NK cells", "CELL_TYPE", 262, 270], ["DiscussionuNK cells", "CELL_LINE", 340, 359], ["growth and angiogenic factors", "PROTEIN", 376, 405], ["decidua stromal cells", "CELL_TYPE", 439, 460], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["uNK cells", "PROBLEM", 26, 35], ["their frequent apoptotic-like phenotype", "PROBLEM", 40, 79], ["both decidual cultures", "TEST", 92, 114], ["lopinavir/r-cART", "TREATMENT", 140, 156], ["defective decidua stromal cell function", "PROBLEM", 180, 219], ["poor chemo-attraction of NK cells", "PROBLEM", 237, 270], ["DiscussionuNK cells secrete various growth and angiogenic factors", "PROBLEM", 340, 405], ["decidua stromal cells", "PROBLEM", 439, 460], ["lower", "OBSERVATION_MODIFIER", 10, 15], ["uNK cells", "OBSERVATION", 26, 35], ["frequent apoptotic", "OBSERVATION_MODIFIER", 46, 64], ["defective decidua stromal cell function", "OBSERVATION", 180, 219], ["NK cells", "OBSERVATION", 262, 270], ["growth", "OBSERVATION_MODIFIER", 376, 382], ["stromal cells", "OBSERVATION", 447, 460], ["remodeling", "OBSERVATION", 493, 503], ["decidual spiral arteries", "ANATOMY", 511, 535]]], ["We found lower expression of a number of factors predominantly produced by uNK cells, such as VEGF, PlGF, angiopoietin-2, GM-CSF, IFN-c and MMP-9, which aligns with the selective depletion of uNK cells upon lopinavir exposure of primary decidual cell cultures.DiscussionOur data suggested that lopinavir did not directly impair trophoblast migration, since EVT outgrowth in matrigel was not affected by drug treatment alone.", [["uNK cells", "ANATOMY", 75, 84], ["uNK cells", "ANATOMY", 192, 201], ["decidual cell cultures", "ANATOMY", 237, 259], ["trophoblast", "ANATOMY", 328, 339], ["EVT", "ANATOMY", 357, 360], ["matrigel", "ANATOMY", 374, 382], ["lopinavir", "CHEMICAL", 207, 216], ["lopinavir", "CHEMICAL", 294, 303], ["lopinavir", "CHEMICAL", 207, 216], ["lopinavir", "CHEMICAL", 294, 303], ["uNK cells", "CELL", 75, 84], ["VEGF", "GENE_OR_GENE_PRODUCT", 94, 98], ["PlGF", "GENE_OR_GENE_PRODUCT", 100, 104], ["angiopoietin-2", "GENE_OR_GENE_PRODUCT", 106, 120], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 122, 128], ["IFN-c", "GENE_OR_GENE_PRODUCT", 130, 135], ["MMP-9", "GENE_OR_GENE_PRODUCT", 140, 145], ["uNK cells", "CELL", 192, 201], ["lopinavir", "SIMPLE_CHEMICAL", 207, 216], ["decidual cell cultures", "CELL", 237, 259], ["lopinavir", "SIMPLE_CHEMICAL", 294, 303], ["trophoblast", "CELL", 328, 339], ["EVT", "CELL", 357, 360], ["uNK cells", "CELL_TYPE", 75, 84], ["VEGF", "PROTEIN", 94, 98], ["PlGF", "PROTEIN", 100, 104], ["angiopoietin-2", "PROTEIN", 106, 120], ["GM", "PROTEIN", 122, 124], ["CSF", "PROTEIN", 125, 128], ["IFN", "PROTEIN", 130, 133], ["MMP-9", "PROTEIN", 140, 145], ["uNK cells", "CELL_TYPE", 192, 201], ["primary decidual cell cultures", "CELL_LINE", 229, 259], ["uNK cells", "PROBLEM", 75, 84], ["VEGF", "TEST", 94, 98], ["PlGF", "TEST", 100, 104], ["angiopoietin", "TEST", 106, 118], ["GM", "TEST", 122, 124], ["CSF", "TEST", 125, 128], ["IFN", "TEST", 130, 133], ["MMP", "TEST", 140, 143], ["uNK cells", "PROBLEM", 192, 201], ["lopinavir exposure", "TREATMENT", 207, 225], ["primary decidual cell cultures", "PROBLEM", 229, 259], ["lopinavir", "TREATMENT", 294, 303], ["trophoblast migration", "PROBLEM", 328, 349], ["EVT outgrowth in matrigel", "PROBLEM", 357, 382], ["drug treatment", "TREATMENT", 403, 417], ["lower expression", "OBSERVATION_MODIFIER", 9, 25], ["uNK cells", "OBSERVATION", 75, 84], ["selective depletion", "OBSERVATION", 169, 188], ["uNK cells", "OBSERVATION", 192, 201], ["primary decidual cell cultures", "OBSERVATION", 229, 259], ["trophoblast migration", "OBSERVATION", 328, 349]]], ["However, trophoblast migration was reduced in response to lopinavir-treated DCM (obtained from primary decidual cell culture treated with lopinavir/r or lopinavir/r-cART), suggesting that lopinavir treatment indirectly affects trophoblast migration and invasion by disrupting decidual secretion of factors which play a key role in this process (Wright et al., 2010) .DiscussionThe deficiencies in uterine decidualization, vessel remodeling and local immune cell number/profile were accompanied by malformations in early placental development at GD9.5 of mouse pregnancy.", [["trophoblast", "ANATOMY", 9, 20], ["decidual cell culture", "ANATOMY", 103, 124], ["trophoblast", "ANATOMY", 227, 238], ["decidual", "ANATOMY", 276, 284], ["uterine", "ANATOMY", 397, 404], ["vessel", "ANATOMY", 422, 428], ["immune cell", "ANATOMY", 450, 461], ["placental", "ANATOMY", 520, 529], ["lopinavir", "CHEMICAL", 58, 67], ["DCM", "DISEASE", 76, 79], ["lopinavir/r or lopinavir/r-cART", "CHEMICAL", 138, 169], ["lopinavir", "CHEMICAL", 188, 197], ["malformations", "DISEASE", 497, 510], ["lopinavir", "CHEMICAL", 58, 67], ["lopinavir", "CHEMICAL", 138, 147], ["lopinavir", "CHEMICAL", 153, 162], ["r-cART", "CHEMICAL", 163, 169], ["lopinavir", "CHEMICAL", 188, 197], ["trophoblast", "CELL", 9, 20], ["lopinavir", "SIMPLE_CHEMICAL", 58, 67], ["DCM", "SIMPLE_CHEMICAL", 76, 79], ["decidual cell", "CELL", 103, 116], ["lopinavir", "SIMPLE_CHEMICAL", 138, 147], ["lopinavir", "SIMPLE_CHEMICAL", 153, 162], ["r-cART", "SIMPLE_CHEMICAL", 163, 169], ["lopinavir", "SIMPLE_CHEMICAL", 188, 197], ["trophoblast", "CELL", 227, 238], ["uterine", "MULTI-TISSUE_STRUCTURE", 397, 404], ["vessel", "MULTI-TISSUE_STRUCTURE", 422, 428], ["immune cell", "CELL", 450, 461], ["placental", "DEVELOPING_ANATOMICAL_STRUCTURE", 520, 529], ["mouse", "ORGANISM", 554, 559], ["primary decidual cell culture", "CELL_LINE", 95, 124], ["mouse", "SPECIES", 554, 559], ["mouse", "SPECIES", 554, 559], ["trophoblast migration", "PROBLEM", 9, 30], ["lopinavir", "TREATMENT", 58, 67], ["DCM", "PROBLEM", 76, 79], ["primary decidual cell culture", "TREATMENT", 95, 124], ["lopinavir", "TREATMENT", 138, 147], ["lopinavir", "TREATMENT", 153, 162], ["r-cART", "TREATMENT", 163, 169], ["lopinavir treatment", "TREATMENT", 188, 207], ["trophoblast migration", "PROBLEM", 227, 248], ["invasion", "PROBLEM", 253, 261], ["disrupting decidual secretion of factors", "PROBLEM", 265, 305], ["The deficiencies in uterine decidualization", "PROBLEM", 377, 420], ["vessel remodeling", "PROBLEM", 422, 439], ["local immune cell number/profile", "TEST", 444, 476], ["malformations", "PROBLEM", 497, 510], ["early placental development", "PROBLEM", 514, 541], ["mouse pregnancy", "PROBLEM", 554, 569], ["uterine", "ANATOMY", 397, 404], ["decidualization", "OBSERVATION", 405, 420], ["vessel", "ANATOMY", 422, 428], ["malformations", "OBSERVATION", 497, 510]]], ["Lopinavir/r-cART treatment led to an overabundance of P-TGCs at the cost of spongiotrophoblast and labyrinth layers.", [["spongiotrophoblast", "ANATOMY", 76, 94], ["labyrinth layers", "ANATOMY", 99, 115], ["Lopinavir", "CHEMICAL", 0, 9], ["-cART", "CHEMICAL", 11, 16], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["r-cART", "SIMPLE_CHEMICAL", 10, 16], ["spongiotrophoblast", "CELL", 76, 94], ["labyrinth layers", "TISSUE", 99, 115], ["P", "DNA", 54, 55], ["Lopinavir/r-cART treatment", "TREATMENT", 0, 26], ["P-TGCs", "PROBLEM", 54, 60], ["spongiotrophoblast and labyrinth layers", "TREATMENT", 76, 115]]], ["This particular phenotype has been previously reported in mice with deletions in transcription factors such as Mash2 (Guillemot et al., 1995; Tanaka et al., 1997) and FOXA2 (Kelleher et al., 2017) .", [["mice", "ORGANISM", 58, 62], ["Mash2", "GENE_OR_GENE_PRODUCT", 111, 116], ["FOXA2", "GENE_OR_GENE_PRODUCT", 167, 172], ["transcription factors", "PROTEIN", 81, 102], ["Mash2", "PROTEIN", 111, 116], ["FOXA2", "PROTEIN", 167, 172], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["FOXA2", "ANATOMY", 167, 172]]], ["In the case of FOXA2, the phenotype was reported to be associated with defects in stroma cell decidualization, similar to our observation.DiscussionSome studies have reported that HIV infection and/or cART are associated with morphological changes in placentas such as hypervascularity and maternal vascular malperfusion (Kalk et al., 2017; Obimbo et al., 2019) .", [["stroma cell", "ANATOMY", 82, 93], ["placentas", "ANATOMY", 251, 260], ["vascular", "ANATOMY", 299, 307], ["HIV infection", "DISEASE", 180, 193], ["hypervascularity", "DISEASE", 269, 285], ["vascular malperfusion", "DISEASE", 299, 320], ["FOXA2", "GENE_OR_GENE_PRODUCT", 15, 20], ["stroma cell", "CELL", 82, 93], ["HIV", "ORGANISM", 180, 183], ["placentas", "MULTI-TISSUE_STRUCTURE", 251, 260], ["vascular", "MULTI-TISSUE_STRUCTURE", 299, 307], ["FOXA2", "PROTEIN", 15, 20], ["HIV", "SPECIES", 180, 183], ["HIV", "SPECIES", 180, 183], ["defects in stroma cell decidualization", "PROBLEM", 71, 109], ["our observation", "TEST", 122, 137], ["DiscussionSome studies", "TEST", 138, 160], ["HIV infection", "PROBLEM", 180, 193], ["cART", "TREATMENT", 201, 205], ["morphological changes in placentas", "PROBLEM", 226, 260], ["hypervascularity", "PROBLEM", 269, 285], ["maternal vascular malperfusion", "PROBLEM", 290, 320], ["FOXA2", "ANATOMY", 15, 20], ["defects", "OBSERVATION", 71, 78], ["stroma cell decidualization", "OBSERVATION", 82, 109], ["infection", "OBSERVATION", 184, 193], ["hypervascularity", "OBSERVATION", 269, 285], ["vascular", "ANATOMY", 299, 307], ["malperfusion", "OBSERVATION", 308, 320]]], ["We previously reported the effect of lopinavir/r-cART treatment on placenta development and fetal outcomes in mouse pregnancy.", [["placenta", "ANATOMY", 67, 75], ["fetal", "ANATOMY", 92, 97], ["lopinavir/r-cART", "CHEMICAL", 37, 53], ["lopinavir", "CHEMICAL", 37, 46], ["r-cART", "CHEMICAL", 47, 53], ["lopinavir", "SIMPLE_CHEMICAL", 37, 46], ["r-cART", "SIMPLE_CHEMICAL", 47, 53], ["placenta", "MULTI-TISSUE_STRUCTURE", 67, 75], ["fetal", "ANATOMICAL_SYSTEM", 92, 97], ["mouse", "ORGANISM", 110, 115], ["mouse", "SPECIES", 110, 115], ["mouse", "SPECIES", 110, 115], ["lopinavir", "TREATMENT", 37, 46], ["r-cART treatment", "TREATMENT", 47, 63], ["placenta development", "TREATMENT", 67, 87], ["fetal outcomes in mouse pregnancy", "PROBLEM", 92, 125]]], ["We showed that pregnant mice exposed to lopinavir/r-cART treatment at the onset of pregnancy had significantly lower levels of plasma progesterone, which was associated with lower fetal and placental weights (Papp et al., 2015) , as well as alterations in the placental vasculature at GD14.5 (Mohammadi et al., 2018) and GD17.5 (Cahill et al., 2019) .", [["plasma", "ANATOMY", 127, 133], ["fetal", "ANATOMY", 180, 185], ["placental", "ANATOMY", 190, 199], ["placental vasculature", "ANATOMY", 260, 281], ["lopinavir/r-cART", "CHEMICAL", 40, 56], ["progesterone", "CHEMICAL", 134, 146], ["lopinavir", "CHEMICAL", 40, 49], ["r-cART", "CHEMICAL", 50, 56], ["progesterone", "CHEMICAL", 134, 146], ["mice", "ORGANISM", 24, 28], ["lopinavir", "SIMPLE_CHEMICAL", 40, 49], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["progesterone", "SIMPLE_CHEMICAL", 134, 146], ["fetal", "TISSUE", 180, 185], ["placental", "ORGAN", 190, 199], ["placental vasculature", "MULTI-TISSUE_STRUCTURE", 260, 281], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["lopinavir", "TREATMENT", 40, 49], ["r-cART treatment", "TREATMENT", 50, 66], ["plasma progesterone", "TREATMENT", 127, 146], ["lower fetal and placental weights", "PROBLEM", 174, 207], ["alterations in the placental vasculature", "PROBLEM", 241, 281], ["GD", "TEST", 321, 323], ["placental vasculature", "ANATOMY", 260, 281]]], ["Delaying the initiation of lopinavir/r-cART, or supplementing lopinavir/r-cART-treated mice with progesterone throughout pregnancy, prevented the associated placenta vascular changes and significantly improved fetal weights (Mohammadi et al., 2018) .", [["placenta vascular", "ANATOMY", 157, 174], ["fetal", "ANATOMY", 210, 215], ["lopinavir/r-cART", "CHEMICAL", 27, 43], ["lopinavir/r-cART", "CHEMICAL", 62, 78], ["progesterone", "CHEMICAL", 97, 109], ["lopinavir", "CHEMICAL", 27, 36], ["r-cART", "CHEMICAL", 37, 43], ["lopinavir", "CHEMICAL", 62, 71], ["r-cART", "CHEMICAL", 72, 78], ["progesterone", "CHEMICAL", 97, 109], ["lopinavir", "SIMPLE_CHEMICAL", 27, 36], ["r-cART", "SIMPLE_CHEMICAL", 37, 43], ["lopinavir", "SIMPLE_CHEMICAL", 62, 71], ["r-cART", "SIMPLE_CHEMICAL", 72, 78], ["mice", "ORGANISM", 87, 91], ["progesterone", "SIMPLE_CHEMICAL", 97, 109], ["placenta vascular", "MULTI-TISSUE_STRUCTURE", 157, 174], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 210, 215], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 87, 91], ["lopinavir/r-cART", "TREATMENT", 27, 43], ["lopinavir", "TREATMENT", 62, 71], ["r-cART", "TREATMENT", 72, 78], ["progesterone", "TREATMENT", 97, 109], ["the associated placenta vascular changes", "PROBLEM", 142, 182], ["significantly improved fetal weights", "PROBLEM", 187, 223], ["placenta", "OBSERVATION", 157, 165], ["vascular", "ANATOMY", 166, 174]]], ["We have now demonstrated that lopinavir/r-cART compromises the process of uterine remodeling during early pregnancy, leading to downstream effects on placenta formation or function that are either negative or fail to fully compensate for these early defects, thus are associated with poor outcomes.DiscussionOur study has some limitations.", [["uterine", "ANATOMY", 74, 81], ["placenta", "ANATOMY", 150, 158], ["lopinavir", "CHEMICAL", 30, 39], ["lopinavir", "CHEMICAL", 30, 39], ["r-cART", "CHEMICAL", 40, 46], ["lopinavir", "SIMPLE_CHEMICAL", 30, 39], ["uterine", "MULTI-TISSUE_STRUCTURE", 74, 81], ["placenta", "TISSUE", 150, 158], ["lopinavir", "TREATMENT", 30, 39], ["uterine remodeling", "PROBLEM", 74, 92], ["early pregnancy", "PROBLEM", 100, 115], ["downstream effects", "PROBLEM", 128, 146], ["placenta formation", "PROBLEM", 150, 168], ["these early defects", "PROBLEM", 238, 257], ["DiscussionOur study", "TEST", 298, 317], ["uterine", "ANATOMY", 74, 81], ["remodeling", "OBSERVATION", 82, 92], ["early", "OBSERVATION_MODIFIER", 244, 249], ["defects", "OBSERVATION", 250, 257]]], ["The human first-trimester placenta/ decidua samples could only be obtained from healthy females undergoing elective termination of pregnancy.", [["placenta", "ANATOMY", 26, 34], ["decidua samples", "ANATOMY", 36, 51], ["human", "ORGANISM", 4, 9], ["placenta", "TISSUE", 26, 34], ["decidua samples", "ORGANISM_SUBSTANCE", 36, 51], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human first-trimester placenta/ decidua samples", "TREATMENT", 0, 51], ["elective termination of pregnancy", "TREATMENT", 107, 140]]], ["As biopsy is the only way to obtain first-trimester decidua from pregnant women living with HIV on PI-cART, ethics approval and participant consent are difficult to obtain.", [["decidua", "ANATOMY", 52, 59], ["decidua", "MULTI-TISSUE_STRUCTURE", 52, 59], ["women", "ORGANISM", 74, 79], ["women", "SPECIES", 74, 79], ["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 92, 95], ["biopsy", "TEST", 3, 9]]], ["Furthermore, our animal model is limited to the study of cART and does not include HIV.", [["HIV", "ORGANISM", 83, 86], ["HIV", "SPECIES", 83, 86], ["HIV", "SPECIES", 83, 86], ["the study", "TEST", 44, 53], ["cART", "TREATMENT", 57, 61], ["HIV", "PROBLEM", 83, 86]]], ["HIV infection is also associated with immune dysregulation, inflammation, alterations in angiogenic factors and complement activation, all of which could influence decidual and placental vascular remodeling and modify any cART effects.", [["decidual", "ANATOMY", 164, 172], ["placental vascular", "ANATOMY", 177, 195], ["HIV infection", "DISEASE", 0, 13], ["inflammation", "DISEASE", 60, 72], ["HIV", "ORGANISM", 0, 3], ["decidual", "CELL", 164, 172], ["placental vascular", "MULTI-TISSUE_STRUCTURE", 177, 195], ["angiogenic factors", "PROTEIN", 89, 107], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV infection", "PROBLEM", 0, 13], ["immune dysregulation", "PROBLEM", 38, 58], ["inflammation", "PROBLEM", 60, 72], ["alterations in angiogenic factors", "PROBLEM", 74, 107], ["complement activation", "PROBLEM", 112, 133], ["placental vascular remodeling", "TREATMENT", 177, 206], ["infection", "OBSERVATION", 4, 13], ["associated with", "UNCERTAINTY", 22, 37], ["immune dysregulation", "OBSERVATION", 38, 58], ["inflammation", "OBSERVATION", 60, 72], ["angiogenic", "OBSERVATION_MODIFIER", 89, 99], ["vascular", "ANATOMY", 187, 195], ["remodeling", "OBSERVATION", 196, 206]]], ["The strength of our study is that we are able to pinpoint that among PIs, lopinavir but not darunavir-based cART leads to deficiencies in uterine decidualization and spiral artery remodeling.", [["uterine", "ANATOMY", 138, 145], ["spiral artery", "ANATOMY", 166, 179], ["lopinavir", "CHEMICAL", 74, 83], ["darunavir", "CHEMICAL", 92, 101], ["lopinavir", "CHEMICAL", 74, 83], ["darunavir", "CHEMICAL", 92, 101], ["lopinavir", "SIMPLE_CHEMICAL", 74, 83], ["darunavir", "SIMPLE_CHEMICAL", 92, 101], ["uterine", "MULTI-TISSUE_STRUCTURE", 138, 145], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 166, 179], ["our study", "TEST", 16, 25], ["lopinavir", "TREATMENT", 74, 83], ["darunavir", "TREATMENT", 92, 101], ["deficiencies in uterine decidualization", "PROBLEM", 122, 161], ["spiral artery remodeling", "PROBLEM", 166, 190], ["uterine", "ANATOMY", 138, 145], ["decidualization", "OBSERVATION", 146, 161], ["spiral artery", "ANATOMY", 166, 179]]], ["By using the same backbone (zidovudine plus lamivudine) with both PIs across all experiments, we are also able to rule out the association of zidovudine and lamivudine with early pregnancy defects.", [["zidovudine", "CHEMICAL", 28, 38], ["lamivudine", "CHEMICAL", 44, 54], ["zidovudine", "CHEMICAL", 142, 152], ["lamivudine", "CHEMICAL", 157, 167], ["pregnancy defects", "DISEASE", 179, 196], ["zidovudine", "CHEMICAL", 28, 38], ["lamivudine", "CHEMICAL", 44, 54], ["zidovudine", "CHEMICAL", 142, 152], ["lamivudine", "CHEMICAL", 157, 167], ["zidovudine", "SIMPLE_CHEMICAL", 28, 38], ["lamivudine", "SIMPLE_CHEMICAL", 44, 54], ["zidovudine", "SIMPLE_CHEMICAL", 142, 152], ["lamivudine", "SIMPLE_CHEMICAL", 157, 167], ["the same backbone (zidovudine", "TREATMENT", 9, 38], ["lamivudine", "TREATMENT", 44, 54], ["zidovudine", "TREATMENT", 142, 152], ["lamivudine", "TREATMENT", 157, 167], ["early pregnancy defects", "PROBLEM", 173, 196]]], ["Our findings correlate well with the higher incidence of poor birth outcomes in pregnant women living with HIV who initiate lopinavir-based cART before conception or in the first trimester of pregnancy.DiscussionIn conclusion, our results suggest that initiation of lopinavir/r-cART during periconception dysregulates decidualization, leading to reduced uNK cell numbers.", [["uNK cell", "ANATOMY", 354, 362], ["HIV", "DISEASE", 107, 110], ["lopinavir", "CHEMICAL", 124, 133], ["lopinavir/r-cART", "CHEMICAL", 266, 282], ["lopinavir", "CHEMICAL", 124, 133], ["lopinavir", "CHEMICAL", 266, 275], ["r-cART", "CHEMICAL", 276, 282], ["women", "ORGANISM", 89, 94], ["lopinavir", "SIMPLE_CHEMICAL", 124, 133], ["lopinavir", "SIMPLE_CHEMICAL", 266, 275], ["uNK cell", "CELL", 354, 362], ["women", "SPECIES", 89, 94], ["HIV", "SPECIES", 107, 110], ["HIV", "SPECIES", 107, 110], ["lopinavir", "TREATMENT", 124, 133], ["lopinavir", "TREATMENT", 266, 275], ["r-cART", "TREATMENT", 276, 282], ["decidualization", "PROBLEM", 318, 333], ["reduced uNK cell numbers", "PROBLEM", 346, 370], ["reduced", "OBSERVATION_MODIFIER", 346, 353], ["uNK cell numbers", "OBSERVATION", 354, 370]]], ["These decidual defects hinder trophoblast invasion, spiral artery remodeling, placentation and consequently could lead to adverse birth outcomes in pregnancies exposed to lopinavir/r-cART from conception.", [["decidual", "ANATOMY", 6, 14], ["trophoblast", "ANATOMY", 30, 41], ["spiral artery", "ANATOMY", 52, 65], ["lopinavir/r-cART", "CHEMICAL", 171, 187], ["lopinavir", "CHEMICAL", 171, 180], ["r-cART", "CHEMICAL", 181, 187], ["decidual", "CELL", 6, 14], ["trophoblast", "CELL", 30, 41], ["spiral artery", "MULTI-TISSUE_STRUCTURE", 52, 65], ["lopinavir", "SIMPLE_CHEMICAL", 171, 180], ["These decidual defects", "PROBLEM", 0, 22], ["trophoblast invasion", "PROBLEM", 30, 50], ["spiral artery remodeling", "PROBLEM", 52, 76], ["adverse birth outcomes", "PROBLEM", 122, 144], ["pregnancies", "PROBLEM", 148, 159], ["lopinavir", "TREATMENT", 171, 180], ["decidual", "OBSERVATION_MODIFIER", 6, 14], ["defects", "OBSERVATION", 15, 22], ["hinder", "UNCERTAINTY", 23, 29], ["trophoblast", "OBSERVATION_MODIFIER", 30, 41], ["invasion", "OBSERVATION_MODIFIER", 42, 50], ["spiral artery", "ANATOMY", 52, 65]]], ["Unlike lopinavir, darunavir/r-cART was not associated with any defects in the decidualization process.", [["lopinavir", "CHEMICAL", 7, 16], ["darunavir/r-cART", "CHEMICAL", 18, 34], ["lopinavir", "CHEMICAL", 7, 16], ["darunavir", "CHEMICAL", 18, 27], ["r-cART", "CHEMICAL", 28, 34], ["lopinavir", "SIMPLE_CHEMICAL", 7, 16], ["darunavir", "SIMPLE_CHEMICAL", 18, 27], ["r-cART", "SIMPLE_CHEMICAL", 28, 34], ["lopinavir", "TREATMENT", 7, 16], ["darunavir", "TREATMENT", 18, 27], ["cART", "TREATMENT", 30, 34], ["any defects in the decidualization process", "PROBLEM", 59, 101], ["defects", "OBSERVATION", 63, 70], ["decidualization", "OBSERVATION", 78, 93]]], ["Although lopinavir is no longer a first-line regimen in pregnancy, it remains an alternate regimen in many guidelines.", [["lopinavir", "CHEMICAL", 9, 18], ["lopinavir", "CHEMICAL", 9, 18], ["lopinavir", "SIMPLE_CHEMICAL", 9, 18], ["lopinavir", "TREATMENT", 9, 18], ["a first-line regimen", "TREATMENT", 32, 52], ["an alternate regimen", "TREATMENT", 78, 98]]], ["In low resource settings, lopinavir is often the only PI available in cases where first-line regimens fail.", [["lopinavir", "CHEMICAL", 26, 35], ["lopinavir", "CHEMICAL", 26, 35], ["lopinavir", "SIMPLE_CHEMICAL", 26, 35], ["PI", "SIMPLE_CHEMICAL", 54, 56], ["lopinavir", "TREATMENT", 26, 35], ["first-line regimens", "TREATMENT", 82, 101]]], ["Current guidelines also recommend that if an HIV\u00fe pregnancy is conceived on lopinavir/r-cART, the same therapy should be continued.", [["lopinavir/r-cART", "CHEMICAL", 76, 92], ["lopinavir", "CHEMICAL", 76, 85], ["r-cART", "CHEMICAL", 86, 92], ["HIV", "ORGANISM", 45, 48], ["lopinavir", "SIMPLE_CHEMICAL", 76, 85], ["HIV", "SPECIES", 45, 48], ["HIV", "SPECIES", 45, 48], ["an HIV\u00fe pregnancy", "PROBLEM", 42, 59], ["lopinavir", "TREATMENT", 76, 85], ["cART", "TREATMENT", 88, 92], ["the same therapy", "TREATMENT", 94, 110]]], ["Our data indicate that lopinavir-based cART should be avoided in the first trimester of pregnancy to improve endometrial maturation and facilitate normal placentation, which could possibly reduce the risk of poor birth outcomes.", [["endometrial", "ANATOMY", 109, 120], ["lopinavir", "CHEMICAL", 23, 32], ["lopinavir", "CHEMICAL", 23, 32], ["lopinavir", "SIMPLE_CHEMICAL", 23, 32], ["endometrial", "MULTI-TISSUE_STRUCTURE", 109, 120], ["Our data", "TEST", 0, 8], ["lopinavir-based cART", "TREATMENT", 23, 43], ["endometrial maturation", "PROBLEM", 109, 131], ["poor birth outcomes", "PROBLEM", 208, 227], ["normal placentation", "OBSERVATION", 147, 166]]], ["Alternate PIs, such as darunavir, should be preferred over lopinavir for use in pregnancy.DiscussionFurthermore, in current times of the COVID-19 pandemic, lopinavir/r is among the top drug candidates which are being repurposed for inclusion in clinical trials world-over (https://doi.org/10.1186/ ISRCTN83971151), to assess their therapeutic potential against the dangerous respiratory disease.", [["respiratory", "ANATOMY", 375, 386], ["darunavir", "CHEMICAL", 23, 32], ["lopinavir", "CHEMICAL", 59, 68], ["lopinavir", "CHEMICAL", 156, 165], ["respiratory disease", "DISEASE", 375, 394], ["darunavir", "CHEMICAL", 23, 32], ["lopinavir", "CHEMICAL", 59, 68], ["lopinavir", "CHEMICAL", 156, 165], ["darunavir", "SIMPLE_CHEMICAL", 23, 32], ["lopinavir", "SIMPLE_CHEMICAL", 59, 68], ["lopinavir", "SIMPLE_CHEMICAL", 156, 165], ["Alternate PIs", "TREATMENT", 0, 13], ["darunavir", "TREATMENT", 23, 32], ["lopinavir", "TREATMENT", 59, 68], ["the COVID", "TREATMENT", 133, 142], ["lopinavir", "TREATMENT", 156, 165], ["the top drug candidates", "TREATMENT", 177, 200], ["the dangerous respiratory disease", "PROBLEM", 361, 394], ["dangerous", "OBSERVATION_MODIFIER", 365, 374], ["respiratory disease", "OBSERVATION", 375, 394]]], ["The efficacy of lopinavir/r given prophylactically to protect health care workers and people with potential exposures is also being tested (NCT04321174).", [["lopinavir", "CHEMICAL", 16, 25], ["lopinavir", "CHEMICAL", 16, 25], ["lopinavir", "SIMPLE_CHEMICAL", 16, 25], ["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["lopinavir/r", "TREATMENT", 16, 27]]], ["Given the current extraordinary numbers, these might include women with early pregnancies, who may or may not be cognizant of their gestational status.", [["women", "ORGANISM", 61, 66], ["women", "SPECIES", 61, 66]]], ["This is a matter of concern as it could mean that women with early pregnancies might be exposed to this drug, which can cause decidualization defects.", [["decidualization defects", "DISEASE", 126, 149], ["women", "ORGANISM", 50, 55], ["women", "SPECIES", 50, 55], ["early pregnancies", "PROBLEM", 61, 78], ["decidualization defects", "PROBLEM", 126, 149], ["decidualization defects", "OBSERVATION", 126, 149]]], ["Our findings provide evidence of safety concerns surrounding lopinavir/r use in pregnancy that women of reproductive age", [["lopinavir", "CHEMICAL", 61, 70], ["lopinavir", "CHEMICAL", 61, 70], ["lopinavir", "SIMPLE_CHEMICAL", 61, 70], ["women", "ORGANISM", 95, 100], ["women", "SPECIES", 95, 100], ["lopinavir", "TREATMENT", 61, 70]]]], "PMC7474572": [["IntroductionPeer support (PS) provided by \u201ccommunity health workers,\u201d \u201clay health advisors,\u201d \u201cpromotores,\u201d \u201cpatient navigators,\u201d \u201cpeer supporters,\u201d and individuals with a number of other designations has been shown effective in enhancing linkages to care and attending to the dynamic conditions of real-world circumstances that influence health behavior [14, 15, 20].", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115]]], ["Although medical care and self-management programs may help individuals understand what to do to stay healthy, individuals often find themselves disconnected from resources and emotional support needed to initiate and sustain behavior change.", [["self-management programs", "TREATMENT", 26, 50], ["emotional support", "TREATMENT", 177, 194]]], ["PS addresses this gap by offering emotional, social, and practical assistance for achieving and sustaining complex disease management or lifestyle changes and for enhancing quality of life [6, 23].", [["sustaining complex disease management", "TREATMENT", 96, 133], ["lifestyle changes", "PROBLEM", 137, 154]]], ["PS can complement and enhance other health care services to improve patients\u2019 adherence to treatment regimens, motivation, and ability to cope, and it can help them stay connected to their health care providers, often in a cost-effective manner [24, 25].IntroductionPS is recognized as a valuable strategy for the prevention and management of chronic illnesses including cancer [6, 18].", [["cancer", "ANATOMY", 371, 377], ["cancer", "DISEASE", 371, 377], ["patients", "ORGANISM", 68, 76], ["cancer", "CANCER", 371, 377], ["patients", "SPECIES", 68, 76], ["treatment regimens", "TREATMENT", 91, 109], ["IntroductionPS", "TREATMENT", 254, 268], ["a valuable strategy", "TREATMENT", 286, 305], ["chronic illnesses", "PROBLEM", 343, 360], ["cancer", "PROBLEM", 371, 377], ["chronic", "OBSERVATION_MODIFIER", 343, 350], ["illnesses", "OBSERVATION", 351, 360], ["cancer", "OBSERVATION", 371, 377]]], ["We and our colleagues published a scoping review [17] that examined peer-reviewed literature on PS across the cancer care continuum.", [["cancer", "ANATOMY", 110, 116], ["cancer", "DISEASE", 110, 116], ["cancer", "CANCER", 110, 116], ["PS", "TREATMENT", 96, 98], ["cancer", "OBSERVATION", 110, 116]]], ["Although there are types of cancer (e.g., lung) and phases of the continuum (e.g., survivorship, end-of-life care) in which research on PS is sparse, nevertheless, the scope is broad.", [["cancer", "ANATOMY", 28, 34], ["lung", "ANATOMY", 42, 46], ["cancer", "DISEASE", 28, 34], ["cancer", "CANCER", 28, 34], ["lung", "ORGAN", 42, 46], ["cancer", "PROBLEM", 28, 34], ["end-of-life care", "TREATMENT", 97, 113], ["cancer", "OBSERVATION", 28, 34], ["lung", "ANATOMY", 42, 46], ["broad", "OBSERVATION_MODIFIER", 177, 182]]], ["Starting with prevention, peer supporters promote healthy behaviors such as smoking cessation [12] and provide education to promote screening for cancers like cervical and colorectal cancer [9].", [["cancers", "ANATOMY", 146, 153], ["cervical", "ANATOMY", 159, 167], ["colorectal cancer", "ANATOMY", 172, 189], ["cancers", "DISEASE", 146, 153], ["cervical and colorectal cancer", "DISEASE", 159, 189], ["cancers", "CANCER", 146, 153], ["cervical", "ORGAN", 159, 167], ["colorectal cancer", "CANCER", 172, 189], ["cancers", "PROBLEM", 146, 153], ["cervical and colorectal cancer", "PROBLEM", 159, 189], ["cervical", "ANATOMY", 159, 167], ["colorectal", "ANATOMY", 172, 182], ["cancer", "OBSERVATION", 183, 189]]], ["Peer supporters assist with linkages to clinical care and community resources to help individuals cope with the challenges of diagnosis and treatment [9, 16].", [["treatment", "TREATMENT", 140, 149]]], ["Beyond the research literature, however, little is known about how PS programs for cancer operate in ongoing clinical and community settings.", [["cancer", "ANATOMY", 83, 89], ["cancer", "DISEASE", 83, 89], ["cancer", "CANCER", 83, 89], ["cancer", "PROBLEM", 83, 89]]], ["Programs in \u201creal world\u201d (i.e., non-research) settings may experience unique challenges compared with those operating within a research protocol, particularly in regard to funding and personnel.", [["a research protocol", "TREATMENT", 125, 144]]], ["The purpose of this study was to learn more about such cancer peer support programs and how they are organized, managed, and supported by their hosting organizations.Participants ::: MethodsWe conducted a web search to identify programs inside National Cancer Institute (NCI)\u2013designated cancer centers as well as community-based programs.", [["cancer", "ANATOMY", 55, 61], ["cancer", "ANATOMY", 287, 293], ["cancer", "DISEASE", 55, 61], ["Cancer", "DISEASE", 253, 259], ["cancer", "DISEASE", 287, 293], ["cancer", "CANCER", 55, 61], ["cancer", "CANCER", 287, 293], ["Participants", "SPECIES", 166, 178], ["this study", "TEST", 15, 25]]], ["To do this, we first reviewed the websites of all 71 NCI-designated cancer centers for information about cancer PS programs available for cancer patients and/or survivors, including support groups and patient navigation services.", [["cancer", "ANATOMY", 68, 74], ["cancer", "ANATOMY", 105, 111], ["cancer", "ANATOMY", 138, 144], ["cancer", "DISEASE", 68, 74], ["cancer", "DISEASE", 105, 111], ["cancer", "DISEASE", 138, 144], ["cancer", "CANCER", 68, 74], ["cancer", "CANCER", 105, 111], ["cancer", "CANCER", 138, 144], ["patients", "ORGANISM", 145, 153], ["patient", "ORGANISM", 201, 208], ["patients", "SPECIES", 145, 153], ["patient", "SPECIES", 201, 208], ["cancer PS programs", "TREATMENT", 105, 123], ["cancer", "PROBLEM", 138, 144]]], ["To locate cancer PS programs outside of cancer centers, we utilized Google to search for \u201ccancer peer support.\u201d", [["cancer", "ANATOMY", 10, 16], ["cancer", "ANATOMY", 40, 46], ["cancer", "ANATOMY", 90, 96], ["cancer", "DISEASE", 10, 16], ["cancer", "DISEASE", 40, 46], ["cancer", "DISEASE", 90, 96], ["cancer", "CANCER", 10, 16], ["cancer", "CANCER", 40, 46], ["cancer", "CANCER", 90, 96], ["cancer PS programs", "TREATMENT", 10, 28], ["cancer", "OBSERVATION", 10, 16], ["cancer", "OBSERVATION", 90, 96]]], ["Because this was a program review and not a study of human subjects, informed consent was not required.", [["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["a study", "TEST", 42, 49]]], ["The purpose of the study was to characterize the variety of ways in which cancer PS programs address prevention, care, and survivorship needs.", [["cancer", "ANATOMY", 74, 80], ["cancer", "DISEASE", 74, 80], ["cancer", "CANCER", 74, 80], ["the study", "TEST", 15, 24], ["cancer PS programs", "TREATMENT", 74, 92], ["cancer", "OBSERVATION", 74, 80]]], ["Because the 29 interviews reached saturation (no new information emerging), we did not interview leaders of additional cancer PS programs.Procedures ::: MethodsUsing a deductive approach, we developed a phone interview guide (available as online supplement) based on prior work with peer support programs and topics included in the parallel scoping review [17].", [["cancer", "ANATOMY", 119, 125], ["cancer", "DISEASE", 119, 125], ["cancer", "CANCER", 119, 125], ["additional cancer PS programs", "TREATMENT", 108, 137], ["peer support programs", "TREATMENT", 283, 304], ["cancer", "OBSERVATION", 119, 125]]], ["Based on detailed notes from these, the research team finalized the guide, which included items about the program model, eligibility criteria, peer supporter training, support from clinical staff and integration with other supportive services, funding and administrative information, diversity and inclusion, program evaluation, and challenges and barriers.", [["peer supporter training", "TREATMENT", 143, 166], ["program evaluation", "TEST", 309, 327]]], ["KB completed interviews with the remaining 26 programs.", [["KB", "CANCER", 0, 2]]], ["These responses were later checked against interview recordings for accuracy and summarized.", [["interview recordings", "TEST", 43, 63], ["accuracy", "TEST", 68, 76]]], ["We used these themes as the basis for the characterization of programs and observations that follow.Recruitment, Training, and Ongoing Support for Peer Supporters ::: ResultsAllocating time and effort to recruit, train, track, and retain PSers was a constant challenge.", [["PSers", "GENE_OR_GENE_PRODUCT", 238, 243], ["a constant challenge", "TREATMENT", 248, 268]]], ["Solutions included recruiting previous recipients to become PSers or incorporating PSers as paid staff.", [["recipients", "ORGANISM", 39, 49]]], ["Most training shared similar content (e.g., empathic listening, role play) but varied considerably in duration (from none to 2 days, from no to required supplemental training), or format (in-person, online training).", [["person", "SPECIES", 191, 197], ["supplemental training", "TREATMENT", 153, 174]]], ["All programs, however, mentioned the importance of ongoing support and back-up for the PSers, given the difficult circumstances PSers face.", [["ongoing support", "TREATMENT", 51, 66]]], ["For example, PSers may need support to handle situations outside of their competency, like mental health emergencies, or may need staff support to cope with difficult experiences like the death of their supportee.Recruitment, Training, and Ongoing Support for Peer Supporters ::: ResultsQuality control tended to be linked with ongoing training, monitoring, and supervision/consultation for the PSers.", [["death", "DISEASE", 188, 193], ["PSers", "GENE_OR_GENE_PRODUCT", 13, 18], ["ResultsQuality control", "TREATMENT", 280, 302], ["ongoing training", "TREATMENT", 328, 344], ["monitoring", "TEST", 346, 356]]], ["Most programs specifically trained volunteers not to provide medical advice.", [["volunteers", "ORGANISM", 35, 45]]], ["Ongoing supervision of peer supporters ensured quality of information and support being provided such as in answering patients\u2019 questions, though programs differed greatly in the amount of supervision provided.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126]]], ["Most programs required participation in some type of formal training at least once per year and had staff members available to provide support to PSers on an as-needed basis, while a few programs reported more frequent oversight, such as monthly conference calls.Promoting Cancer PS Programs to Support Seekers ::: ResultsPatients connected with programs in many ways.", [["Cancer", "ANATOMY", 273, 279], ["Cancer", "DISEASE", 273, 279], ["Cancer", "CANCER", 273, 279], ["formal training", "TREATMENT", 53, 68], ["Cancer", "OBSERVATION", 273, 279]]], ["In addition to one-to-one peer support were a variety of channels, e.g., web-based communities, blogs, social media, video chat, and online forums, which sometimes lead to informal, one-to-one support.Promoting Cancer PS Programs to Support Seekers ::: ResultsHIPPAA compliance may limit the ability of PSers to directly contact individuals who have not consented.", [["Cancer", "ANATOMY", 211, 217], ["Cancer", "DISEASE", 211, 217], ["Cancer", "CANCER", 211, 217], ["PSers", "GENE_OR_GENE_PRODUCT", 303, 308], ["Cancer", "OBSERVATION", 211, 217]]], ["Programs outside cancer centers noted that they are generally not required to be HIPAA-compliant, lessening confidentiality-related barriers.The Match ::: ResultsCareful matching (aka \u201cmicro-matching\u201d) pairs those seeking support with PSers based on diagnosis, stage, treatment, age, gender, and, sometimes, occupation, interests, or hobbies.", [["cancer", "ANATOMY", 17, 23], ["cancer", "DISEASE", 17, 23], ["cancer", "CANCER", 17, 23], ["treatment", "TREATMENT", 268, 277], ["cancer", "OBSERVATION", 17, 23]]], ["Some programs even referred to other cancer PS programs if they could not provide a close match.", [["cancer", "ANATOMY", 37, 43], ["cancer", "DISEASE", 37, 43], ["cancer", "CANCER", 37, 43], ["other cancer PS programs", "TREATMENT", 31, 55]]], ["Some PSers also look forward to matching and the opportunity to help someone going through what they have endured.The Match ::: ResultsMatching raised a number of other issues for programs.", [["PSers", "GENE_OR_GENE_PRODUCT", 5, 10]]], ["Some managers noted, however, that young adults who feel isolated may benefit from a PSer with common age or interests more than a similar diagnosis or treatment plan.", [["adults", "ORGANISM", 41, 47], ["treatment plan", "TREATMENT", 152, 166]]], ["Rapid developments in treatment may also provide challenges to matching based on diagnosis and treatment.", [["treatment", "TREATMENT", 22, 31], ["treatment", "TREATMENT", 95, 104]]], ["Some PSers may no longer match current patients facing the same cancer but with newer, very different treatments.", [["cancer", "ANATOMY", 64, 70], ["cancer", "DISEASE", 64, 70], ["PSers", "GENE_OR_GENE_PRODUCT", 5, 10], ["patients", "ORGANISM", 39, 47], ["cancer", "CANCER", 64, 70], ["patients", "SPECIES", 39, 47], ["the same cancer", "PROBLEM", 55, 70], ["no longer", "UNCERTAINTY", 15, 24], ["cancer", "OBSERVATION", 64, 70]]], ["Several programs found continued roles for these PSers through additional opportunities, such as speaking at fundraising events, writing blogs, or helping spread information about cancer prevention or testing.", [["cancer", "ANATOMY", 180, 186], ["cancer", "DISEASE", 180, 186], ["PSers", "GENE_OR_GENE_PRODUCT", 49, 54], ["cancer", "CANCER", 180, 186], ["cancer prevention", "TREATMENT", 180, 197], ["testing", "TEST", 201, 208]]], ["In perhaps a cohort effect, all the programs for young adults mentioned the importance of online support.", [["online support", "TREATMENT", 90, 104]]], ["Length of support varied from one contact to the duration of treatment.", [["treatment", "TREATMENT", 61, 70]]], ["Several leaders indicated that many seeking support are interested in just one or two contacts, sufficient to learn that someone else had a similar disease and prognosis, made it through treatment, and is still living.", [["a similar disease", "PROBLEM", 138, 155], ["treatment", "TREATMENT", 187, 196]]], ["Indeed, for some patients, simply having someone\u2019s contact information and knowing there are \u201cothers like me\u201d was adequate with little or no actual contact.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Program leaders suggested women are more likely to stay in touch and to seek emotional support, while men primarily use PS for information.Diversity, Inclusion, and Access ::: ResultsMost cancer PS programs do not collect data on race, ethnicity, or income.", [["cancer", "ANATOMY", 188, 194], ["cancer", "DISEASE", 188, 194], ["women", "ORGANISM", 26, 31], ["men", "ORGANISM", 102, 105], ["cancer", "CANCER", 188, 194], ["women", "SPECIES", 26, 31], ["men", "SPECIES", 102, 105], ["cancer PS programs", "TREATMENT", 188, 206]]], ["Except for those focused on men or young adults, however, nearly every program reported that older, white women are most likely to use their services, regardless of program size, location, or mode of communication.", [["men", "ORGANISM", 28, 31], ["women", "ORGANISM", 106, 111], ["men", "SPECIES", 28, 31], ["women", "SPECIES", 106, 111], ["size", "OBSERVATION_MODIFIER", 173, 177]]], ["Leaders reported that Spanish-speaking PSers are frequently overloaded with matches.", [["PSers", "ORGANISM", 39, 44], ["frequently overloaded", "PROBLEM", 49, 70]]], ["Challenges reaching men, racial/ethnic minorities subject to discrimination, or socially/economically disadvantaged groups include stigma and difficulty recruiting PSers from these communities [22].", [["men", "ORGANISM", 20, 23], ["men", "SPECIES", 20, 23], ["stigma", "PROBLEM", 131, 137], ["difficulty recruiting PSers", "PROBLEM", 142, 169]]], ["One program serving a predominantly low-income, racial-minority area explained that their PSers may themselves encounter struggles with homelessness, family illness, unemployment, or other stressors, compromising their ability to be present as a PSer.Buy-in from Clinicians ::: ResultsPrograms reported strong buy-in and support from social workers, nurses, and nurse navigators, but variable buy-in and support from physicians.", [["homelessness", "DISEASE", 136, 148], ["illness", "DISEASE", 157, 164]]], ["Most reported that physicians focus on biomedical treatment, leave psychosocial issues to other staff, and support the programs, but are not programs\u2019 best champions.", [["biomedical treatment", "TREATMENT", 39, 59]]], ["Most referrals are reported to come from nurses and social workers.Buy-in from Clinicians ::: ResultsA few programs mentioned lack of support or even antagonism from some physicians, which was attributed to concerns about losing control over patients\u2019 care and worry that PSers may encourage patients to question their treatment plans, not to trust their medical provider, and to seek other opinions or alternative remedies.", [["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 292, 300], ["alternative remedies", "TREATMENT", 403, 423]]], ["Reports indicated physicians are not opposed to the idea of PS but prefer to maintain control over with whom patients are matched; for example, some physicians reportedly informally match their own current and former patients.", [["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 217, 225], ["PS", "TREATMENT", 60, 62]]], ["Program leaders indicated this may undermine the cancer PS program.", [["cancer", "ANATOMY", 49, 55], ["cancer", "DISEASE", 49, 55], ["cancer", "CANCER", 49, 55], ["the cancer PS program", "TREATMENT", 45, 66], ["cancer", "OBSERVATION", 49, 55]]], ["Participation in local cancer coalitions may gain credibility among and cooperation from physicians as well as facilitating use of services by other organizations and clinical teams and sharing resources and information.", [["cancer", "ANATOMY", 23, 29], ["cancer", "DISEASE", 23, 29], ["cancer", "CANCER", 23, 29], ["cancer", "OBSERVATION", 23, 29]]], ["Developing relationships with institutions rather than individual champions was recommended.Program Evaluation ::: ResultsNearly all programs collected some information about patient satisfaction but did not assess psychosocial or health outcomes or maintain formal program evaluation.", [["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["Program Evaluation", "TEST", 92, 110], ["formal program evaluation", "TEST", 259, 284]]], ["Planning, conducting, or publishing an evaluation was more likely for programs connected with a university or academic medical center.", [["an evaluation", "TEST", 36, 49]]], ["One respondent mentioned researchers collecting participant data but failing to share findings with the program.Funding Model ::: ResultsManagers reported a need for creative and diverse funding strategies.", [["creative and diverse funding strategies", "TREATMENT", 166, 205]]], ["Within NCI-designated cancer centers, cancer PS programs were allocated budgets and staff and funded through social work, psychosocial support programs, survivorship programs, volunteer services, or foundation grants.", [["cancer", "ANATOMY", 22, 28], ["cancer", "ANATOMY", 38, 44], ["cancer", "DISEASE", 22, 28], ["cancer", "DISEASE", 38, 44], ["cancer", "CANCER", 22, 28], ["cancer", "CANCER", 38, 44], ["cancer PS programs", "TREATMENT", 38, 56], ["cancer", "OBSERVATION", 22, 28]]], ["Outside of cancer centers, funding presented a major obstacle.", [["cancer", "ANATOMY", 11, 17], ["cancer", "DISEASE", 11, 17], ["cancer", "CANCER", 11, 17], ["cancer", "OBSERVATION", 11, 17]]], ["Sources included grants, private donations, in-kind donations like office space from cancer centers for which programs provide services, or being part of a non-profit.", [["cancer", "ANATOMY", 85, 91], ["cancer", "DISEASE", 85, 91], ["cancer", "CANCER", 85, 91]]], ["One respondent noted the \u201cNPR/PBS model\u201d in which grateful patients donate as they judge appropriate to their use of the program.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67]]], ["Some provide fee-based services (e.g., patient navigation) to cancer patients or hospitals.", [["cancer", "ANATOMY", 62, 68], ["cancer", "DISEASE", 62, 68], ["patient", "ORGANISM", 39, 46], ["cancer", "CANCER", 62, 68], ["patients", "ORGANISM", 69, 77], ["patient", "SPECIES", 39, 46], ["patients", "SPECIES", 69, 77]]], ["Several programs noted difficulties in funding ongoing monitoring and quality control that require appreciable staff time.PSer Training: Need for Standardization? ::: Strategic Challenges ::: DiscussionProgram training varies greatly.", [["difficulties", "PROBLEM", 23, 35], ["ongoing monitoring", "TEST", 47, 65], ["quality control", "TREATMENT", 70, 85]]], ["A standardized curriculum for PS in cancer care might have substantial appeal as a step toward legitimacy.", [["cancer", "ANATOMY", 36, 42], ["cancer", "DISEASE", 36, 42], ["cancer", "CANCER", 36, 42], ["PS in cancer care", "TREATMENT", 30, 47]]], ["However, the variety of approaches and PSers, from full-time employees to volunteers offering PS a few hours a week, suggests standardizing training and qualifications might constrain the range, vitality, and flexibility of PS to meet the needs of different patient groups, settings, and communities.", [["patient", "ORGANISM", 258, 265], ["patient", "SPECIES", 258, 265], ["PS", "TREATMENT", 94, 96], ["standardizing training", "TREATMENT", 126, 148], ["flexibility of PS", "TREATMENT", 209, 226]]], ["That is, emphasizing functions may enable a compromise between standardization and adaptation to local circumstances.PSer Training: Need for Standardization? ::: Strategic Challenges ::: DiscussionFlexibility might also be enhanced by credentialing programs as meeting quality standards and qualifying for funding.", [["a compromise between standardization", "PROBLEM", 42, 78]]], ["Once reviewed and approved, a program might then be able to recruit, train, and deploy PSers without each individual having to gain certification, a barrier to many such as retired volunteers and an administrative burden for programs.", [["volunteers", "ORGANISM", 181, 191]]], ["Amidst the variety of approaches and providers of PS in cancer, such recognition of programs may be more nimble than certifying individuals, although pursuing both approaches is surely feasible as suggested in guidelines developed by Peers for Progress with several collaborating groups [4].Match Specificity ::: Strategic Challenges ::: DiscussionThe ability of a cancer PS program to provide specific matches is largely dependent on its number of PSers.", [["cancer", "ANATOMY", 56, 62], ["cancer", "ANATOMY", 365, 371], ["cancer", "DISEASE", 56, 62], ["cancer", "DISEASE", 365, 371], ["cancer", "CANCER", 56, 62], ["cancer", "CANCER", 365, 371], ["PSers", "GENE_OR_GENE_PRODUCT", 449, 454], ["PSers", "PROTEIN", 449, 454], ["PS in cancer", "PROBLEM", 50, 62], ["a cancer PS program", "TREATMENT", 363, 382], ["variety", "OBSERVATION_MODIFIER", 11, 18], ["cancer", "OBSERVATION", 56, 62], ["dependent", "OBSERVATION_MODIFIER", 422, 431]]], ["Smaller, community- or hospital-based programs may provide a local sense of community and spaces for peer support to occur naturally, obviating the need for a large number of PSers to facilitate specific matches.", [["PSers", "GENE_OR_GENE_PRODUCT", 175, 180], ["peer support", "TREATMENT", 101, 113], ["a large number of PSers", "TREATMENT", 157, 180]]], ["The availability of both might be ideal\u2014a remote PSer with similar diagnosis and treatment but also a local PSer or support group that could provide more varied forms of support.", [["treatment", "TREATMENT", 81, 90], ["a local PSer or support group", "TREATMENT", 100, 129]]], ["For young adults who often feel isolated, receiving PS from someone their own age may be most critical.Concerns Related to Diversity, Access, and Inclusion ::: Strategic Challenges ::: DiscussionProgram leaders noted that older, white women were both most likely to use PS and most likely to serve as PSers.", [["adults", "ORGANISM", 10, 16], ["women", "ORGANISM", 235, 240], ["PSers", "GENE_OR_GENE_PRODUCT", 301, 306], ["women", "SPECIES", 235, 240], ["PS", "TREATMENT", 52, 54], ["PS", "TREATMENT", 270, 272]]], ["A challenge is recruiting PSers from groups that are underrepresented: those with cancers other than breast, ovarian, and gynecological; males; and racial/ethnic minority and socially/economically disadvantaged groups, some of whom may need extra support and flexibility to participate.", [["cancers", "ANATOMY", 82, 89], ["breast", "ANATOMY", 101, 107], ["ovarian", "ANATOMY", 109, 116], ["cancers", "DISEASE", 82, 89], ["breast, ovarian, and gynecological", "DISEASE", 101, 135], ["PSers", "GENE_OR_GENE_PRODUCT", 26, 31], ["cancers", "CANCER", 82, 89], ["breast", "CANCER", 101, 107], ["ovarian", "CANCER", 109, 116], ["A challenge", "TREATMENT", 0, 11], ["cancers", "PROBLEM", 82, 89], ["extra support", "TREATMENT", 241, 254], ["breast", "ANATOMY", 101, 107], ["ovarian", "ANATOMY", 109, 116], ["gynecological", "ANATOMY", 122, 135]]], ["Stigma surrounding cancer may also reduce participation in some communities.Concerns Related to Diversity, Access, and Inclusion ::: Strategic Challenges ::: DiscussionFrom the perspective of social networks, programs led by and serving a particular group will be less likely to engage those outside the group, creating a vicious circle of lack of diversity.", [["cancer", "ANATOMY", 19, 25], ["cancer", "DISEASE", 19, 25], ["cancer", "CANCER", 19, 25], ["social networks", "MULTI-TISSUE_STRUCTURE", 192, 207], ["Stigma surrounding cancer", "PROBLEM", 0, 25], ["cancer", "OBSERVATION", 19, 25]]], ["Inclusion efforts should prioritize recruiting diverse PSers and program leaders.", [["PSers", "CANCER", 55, 60]]], ["Those with greater social privilege and economic resources may be more able to volunteer time while resources for transportation, telephone access, etc. are particularly critical when recruiting socially/economically disadvantaged PSers.", [["PSers", "CANCER", 231, 236]]], ["The success of programs such as the Sisters Network [19], a mutual support program for African American women with breast cancer, makes clear that PS may be welcomed in diverse communities.", [["breast cancer", "ANATOMY", 115, 128], ["breast cancer", "DISEASE", 115, 128], ["women", "ORGANISM", 104, 109], ["breast cancer", "CANCER", 115, 128], ["women", "SPECIES", 104, 109], ["breast cancer", "PROBLEM", 115, 128], ["breast", "ANATOMY", 115, 121], ["cancer", "OBSERVATION", 122, 128]]], ["Amidst the myriad of alternative remedies, physicians treating cancer may feel especially a need to protect patients from frivolous or harmful approaches.", [["cancer", "ANATOMY", 63, 69], ["cancer", "DISEASE", 63, 69], ["cancer", "CANCER", 63, 69], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["alternative remedies", "TREATMENT", 21, 41], ["cancer", "PROBLEM", 63, 69]]], ["Some may fear PSers will lead their patients to \u201cbogus\u201d treatments or encourage patients to question their physician\u2019s judgment.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 80, 88], ["treatments", "TREATMENT", 56, 66]]], ["Program leaders reported success in gaining physician support through inviting them to learn about PS, the match process, and PSer training, and to serve on advisory committees.", [["PSer training", "TREATMENT", 126, 139]]], ["Additionally, by providing more comprehensive training and ongoing monitoring of PSers, and conducting regular program evaluations, cancer PS programs may secure greater confidence in program quality and support among physicians.Funding Priorities ::: Strategic Challenges ::: DiscussionThe Affordable Care Act has spurred accountable care organizations (ACOs), development of an oncology-focused medical home model (COME HOME project), value-based payments, health homes that provide ongoing support for those with multiple chronic conditions, and bundled and episode-based payment initiatives in specialty care (Oncology Care Model) [3].", [["cancer", "ANATOMY", 132, 138], ["cancer", "DISEASE", 132, 138], ["cancer", "CANCER", 132, 138], ["ongoing monitoring", "TEST", 59, 77], ["regular program evaluations", "TEST", 103, 130], ["cancer PS programs", "TREATMENT", 132, 150], ["ongoing support", "TREATMENT", 485, 500], ["multiple chronic conditions", "PROBLEM", 516, 543]]], ["These population- and performance-based payment reforms can utilize PS in varied ways such as care navigation, patient education, enhancing access, service integration including palliative care, home care, and caregiver engagement.", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["PS", "TREATMENT", 68, 70], ["care navigation", "TREATMENT", 94, 109], ["palliative care", "TREATMENT", 178, 193], ["home care", "TREATMENT", 195, 204]]], ["As much as PS may play an important role, stronger advocacy efforts are needed to direct a portion of these funding streams for PS within both clinical and community settings.Building Community ::: Practice-Oriented Issues ::: DiscussionFrom interviews, the more a program worked to create community among its recipients and PSers, the longer individuals stayed involved.", [["recipients", "ORGANISM", 310, 320], ["PSers", "CANCER", 325, 330], ["PS", "TREATMENT", 128, 130]]], ["Support from staff as well as other PSers creates a sense of community that extends then to other issues such as helping cancer survivors make meaning of their experience by helping others.", [["cancer", "ANATOMY", 121, 127], ["cancer", "DISEASE", 121, 127], ["cancer", "CANCER", 121, 127]]], ["However, PSers who are several years out of treatment may not be able to be matched because their experience is different from current patients.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["treatment", "TREATMENT", 44, 53]]], ["This may discourage PSers, so programs may offer alternative ways for PSers to be involved.", [["PSers", "GENE_OR_GENE_PRODUCT", 20, 25], ["PSers", "GENE_OR_GENE_PRODUCT", 70, 75], ["PSers", "PROTEIN", 70, 75]]], ["They may also need emotional support from staff or other PSers to cope with situations like the death of their supportee.", [["death", "DISEASE", 96, 101], ["emotional support", "TREATMENT", 19, 36]]], ["In several studies [5, 13], providing descriptions of PS programs and then inviting individuals to participate does not result in high recruitment.", [["several studies", "TEST", 3, 18], ["PS programs", "TREATMENT", 54, 65], ["high", "OBSERVATION_MODIFIER", 130, 134], ["recruitment", "OBSERVATION", 135, 146]]], ["On the other hand, if PSers are able to contact individuals directly, they are able to reach and engage large proportions of populations including those too often \u201chardly reached\u201d [22].", [["PSers", "GENE_OR_GENE_PRODUCT", 22, 27], ["PSers", "PROTEIN", 22, 27]]], ["Continuous quality improvement efforts might explore varied strategies, including arranging for PSers to meet patients in the clinical setting.", [["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["PSers", "TREATMENT", 96, 101]]], ["Another approach might be for clinicians simply to inform patients that a PSer will contact them as a routine part of clinical care and to suggest they consider carefully the services offered.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["Outside the context of rushed clinical encounters, PSers might have more time to describe the potential benefits of PS to the patient and encourage them to participate.Knowing There Are \u201cOthers Like Me\u201d Versus Actual Contact ::: Practice-Oriented Issues ::: DiscussionStriking were reports that patients knowing they could contact \u201cothers like me\u201d is helpful in and of itself, even without actual contact.", [["patient", "ORGANISM", 126, 133], ["patients", "ORGANISM", 295, 303], ["patient", "SPECIES", 126, 133], ["patients", "SPECIES", 295, 303], ["PS", "TREATMENT", 116, 118]]], ["A study of telephone support for high risk groups (e.g., veterans, police) identified the value just of voicemails as conveying \u201cpresence,\u201d interest, support, and availability of help [8, 11].", [["A study", "TEST", 0, 7], ["telephone support", "TREATMENT", 11, 28]]], ["This underscores the importance of simply \u201cbeing there\u201d and the importance of emphasizing to PSers that they do not necessarily have to solve problems to be helpful.Need for Diversifying Mode of Support ::: Practice-Oriented Issues ::: DiscussionManagers mentioned that people receive PS informally from social media sites and that they expect this mode of support-seeking to continue to grow.", [["people", "ORGANISM", 270, 276], ["people", "SPECIES", 270, 276], ["PS", "TREATMENT", 285, 287]]], ["This may imply a need to diversify modes of support available to patients.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73]]], ["Suggesting a cohort effect, all the programs focusing on young adults mentioned the importance of utilizing online modes of support.", [["online modes of support", "TREATMENT", 108, 131]]], ["Online support may also make PS more convenient and accessible, especially amidst time constraints of work and family commitments and following experience with COVID-19 in which many have learned to connect through digital channels.Strengths and Limitations ::: DiscussionThis study offers insight on challenges for cancer PS programs.", [["cancer", "ANATOMY", 316, 322], ["cancer", "DISEASE", 316, 322], ["cancer", "CANCER", 316, 322], ["Online support", "TREATMENT", 0, 14], ["This study", "TEST", 272, 282], ["cancer PS programs", "TREATMENT", 316, 334]]], ["Interviews included program leaders representing a wide range of \u201con-the-ground\u201d programs that actively work with patients every day.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122]]], ["This information expands on our scoping review of research literature [17] by providing real-world examples of issues commonly faced by cancer PS programs.", [["cancer", "ANATOMY", 136, 142], ["cancer", "DISEASE", 136, 142], ["cancer", "CANCER", 136, 142], ["cancer PS programs", "TREATMENT", 136, 154]]], ["Limitations however include a convenience sample and possible selection bias arising from inclusion only of those responding to emails and agreeing to participate.", [["a convenience sample", "TEST", 28, 48], ["selection bias", "PROBLEM", 62, 76]]], ["Findings were based on detailed interviewer notes that were checked against audio recordings.", [["audio recordings", "TEST", 76, 92]]], ["Interpretations of those notes were refined through detailed discussion and consensus among the research team comprised of the present authors, with recourse again to audio recordings as needed.Conclusions ::: DiscussionPrograms offered through cancer centers, hospitals, and other clinical and community settings provide a wide range of PS for cancer prevention and care.", [["cancer", "ANATOMY", 245, 251], ["cancer", "ANATOMY", 345, 351], ["cancer", "DISEASE", 245, 251], ["cancer", "DISEASE", 345, 351], ["cancer", "CANCER", 245, 251], ["cancer", "CANCER", 345, 351], ["a wide range of PS", "TREATMENT", 322, 340], ["cancer prevention", "TREATMENT", 345, 362]]], ["Clearly, those directly involved in assisting and supporting individuals with cancer view PS as valuable in the continuum of cancer care from primary prevention and detection to end-of-life care.", [["cancer", "ANATOMY", 78, 84], ["cancer", "ANATOMY", 125, 131], ["cancer", "DISEASE", 78, 84], ["cancer", "DISEASE", 125, 131], ["cancer", "CANCER", 78, 84], ["cancer", "CANCER", 125, 131], ["cancer view PS", "TREATMENT", 78, 92], ["cancer care", "TREATMENT", 125, 136], ["primary prevention", "TREATMENT", 142, 160], ["end-of-life care", "TREATMENT", 178, 194], ["cancer", "OBSERVATION", 125, 131]]], ["The field is robust.", [["robust", "OBSERVATION_MODIFIER", 13, 19]]], ["However, a number of challenges have prevented the extension of PS to all those affected by cancer who might benefit from it.", [["cancer", "ANATOMY", 92, 98], ["cancer", "DISEASE", 92, 98], ["cancer", "CANCER", 92, 98], ["cancer", "OBSERVATION", 92, 98]]], ["Critical for future growth will be recognition of PS as a routine part of cancer care and support and, with it, sufficient funding to meet important challenges such as increasing diversity, standardization and evaluation, and development of a shared state-of-the-art in the field.", [["cancer", "ANATOMY", 74, 80], ["cancer", "DISEASE", 74, 80], ["cancer", "CANCER", 74, 80], ["PS", "TREATMENT", 50, 52], ["a routine part of cancer care", "TREATMENT", 56, 85], ["support", "TREATMENT", 90, 97], ["evaluation", "TEST", 210, 220]]]], "5befbf38862f5372fbf58bee407b78f440fcffa3": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causative pathogen of an ongoing outbreak of respiratory disease known as coronavirus disease 2019 .", [["respiratory", "ANATOMY", 145, 156], ["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["respiratory disease", "DISEASE", 145, 164], ["coronavirus disease", "DISEASE", 174, 193], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS-CoV", "TEST", 61, 69], ["respiratory disease", "PROBLEM", 145, 164], ["coronavirus disease", "PROBLEM", 174, 193], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["respiratory disease", "OBSERVATION", 145, 164], ["coronavirus disease", "OBSERVATION", 174, 193]]], ["The virus spread quickly and the number of people infected is rising dramatically worldwide [1] .", [["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["The virus spread", "PROBLEM", 0, 16], ["virus", "OBSERVATION", 4, 9]]], ["The first interpersonal transmission in Italy was reported on February 20, 2020 and now Italy is undergoing one of the largest outbreaks of COVID-19 outside Asia [2] .IntroductionThe fast-evolving nature of the COVID-19 pandemic and the lack of information about this new virus led to exceptional challenges for health care systems as well as to dramatic socio-economic impacts in Europe and worldwide.", [["COVID", "TEST", 140, 145], ["the COVID", "TEST", 207, 216], ["this new virus", "PROBLEM", 263, 277], ["health care systems", "TREATMENT", 312, 331], ["largest", "OBSERVATION_MODIFIER", 119, 126]]], ["As of 16 May 2020 a total of 4,425,485 confirmed COVID-19 cases and 302,059 deaths have been reported worldwide [3] , while 224,760 confirmed cases and 31,763 deaths have been reported in Italy [4] .IntroductionReported diseases ranged from those with few to no symptoms to severe cases where the infection can cause pneumonia, severe acute respiratory syndrome and even death.", [["deaths", "DISEASE", 76, 82], ["deaths", "DISEASE", 159, 165], ["infection", "DISEASE", 297, 306], ["pneumonia", "DISEASE", 317, 326], ["acute respiratory syndrome", "DISEASE", 335, 361], ["death", "DISEASE", 371, 376], ["COVID", "TEST", 49, 54], ["Reported diseases", "PROBLEM", 211, 228], ["symptoms", "PROBLEM", 262, 270], ["severe cases", "PROBLEM", 274, 286], ["the infection", "PROBLEM", 293, 306], ["pneumonia", "PROBLEM", 317, 326], ["severe acute respiratory syndrome", "PROBLEM", 328, 361], ["even death", "PROBLEM", 366, 376], ["infection", "OBSERVATION", 297, 306], ["pneumonia", "OBSERVATION", 317, 326], ["severe", "OBSERVATION_MODIFIER", 328, 334], ["acute", "OBSERVATION_MODIFIER", 335, 340], ["respiratory syndrome", "OBSERVATION", 341, 361]]], ["Various reports indicate advanced age and male gender, which are independent variables, as predictors for severe disease and fatal outcome.", [["severe disease and fatal outcome", "PROBLEM", 106, 138], ["advanced", "OBSERVATION_MODIFIER", 25, 33], ["fatal", "OBSERVATION_MODIFIER", 125, 130]]], ["Additional risk factors are also reported, including the presence of pre-existing health conditions such as hypertension, type 2 diabetes and chronic obstructive pulmonary disease, which are dependent variables [5, 6] .", [["pulmonary", "ANATOMY", 162, 171], ["hypertension", "DISEASE", 108, 120], ["type 2 diabetes", "DISEASE", 122, 137], ["chronic obstructive pulmonary disease", "DISEASE", 142, 179], ["pulmonary", "ORGAN", 162, 171], ["pre-existing health conditions", "PROBLEM", 69, 99], ["hypertension", "PROBLEM", 108, 120], ["type 2 diabetes", "PROBLEM", 122, 137], ["chronic obstructive pulmonary disease", "PROBLEM", 142, 179], ["hypertension", "OBSERVATION", 108, 120], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["obstructive", "OBSERVATION_MODIFIER", 150, 161], ["pulmonary", "ANATOMY", 162, 171], ["disease", "OBSERVATION", 172, 179], ["dependent", "OBSERVATION_MODIFIER", 191, 200]]], ["Although it is not clear whether the severity of underlying health conditions affects the risk for severe SARS-CoV-2 infection, the emerging significant differences in lethality are striking.IntroductionThe case fatality rate (CFR) (number of deaths in persons who tested positive for SARS-CoV-2 divided by the number of SARS-CoV-2 cases) in Italy appears higher than that reported in other European countries and in China (14.1% in Italy, 11.9% in Europe and 5.5% in China on May 16, 2020) [3, 4, 7] and presents numerous differences in the various regional settings (18.3% in Lombardy in the northern part of Italy and 5.1% in Umbria in the center), highlighting that the geographical spread of the COVID-19 epidemic is very heterogeneous [8] .", [["SARS-CoV-2 infection", "DISEASE", 106, 126], ["deaths", "DISEASE", 243, 249], ["SARS", "DISEASE", 285, 289], ["SARS", "DISEASE", 321, 325], ["CoV-2", "ORGANISM", 111, 116], ["persons", "ORGANISM", 253, 260], ["SARS-CoV", "ORGANISM", 321, 329], ["persons", "SPECIES", 253, 260], ["SARS-CoV-2", "SPECIES", 106, 116], ["SARS-CoV", "SPECIES", 285, 293], ["SARS-CoV", "SPECIES", 321, 329], ["underlying health conditions", "PROBLEM", 49, 77], ["severe SARS", "PROBLEM", 99, 110], ["CoV-2 infection", "PROBLEM", 111, 126], ["lethality", "PROBLEM", 168, 177], ["SARS", "PROBLEM", 285, 289], ["CoV", "TEST", 290, 293], ["SARS", "TEST", 321, 325], ["CoV", "TEST", 326, 329], ["the COVID", "TEST", 697, 706], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["SARS", "OBSERVATION", 106, 110], ["infection", "OBSERVATION", 117, 126], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["differences", "OBSERVATION_MODIFIER", 153, 164], ["higher", "OBSERVATION_MODIFIER", 356, 362], ["heterogeneous", "OBSERVATION_MODIFIER", 727, 740]]], ["Nevertheless, the number of deaths cannot be solely attributed to the fact that the epidemic started earlier in Italy compared with other countries.IntroductionDespite the publication of national statistics, such information does not allow a complete interpretation of the COVID-19 outbreak in Italy, as the Italian national health service is made up of numerous regional structures which have provided varied regional responses to the emergency, and because of the intrinsic characteristics of the diverse population between and within regions [9] .IntroductionSardinia, an island with a population of 1,639,591 inhabitants [10] , experienced phenomena such as isolation, endogamy and little genetic flow from the various populations that have invaded the Mediterranean area.", [["deaths", "DISEASE", 28, 34], ["the epidemic", "PROBLEM", 80, 92], ["phenomena", "PROBLEM", 644, 653], ["endogamy", "TREATMENT", 673, 681], ["little genetic flow", "PROBLEM", 686, 705], ["diverse", "OBSERVATION_MODIFIER", 499, 506], ["population", "OBSERVATION", 507, 517], ["island", "OBSERVATION_MODIFIER", 575, 581], ["Mediterranean", "OBSERVATION_MODIFIER", 757, 770]]], ["This suggests that its population is relatively homogeneous and suitable for epidemiological studies, in particular for the understanding of different pathologies through case-control association studies [11] .IntroductionThe present study focuses on the clinical characteristics of patients dying with SARS-CoV-2 infection in Sardinia and investigates the influence of underlying health conditions on the fatal outcome.", [["SARS-CoV-2 infection", "DISEASE", 303, 323], ["patients", "ORGANISM", 283, 291], ["SARS-CoV-2", "ORGANISM", 303, 313], ["patients", "SPECIES", 283, 291], ["SARS-CoV-2", "SPECIES", 303, 313], ["epidemiological studies", "TEST", 77, 100], ["different pathologies", "PROBLEM", 141, 162], ["The present study", "TEST", 222, 239], ["SARS", "PROBLEM", 303, 307], ["CoV-2 infection", "PROBLEM", 308, 323], ["population", "OBSERVATION_MODIFIER", 23, 33], ["relatively", "OBSERVATION_MODIFIER", 37, 47], ["homogeneous", "OBSERVATION_MODIFIER", 48, 59], ["infection", "OBSERVATION", 314, 323]]], ["Identifying the epidemiological characteristics of the infection might provide evidence for risk stratification and assist in making appropriate decisions to control the outbreak.Study PopulationSardinia lies in the center of the western Mediterranean Sea and its population has a genetic structure very different from that of the rest of Italy.", [["infection", "DISEASE", 55, 64], ["the infection", "PROBLEM", 51, 64], ["the outbreak", "PROBLEM", 166, 178], ["Study PopulationSardinia", "TEST", 179, 203], ["infection", "OBSERVATION", 55, 64], ["very", "OBSERVATION_MODIFIER", 299, 303], ["different", "OBSERVATION_MODIFIER", 304, 313]]], ["The genetic drift (variation in gene frequency due to random fluctuations) seems to be the main cause of this difference.", [["The genetic drift", "PROBLEM", 0, 17], ["variation in gene frequency", "PROBLEM", 19, 46], ["random fluctuations", "PROBLEM", 54, 73], ["genetic drift", "OBSERVATION", 4, 17]]], ["Due to its geographical characteristics and in particular to its insularity, Sardinia presents features, such as genetic homogeneity, which make its population suitable for epidemiological studies [12, 13] .Study PopulationWith regard to the demographic composition, Sardinia is composed of 50.9% females and 49.1% males with several differences within the various age groups.", [["epidemiological studies", "TEST", 173, 196], ["several", "OBSERVATION_MODIFIER", 326, 333], ["differences", "OBSERVATION_MODIFIER", 334, 345]]], ["While in the younger age groups the male population is slightly more numerous, large differences are found in the age groups 80\u221289 and >90 where females account for 60.7% and 70.9% respectively.", [["slightly", "OBSERVATION_MODIFIER", 55, 63], ["more numerous", "OBSERVATION_MODIFIER", 64, 77], ["large", "OBSERVATION_MODIFIER", 79, 84]]], ["The population over 65 years of age totals 23.8%, of these 44.2% are male and 55.8% are female [10] .Study DesignA matched case-control study was designed by analyzing the data of the 1223 SARS-CoV-2 positive subjects observed in Sardinia up to April 21, 2020 and whose data were available in the public health department.", [["SARS", "DISEASE", 189, 193], ["SARS-CoV-2", "ORGANISM", 189, 199], ["control study", "TEST", 128, 141], ["CoV", "TEST", 194, 197]]], ["Information collected regarded age, gender, clinical status (synthetic indicator of the severity of the symptoms), the possible presence of several health conditions and potential risk factors (chronic underlying diseases) and the final outcome.Study DesignOf the 97 deceased subjects (45 females and 52 males), underlying health conditions were available for 90 patients (42 females and 48 males).", [["subjects", "ORGANISM", 276, 284], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 363, 371], ["the symptoms", "PROBLEM", 100, 112], ["several health conditions", "PROBLEM", 140, 165], ["chronic underlying diseases", "PROBLEM", 194, 221], ["underlying health conditions", "PROBLEM", 312, 340]]], ["The sample was compared to controls (healed, asymptomatic or pauci-symptomatic subjects) paired (1:1) for age (+/\u22123 years) and gender, consecutively observed from the 1126 surviving positive subjects at the time of study.", [["sample", "ANATOMY", 4, 10], ["The sample", "TEST", 0, 10], ["asymptomatic", "PROBLEM", 45, 57], ["pauci", "TEST", 61, 66], ["study", "TEST", 215, 220]]], ["CFR was calculated by comparing the number of SARS-CoV-2 deaths with the number of positive SARS-CoV-2 subjects.", [["SARS", "DISEASE", 46, 50], ["deaths", "DISEASE", 57, 63], ["SARS", "DISEASE", 92, 96], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 92, 100], ["CFR", "TEST", 0, 3], ["SARS", "TEST", 46, 50], ["positive SARS", "PROBLEM", 83, 96]]], ["To assess the differences in mortality for SARS-CoV-2 and eliminate the heterogeneity of the corresponding populations, Sardinian mortality was indirectly standardized with reference to the Italian-specific mortality rate by age group in order to calculate the expected number of deaths [14] .", [["SARS", "DISEASE", 43, 47], ["deaths", "DISEASE", 280, 286], ["SARS-CoV", "SPECIES", 43, 51], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["populations", "OBSERVATION_MODIFIER", 107, 118]]], ["The SARS-CoV-2 standardized mortality ratio (SMR) for the Sardinian population was then obtained by comparing the number of deaths for SARS-CoV-2 observed in Sardinia with the respective number of expected deceased patients.", [["deaths", "DISEASE", 124, 130], ["SARS", "DISEASE", 135, 139], ["patients", "ORGANISM", 215, 223], ["patients", "SPECIES", 215, 223], ["SARS-CoV", "SPECIES", 135, 143], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143]]], ["Finally, the 95% confidence interval (95% CI) was calculated as proposed by Vandenbroucke [15] .Statistical AnalysisThe conditional logistic regression model was applied to the analysis of matched case-control studies for explanatory variables.", [["CI", "TEST", 42, 44], ["Statistical Analysis", "TEST", 96, 116], ["The conditional logistic regression model", "TREATMENT", 116, 157], ["the analysis", "TEST", 173, 185]]], ["The analysis included case status (deceased patients) as the dependent variable and the variables concerning the presence of active tumors (patients being treated), diabetes mellitus, cardiovascular diseases, HIV, chronic lung diseases, chronic renal diseases, other metabolic diseases, obesity, liver diseases, chronic neurological diseases and other pathologies as risk predictors for fatal outcome.", [["tumors", "ANATOMY", 132, 138], ["cardiovascular", "ANATOMY", 184, 198], ["lung", "ANATOMY", 222, 226], ["renal", "ANATOMY", 245, 250], ["liver", "ANATOMY", 296, 301], ["neurological", "ANATOMY", 320, 332], ["tumors", "DISEASE", 132, 138], ["diabetes mellitus", "DISEASE", 165, 182], ["cardiovascular diseases", "DISEASE", 184, 207], ["chronic lung diseases", "DISEASE", 214, 235], ["chronic renal diseases", "DISEASE", 237, 259], ["metabolic diseases", "DISEASE", 267, 285], ["obesity", "DISEASE", 287, 294], ["liver diseases", "DISEASE", 296, 310], ["chronic neurological diseases", "DISEASE", 312, 341], ["patients", "ORGANISM", 44, 52], ["tumors", "CANCER", 132, 138], ["patients", "ORGANISM", 140, 148], ["lung", "ORGAN", 222, 226], ["renal", "ORGAN", 245, 250], ["liver", "ORGAN", 296, 301], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 140, 148], ["HIV", "SPECIES", 209, 212], ["HIV", "SPECIES", 209, 212], ["The analysis", "TEST", 0, 12], ["the dependent variable", "PROBLEM", 57, 79], ["active tumors", "PROBLEM", 125, 138], ["diabetes mellitus", "PROBLEM", 165, 182], ["cardiovascular diseases", "PROBLEM", 184, 207], ["HIV", "PROBLEM", 209, 212], ["chronic lung diseases", "PROBLEM", 214, 235], ["chronic renal diseases", "PROBLEM", 237, 259], ["other metabolic diseases", "PROBLEM", 261, 285], ["obesity", "PROBLEM", 287, 294], ["liver diseases", "PROBLEM", 296, 310], ["chronic neurological diseases", "PROBLEM", 312, 341], ["other pathologies", "PROBLEM", 346, 363], ["fatal outcome", "PROBLEM", 387, 400], ["active", "OBSERVATION_MODIFIER", 125, 131], ["tumors", "OBSERVATION", 132, 138], ["cardiovascular", "ANATOMY", 184, 198], ["diseases", "OBSERVATION", 199, 207], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["lung", "ANATOMY", 222, 226], ["diseases", "OBSERVATION", 227, 235], ["chronic", "OBSERVATION_MODIFIER", 237, 244], ["renal", "ANATOMY", 245, 250], ["diseases", "OBSERVATION", 251, 259], ["metabolic diseases", "OBSERVATION", 267, 285], ["obesity", "OBSERVATION", 287, 294], ["liver", "ANATOMY", 296, 301], ["diseases", "OBSERVATION", 302, 310], ["chronic", "OBSERVATION_MODIFIER", 312, 319], ["neurological diseases", "OBSERVATION", 320, 341]]], ["Odds ratio (OR) with 95% CI was calculated; the level of significance was established at p < 0.05.", [["Odds ratio", "TEST", 0, 10], ["CI", "TEST", 25, 27]]], ["Statistical analysis was performed using STATA 16.1 (Stata Corp, College Station, TX, US).ResultsAmong all 1223 SARS-CoV-2 patients observed (724 females and 499 males, 59.2% and 40.8% respectively), 97 deaths occurred (Table 1) .", [["SARS", "DISEASE", 112, 116], ["deaths", "DISEASE", 203, 209], ["SARS-CoV", "ORGANISM", 112, 120], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["SARS-CoV", "SPECIES", 112, 120], ["Statistical analysis", "TEST", 0, 20], ["STATA", "TEST", 41, 46], ["SARS", "TEST", 112, 116], ["CoV", "TEST", 117, 120]]], ["Most case patients were in the age group 50\u221259 (n = 238/1223, 19.5%), 5.7% were under the age of 30 and 23% were 80 years of age or older.", [["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18]]], ["Among the 97 deaths, 45 were female (46.4%) and 52 male (53.6%).", [["deaths", "DISEASE", 13, 19]]], ["The mean age of patients dying with SARS-CoV-2 infection was 80.4 +/\u221210.6 (median 82.9, range 42.5\u221297.5) which is significantly higher (p < 0.001) than the mean age of patients who contracted the infection (58.4 +/\u2212 19.9, median 56.1, range 0.1\u221299.1).", [["SARS", "DISEASE", 36, 40], ["infection", "DISEASE", 47, 56], ["infection", "DISEASE", 196, 205], ["patients", "ORGANISM", 16, 24], ["SARS-CoV-2", "ORGANISM", 36, 46], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 168, 176], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["infection", "PROBLEM", 47, 56], ["range", "TEST", 88, 93], ["the infection", "PROBLEM", 192, 205], ["range", "TEST", 235, 240], ["significantly", "OBSERVATION_MODIFIER", 114, 127], ["higher", "OBSERVATION_MODIFIER", 128, 134], ["infection", "OBSERVATION", 196, 205]]], ["Women dying with SARS-CoV-2 were older than men (84.1 +/\u2212 8.9 and 77.1 +/\u2212 11.1 respectively) (p < 0.001).", [["SARS", "DISEASE", 17, 21], ["Women", "ORGANISM", 0, 5], ["men", "ORGANISM", 44, 47], ["Women", "SPECIES", 0, 5], ["men", "SPECIES", 44, 47], ["SARS-CoV", "TEST", 17, 25]]], ["Overall, CFR was 7.9%, but cases in those aged 80\u221289 years had a CFR of 22.9% and cases in those aged 90 years and older had a rate of 18.4%.", [["CFR", "TEST", 9, 12], ["a CFR", "TEST", 63, 68], ["a rate", "TEST", 125, 131]]], ["The number of deaths over 70 years old accounts for 83.5% of the total.", [["deaths", "DISEASE", 14, 20]]], ["No deaths occurred in cases under the age of 40.", [["deaths", "DISEASE", 3, 9], ["deaths", "PROBLEM", 3, 9], ["deaths", "OBSERVATION", 3, 9]]], ["The analysis clearly shows a higher proportion of deaths with SARS-CoV-2 in men than women, with a lethality percentage of approximately double (10.4% and 6.2%, respectively) (p = 0.008).", [["deaths", "DISEASE", 50, 56], ["SARS", "DISEASE", 62, 66], ["SARS-CoV-2", "ORGANISM", 62, 72], ["men", "ORGANISM", 76, 79], ["women", "ORGANISM", 85, 90], ["men", "SPECIES", 76, 79], ["women", "SPECIES", 85, 90], ["The analysis", "TEST", 0, 12], ["SARS", "TEST", 62, 66], ["CoV", "TEST", 67, 70], ["a lethality percentage", "TEST", 97, 119], ["higher", "OBSERVATION_MODIFIER", 29, 35], ["lethality", "OBSERVATION_MODIFIER", 99, 108], ["percentage", "OBSERVATION_MODIFIER", 109, 119]]], ["In the age group >90, a higher lethality is observed in females (19% compared to 16.7% of males), albeit not significant, and this may be due to the demographic structure of the population with a very low number of males.", [["a higher lethality", "PROBLEM", 22, 40], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["lethality", "OBSERVATION", 31, 40], ["not", "UNCERTAINTY", 105, 108], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["may be due to", "UNCERTAINTY", 131, 144], ["very", "OBSERVATION_MODIFIER", 196, 200], ["low", "OBSERVATION_MODIFIER", 201, 204], ["number", "OBSERVATION_MODIFIER", 205, 211], ["males", "OBSERVATION", 215, 220]]], ["No information on underlying health conditions were available for seven deceased patients (7.2%).", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89]]], ["At least one underlying condition or risk factor was present in 89 out of 90 (98.9%) deceased patients for which data were available.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["risk factor", "PROBLEM", 37, 48], ["condition", "OBSERVATION", 24, 33]]], ["The most commonly reported conditions were cardiovascular diseases (n = 63, 64.9%), chronic neurological diseases (n = 25, 25.8%), chronic lung diseases (n = 22, 22.7%) and diabetes mellitus (n = 21, 21.6%) (Figure 1 ).ResultsComparing our results with the data provided by the Italian Higher Institute of Health on April 23, 2020, it can be noticed that also in this case, most of the positive cases are in females, albeit with a less marked difference (51.3% females and 48.4% males).", [["cardiovascular", "ANATOMY", 43, 57], ["neurological", "ANATOMY", 92, 104], ["lung", "ANATOMY", 139, 143], ["cardiovascular diseases", "DISEASE", 43, 66], ["chronic neurological diseases", "DISEASE", 84, 113], ["chronic lung diseases", "DISEASE", 131, 152], ["diabetes mellitus", "DISEASE", 173, 190], ["cardiovascular", "ANATOMICAL_SYSTEM", 43, 57], ["lung", "ORGAN", 139, 143], ["cardiovascular diseases", "PROBLEM", 43, 66], ["chronic neurological diseases", "PROBLEM", 84, 113], ["chronic lung diseases", "PROBLEM", 131, 152], ["diabetes mellitus", "PROBLEM", 173, 190], ["a less marked difference", "PROBLEM", 429, 453], ["chronic", "OBSERVATION_MODIFIER", 84, 91], ["neurological diseases", "OBSERVATION", 92, 113], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["lung", "ANATOMY", 139, 143], ["diseases", "OBSERVATION", 144, 152], ["marked", "OBSERVATION_MODIFIER", 436, 442]]], ["The Italian CFR, with a crude rate of 13.1%, is much higher than in Sardinia and peaks in the age group 80\u221289 (30.8%).", [["The Italian CFR", "TEST", 0, 15], ["a crude rate", "TEST", 22, 34], ["higher", "OBSERVATION_MODIFIER", 53, 59]]], ["In this case too, lethality is higher for males than for females (17.1% and 9.3% respectively) (p < 0.001) and it was higher in all age groups, unlike what was found in our results [14] .", [["lethality", "PROBLEM", 18, 27], ["females", "TEST", 57, 64], ["higher", "OBSERVATION_MODIFIER", 31, 37]]], ["Comparing our results with the data provided by the Italian Higher Institute of Health on April 23, 2020, it can be noticed that also in this case, most of the positive cases are in females, albeit with a less marked difference (51.3% females and 48.4% males).", [["a less marked difference", "PROBLEM", 203, 227], ["marked", "OBSERVATION_MODIFIER", 210, 216]]], ["The Italian CFR, with a crude rate of 13.1%, is much higher than in Sardinia and peaks in the age group 80\u221289 (30.8%).", [["The Italian CFR", "TEST", 0, 15], ["a crude rate", "TEST", 22, 34], ["higher", "OBSERVATION_MODIFIER", 53, 59]]], ["In this case too, lethality is higher for males than for females (17.1% and 9.3% respectively) (p < 0.001) and it was higher in all age groups, unlike what was found in our results [14] .ResultsThe age-and gender-specific trajectories of CFR for both the Sardinian and the Italian population are reported in Figure 2 .", [["lethality", "PROBLEM", 18, 27], ["females", "TEST", 57, 64], ["higher", "OBSERVATION_MODIFIER", 31, 37]]], ["Apart from the quantitative values, higher in the national population (in particular in males), the shapes of the curves appear similar between the two populations, with a low mortality rate up to the age of 40\u221249 for men and up to the age of 50\u221259 for women, followed by steady growth up to the age of 80\u221289 and a plateau for people over 90, except for a slight fall for men in Sardinia.", [["men", "ORGANISM", 218, 221], ["women", "ORGANISM", 253, 258], ["people", "ORGANISM", 327, 333], ["men", "ORGANISM", 372, 375], ["men", "SPECIES", 218, 221], ["women", "SPECIES", 253, 258], ["people", "SPECIES", 327, 333], ["men", "SPECIES", 372, 375], ["the quantitative values", "TEST", 11, 34], ["a low mortality rate", "PROBLEM", 170, 190], ["a slight fall", "PROBLEM", 354, 367], ["quantitative", "OBSERVATION_MODIFIER", 15, 27], ["values", "OBSERVATION_MODIFIER", 28, 34], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["similar", "OBSERVATION_MODIFIER", 128, 135], ["two", "OBSERVATION_MODIFIER", 148, 151], ["populations", "OBSERVATION_MODIFIER", 152, 163], ["low", "OBSERVATION_MODIFIER", 172, 175], ["slight", "OBSERVATION_MODIFIER", 356, 362], ["fall", "OBSERVATION", 363, 367]]], ["Apart from the quantitative values, higher in the national population (in particular in males), the shapes of the curves appear similar between the two populations, with a low mortality rate up to the age of 40\u221249 for men and up to the age of 50\u221259 for women, followed by steady growth up to the age of 80\u221289 and a plateau for people over 90, except for a slight fall for men in Sardinia.", [["men", "ORGANISM", 218, 221], ["women", "ORGANISM", 253, 258], ["people", "ORGANISM", 327, 333], ["men", "ORGANISM", 372, 375], ["men", "SPECIES", 218, 221], ["women", "SPECIES", 253, 258], ["people", "SPECIES", 327, 333], ["men", "SPECIES", 372, 375], ["the quantitative values", "TEST", 11, 34], ["a low mortality rate", "PROBLEM", 170, 190], ["a slight fall", "PROBLEM", 354, 367], ["quantitative", "OBSERVATION_MODIFIER", 15, 27], ["values", "OBSERVATION_MODIFIER", 28, 34], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["similar", "OBSERVATION_MODIFIER", 128, 135], ["two", "OBSERVATION_MODIFIER", 148, 151], ["populations", "OBSERVATION_MODIFIER", 152, 163], ["low", "OBSERVATION_MODIFIER", 172, 175], ["slight", "OBSERVATION_MODIFIER", 356, 362], ["fall", "OBSERVATION", 363, 367]]], ["Specific SMR was 0.15 (95% CI: 0.12\u22120.19), 0.13 (95% CI: 0.1\u22120.17) for males and 0.2 (95% CI: 0.15\u22120.26) for females, showing that Sardinian specific mortality for SARS-Cov-2 is far lower than expected in respect to Italy.ResultsIn regard to risk factors, medical records were available for 93% (90/97) of deceased patients.", [["SARS", "DISEASE", 164, 168], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["Specific SMR", "TEST", 0, 12], ["CI", "TEST", 27, 29], ["CI", "TEST", 53, 55], ["males", "TEST", 71, 76], ["CI", "TEST", 90, 92], ["SARS", "TEST", 164, 168], ["Cov", "TEST", 169, 172]]], ["The average number of pathologies observed in this population is 2.3 (median 2, range 0\u22126).", [["pathologies", "PROBLEM", 22, 33], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["pathologies", "OBSERVATION", 22, 33]]], ["Overall, 3 patients (3.3%) had 0 pathologies, 23 (25.6%) had 1 pathology, 29 (32.2%) had 2 pathologies and 35 (38.9%) had 3 or more pathologies.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["0 pathologies", "PROBLEM", 31, 44], ["1 pathology", "TEST", 61, 72], ["pathologies", "TEST", 91, 102], ["more pathologies", "PROBLEM", 127, 143]]], ["In Figure 3 the distribution of the observed pathologies for cases and controls is reported by gender.", [["the observed pathologies", "PROBLEM", 32, 56]]], ["In women, the average number of pathologies observed is 2.1 (median 2, range 0\u22125), and in men, the average number of pathologies observed is 2.4 (median 2, range 0\u22126).", [["women", "ORGANISM", 3, 8], ["men", "ORGANISM", 90, 93], ["women", "SPECIES", 3, 8], ["men", "SPECIES", 90, 93], ["pathologies", "PROBLEM", 32, 43], ["pathologies", "PROBLEM", 117, 128], ["average", "OBSERVATION_MODIFIER", 14, 21], ["number", "OBSERVATION_MODIFIER", 22, 28], ["pathologies", "OBSERVATION", 32, 43], ["average", "OBSERVATION_MODIFIER", 99, 106], ["number", "OBSERVATION_MODIFIER", 107, 113], ["pathologies", "OBSERVATION", 117, 128]]], ["Both for males and females, statistically significant differences between cases and controls were observed in the prevalence of cardiovascular diseases (p <0.05).", [["cardiovascular", "ANATOMY", 128, 142], ["cardiovascular diseases", "DISEASE", 128, 151], ["cardiovascular", "ANATOMICAL_SYSTEM", 128, 142], ["statistically significant differences between cases and controls", "PROBLEM", 28, 92], ["cardiovascular diseases", "PROBLEM", 128, 151], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["cardiovascular", "ANATOMY", 128, 142], ["diseases", "OBSERVATION", 143, 151]]], ["Statistically significant differences between cases and controls were also observed among males in relation to diabetes mellitus and chronic lung diseases.", [["lung", "ANATOMY", 141, 145], ["diabetes mellitus", "DISEASE", 111, 128], ["chronic lung diseases", "DISEASE", 133, 154], ["lung", "ORGAN", 141, 145], ["significant differences between cases and controls", "PROBLEM", 14, 64], ["diabetes mellitus", "PROBLEM", 111, 128], ["chronic lung diseases", "PROBLEM", 133, 154], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["diabetes mellitus", "OBSERVATION", 111, 128], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["lung", "ANATOMY", 141, 145], ["diseases", "OBSERVATION", 146, 154]]], ["It is worth noting that among females, while a higher, albeit not significant, prevalence of chronic lung diseases was also observed in cases, a very low prevalence without a significant difference between cases and controls was observed for diabetes mellitus.", [["lung", "ANATOMY", 101, 105], ["chronic lung diseases", "DISEASE", 93, 114], ["diabetes mellitus", "DISEASE", 242, 259], ["lung", "ORGAN", 101, 105], ["chronic lung diseases", "PROBLEM", 93, 114], ["diabetes mellitus", "PROBLEM", 242, 259], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["lung", "ANATOMY", 101, 105], ["diseases", "OBSERVATION", 106, 114]]], ["Since significant differences in CFR were observed between genders and age groups, we chose to implement a conditional logistic analysis pairing death cases with 1:1 controls for these two variables.", [["death", "DISEASE", 145, 150], ["significant differences in CFR", "PROBLEM", 6, 36], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["differences", "OBSERVATION_MODIFIER", 18, 29]]], ["Table 2 shows the results of the conditional regression analysis for the association between case status with available underlying health conditions and the background explanatory variables.", [["the conditional regression analysis", "TEST", 29, 64]]], ["The presence of diabetes mellitus (OR = 3.2, p = 0.028, 95% CI: 1.1\u22129.1), cardiovascular diseases (OR = 4.0, p = 0.002, 95% CI: 1.7\u22129.7) and chronic lung diseases (OR = 3.5, p = 0.021, 95% CI: 1.2\u22129.9) showed Since significant differences in CFR were observed between genders and age groups, we chose to implement a conditional logistic analysis pairing death cases with 1:1 controls for these two variables.", [["cardiovascular", "ANATOMY", 74, 88], ["lung", "ANATOMY", 149, 153], ["diabetes mellitus", "DISEASE", 16, 33], ["cardiovascular diseases", "DISEASE", 74, 97], ["chronic lung diseases", "DISEASE", 141, 162], ["death", "DISEASE", 354, 359], ["cardiovascular", "ANATOMICAL_SYSTEM", 74, 88], ["lung", "ORGAN", 149, 153], ["diabetes mellitus", "PROBLEM", 16, 33], ["p", "TEST", 45, 46], ["CI", "TEST", 60, 62], ["cardiovascular diseases", "PROBLEM", 74, 97], ["p", "TEST", 109, 110], ["CI", "TEST", 124, 126], ["chronic lung diseases", "PROBLEM", 141, 162], ["p", "TEST", 174, 175], ["CI", "TEST", 189, 191], ["significant differences in CFR", "PROBLEM", 215, 245], ["diabetes mellitus", "OBSERVATION", 16, 33], ["cardiovascular", "ANATOMY", 74, 88], ["diseases", "OBSERVATION", 89, 97], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["lung", "ANATOMY", 149, 153], ["diseases", "OBSERVATION", 154, 162], ["significant", "OBSERVATION_MODIFIER", 215, 226]]], ["Table 2 shows the results of the conditional regression analysis for the association between case status with available underlying health conditions and the background explanatory variables.", [["the conditional regression analysis", "TEST", 29, 64]]], ["The presence of diabetes mellitus (OR = 3.2, p = 0.028, 95% CI: 1.1\u22129.1), cardiovascular diseases (OR = 4.0, p = 0.002, 95% CI: 1.7\u22129.7) and chronic lung diseases (OR = 3.5, p = 0.021, 95% CI: 1.2\u22129.9) showed significant association with the case status.", [["cardiovascular", "ANATOMY", 74, 88], ["lung", "ANATOMY", 149, 153], ["diabetes mellitus", "DISEASE", 16, 33], ["cardiovascular diseases", "DISEASE", 74, 97], ["chronic lung diseases", "DISEASE", 141, 162], ["cardiovascular", "ANATOMICAL_SYSTEM", 74, 88], ["lung", "ORGAN", 149, 153], ["diabetes mellitus", "PROBLEM", 16, 33], ["p", "TEST", 45, 46], ["CI", "TEST", 60, 62], ["cardiovascular diseases", "PROBLEM", 74, 97], ["p", "TEST", 109, 110], ["CI", "TEST", 124, 126], ["chronic lung diseases", "PROBLEM", 141, 162], ["p", "TEST", 174, 175], ["CI", "TEST", 189, 191], ["diabetes mellitus", "OBSERVATION", 16, 33], ["cardiovascular", "ANATOMY", 74, 88], ["diseases", "OBSERVATION", 89, 97], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["lung", "ANATOMY", 149, 153], ["diseases", "OBSERVATION", 154, 162]]], ["No significant association with case status was found with active tumors, HIV, chronic renal diseases, other metabolic diseases, obesity, liver diseases, chronic neurological diseases and other pathologies (p >0.05).DiscussionIn the present study, we described the clinical characteristics of patients who died while positive for SARS-CoV-2 infection in Sardinia and investigated the influence of underlying health conditions as prognostic factors for fatal outcomes.", [["tumors", "ANATOMY", 66, 72], ["renal", "ANATOMY", 87, 92], ["liver", "ANATOMY", 138, 143], ["neurological", "ANATOMY", 162, 174], ["tumors", "DISEASE", 66, 72], ["chronic renal diseases", "DISEASE", 79, 101], ["metabolic diseases", "DISEASE", 109, 127], ["obesity", "DISEASE", 129, 136], ["liver diseases", "DISEASE", 138, 152], ["chronic neurological diseases", "DISEASE", 154, 183], ["SARS-CoV-2 infection", "DISEASE", 330, 350], ["tumors", "CANCER", 66, 72], ["renal", "ORGAN", 87, 92], ["liver", "ORGAN", 138, 143], ["patients", "ORGANISM", 293, 301], ["SARS-CoV-2", "ORGANISM", 330, 340], ["HIV", "SPECIES", 74, 77], ["patients", "SPECIES", 293, 301], ["HIV", "SPECIES", 74, 77], ["SARS-CoV-2", "SPECIES", 330, 340], ["active tumors", "PROBLEM", 59, 72], ["HIV", "PROBLEM", 74, 77], ["chronic renal diseases", "PROBLEM", 79, 101], ["other metabolic diseases", "PROBLEM", 103, 127], ["obesity", "PROBLEM", 129, 136], ["liver diseases", "PROBLEM", 138, 152], ["chronic neurological diseases", "PROBLEM", 154, 183], ["other pathologies", "PROBLEM", 188, 205], ["the present study", "TEST", 229, 246], ["SARS", "PROBLEM", 330, 334], ["CoV", "PROBLEM", 335, 338], ["2 infection", "PROBLEM", 339, 350], ["fatal outcomes", "PROBLEM", 452, 466], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["active", "OBSERVATION_MODIFIER", 59, 65], ["tumors", "OBSERVATION", 66, 72], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["renal", "ANATOMY", 87, 92], ["diseases", "OBSERVATION", 93, 101], ["metabolic diseases", "OBSERVATION", 109, 127], ["obesity", "OBSERVATION", 129, 136], ["liver", "ANATOMY", 138, 143], ["diseases", "OBSERVATION", 144, 152], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["neurological diseases", "OBSERVATION", 162, 183], ["infection", "OBSERVATION", 341, 350]]], ["The report has shown that, in regard to the individual characteristics age and gender, the CFR pattern in Sardinia is substantially similar, at least from a qualitative point of view, to the national one, with some exceptions related to lethality in women of older age.", [["women", "ORGANISM", 250, 255], ["women", "SPECIES", 250, 255], ["the CFR pattern", "TEST", 87, 102], ["lethality", "PROBLEM", 237, 246], ["substantially", "OBSERVATION_MODIFIER", 118, 131], ["similar", "OBSERVATION_MODIFIER", 132, 139], ["lethality", "OBSERVATION", 237, 246]]], ["In general, the higher proportion of male deaths can be explained by the natural longer life expectancy of women.", [["deaths", "DISEASE", 42, 48], ["women", "ORGANISM", 107, 112], ["women", "SPECIES", 107, 112]]], ["Therefore, what remains to be explained is the substantial difference in lethality, from a quantitative point of view.", [["lethality", "PROBLEM", 73, 82], ["substantial", "OBSERVATION_MODIFIER", 47, 58], ["difference", "OBSERVATION_MODIFIER", 59, 69], ["lethality", "OBSERVATION", 73, 82]]], ["In fact, CFR in Sardinia is far lower than the national one (7.9% and 13.1%, respectively), despite the fact that the island is known for the extreme longevity of the resident population and even boasts many centenarians (n = 412) [10] .", [["CFR", "TEST", 9, 12], ["CFR", "OBSERVATION_MODIFIER", 9, 12], ["Sardinia", "OBSERVATION_MODIFIER", 16, 24], ["lower", "OBSERVATION_MODIFIER", 32, 37]]], ["A possible explanation might be the quality of life or a particular diet.", [["possible explanation might", "UNCERTAINTY", 2, 28]]], ["If we consider [16, 17] , one may wonder if this difference could be related to specific genetic factors, whose variability have progressively decreased due to low immigration rates and facilitated the emergence of specific genetic characteristics that either do not predispose towards or might actually protect from diseases that are major causes of mortality, particularly in the elderly.DiscussionAnother possible reason could be related to the fact that Sardinia immediately closed all borders as cases arose in Italy and, being an island, it was quite straightforward to shut down all airports and maritime access points, thus avoiding any type of external interference.", [["low immigration rates", "PROBLEM", 160, 181], ["diseases", "PROBLEM", 317, 325], ["external interference", "PROBLEM", 653, 674], ["interference", "OBSERVATION", 662, 674]]], ["From that moment on, any person arriving on the island, including those who arrived in the previous 14 days, had to carry out a 2-week isolation period in their own home, further reducing the possibility of contagion.", [["person", "SPECIES", 25, 31]]], ["As a consequence, the low number of infections, with most of the municipalities being free of cases, may have protected those population groups at higher risk.", [["infections", "DISEASE", 36, 46], ["the low number of infections", "PROBLEM", 18, 46], ["low number", "OBSERVATION_MODIFIER", 22, 32], ["infections", "OBSERVATION", 36, 46]]], ["In this regard, it is important to consider that there was a delay of about 10 days between the first case in Italy and the first case in Sardinia.DiscussionAs uncovered by the logistic regression, several concomitant serious diseases were found to be strong predictors for fatal outcome, such as diabetes mellitus, cardiovascular diseases and chronic lung diseases.", [["cardiovascular", "ANATOMY", 316, 330], ["lung", "ANATOMY", 352, 356], ["diabetes mellitus", "DISEASE", 297, 314], ["cardiovascular diseases", "DISEASE", 316, 339], ["chronic lung diseases", "DISEASE", 344, 365], ["lung", "ORGAN", 352, 356], ["several concomitant serious diseases", "PROBLEM", 198, 234], ["fatal outcome", "PROBLEM", 274, 287], ["diabetes mellitus", "PROBLEM", 297, 314], ["cardiovascular diseases", "PROBLEM", 316, 339], ["chronic lung diseases", "PROBLEM", 344, 365], ["cardiovascular", "ANATOMY", 316, 330], ["diseases", "OBSERVATION", 331, 339], ["chronic", "OBSERVATION_MODIFIER", 344, 351], ["lung", "ANATOMY", 352, 356], ["diseases", "OBSERVATION", 357, 365]]], ["It is important to consider these factors for risk stratification, as close monitoring and appropriate treatment might help to improve the outcome.", [["close monitoring", "TEST", 70, 86], ["appropriate treatment", "TREATMENT", 91, 112]]], ["Sardinia, as well as Italy as a whole, has a large proportion of patients with high rates of chronic obstructive pulmonary diseases and ischemic heart diseases, and this might explain, as suggested by Boccia et al. [18] , the higher probability of fatal outcome compared to that observed in China.", [["pulmonary", "ANATOMY", 113, 122], ["heart", "ANATOMY", 145, 150], ["chronic obstructive pulmonary diseases", "DISEASE", 93, 131], ["ischemic heart diseases", "DISEASE", 136, 159], ["patients", "ORGANISM", 65, 73], ["pulmonary", "ORGAN", 113, 122], ["heart", "ORGAN", 145, 150], ["patients", "SPECIES", 65, 73], ["chronic obstructive pulmonary diseases", "PROBLEM", 93, 131], ["ischemic heart diseases", "PROBLEM", 136, 159], ["fatal outcome", "PROBLEM", 248, 261], ["large", "OBSERVATION_MODIFIER", 45, 50], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["obstructive", "OBSERVATION_MODIFIER", 101, 112], ["pulmonary", "ANATOMY", 113, 122], ["diseases", "OBSERVATION", 123, 131], ["ischemic", "OBSERVATION_MODIFIER", 136, 144], ["heart", "ANATOMY", 145, 150], ["diseases", "OBSERVATION", 151, 159], ["fatal", "OBSERVATION_MODIFIER", 248, 253]]], ["In fact, in patients with cardiovascular diseases and chronic lung diseases, we found a risk of death respectively four and three and a half times higher.", [["cardiovascular", "ANATOMY", 26, 40], ["lung", "ANATOMY", 62, 66], ["cardiovascular diseases", "DISEASE", 26, 49], ["chronic lung diseases", "DISEASE", 54, 75], ["death", "DISEASE", 96, 101], ["patients", "ORGANISM", 12, 20], ["cardiovascular", "ANATOMICAL_SYSTEM", 26, 40], ["lung", "ORGAN", 62, 66], ["patients", "SPECIES", 12, 20], ["cardiovascular diseases", "PROBLEM", 26, 49], ["chronic lung diseases", "PROBLEM", 54, 75], ["death", "PROBLEM", 96, 101], ["cardiovascular", "ANATOMY", 26, 40], ["diseases", "OBSERVATION", 41, 49], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["lung", "ANATOMY", 62, 66], ["diseases", "OBSERVATION", 67, 75]]], ["In regard to diabetes mellitus, the present study showed that patients affected had a three times higher probability of fatal outcome, although this should be attributed mainly to males.", [["diabetes mellitus", "DISEASE", 13, 30], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["diabetes mellitus", "PROBLEM", 13, 30], ["the present study", "TEST", 32, 49], ["fatal outcome", "PROBLEM", 120, 133], ["diabetes mellitus", "OBSERVATION", 13, 30], ["fatal", "OBSERVATION_MODIFIER", 120, 125]]], ["Considering that the Sardinian population has one of the highest incidences in the world of type 1 and type 2 diabetes mellitus [19, 20] we would have expected to observe a higher lethality in Sardinia.DiscussionGenerally speaking, it is important to emphasize that, in Italy, CFR statistics consider COVID-19 related deaths those occurring in patients positive for SARS-CoV-2, independent of pre-existing health conditions, leading to an overestimation of the lethality rate due to the impossibility of differentiating between deaths with SARS-CoV-2 infection and deaths caused by SARS-CoV-2 infection.", [["type 2 diabetes mellitus", "DISEASE", 103, 127], ["deaths", "DISEASE", 318, 324], ["SARS", "DISEASE", 366, 370], ["deaths", "DISEASE", 528, 534], ["SARS-CoV-2 infection", "DISEASE", 540, 560], ["deaths", "DISEASE", 565, 571], ["SARS-CoV-2 infection", "DISEASE", 582, 602], ["patients", "ORGANISM", 344, 352], ["SARS-CoV-2", "ORGANISM", 366, 376], ["SARS-CoV-2", "ORGANISM", 540, 550], ["SARS-CoV-2", "ORGANISM", 582, 592], ["patients", "SPECIES", 344, 352], ["SARS-CoV", "SPECIES", 366, 374], ["SARS-CoV", "SPECIES", 540, 548], ["SARS-CoV-2", "SPECIES", 582, 592], ["type 2 diabetes mellitus", "PROBLEM", 103, 127], ["a higher lethality in Sardinia", "PROBLEM", 171, 201], ["SARS", "PROBLEM", 366, 370], ["pre-existing health conditions", "PROBLEM", 393, 423], ["the lethality rate", "PROBLEM", 457, 475], ["SARS", "PROBLEM", 540, 544], ["CoV-2 infection", "PROBLEM", 545, 560], ["deaths", "PROBLEM", 565, 571], ["SARS", "PROBLEM", 582, 586], ["CoV-2 infection", "PROBLEM", 587, 602], ["infection", "OBSERVATION", 593, 602]]], ["As a matter of fact, SARS-CoV-2 probably accelerated death in individuals suffering from serious diseases.", [["death", "DISEASE", 53, 58], ["SARS", "PROBLEM", 21, 25], ["accelerated death", "PROBLEM", 41, 58], ["serious diseases", "PROBLEM", 89, 105], ["probably", "UNCERTAINTY", 32, 40], ["accelerated", "OBSERVATION_MODIFIER", 41, 52], ["death", "OBSERVATION", 53, 58], ["serious", "OBSERVATION_MODIFIER", 89, 96], ["diseases", "OBSERVATION", 97, 105]]], ["Moreover, in accordance with central government directives, tests were carried out primarily on symptomatic subjects resulting in a higher proportion of positive tests and an apparently increased CFR [21] .", [["tests", "TEST", 60, 65], ["symptomatic subjects", "PROBLEM", 96, 116], ["positive tests", "PROBLEM", 153, 167], ["increased CFR", "PROBLEM", 186, 199]]], ["In particular in Sardinia, the number of tests daily performed per 100,000 inhabitants is lower than the Italian average (53 and 88 tests, respectively), almost a half compared to Lombardy and a quarter compared to Triveneto (Trento-Bolzano, Friuli Venezia Giula, Veneto) [22] .DiscussionAt the same time, it can be assumed that some cases have not been recorded for several reasons.", [["Triveneto (Trento-Bolzano, Friuli Venezia Giula", "TREATMENT", 215, 262], ["Sardinia", "OBSERVATION", 17, 25], ["lower", "OBSERVATION_MODIFIER", 90, 95]]], ["First of all, especially in the initial period of the emergency, in some cases the test for SARS-CoV-2 was not performed.", [["SARS", "DISEASE", 92, 96], ["SARS-CoV", "SPECIES", 92, 100], ["the test", "TEST", 79, 87], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100]]], ["Furthermore, some deaths in untested people have been related to organ dysfunctions (heart or kidney) without considering that the virus could have triggered the disorder [23] .DiscussionThis report, like almost all the studies carried out in this period of emergency, presents indeed an important limitation: data collected are preliminary and in a continuous consolidation phase, consequently, results are likely to change as additional data become available.", [["organ", "ANATOMY", 65, 70], ["heart", "ANATOMY", 85, 90], ["kidney", "ANATOMY", 94, 100], ["deaths", "DISEASE", 18, 24], ["organ dysfunctions", "DISEASE", 65, 83], ["heart or kidney)", "DISEASE", 85, 101], ["people", "ORGANISM", 37, 43], ["organ", "ORGAN", 65, 70], ["heart", "ORGAN", 85, 90], ["kidney", "ORGAN", 94, 100], ["people", "SPECIES", 37, 43], ["organ dysfunctions (heart or kidney)", "PROBLEM", 65, 101], ["the virus", "PROBLEM", 127, 136], ["the disorder", "PROBLEM", 158, 170], ["the studies", "TEST", 216, 227], ["heart", "ANATOMY", 85, 90], ["kidney", "ANATOMY", 94, 100], ["virus", "OBSERVATION", 131, 136], ["consolidation", "OBSERVATION", 361, 374]]], ["A possible limitation, experienced in different countries, might be the difficulties in accounting for deaths in retirement homes.", [["deaths", "DISEASE", 103, 109], ["possible", "UNCERTAINTY", 2, 10], ["limitation", "OBSERVATION_MODIFIER", 11, 21]]], ["However, Italy presents a lower proportion of elderly persons living in retirement homes and, in our experience, there have been no difficulties in finding these data.", [["persons", "ORGANISM", 54, 61], ["persons", "SPECIES", 54, 61], ["difficulties in finding these data", "PROBLEM", 132, 166]]], ["Another further limitation is that the study focused on the influence of underlying health conditions.", [["the study", "TEST", 35, 44]]], ["Nevertheless, the analysis of gender-and age-related lethality could be the subject of further studies.", [["the analysis", "TEST", 14, 26], ["gender", "TEST", 30, 36], ["related lethality", "PROBLEM", 45, 62], ["further studies", "TEST", 87, 102]]], ["On the other hand, the studies in this first phase of pandemic are fundamental in order to fully understand the role of comorbidity in the risk of death.", [["death", "DISEASE", 147, 152], ["the studies", "TEST", 19, 30], ["death", "PROBLEM", 147, 152]]], ["In fact, recent acquisitions of knowledge in the therapeutic field, such as the efficacy of the use of hydroxychloroquine, azithromycin, low molecular weight heparin, etc., tend to significantly alter the risk of death with SARS-Cov2 infection [24, 25] .", [["hydroxychloroquine", "CHEMICAL", 103, 121], ["azithromycin", "CHEMICAL", 123, 135], ["heparin", "CHEMICAL", 158, 165], ["death", "DISEASE", 213, 218], ["SARS-Cov2 infection", "DISEASE", 224, 243], ["hydroxychloroquine", "CHEMICAL", 103, 121], ["azithromycin", "CHEMICAL", 123, 135], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 103, 121], ["azithromycin", "SIMPLE_CHEMICAL", 123, 135], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 137, 165], ["hydroxychloroquine", "TREATMENT", 103, 121], ["azithromycin", "TREATMENT", 123, 135], ["low molecular weight heparin", "TREATMENT", 137, 165], ["death", "PROBLEM", 213, 218], ["SARS", "PROBLEM", 224, 228], ["Cov2 infection", "PROBLEM", 229, 243]]], ["Firstly, the peculiar characteristics of Sardinian history made its population optimal for case-control studies.", [["case-control studies", "TEST", 91, 111]]], ["Furthermore, the statistical analysis of our study was strong in its consistency.ConclusionsIn summary, this study was planned to underline the clinical characteristics of patients dying with SARS-CoV-2 infection and to evaluate the influence of underlying health conditions on the fatal outcome.", [["SARS-CoV-2 infection", "DISEASE", 192, 212], ["patients", "ORGANISM", 172, 180], ["SARS-CoV-2", "ORGANISM", 192, 202], ["patients", "SPECIES", 172, 180], ["SARS-CoV-2", "SPECIES", 192, 202], ["the statistical analysis", "TEST", 13, 37], ["our study", "TEST", 41, 50], ["this study", "TEST", 104, 114], ["SARS", "PROBLEM", 192, 196], ["CoV-2 infection", "PROBLEM", 197, 212], ["underlying health conditions", "PROBLEM", 246, 274]]], ["To our best knowledge, this is one of the first reports analyzing lethality in SARS-CoV-2 positive patients taking into consideration an entire Italian Region and evaluating independent and dependent variables separately, calculating to what extent clinical features affect lethality.ConclusionsAs our results highlighted that lethality is strongly dependent on the presence of multiple concomitant serious diseases, it is essential to adopt epidemiological strategies to ensure adequate protection to these high-risk groups and to offer effective guidance on public health actions in order to improve chances of survival.", [["SARS", "DISEASE", 79, 83], ["SARS-CoV-2", "ORGANISM", 79, 89], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 79, 87], ["analyzing lethality", "PROBLEM", 56, 75], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["lethality", "PROBLEM", 274, 283], ["lethality", "PROBLEM", 327, 336], ["multiple concomitant serious diseases", "PROBLEM", 378, 415], ["epidemiological strategies", "TREATMENT", 442, 468], ["public health actions", "TREATMENT", 560, 581], ["multiple", "OBSERVATION_MODIFIER", 378, 386], ["concomitant", "OBSERVATION_MODIFIER", 387, 398], ["serious", "OBSERVATION_MODIFIER", 399, 406], ["diseases", "OBSERVATION", 407, 415]]], ["It is worth highlighting the importance of further investigating which characteristics might have decreased lethality in Sardinia compared to the rest of Italy.ConclusionsAdditionally, given the little experience in dealing with the new virus, it is compulsory to maintain a high level of attention and to continue monitoring the evolution of the phenomenon.", [["decreased lethality in Sardinia", "PROBLEM", 98, 129], ["the new virus", "PROBLEM", 229, 242], ["the phenomenon", "PROBLEM", 343, 357], ["decreased", "OBSERVATION_MODIFIER", 98, 107], ["lethality", "OBSERVATION_MODIFIER", 108, 117], ["phenomenon", "OBSERVATION", 347, 357]]], ["Indeed, health authorities at the national, regional and global levels should increase constant surveillance to be prepared for any evolution of the pandemic and to avoid strategic mistakes.", [["constant surveillance", "TEST", 87, 108], ["the pandemic", "PROBLEM", 145, 157], ["strategic mistakes", "PROBLEM", 171, 189]]]], "PMC7519608": [["The novel coronavirus, SARS-COV-2, has changed our world like never before.", [["SARS", "DISEASE", 23, 27], ["coronavirus", "ORGANISM", 10, 21], ["SARS-COV-2", "CELL", 23, 33], ["coronavirus", "SPECIES", 10, 21], ["The novel coronavirus", "PROBLEM", 0, 21], ["coronavirus", "OBSERVATION", 10, 21]]], ["COVID-19 infection has now affected more than 16 million people across the world and India has contributed almost 1.4 million patients so far.", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 9, 18], ["people", "ORGANISM", 57, 63], ["patients", "ORGANISM", 126, 134], ["people", "SPECIES", 57, 63], ["patients", "SPECIES", 126, 134], ["COVID-19", "SPECIES", 0, 8], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["infection", "OBSERVATION", 9, 18]]], ["Most infections have been mild and the infection fatality rate is about 1.4%.1 In addition to this direct assault, COVID-19 has affected health care in myriad ways.", [["infections", "DISEASE", 5, 15], ["infection", "DISEASE", 39, 48], ["COVID-19", "CHEMICAL", 115, 123], ["COVID-19", "DNA", 115, 123], ["Most infections", "PROBLEM", 0, 15], ["the infection fatality rate", "TEST", 35, 62], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION_MODIFIER", 39, 48]]], ["COVID collateral refers not only to the economic hardship caused by the pandemic but also the health consequences in various domains like cardiovascular diseases, cancer care, and public health, to name just a few.", [["cardiovascular", "ANATOMY", 138, 152], ["cancer", "ANATOMY", 163, 169], ["cardiovascular diseases", "DISEASE", 138, 161], ["cancer", "DISEASE", 163, 169], ["cardiovascular", "ANATOMICAL_SYSTEM", 138, 152], ["cancer", "CANCER", 163, 169], ["cardiovascular diseases", "PROBLEM", 138, 161], ["cancer care", "TREATMENT", 163, 174], ["collateral", "OBSERVATION", 6, 16], ["cardiovascular", "ANATOMY", 138, 152], ["diseases", "OBSERVATION", 153, 161]]], ["The collateral damage is not only limited to the patients but also healthcare workers (HCWs), who have a threefold higher incidence of acquiring COVID-19 infection as compared to the general public.", [["collateral", "ANATOMY", 4, 14], ["collateral damage", "DISEASE", 4, 21], ["infection", "DISEASE", 154, 163], ["collateral", "MULTI-TISSUE_STRUCTURE", 4, 14], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["The collateral damage", "PROBLEM", 0, 21], ["acquiring COVID-19 infection", "PROBLEM", 135, 163], ["collateral", "OBSERVATION_MODIFIER", 4, 14], ["damage", "OBSERVATION", 15, 21], ["infection", "OBSERVATION", 154, 163]]], ["In addition, the pressure of working with critically ill patients imposes significant stress on the caregiver.", [["critically ill", "DISEASE", 42, 56], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["significant stress on the caregiver", "PROBLEM", 74, 109], ["pressure", "OBSERVATION_MODIFIER", 17, 25], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["stress", "OBSERVATION", 86, 92]]], ["Working in an intensive care unit (ICU) can be extremely stressful due to high morbidity and mortality.", [["high morbidity", "PROBLEM", 74, 88]]], ["The tension and anxiety associated with providing care are by no means a reflection of the HCW's ability or weakness; they are intrinsic to the job.", [["anxiety", "DISEASE", 16, 23], ["The tension and anxiety", "PROBLEM", 0, 23], ["weakness", "PROBLEM", 108, 116], ["tension", "OBSERVATION_MODIFIER", 4, 11]]]], "d3d060dd9c2f6ef77894e8c97036eb6d7e4068bd": [["On the other hand, a document, titled \"Evaluating the Performance of Dynamic Database Applications\" is not related to the query RDBMS along the application aspect although its title contains the term applications.", [["Dynamic Database Applications", "TREATMENT", 69, 98], ["the query RDBMS", "PROBLEM", 118, 133]]], ["The query and aspect models are derived using domain-specific knowledge bases (KBs), which is challenging in itself due to the inherent sparsity of relations in these KBs.", [["KBs", "CANCER", 167, 170], ["KBs", "TEST", 79, 82], ["these KBs", "TEST", 161, 170]]], ["By using a domain-specific KB of computer science, like TeKnowbase [14] , we show how to overcome the sparsity issue in KB via inference using meta-paths derived from the KB.", [["KB", "CANCER", 120, 122], ["KB", "CANCER", 171, 173], ["KB", "CELL_LINE", 120, 122], ["KB", "CELL_LINE", 171, 173]]], ["A retrieval model transforms the document space into an intermediate representation and returns a ranked list of documents according to some scoring function.Retrieval Model and EstimationLanguage modelling techniques [10] model the relevance of a document as the probability of generating the query from the document.", [["A retrieval model transforms", "TREATMENT", 0, 28], ["Retrieval Model", "TREATMENT", 158, 173], ["EstimationLanguage modelling techniques", "TREATMENT", 178, 217], ["intermediate representation", "OBSERVATION", 56, 83]]], ["P (w|a) is the prior, which is the probability of a term w appearing in d given an aspect a, independent of the query.Retrieval Model and EstimationQuery and Aspect Dependent Probability.", [["P", "DNA", 0, 1], ["Retrieval Model", "TREATMENT", 118, 133]]], ["The probability of a term appearing in d given a query q and aspect a is denoted by P (w|q, a).Mixture of the Two Probability Distributions.The relevance of d will be determined by a mixture model of both the probability distributions.", [["Two", "OBSERVATION_MODIFIER", 110, 113], ["Probability Distributions", "OBSERVATION", 114, 139]]], ["It is denoted as MM.Mixture of the Two Probability Distributions.Scoring of Documents.", [["MM", "ANATOMY", 17, 19], ["MM", "DISEASE", 17, 19], ["MM", "CANCER", 17, 19], ["Two", "OBSERVATION_MODIFIER", 35, 38], ["Probability Distributions", "OBSERVATION", 39, 64]]], ["Dirichlet smoothing is used for M d .Mixture of the Two Probability Distributions.where tf (w, d) is the frequency of w in d, and P (w|C) is the probability of w appearing in the entire collection.", [["w|C)", "TREATMENT", 133, 137], ["Two", "OBSERVATION_MODIFIER", 52, 55], ["Probability Distributions", "OBSERVATION", 56, 81]]], ["The risk associated with using MM to approximate M d is expressed by KL-divergence between MM and M d and the documents are returned in an order of increasing KL-divergence.Mixture of the Two Probability Distributions.Estimation of Query-Independent Component.", [["KL", "GENE_OR_GENE_PRODUCT", 69, 71], ["KL", "GENE_OR_GENE_PRODUCT", 159, 161], ["KL", "PROTEIN", 69, 71], ["KL", "PROTEIN", 159, 161], ["Two", "OBSERVATION_MODIFIER", 188, 191], ["Probability Distributions", "OBSERVATION", 192, 217], ["Independent", "OBSERVATION_MODIFIER", 238, 249], ["Component", "OBSERVATION_MODIFIER", 250, 259]]], ["P (w|a) is estimated using a narrow set of documents from our dataset acquired as follows.", [["P", "DNA", 0, 1]]], ["In order to increase the size of our document set, we used heuristics to collect more documents given an aspect.", [["size", "OBSERVATION_MODIFIER", 25, 29]]], ["But, we retained only those documents which contained the name of the aspect in the title on the intuition that such documents are highly likely (though not guaranteed) to be about those aspects.", [["highly likely", "UNCERTAINTY", 131, 144]]], ["(4).Mixture of the Two Probability Distributions.Estimation of Query-Dependent Component.", [["Two", "OBSERVATION_MODIFIER", 19, 22], ["Probability Distributions", "OBSERVATION", 23, 48], ["Dependent", "OBSERVATION_MODIFIER", 69, 78], ["Component", "OBSERVATION_MODIFIER", 79, 88]]], ["T KB consists of entities such as hidden markov model or speech recognition and other domain-specific relationships like application, implementation or algorithm.", [["T KB", "CELL_LINE", 0, 4], ["hidden markov model", "TEST", 34, 53], ["speech recognition", "PROBLEM", 57, 75], ["algorithm", "TEST", 152, 161]]], ["The entities connected via application relation in T KB have a higher probability of appearing in documents addressing application aspect.", [["T KB", "CANCER", 51, 55], ["T KB", "CELL_LINE", 51, 55]]], ["However, T KB is sparse.", [["T KB", "ANATOMY", 9, 13], ["T KB", "CANCER", 9, 13], ["T KB", "CELL_LINE", 9, 13], ["sparse", "OBSERVATION_MODIFIER", 17, 23]]], ["A meta-path is a sequence of edges with labels connecting two nodes which have been used previously for KB completion tasks [6] , link prediction [8] as well as to find similarity between two nodes [11, 13] .", [["KB completion tasks", "TEST", 104, 123], ["nodes", "OBSERVATION", 62, 67], ["nodes", "OBSERVATION", 192, 197]]], ["To automatically determine entities that participate in a given relationship type with entity ei, we used the path-constrained random walk algorithm (P RA) proposed in [6] .", [["random walk algorithm (P RA)", "TREATMENT", 127, 155]]], ["Given a set E of entities in T KB, a source node ei and a meta-path P , a path-constrained random walk defines a probability distribution he i ,P (ej) to all entities in E which is the probability of reaching ej from ei by doing a random walk along P .", [["T KB", "CELL", 29, 33], ["T KB", "CELL_LINE", 29, 33], ["meta-path P", "DNA", 58, 69], ["ej", "DNA", 209, 211], ["P", "DNA", 249, 250], ["a path", "TEST", 72, 78], ["ej", "ANATOMY", 147, 149]]], ["The key idea is to acquire the set of meta-paths representing the given relationship type and use P RA for inferencing.", [["P RA", "TREATMENT", 98, 102]]], ["To do so, we retrieved the set of all meta-paths (MP ) connecting the given relationship type in T KB and scored them according to their frequency.", [["T KB", "ANATOMY", 97, 101], ["T KB", "CANCER", 97, 101], ["T KB", "CELL_LINE", 97, 101]]], ["Given a set of metapaths MP = P1, P2, ..., Pn, the score for each node reachable from source ei is given by:Mixture of the Two Probability Distributions.is the frequency of meta-path P l . scoree i (ej) is converted to a probability distribution using softmax and denoted by Eq.", [["node", "ANATOMY", 66, 70], ["MP", "DISEASE", 25, 27], ["P2", "DNA", 34, 36], ["meta-path P l", "DNA", 173, 186], ["Pn", "TREATMENT", 43, 45], ["softmax", "TREATMENT", 252, 259], ["node", "OBSERVATION", 66, 70], ["ej", "ANATOMY", 199, 201]]], ["(5).Mixture of the Two Probability Distributions.(2) Indirect inference using meta-paths.", [["Two", "OBSERVATION_MODIFIER", 19, 22], ["Probability Distributions", "OBSERVATION", 23, 48]]], ["P RA assigns zero probability to nodes that are not reachable via any meta-paths in MP .", [["MP", "DISEASE", 84, 86], ["MP", "GENE_OR_GENE_PRODUCT", 84, 86], ["zero probability to nodes", "PROBLEM", 13, 38], ["nodes", "OBSERVATION", 33, 38]]], ["We used the top-k meta-paths in MP as input to metapath2vec and obtained vector representations Ve for entity e.", [["MP", "GENE_OR_GENE_PRODUCT", 32, 34], ["top-k meta-paths", "DNA", 12, 28], ["metapath2vec", "DNA", 47, 59], ["the top-k meta-paths in MP", "TREATMENT", 8, 34]]], ["(6) .Mixture of the Two Probability Distributions.The probability distribution for inferencing is a mixture of DIe i (ej) and h e i (ej) using \u03b2 as given in Eq.", [["\u03b2", "PROTEIN", 143, 144], ["h e i (ej)", "TREATMENT", 126, 136], ["Two", "OBSERVATION_MODIFIER", 20, 23], ["Probability Distributions", "OBSERVATION", 24, 49], ["distribution", "OBSERVATION_MODIFIER", 66, 78]]], ["(1) .SetupDataset.", [["SetupDataset", "TREATMENT", 5, 17]]], ["We used the Open Research Corpus dataset and indexed it using Galago.", [["the Open Research Corpus dataset", "TREATMENT", 8, 40]]], ["We restricted ourselves to meta-paths of size at most 3.", [["meta-paths of size", "TREATMENT", 27, 45], ["size", "OBSERVATION_MODIFIER", 41, 45]]], ["We set k = 5 for choosing the top-k meta-paths for generating embeddings using MetaP-ath2Vec (described in Sect.", [["MetaP-ath2Vec", "GENE_OR_GENE_PRODUCT", 79, 92], ["MetaP", "PROTEIN", 79, 84], ["ath2Vec", "PROTEIN", 85, 92], ["the top", "TEST", 26, 33], ["MetaP-ath2Vec", "TREATMENT", 79, 92]]], ["Benchmark queries were taken from a set of 100 queries released by [15] out of which 43 existed as whole entities in T KB, shown in Fig. 2 .Fig.", [["T KB", "CELL", 117, 121], ["T KB", "CELL_LINE", 117, 121], ["Fig", "OBSERVATION", 140, 143]]], ["We explicitly added the keyword representing the aspect to the query and used standard retrieval models with/without relevance feedback techniques as baselines described below:Fig. 2.", [["standard retrieval models", "TREATMENT", 78, 103]]], ["Query likelihood [10] estimates a language model for each document in the collection and ranks them by the likelihood of seeing the query terms as a random sample given that document model.Fig.", [["a language model", "TREATMENT", 32, 48], ["a random sample", "TEST", 147, 162]]], ["We used the same model as above but added the terms application, algorithm or implementation to the query based on the aspect and retrieved the results.Fig.", [["algorithm", "TREATMENT", 65, 74]]], ["Benchmark queries(3) Query expansion with pseudo relevance feedback on QL + query + aspect (QL + query + aspect + QE).", [["Query expansion", "TEST", 21, 36], ["pseudo relevance feedback", "PROBLEM", 42, 67], ["QL", "TEST", 71, 73], ["QL", "TEST", 92, 94]]], ["The weight of the original query was set as 0.75.", [["The weight", "TEST", 0, 10]]], ["2.Evaluation Scheme and MetricsEvaluation Scheme.", [["Evaluation", "TEST", 2, 12]]], ["In the absence of an extensive ground-truth dataset, we conducted a crowd-sourced user-evaluation exercise (involving Computer Science students and researchers, not related to the project) to measure the performance of our model.", [["extensive", "OBSERVATION_MODIFIER", 21, 30]]], ["We formulated domainspecific questions, and depending on the answers marked by the evaluators, the documents were assigned a particular score for a query and aspect pair.Evaluation Scheme and MetricsEvaluation Metrics.", [["Evaluation", "TEST", 170, 180]]], ["Table 1 shows the results for algorithm, application and implementation aspects.", [["algorithm", "TEST", 30, 39]]], ["We observe that our model outperforms the rest of the baselines in terms of precision@5 and DCG for all of the 3 aspects.", [["DCG", "TREATMENT", 92, 95]]], ["QL + query + aspect + QE comes second after our retrieval model.", [["QL", "TEST", 0, 2], ["our retrieval model", "TREATMENT", 44, 63]]], ["By modelling the aspect and query dependant probability explicitly, we were able to address the problems of simple keyword-based match for aspects described in Sects.", [["dependant", "OBSERVATION_MODIFIER", 34, 43]]], ["For example, the top-2 papers retrieved for genetic algorithm for application aspect by our model were Genetic Ant Algorithm for Continuous Function Optimization and Its MATLAB Implementation and Solve Zero-One Knapsack Problem by Greedy Genetic Algorithm.", [["genetic algorithm", "TEST", 44, 61], ["Continuous Function Optimization", "TREATMENT", 129, 161], ["Its MATLAB Implementation", "TREATMENT", 166, 191], ["Solve Zero", "TREATMENT", 196, 206]]], ["The top-2 papers retrieved by QL + query + aspect + QE for application aspect do not describe any application of genetic algorithm but contained a few terms like \"a wide application prospect\" in the abstract due to which it was retrieved in the top positions.", [["genetic algorithm", "TEST", 113, 130]]], ["Both the papers retrieved by our method address application aspect for genetic algorithm even if \"application\" is not mentioned in the title.ConclusionIn this paper, we built an aspect-based retrieval model for scientific literature using TeKnowbase.", [["genetic algorithm", "TREATMENT", 71, 88]]]], "3cd7b97a56a72edc5c01bff6288c22177ebda4d0": [["INTRODUCTIONrespiratory, digestive, neurological, and immune-mediated diseases in human and animals.", [["digestive", "ANATOMY", 25, 34], ["neurological", "ANATOMY", 36, 48], ["digestive, neurological, and immune-mediated diseases", "DISEASE", 25, 78], ["digestive", "ORGAN", 25, 34], ["human", "ORGANISM", 82, 87], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["mediated diseases in human", "PROBLEM", 61, 87], ["digestive", "ANATOMY", 25, 34], ["diseases", "OBSERVATION", 70, 78]]], ["The outbreak of the severe acute respiratory syndrome (SARS) in 2003 was caused by SARS-CoV, which is most closely related to group II CoV, especially the bovine CoV (BCoV).", [["acute respiratory syndrome", "DISEASE", 27, 53], ["SARS", "DISEASE", 55, 59], ["SARS-CoV", "DISEASE", 83, 91], ["SARS-CoV", "ORGANISM", 83, 91], ["group II CoV", "ORGANISM", 126, 138], ["bovine CoV", "ORGANISM", 155, 165], ["BCoV", "CANCER", 167, 171], ["bovine", "SPECIES", 155, 161], ["SARS-CoV", "SPECIES", 83, 91], ["II CoV", "SPECIES", 132, 138], ["bovine CoV", "SPECIES", 155, 165], ["BCoV", "SPECIES", 167, 171], ["the severe acute respiratory syndrome", "PROBLEM", 16, 53], ["SARS", "PROBLEM", 55, 59], ["SARS-CoV", "PROBLEM", 83, 91], ["group II CoV", "PROBLEM", 126, 138], ["the bovine CoV (BCoV)", "TREATMENT", 151, 172], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["respiratory syndrome", "OBSERVATION", 33, 53], ["bovine CoV", "OBSERVATION", 155, 165]]], ["Although the exact origin of SARS-CoV remains to be identified, the fact that similar SARS-CoV has been repeatedly isolated in wild animals, including civet cat, raccoon dog, and badges, strongly suggests that SARS-CoV originates from animals.", [["SARS", "DISEASE", 29, 33], ["SARS", "DISEASE", 86, 90], ["SARS", "DISEASE", 210, 214], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "ORGANISM", 86, 94], ["civet cat", "ORGANISM", 151, 160], ["raccoon dog", "ORGANISM", 162, 173], ["SARS-CoV", "ORGANISM", 210, 218], ["cat", "SPECIES", 157, 160], ["raccoon dog", "SPECIES", 162, 173], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 86, 94], ["raccoon dog", "SPECIES", 162, 173], ["SARS-CoV", "SPECIES", 210, 218], ["SARS", "PROBLEM", 29, 33], ["similar SARS-CoV", "PROBLEM", 78, 94], ["SARS", "PROBLEM", 210, 214], ["SARS", "OBSERVATION", 29, 33]]], ["It was postulated that SARS-CoV is a zoonotic pathogen.", [["SARS-CoV", "DISEASE", 23, 31], ["SARS-CoV", "ORGANISM", 23, 31], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["CoV", "PROBLEM", 28, 31], ["a zoonotic pathogen", "PROBLEM", 35, 54], ["zoonotic", "OBSERVATION_MODIFIER", 37, 45], ["pathogen", "OBSERVATION", 46, 54]]], ["1 Ironically, the zoonotic nature of CoV had been documented long before the outbreak of SARS.", [["SARS", "DISEASE", 89, 93], ["CoV", "ORGANISM", 37, 40], ["SARS", "PROBLEM", 89, 93]]], ["In 1994, Zhang et al., 2 reported the isolation of a human enteric CoV (HECoV) from a 6-year old child with partial sequence of the structural genes revealed that HECoV is more closely related to BCoV than to other members of the CoV family.", [["human enteric CoV", "ORGANISM", 53, 70], ["HECoV", "CANCER", 72, 77], ["child", "ORGANISM", 97, 102], ["HECoV", "GENE_OR_GENE_PRODUCT", 163, 168], ["BCoV", "GENE_OR_GENE_PRODUCT", 196, 200], ["CoV", "GENE_OR_GENE_PRODUCT", 230, 233], ["HECoV", "PROTEIN", 163, 168], ["BCoV", "PROTEIN", 196, 200], ["CoV family", "PROTEIN", 230, 240], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["HECoV", "SPECIES", 72, 77]]], ["Interestingly, several studies showed that BCoV was able to infect other small ruminants, turkey, and dogs and cause clinical diseases in these animals, thus further supporting the idea that BCoV is a zoonotic pathogen.", [["BCoV", "CHEMICAL", 191, 195], ["BCoV", "GENE_OR_GENE_PRODUCT", 43, 47], ["turkey", "ORGANISM", 90, 96], ["dogs", "ORGANISM", 102, 106], ["BCoV", "GENE_OR_GENE_PRODUCT", 191, 195], ["turkey", "SPECIES", 90, 96], ["dogs", "SPECIES", 102, 106], ["BCoV", "SPECIES", 43, 47], ["turkey", "SPECIES", 90, 96], ["BCoV", "SPECIES", 191, 195], ["several studies", "TEST", 15, 30], ["clinical diseases in these animals", "PROBLEM", 117, 151], ["a zoonotic pathogen", "PROBLEM", 199, 218], ["zoonotic", "OBSERVATION_MODIFIER", 201, 209]]], ["Therefore, BCoV is the first documented CoV that can cross species barrier and infect animals ranging from avian, ruminant, carnivore, to humans.", [["BCoV", "GENE_OR_GENE_PRODUCT", 11, 15], ["CoV", "ORGANISM", 40, 43], ["humans", "ORGANISM", 138, 144], ["humans", "SPECIES", 138, 144], ["humans", "SPECIES", 138, 144]]], ["In the present study, we attempted to develop an infectious cDNA clone of HECoV by reverse genetics, which will provide a powerful genetic tool for future studies of the molecular evolution and animal to human transmission, and the molecular pathogenesis, and for the design of preventive and therapeutic interventions.Cells and VirusThe human rectal tumor (HRT)-18 cells and baby hamster kidney (BHK) cells were maintained in Dulbecco's Minimum Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), which were used for virus propagation and RNA transfection, respectively.", [["Cells", "ANATOMY", 319, 324], ["rectal tumor (HRT)-18 cells", "ANATOMY", 344, 371], ["hamster kidney (BHK) cells", "ANATOMY", 381, 407], ["fetal bovine serum", "ANATOMY", 492, 510], ["FBS", "ANATOMY", 512, 515], ["rectal tumor", "DISEASE", 344, 356], ["HECoV", "GENE_OR_GENE_PRODUCT", 74, 79], ["human", "ORGANISM", 204, 209], ["Cells", "CELL", 319, 324], ["Virus", "ORGANISM", 329, 334], ["human", "ORGANISM", 338, 343], ["rectal tumor (HRT)-18 cells", "CELL", 344, 371], ["baby hamster kidney", "CELL", 376, 395], ["BHK) cells", "CELL", 397, 407], ["bovine", "ORGANISM", 498, 504], ["serum", "ORGANISM_SUBSTANCE", 505, 510], ["FBS", "ORGANISM_SUBSTANCE", 512, 515], ["infectious cDNA clone", "DNA", 49, 70], ["human rectal tumor (HRT)-18 cells", "CELL_LINE", 338, 371], ["baby hamster kidney (BHK) cells", "CELL_LINE", 376, 407], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 338, 343], ["hamster", "SPECIES", 381, 388], ["bovine", "SPECIES", 498, 504], ["HECoV", "SPECIES", 74, 79], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 338, 343], ["hamster", "SPECIES", 381, 388], ["BHK", "SPECIES", 397, 400], ["bovine", "SPECIES", 498, 504], ["an infectious cDNA clone", "PROBLEM", 46, 70], ["future studies", "TEST", 148, 162], ["therapeutic interventions", "TREATMENT", 293, 318], ["Cells", "TEST", 319, 324], ["Virus", "PROBLEM", 329, 334], ["HRT", "TEST", 358, 361], ["baby hamster kidney (BHK) cells", "TREATMENT", 376, 407], ["Dulbecco", "TEST", 427, 435], ["Essential Medium (DMEM)", "TREATMENT", 446, 469], ["10% fetal bovine serum (FBS", "TREATMENT", 488, 515], ["virus propagation", "TREATMENT", 538, 555], ["RNA transfection", "TREATMENT", 560, 576], ["infectious", "OBSERVATION", 49, 59], ["rectal", "ANATOMY", 344, 350], ["tumor", "OBSERVATION", 351, 356], ["kidney", "ANATOMY", 389, 395], ["RNA transfection", "OBSERVATION", 560, 576]]], ["The human enteric coronavirus (HECoV) isolate 4408 2 was propagated inViral RNA Isolation and Reverse Transcription-Polymerase Chain ReactionFor viral RNA isolation, HRT-18 cells were infected with HECoV at a multiplicity of infection (m.o.i.) of 5 in the presence of actinomycin D. At 48 h p.i., intracellular RNAs were isolated with Trizol reagent according to the manufacturer's protocol (Invitrogen). cDNA was synthesized by reverse transcription (RT) with Maloney murine leukemia virus (M-MLV) reverse transcriptase (Promega) using a primer specific to the nucleotide (nt) sequence at the 3'-end of HECoV nucleocapsid (N) gene 2 or a nonspecific oligo (dT) primer.", [["HRT-18 cells", "ANATOMY", 166, 178], ["intracellular", "ANATOMY", 297, 310], ["enteric coronavirus", "DISEASE", 10, 29], ["HECoV", "CHEMICAL", 198, 203], ["infection", "DISEASE", 225, 234], ["actinomycin", "CHEMICAL", 268, 279], ["nucleotide", "CHEMICAL", 562, 572], ["actinomycin", "CHEMICAL", 268, 279], ["nucleotide", "CHEMICAL", 562, 572], ["human enteric coronavirus", "ORGANISM", 4, 29], ["HECoV", "CELL", 31, 36], ["HRT-18 cells", "CELL", 166, 178], ["actinomycin", "SIMPLE_CHEMICAL", 268, 279], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 297, 310], ["Maloney murine leukemia virus", "ORGANISM", 461, 490], ["M-MLV", "ORGANISM", 492, 497], ["Promega", "ORGANISM", 522, 529], ["HECoV nucleocapsid (N) gene 2", "GENE_OR_GENE_PRODUCT", 604, 633], ["HRT-18 cells", "CELL_LINE", 166, 178], ["intracellular RNAs", "RNA", 297, 315], ["cDNA", "DNA", 405, 409], ["reverse transcriptase", "PROTEIN", 499, 520], ["nucleotide (nt) sequence", "DNA", 562, 586], ["3'-end", "DNA", 594, 600], ["HECoV nucleocapsid (N) gene 2", "DNA", 604, 633], ["nonspecific oligo (dT) primer", "DNA", 639, 668], ["human", "SPECIES", 4, 9], ["enteric coronavirus", "SPECIES", 10, 29], ["murine", "SPECIES", 469, 475], ["leukemia virus", "SPECIES", 476, 490], ["human enteric coronavirus", "SPECIES", 4, 29], ["HECoV", "SPECIES", 31, 36], ["HECoV", "SPECIES", 198, 203], ["Maloney murine leukemia virus", "SPECIES", 461, 490], ["MLV", "SPECIES", 494, 497], ["The human enteric coronavirus (HECoV) isolate", "TREATMENT", 0, 45], ["propagated inViral RNA Isolation", "TREATMENT", 57, 89], ["Reverse Transcription", "TREATMENT", 94, 115], ["viral RNA isolation", "PROBLEM", 145, 164], ["HRT", "TEST", 166, 169], ["HECoV", "TREATMENT", 198, 203], ["infection", "PROBLEM", 225, 234], ["actinomycin D.", "TREATMENT", 268, 282], ["intracellular RNAs", "TREATMENT", 297, 315], ["Trizol reagent", "TREATMENT", 335, 349], ["the manufacturer's protocol", "TREATMENT", 363, 390], ["Maloney murine leukemia virus", "PROBLEM", 461, 490], ["transcriptase (Promega)", "TREATMENT", 507, 530], ["a primer", "TREATMENT", 537, 545], ["the nucleotide (nt) sequence", "TEST", 558, 586], ["a nonspecific oligo (dT) primer", "PROBLEM", 637, 668], ["enteric coronavirus", "ANATOMY", 10, 29], ["infection", "OBSERVATION", 225, 234], ["leukemia virus", "OBSERVATION", 476, 490]]], ["Additional 20 pairs of primers were designed for RT and PCR amplification of the entire viral genome.", [["viral genome", "DNA", 88, 100], ["primers", "TREATMENT", 23, 30], ["RT and PCR amplification", "TREATMENT", 49, 73], ["the entire viral genome", "PROBLEM", 77, 100], ["viral genome", "OBSERVATION", 88, 100]]], ["The RT-PCR products were directly sequenced. cDNAs corresponding to the 5'-end of the viral genome was synthesized using the RNAligation-mediated rapid amplification of cDNA end (RLM-RACE) kit (Ambion) and was then sequenced directly.", [["RT-PCR products", "DNA", 4, 19], ["cDNAs", "DNA", 45, 50], ["5'-end", "DNA", 72, 78], ["viral genome", "DNA", 86, 98], ["cDNA end", "DNA", 169, 177], ["RLM", "DNA", 179, 182], ["The RT-PCR products", "TREATMENT", 0, 19], ["cDNAs", "TEST", 45, 50], ["the viral genome", "PROBLEM", 82, 98], ["the RNAligation", "TREATMENT", 121, 136], ["cDNA end (RLM-RACE) kit (Ambion)", "TREATMENT", 169, 201], ["viral genome", "OBSERVATION", 86, 98]]], ["For cloning purpose, PCR was carried out using the Expand Long Taq polymerase (Roche) for 25 cycles.", [["Expand Long Taq polymerase", "PROTEIN", 51, 77], ["cloning purpose", "TEST", 4, 19], ["PCR", "TEST", 21, 24], ["the Expand Long Taq polymerase", "TREATMENT", 47, 77]]], ["Each cycle consists of 94\u00b0C for 45 sec, 58~62\u00b0C for 45 sec, and 68\u00b0C for 3~4 min followed by a final extension at 68\u00b0C for 10 min.Cloning of cDNA Fragments and DNA SequencingFor molecular cloning, 9 pairs of primers encompassing the entire viral genome were designed for RT-PCR amplification.", [["DNA", "CELLULAR_COMPONENT", 160, 163], ["cDNA Fragments", "DNA", 141, 155], ["viral genome", "DNA", 240, 252], ["Cloning of cDNA Fragments", "TREATMENT", 130, 155], ["DNA Sequencing", "TREATMENT", 160, 174], ["molecular cloning", "TREATMENT", 178, 195], ["primers", "PROBLEM", 208, 215], ["RT-PCR amplification", "TREATMENT", 271, 291], ["viral genome", "OBSERVATION", 240, 252]]], ["The strategy for designing the primers is illustrated in Fig. 1 .", [["The strategy", "TREATMENT", 0, 12], ["the primers", "TREATMENT", 27, 38]]], ["A T7 promoter was inserted at the most 5'-end primer and a poly (A) tail of 25 As was included at the 3' end primer for the last fragment.", [["T7", "GENE_OR_GENE_PRODUCT", 2, 4], ["fragment", "CELLULAR_COMPONENT", 129, 137], ["T7 promoter", "DNA", 2, 13], ["5'-end primer", "DNA", 39, 52], ["poly (A) tail", "DNA", 59, 72], ["3' end primer", "DNA", 102, 115], ["A T7 promoter", "TREATMENT", 0, 13], ["a poly (A) tail", "TREATMENT", 57, 72], ["the 3' end primer", "TREATMENT", 98, 115], ["the last fragment", "PROBLEM", 120, 137], ["T7", "ANATOMY", 2, 4], ["fragment", "OBSERVATION", 129, 137]]], ["An Xho I site was created in the 3' end primer of fragment A without changing the coding amino acid for distinguishing the molecular clone from wild-type virus.", [["amino acid", "CHEMICAL", 89, 99], ["amino acid", "CHEMICAL", 89, 99], ["Xho I", "GENE_OR_GENE_PRODUCT", 3, 8], ["amino acid", "AMINO_ACID", 89, 99], ["wild-type virus", "ORGANISM", 144, 159], ["Xho I site", "DNA", 3, 13], ["3' end primer", "DNA", 33, 46], ["An Xho I site", "TREATMENT", 0, 13], ["the coding amino acid", "TEST", 78, 99], ["the molecular clone", "PROBLEM", 119, 138], ["type virus", "PROBLEM", 149, 159], ["fragment", "OBSERVATION", 50, 58], ["molecular clone", "OBSERVATION", 123, 138]]], ["A unique BsmB I or Bsa I site was inserted at the terminus of each primer.", [["BsmB I", "GENE_OR_GENE_PRODUCT", 9, 15], ["Bsa I", "GENE_OR_GENE_PRODUCT", 19, 24], ["BsmB I or Bsa I site", "DNA", 9, 29], ["A unique BsmB I or Bsa I site", "TREATMENT", 0, 29]]], ["RT-PCR products were isolated with the gel extract and purification kit (Qiagen) and cloned into Topo II TA vector (Invitrogen) or the pSMART vector (Lucigen).DNA Ligation, in Vitro RNA Transcription, and RNA TransfectionEach cDNA fragment was released from plasmid DNAs by digestion with appropriate restriction enzymes, separated on 0.8% agarose gel by electrophoresis, and purified using Qiaex II gel extraction kit (Qiagen).", [["DNAs", "ANATOMY", 266, 270], ["Qiaex II", "CHEMICAL", 391, 399], ["Topo II TA", "GENE_OR_GENE_PRODUCT", 97, 107], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 116, 126], ["pSMART", "GENE_OR_GENE_PRODUCT", 135, 141], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["agarose", "SIMPLE_CHEMICAL", 340, 347], ["Topo II TA vector", "DNA", 97, 114], ["pSMART vector", "DNA", 135, 148], ["Lucigen", "DNA", 150, 157], ["cDNA fragment", "DNA", 226, 239], ["plasmid DNAs", "DNA", 258, 270], ["restriction enzymes", "PROTEIN", 301, 320], ["Topo II TA", "SPECIES", 97, 107], ["RT-PCR products", "TREATMENT", 0, 15], ["the gel extract", "TREATMENT", 35, 50], ["purification kit (Qiagen)", "TREATMENT", 55, 80], ["Topo II TA vector (Invitrogen", "TREATMENT", 97, 126], ["the pSMART vector", "TREATMENT", 131, 148], ["DNA Ligation", "TREATMENT", 159, 171], ["Vitro RNA Transcription", "TREATMENT", 176, 199], ["RNA TransfectionEach cDNA fragment", "TREATMENT", 205, 239], ["plasmid DNAs", "TREATMENT", 258, 270], ["appropriate restriction enzymes", "TEST", 289, 320], ["0.8% agarose gel", "TREATMENT", 335, 351], ["electrophoresis", "TEST", 355, 370], ["Qiaex II gel extraction kit", "TREATMENT", 391, 418], ["Ligation", "OBSERVATION", 163, 171]]], ["The 9 fragments were then mixed at an equal molar ratio and ligated with T4 DNA ligase (New England Biolab) at 16\u00b0C overnight.", [["fragments", "ANATOMY", 6, 15], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["T4 DNA ligase", "PROTEIN", 73, 86], ["The 9 fragments", "PROBLEM", 0, 15], ["T4 DNA ligase", "TREATMENT", 73, 86], ["9 fragments", "OBSERVATION_MODIFIER", 4, 15]]], ["The ligation products were purified by phenol-chloroform-isoamyl and chloroform extraction, and precipitated by ethanol.528HRT-18 cells.DEVELOPMENT OF AN INFECTIOUS cDNA CLONE OF HECOVIn vitro RNA transcription was carried out using the mMESSAGE, mMACHINE T7 kit (Ambion) with slight modifications.", [["HRT-18 cells", "ANATOMY", 123, 135], ["phenol-chloroform-isoamyl", "CHEMICAL", 39, 64], ["ethanol", "CHEMICAL", 112, 119], ["phenol", "CHEMICAL", 39, 45], ["chloroform", "CHEMICAL", 46, 56], ["isoamyl", "CHEMICAL", 57, 64], ["chloroform", "CHEMICAL", 69, 79], ["ethanol", "CHEMICAL", 112, 119], ["phenol-chloroform-isoamyl", "SIMPLE_CHEMICAL", 39, 64], ["chloroform", "SIMPLE_CHEMICAL", 69, 79], ["ethanol", "SIMPLE_CHEMICAL", 112, 119], ["HRT-18 cells", "CELL", 123, 135], ["HRT-18 cells", "CELL_LINE", 123, 135], ["mMESSAGE", "DNA", 237, 245], ["The ligation products", "TREATMENT", 0, 21], ["phenol-chloroform", "TREATMENT", 39, 56], ["isoamyl", "TREATMENT", 57, 64], ["chloroform extraction", "TREATMENT", 69, 90], ["HRT", "TEST", 123, 126], ["HECOVIn vitro RNA transcription", "TREATMENT", 179, 210], ["the mMESSAGE", "TREATMENT", 233, 245], ["mMACHINE T7 kit (Ambion", "TREATMENT", 247, 270], ["slight modifications", "TREATMENT", 277, 297], ["ligation", "OBSERVATION", 4, 12], ["INFECTIOUS", "OBSERVATION_MODIFIER", 154, 164], ["cDNA CLONE", "OBSERVATION", 165, 175]]], ["The in vitro transcription products were then treated with RNase-free DNase I (Promega) at 37\u00b0C overnight, followed by extraction with phenol-chloroform-isoamyl and chloroform, and ethanol precipitation.DEVELOPMENT OF AN INFECTIOUS cDNA CLONE OF HECOVFor transfection, a mixture of 80 \u00b5l of the full-length HECoV transcripts and 40 \u00b5l of the N gene transcripts was electroporated into BHK cell suspension (10 6 cell/ml) at 360 V, 80 \u00b5s in an electroporator (Eppendorf).", [["BHK cell", "ANATOMY", 385, 393], ["cell", "ANATOMY", 411, 415], ["phenol-chloroform-isoamyl and chloroform", "CHEMICAL", 135, 175], ["ethanol", "CHEMICAL", 181, 188], ["phenol", "CHEMICAL", 135, 141], ["chloroform", "CHEMICAL", 142, 152], ["isoamyl", "CHEMICAL", 153, 160], ["chloroform", "CHEMICAL", 165, 175], ["ethanol", "CHEMICAL", 181, 188], ["RNase", "GENE_OR_GENE_PRODUCT", 59, 64], ["DNase I", "GENE_OR_GENE_PRODUCT", 70, 77], ["Promega", "ORGANISM", 79, 86], ["phenol-chloroform-isoamyl", "SIMPLE_CHEMICAL", 135, 160], ["chloroform", "SIMPLE_CHEMICAL", 165, 175], ["ethanol", "SIMPLE_CHEMICAL", 181, 188], ["HECoV", "GENE_OR_GENE_PRODUCT", 307, 312], ["BHK cell", "CELL", 385, 393], ["in vitro transcription products", "PROTEIN", 4, 35], ["RNase", "PROTEIN", 59, 64], ["DNase I", "PROTEIN", 70, 77], ["cDNA CLONE", "DNA", 232, 242], ["full-length HECoV transcripts", "RNA", 295, 324], ["N gene transcripts", "RNA", 342, 360], ["BHK cell suspension", "CELL_LINE", 385, 404], ["RNase-free DNase I (Promega)", "TREATMENT", 59, 87], ["phenol", "TREATMENT", 135, 141], ["chloroform", "TREATMENT", 165, 175], ["ethanol precipitation", "TREATMENT", 181, 202], ["the full-length HECoV transcripts", "TREATMENT", 291, 324], ["the N gene transcripts", "TREATMENT", 338, 360], ["BHK cell suspension", "TREATMENT", 385, 404], ["INFECTIOUS", "OBSERVATION_MODIFIER", 221, 231], ["cDNA CLONE", "OBSERVATION", 232, 242]]], ["Transfected BHK cells were seeded onto a dish with HRT-18 cells and the co-culture was incubated at 37\u00b0C under 5% CO2 for 3 days.Sequencing of the Complete HECoV Genome and Sequence Comparison with Other Related CoronavirusesThe sequence of the entire HECoV genome was determined by directly sequencing the RT-PCR products.", [["BHK cells", "ANATOMY", 12, 21], ["HRT-18 cells", "ANATOMY", 51, 63], ["CO2", "CHEMICAL", 114, 117], ["CO2", "CHEMICAL", 114, 117], ["BHK cells", "CELL", 12, 21], ["HRT-18 cells", "CELL", 51, 63], ["CO2", "SIMPLE_CHEMICAL", 114, 117], ["BHK cells", "CELL_LINE", 12, 21], ["HRT-18 cells", "CELL_LINE", 51, 63], ["Complete HECoV Genome", "DNA", 147, 168], ["Other Related Coronaviruses", "DNA", 198, 225], ["HECoV genome", "DNA", 252, 264], ["RT-PCR products", "DNA", 307, 322], ["BHK", "SPECIES", 12, 15], ["Transfected BHK cells", "PROBLEM", 0, 21], ["HRT", "TEST", 51, 54], ["the co-culture", "TEST", 68, 82], ["BHK cells", "OBSERVATION", 12, 21]]], ["In some instances, multiple independent RT-PCR products for the same fragments were sequenced.", [["fragments", "ANATOMY", 69, 78], ["RT-PCR products", "DNA", 40, 55], ["multiple independent RT-PCR products", "TREATMENT", 19, 55], ["the same fragments", "PROBLEM", 60, 78], ["multiple", "OBSERVATION_MODIFIER", 19, 27]]], ["Thus, although quasispecies may exist in the viral populations, the sequence so determined must represent the vast majority of the viral genome in the RNA pools.", [["viral genome", "DNA", 131, 143], ["quasispecies", "PROBLEM", 15, 27], ["the viral populations", "PROBLEM", 41, 62], ["the sequence", "TEST", 64, 76], ["the viral genome in the RNA pools", "PROBLEM", 127, 160], ["quasispecies", "OBSERVATION", 15, 27], ["viral populations", "OBSERVATION", 45, 62], ["viral genome", "OBSERVATION", 131, 143], ["RNA pools", "OBSERVATION", 151, 160]]], ["Analysis of the sequence data revealed that the entire HECoV genome consists of 31,029-nt plus the poly(A) tail.", [["poly(A) tail", "GENE_OR_GENE_PRODUCT", 99, 111], ["HECoV genome", "DNA", 55, 67], ["31,029-nt", "DNA", 80, 89], ["poly(A) tail", "DNA", 99, 111], ["the sequence data", "TEST", 12, 29], ["tail", "ANATOMY", 107, 111]]], ["The genome organization is similar to those of other CoV, with the ORFs in the order of 1a-1b-32kDa-HE-S-ORF5-6-7-E-M-N.", [["CoV", "ORGANISM", 53, 56], ["CoV", "DNA", 53, 56], ["ORFs", "DNA", 67, 71], ["the ORFs", "TEST", 63, 71], ["genome organization", "OBSERVATION", 4, 23]]], ["The 5'-end of the genome is capped as inferred from the result with RLM-RACE and the penultimate nt is guanine.", [["guanine", "CHEMICAL", 103, 110], ["guanine", "CHEMICAL", 103, 110], ["genome", "CELLULAR_COMPONENT", 18, 24], ["guanine", "SIMPLE_CHEMICAL", 103, 110], ["5'-end", "DNA", 4, 10], ["RLM", "DNA", 68, 71], ["RACE", "DNA", 72, 76], ["capped", "OBSERVATION", 28, 34]]], ["There is a 70-nt leader at the 5'-end, and a core consensus UCUAAAC at the 3'-end of the leader and the intergenic region proceeding each gene.", [["70-nt leader", "DNA", 11, 23], ["5'-end", "DNA", 31, 37], ["core consensus UCUAAAC", "DNA", 45, 67], ["3'-end", "DNA", 75, 81], ["intergenic region", "DNA", 104, 121], ["a 70-nt leader", "PROBLEM", 9, 23], ["70-nt leader", "OBSERVATION_MODIFIER", 11, 23], ["intergenic", "OBSERVATION_MODIFIER", 104, 114]]], ["Sequence comparison with other human CoV such as HCoV-229E, 3 HCoV-OC43, 4 SARS-CoV, 5 and a most recent isolate HCoV-NL63 6 and animal CoV revealed that HECoV-4408 is most closely related to BCoV 7 with a nt identity of 98%, whereas the nt identity with HCoV-OC43 is 95%.", [["HECoV-4408", "CHEMICAL", 154, 164], ["human", "ORGANISM", 31, 36], ["CoV", "ORGANISM", 37, 40], ["HCoV-229E", "ORGANISM", 49, 58], ["3 HCoV-OC43", "ORGANISM", 60, 71], ["4 SARS-CoV", "ORGANISM", 73, 83], ["5", "ORGANISM", 85, 86], ["HCoV-NL63 6", "ORGANISM", 113, 124], ["animal CoV", "ORGANISM", 129, 139], ["HECoV-4408", "CELL", 154, 164], ["BCoV 7", "ORGANISM", 192, 198], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 255, 264], ["HCoV-NL63 6", "DNA", 113, 124], ["HECoV-4408", "DNA", 154, 164], ["BCoV 7", "DNA", 192, 198], ["HCoV", "DNA", 255, 259], ["OC43", "DNA", 260, 264], ["human", "SPECIES", 31, 36], ["human CoV", "SPECIES", 31, 40], ["HCoV-229E", "SPECIES", 49, 58], ["SARS-CoV", "SPECIES", 75, 83], ["HECoV-4408", "SPECIES", 154, 164], ["other human CoV", "TEST", 25, 40], ["HCoV", "TEST", 49, 53], ["HCoV", "TEST", 62, 66], ["OC43", "TEST", 67, 71], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["animal CoV", "TEST", 129, 139], ["HECoV", "TEST", 154, 159], ["BCoV", "TEST", 192, 196], ["a nt identity", "TEST", 204, 217], ["the nt identity", "TEST", 234, 249], ["HCoV", "TEST", 255, 259]]], ["Overall, the homology with other three human CoV was less than 60%.", [["human", "ORGANISM", 39, 44], ["CoV", "ORGANISM", 45, 48], ["human", "SPECIES", 39, 44], ["human CoV", "SPECIES", 39, 48]]], ["The fact that HECoV is more closely related the animal BCoV than to other human CoV suggests that HECoV is likely derived from BCoV.", [["HECoV", "GENE_OR_GENE_PRODUCT", 14, 19], ["BCoV", "CANCER", 55, 59], ["human", "ORGANISM", 74, 79], ["CoV", "ORGANISM", 80, 83], ["HECoV", "GENE_OR_GENE_PRODUCT", 98, 103], ["BCoV", "CANCER", 127, 131], ["HECoV", "PROTEIN", 14, 19], ["human", "SPECIES", 74, 79], ["human CoV", "SPECIES", 74, 83], ["HECoV", "SPECIES", 98, 103]]], ["This conclusion is consistent with the previous finding obtained from comparative studies on the biologic and antigenic relatedness among HECoV, HCoV-OC43 and BCoV.", [["HECoV", "CANCER", 138, 143], ["HCoV-OC43", "CELL", 145, 154], ["BCoV", "CELL", 159, 163], ["HECoV", "SPECIES", 138, 143], ["HCoV-OC43", "SPECIES", 145, 154], ["BCoV", "SPECIES", 159, 163], ["comparative studies", "TEST", 70, 89], ["HECoV", "TEST", 138, 143], ["consistent with", "UNCERTAINTY", 19, 34]]], ["2Assembly and Confirmation of a Full-Length HECoV cDNA CloneTo assemble a full-length HECoV cDNA, 9 fragments spanning the HECoV genome was cloned and sequenced.", [["fragments", "ANATOMY", 100, 109], ["Full-Length HECoV cDNA CloneTo", "DNA", 32, 62], ["HECoV cDNA", "DNA", 86, 96], ["HECoV genome", "DNA", 123, 135], ["a Full-Length HECoV cDNA CloneTo", "TREATMENT", 30, 62], ["a full-length HECoV cDNA", "TREATMENT", 72, 96], ["9 fragments", "PROBLEM", 98, 109], ["the HECoV genome", "TREATMENT", 119, 135]]], ["Each cDNA in the plasmids was released by digestion with 2 class II enzymes BsmB I and Bsa I as described, 8 generating a unique 4-nt overhang at both ends of each fragment.", [["plasmids", "ANATOMY", 17, 25], ["BsmB I", "GENE_OR_GENE_PRODUCT", 76, 82], ["Bsa I", "GENE_OR_GENE_PRODUCT", 87, 92], ["cDNA", "DNA", 5, 9], ["plasmids", "DNA", 17, 25], ["class II enzymes", "PROTEIN", 59, 75], ["BsmB I", "PROTEIN", 76, 82], ["Bsa I", "PROTEIN", 87, 92], ["4-nt overhang", "DNA", 129, 142], ["a unique 4-nt overhang", "PROBLEM", 120, 142], ["each", "OBSERVATION_MODIFIER", 159, 163], ["fragment", "OBSERVATION", 164, 172]]], ["Consequently, only the two neighboring fragments can join together.", [["fragments", "ANATOMY", 39, 48], ["fragments", "OBSERVATION", 39, 48]]], ["Thus, a unidirectional assembly of a full-length cDNA was achieved by ligation of the 9 fragments in vitro.", [["fragments", "ANATOMY", 88, 97], ["full-length cDNA", "DNA", 37, 53], ["9 fragments", "DNA", 86, 97], ["a full-length cDNA", "TREATMENT", 35, 53], ["ligation of the 9 fragments in vitro", "TREATMENT", 70, 106], ["ligation", "OBSERVATION", 70, 78], ["9 fragments", "OBSERVATION_MODIFIER", 86, 97]]], ["RNAs were then transcribed from the cDNAs in vitro with T7 RNA polymerase.", [["RNAs", "RNA", 0, 4], ["cDNAs", "DNA", 36, 41], ["T7 RNA polymerase", "PROTEIN", 56, 73], ["T7", "ANATOMY", 56, 58]]], ["Transcription of full-length RNAs was verified by RT-PCR with primers specific to the 3'-end of the viral genome (data not shown).", [["full-length RNAs", "RNA", 17, 33], ["3'-end", "DNA", 86, 92], ["viral genome", "DNA", 100, 112], ["full-length RNAs", "TREATMENT", 17, 33], ["RT-PCR", "TEST", 50, 56], ["primers", "TEST", 62, 69], ["viral genome", "OBSERVATION", 100, 112]]], ["To determine whether the in vitro transcribed, full-length RNA is infectious, we transfected the RNAs together with N gene transcripts into BHK cells by electroporation and co-cultured the BHK cells with HRT-18 cells for 3 days.", [["BHK cells", "ANATOMY", 140, 149], ["BHK cells", "ANATOMY", 189, 198], ["HRT-18 cells", "ANATOMY", 204, 216], ["BHK cells", "CELL", 140, 149], ["BHK cells", "CELL", 189, 198], ["HRT-18 cells", "CELL", 204, 216], ["full-length RNA", "RNA", 47, 62], ["N gene transcripts", "RNA", 116, 134], ["BHK cells", "CELL_LINE", 140, 149], ["BHK cells", "CELL_LINE", 189, 198], ["HRT-18 cells", "CELL_LINE", 204, 216], ["infectious", "PROBLEM", 66, 76], ["N gene transcripts into BHK cells", "TREATMENT", 116, 149], ["the BHK cells", "TEST", 185, 198], ["HRT", "TEST", 204, 207], ["infectious", "OBSERVATION", 66, 76]]], ["Medium from the coculture was blindly passaged for several times in fresh HRT-18 cells.", [["HRT-18 cells", "ANATOMY", 74, 86], ["HRT-18 cells", "CELL", 74, 86], ["HRT-18 cells", "CELL_LINE", 74, 86], ["the coculture", "TEST", 12, 25], ["fresh HRT", "TEST", 68, 77]]], ["At 72 h p.i., intracellular RNA was isolated from HRT-18 cells and the synthesis of both genomic and subgenomic mRNAs were determined by RT-PCR using primers specific to genomic fragment A or to the 5'end of N mRNA.", [["intracellular", "ANATOMY", 14, 27], ["HRT-18 cells", "ANATOMY", 50, 62], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["HRT-18 cells", "CELL", 50, 62], ["intracellular RNA", "RNA", 14, 31], ["HRT-18 cells", "CELL_LINE", 50, 62], ["genomic and subgenomic mRNAs", "RNA", 89, 117], ["genomic fragment A", "DNA", 170, 188], ["N mRNA", "RNA", 208, 214], ["intracellular RNA", "PROBLEM", 14, 31], ["HRT", "TEST", 50, 53], ["the synthesis of both genomic and subgenomic mRNAs", "PROBLEM", 67, 117], ["RT-PCR", "TEST", 137, 143], ["primers", "TREATMENT", 150, 157], ["genomic fragment A", "PROBLEM", 170, 188], ["intracellular RNA", "ANATOMY", 14, 31], ["subgenomic mRNAs", "OBSERVATION", 101, 117]]], ["Indeed, both fragments were amplified.", [["fragments", "ANATOMY", 13, 22], ["both", "OBSERVATION_MODIFIER", 8, 12], ["fragments", "OBSERVATION", 13, 22]]], ["Fragment A was digested with XhoI.", [["XhoI", "GENE_OR_GENE_PRODUCT", 29, 33], ["XhoI", "DNA", 29, 33], ["XhoI", "PROBLEM", 29, 33]]], ["Because an Xho I site was engineered specifically into fragment A, this indicates that the RNAs present in HRT-18 cells are derived from transfected RNA.", [["HRT-18 cells", "ANATOMY", 107, 119], ["Xho I", "GENE_OR_GENE_PRODUCT", 11, 16], ["HRT-18 cells", "CELL", 107, 119], ["Xho I site", "DNA", 11, 21], ["HRT-18 cells", "CELL_LINE", 107, 119], ["transfected RNA", "RNA", 137, 152], ["an Xho I site", "PROBLEM", 8, 21], ["the RNAs", "PROBLEM", 87, 95], ["HRT", "TEST", 107, 110], ["transfected RNA", "OBSERVATION", 137, 152]]], ["In contrast, although a similar fragment A was amplified from HECoV-infected HRT-18 cells (which used as a positive control), it could not be digested with XhoI (data not shown).", [["HRT-18 cells", "ANATOMY", 77, 89], ["HRT-18 cells", "CELL", 77, 89], ["XhoI", "GENE_OR_GENE_PRODUCT", 156, 160], ["HECoV-infected HRT-18 cells", "CELL_LINE", 62, 89], ["XhoI", "PROTEIN", 156, 160], ["a similar fragment A", "PROBLEM", 22, 42], ["HECoV", "TEST", 62, 67], ["infected HRT", "TREATMENT", 68, 80], ["a positive control", "TREATMENT", 105, 123], ["XhoI (data", "TEST", 156, 166], ["similar", "OBSERVATION_MODIFIER", 24, 31], ["fragment", "OBSERVATION", 32, 40]]], ["These data demonstrate that the full-length HECoV cDNA clone is infectious in HRT-18 cells.", [["HRT-18 cells", "ANATOMY", 78, 90], ["HECoV", "GENE_OR_GENE_PRODUCT", 44, 49], ["HRT-18 cells", "CELL", 78, 90], ["HECoV cDNA clone", "DNA", 44, 60], ["HRT-18 cells", "CELL_LINE", 78, 90], ["These data", "TEST", 0, 10], ["the full-length HECoV cDNA clone", "TEST", 28, 60], ["infectious", "PROBLEM", 64, 74], ["HRT", "TEST", 78, 81], ["infectious", "OBSERVATION_MODIFIER", 64, 74]]], ["The generation of a full-length HECoV infectious cDNA clone will provide a powerful approach for genetic manipulation of the HECoV genome, for studying viral pathogenesis, and for developing potential vaccines.ACKNOWLEDGMENTSThis work was supported by grants from the National Institutes of Health (AI 59244 and AI61204).", [["HECoV", "GENE_OR_GENE_PRODUCT", 125, 130], ["HECoV infectious cDNA clone", "DNA", 32, 59], ["HECoV genome", "DNA", 125, 137], ["HECoV", "SPECIES", 125, 130], ["a full-length HECoV infectious cDNA clone", "TREATMENT", 18, 59], ["a powerful approach", "TREATMENT", 73, 92], ["genetic manipulation", "TREATMENT", 97, 117], ["the HECoV genome", "TREATMENT", 121, 137], ["viral pathogenesis", "PROBLEM", 152, 170], ["potential vaccines", "TREATMENT", 191, 209]]]], "496274a8915339a0add0af8b5ca1db0c4460bf27": [["A consequence of these facility failures may be a higher transportation cost since customers need to be reassigned from their initial facilities to another operational facility that is more distant (Snyder and Daskin 2005; Cui et al. 2010; Berman et al. 2007) .", [["these facility failures", "PROBLEM", 17, 40], ["facility failures", "OBSERVATION", 23, 40]]], ["Therefore, designing a reliable supply chain network is one of the most effective approaches to deal with disruption risks, failures and uncertainties since alternative plans in the event of a disruption are mostly limited.IntroductionGenerally, uncertainties and risks in the supply chains can be classified into two major categories including operational risks and disruptions.", [["disruption risks", "PROBLEM", 106, 122], ["failures", "PROBLEM", 124, 132], ["a disruption", "PROBLEM", 191, 203], ["disruptions", "PROBLEM", 367, 378], ["disruption", "OBSERVATION", 193, 203]]], ["Risks at operational levels are short term and daily problems that mostly do not affect the functionality of the elements of supply chains.", [["short term", "PROBLEM", 32, 42]]], ["Some examples of operational risks are machine failures, short-term supply-demand imbalances, procurement prices for raw materials, production costs, poor process performance, decrease in production rate of a machine, lead times or transportation times (Ahmadi-Javid and Seddighi 2013).", [["machine failures", "PROBLEM", 39, 55], ["short-term supply", "PROBLEM", 57, 74], ["demand imbalances", "PROBLEM", 75, 92], ["procurement prices", "TREATMENT", 94, 112], ["poor process performance", "PROBLEM", 150, 174], ["decrease", "OBSERVATION_MODIFIER", 176, 184]]], ["However, disruptions can completely or partly block the flow of products in the network for a significant and uncertain amount of time.", [["disruptions", "PROBLEM", 9, 20], ["flow", "OBSERVATION", 56, 60], ["significant", "OBSERVATION_MODIFIER", 94, 105]]], ["Disruptions can be caused by natural disasters (e.g. earthquakes, floods, and hurricanes), terrorist attacks, labor strikes, political instability, power outages, sabotage or even equipment breakdowns.", [["earthquakes", "DISEASE", 53, 64], ["floods", "DISEASE", 66, 72], ["hurricanes", "DISEASE", 78, 88], ["labor strikes", "DISEASE", 110, 123], ["natural disasters", "PROBLEM", 29, 46], ["terrorist attacks", "PROBLEM", 91, 108], ["labor strikes", "PROBLEM", 110, 123], ["political instability", "PROBLEM", 125, 146], ["power outages", "TREATMENT", 148, 161], ["sabotage", "TREATMENT", 163, 171]]], ["Some events such as the Severe Acute Respiratory Syndrome (SARS) outbreak in Asia, the September 11, 2001 terrorist attack, the hurricanes Katrina and Rita (2005) , and more recent disasters like earthquake and Tsunami in Japan, 2011, highlighted the necessity to protect supply chains against disruption (Berman et al. 2009 ).IntroductionDisruption management strategies can be categorized into three main classes: mitigation strategies (in advance of a disruption), recovery strategies (after the occurrence of a disruption), and passive acceptance (Paul et al. 2016) .", [["Acute Respiratory Syndrome", "DISEASE", 31, 57], ["SARS", "DISEASE", 59, 63], ["earthquake", "DISEASE", 196, 206], ["Some events", "PROBLEM", 0, 11], ["the Severe Acute Respiratory Syndrome", "PROBLEM", 20, 57], ["IntroductionDisruption management strategies", "TREATMENT", 327, 371], ["mitigation strategies", "TREATMENT", 416, 437], ["Severe", "OBSERVATION_MODIFIER", 24, 30], ["Acute", "OBSERVATION_MODIFIER", 31, 36], ["Respiratory Syndrome", "OBSERVATION", 37, 57]]], ["Some examples of mitigation strategies are increasing the safety stock, multiple sourcing, increasing capacity, etc. Recovery strategies consist of using alternative sourcing, rescheduling of plans and rerouting the transportation plan in recovery periods.", [["mitigation strategies", "TREATMENT", 17, 38], ["increasing capacity", "PROBLEM", 91, 110], ["increasing", "OBSERVATION_MODIFIER", 43, 53], ["increasing", "OBSERVATION_MODIFIER", 91, 101], ["capacity", "OBSERVATION_MODIFIER", 102, 110]]], ["In this study, we deal with a recovery strategy, in which once a disruption happens, the alternative plan will be applied to hedge against it.", [["this study", "TEST", 3, 13]]], ["Considered network consists of suppliers, cross-docks (as consolidation points) and assembly plants which are connected to suppliers via two transportation methods: crossdocking and direct shipment.IntroductionCross-docking helps to accelerate the flow of parts and material, reduces the number of vehicles and diminishes inventory costs.", [["crossdocking and direct shipment", "TREATMENT", 165, 197], ["IntroductionCross", "TREATMENT", 198, 215], ["number", "OBSERVATION_MODIFIER", 288, 294]]], ["The main purpose of crossdocking in almost all companies is to collect various supply products in the form of pallets (boxes), consolidate them into a collection of mixed pallets of products with the same destination, and dropped them off at the consume point (manufacturing/assembly plants/end user), according to the orders.", [["various supply products", "TREATMENT", 71, 94], ["mixed pallets of products", "TREATMENT", 165, 190], ["main", "OBSERVATION_MODIFIER", 4, 8], ["purpose", "OBSERVATION_MODIFIER", 9, 16], ["collection", "OBSERVATION_MODIFIER", 151, 161], ["mixed", "OBSERVATION_MODIFIER", 165, 170], ["pallets", "OBSERVATION_MODIFIER", 171, 178]]], ["Cross-docking can reduce cost in distribution networks by consolidation, as well as applying fulltruck-load (FTL) shipments, instead of delivering all shipments directly and in less-than-truck-load (LTL).", [["Cross-docking", "TREATMENT", 0, 13], ["consolidation", "PROBLEM", 58, 71], ["applying fulltruck-load (FTL) shipments", "TREATMENT", 84, 123], ["consolidation", "OBSERVATION", 58, 71]]], ["Note that incoming pallets are usually delivered to the cross-dock facility in LTL shipments, while outgoing pallets are shipped in FTL.", [["FTL", "CANCER", 132, 135]]], ["The goal is to maximize the utilization of FTL shipments in order to decrease transportation and distribution cost.", [["FTL shipments", "TREATMENT", 43, 56]]], ["To function correctly, a reliable system of cross-docks and a precise coordination of inbound/outbound vehicles are essential (Ladier and Alpan 2016) .", [["inbound/outbound vehicles", "TREATMENT", 86, 111]]], ["Based on recent studies, JIT may make supply chains more vulnerable to local and global disturbances.", [["JIT", "SIMPLE_CHEMICAL", 25, 28], ["recent studies", "TEST", 9, 23], ["supply chains", "PROBLEM", 38, 51], ["global disturbances", "PROBLEM", 81, 100]]], ["It adds vulnerability in supply process when delays, failures, accidents, breakdowns, or fluctuation in demand occur (Ebrahimi et al. 2012) .IntroductionAs a real case, the earthquakes and tsunami in Japan 2011 reflected the vulnerability of companies to supply chain disruptions caused by natural disasters, and pinpointed the JIT strategy pioneered by Toyota and followed by many other companies.", [["accidents", "DISEASE", 63, 72], ["earthquakes", "DISEASE", 173, 184], ["failures", "PROBLEM", 53, 61], ["breakdowns", "PROBLEM", 74, 84], ["fluctuation in demand", "PROBLEM", 89, 110]]], ["After the occurrence of such events, companies made efforts to address these problems by applying recovery plans, such as using alternative suppliers.", [["such events", "PROBLEM", 24, 35], ["these problems", "PROBLEM", 71, 85], ["alternative suppliers", "TREATMENT", 128, 149]]], ["Another recovery plan in the supply chains with distribution centers is using alternative distribution facilities in the case of disruption, in which, instead of considering many scenarios for disruption, a set of distribution centers are assigned to every supplier.", [["disruption", "PROBLEM", 129, 139], ["disruption", "PROBLEM", 193, 203], ["disruption", "OBSERVATION", 129, 139]]], ["Each supplier is served by the nearest distribution center and if disruption happens, it will get service from the second one in the set and so on.", [["disruption", "PROBLEM", 66, 76]]], ["This approach can be utilized in food, clothing and auto making industries, etc.IntroductionIn this study, we design a cross-docking network that is both reliable and cost efficient.", [["This approach", "TREATMENT", 0, 13], ["this study", "TEST", 95, 105]]], ["Based on cross-docking literature, uncertainty is mostly handled by robust optimization technique and fuzzy approach in cross-docking, while in this study, the aim is to generate recovery plans to manage disruptions at cross-docks after occurrence, without enumerating all possible failure scenarios.", [["this study", "TEST", 144, 154], ["failure scenarios", "PROBLEM", 282, 299]]], ["In a scenario-based method, a large number of probabilistic failure scenarios may complicate the problem (Zhang et al. 2016 ) and increase the computational effort.IntroductionHere, therefore, the optimal location of a set of cross-docking centers is decided, when cross-docks are subject to disruption.", [["probabilistic failure scenarios", "PROBLEM", 46, 77], ["large", "OBSERVATION_MODIFIER", 30, 35], ["failure", "OBSERVATION", 60, 67]]], ["To do so, a location model is developed to minimize establishing cost of cross-docks, transportation costs in both regular and failure conditions and penalty cost of not serving suppliers and plants.", [["failure conditions", "PROBLEM", 127, 145], ["failure", "OBSERVATION", 127, 134]]], ["Moreover, regarding regular and disruption conditions, the optimal capacity of cross-docks can be specified using the formulation, which is another extension to previous reliability models.", [["regular and disruption conditions", "PROBLEM", 20, 53]]], ["The model is formulated as a mixed integer nonlinear programming model, then it is linearized to present a linear model and finally two Lagrangian relaxation methods are proposed as solution algorithms.IntroductionThe remainder of this study is organized as follows.", [["a mixed integer nonlinear programming model", "TREATMENT", 27, 70], ["two Lagrangian relaxation methods", "TREATMENT", 132, 165], ["this study", "TEST", 231, 241], ["Lagrangian relaxation", "OBSERVATION", 136, 157]]], ["3, the problem and mathematical model with heterogeneous disruption probabilities are introduced and linearization process is explained.", [["heterogeneous disruption probabilities", "PROBLEM", 43, 81], ["heterogeneous", "OBSERVATION_MODIFIER", 43, 56], ["disruption", "OBSERVATION", 57, 67]]], ["Lagrangian relaxation methods as the solution algorithms are presented in Sect.", [["Lagrangian relaxation methods", "TREATMENT", 0, 29], ["the solution algorithms", "TEST", 33, 56]]], ["4 and computational tests along with numerical results are addressed in Sect.", [["computational tests", "TEST", 6, 25]]], ["In this section, a case study is investigated, as well.", [["a case study", "TEST", 17, 29]]], ["Finally, we conclude the study in Sect.", [["the study", "TEST", 21, 30]]], ["6.LiteratureBecause of inherent stochastic nature of cross-docking, considering disruption in such environment is unavoidable, while it has not drawn much attention in the literature.", [["disruption in such environment", "PROBLEM", 80, 110], ["inherent", "OBSERVATION_MODIFIER", 23, 31], ["stochastic nature", "OBSERVATION", 32, 49]]], ["Some papers address uncertainty in location problem of cross-docking, as well as in other design or implementation levels, while some others considered a deterministic environment for various cross-docking problems.LiteratureLocation problem in cross-docking can be seen in Sung and Song (2003) , Gumus and Bookbinder (2004) , Jayaraman and Ross (2003) , Ross and Jayaraman (2008) , Bachlaus et al. (2008) , Musa et al. (2010) , Mousavi and Tavakkoli-Moghaddam (2013) , and Mousavi et al. (2014) .", [["cross-docking", "PROBLEM", 55, 68], ["implementation levels", "TEST", 100, 121], ["various cross-docking problems", "PROBLEM", 184, 214], ["LiteratureLocation problem", "PROBLEM", 215, 241]]], ["In these studies, the best location of cross-docks is determined without considering the risk of disruptions.", [["these studies", "TEST", 3, 16], ["disruptions", "PROBLEM", 97, 108], ["disruptions", "OBSERVATION", 97, 108]]], ["Very few research works tackle uncertainties on the operational level.", [["few", "OBSERVATION_MODIFIER", 5, 8]]], ["Babazadeh et al. (2014) propose a robust optimization model for location problem in a responsive supply chain consisting of plants, warehouses and cross-docks.", [["a robust optimization model", "TREATMENT", 32, 59], ["location problem", "PROBLEM", 64, 80], ["a responsive supply chain", "TREATMENT", 84, 109]]], ["They first presented a multi-stage multiproduct deterministic mixed-integer linear programming (MILP) model and then addressed the robust optimization to handle the uncertainty of parameters.", [["integer linear programming (MILP) model", "TREATMENT", 68, 107]]], ["Ladier and Alpan (2016) also use robust optimization for handling uncertainties in truck scheduling in which delay of trucks is the source of uncertainty.", [["Alpan", "TREATMENT", 11, 16], ["robust optimization", "TREATMENT", 33, 52]]], ["They apply classical techniques of robust optimization (minimax and minimization of the expected regret) and techniques from robust project scheduling (resource redundancy and time redundancy) to the problem.", [["robust optimization", "TREATMENT", 35, 54], ["minimax", "TREATMENT", 56, 63], ["the expected regret)", "TREATMENT", 84, 104], ["techniques", "TREATMENT", 109, 119]]], ["Afterward, Rahbari et al (2019) utilized two robust models in order to consider the uncertainty of travel time and freshness-life of perishable products in vehicle routing problem with cross-docking (VRPCD).", [["perishable products", "TREATMENT", 133, 152], ["cross-docking (VRPCD)", "TREATMENT", 185, 206]]], ["The authors apply an approach based on hybrid fuzzy-robust stochastic method in production planning with cross-docking.LiteratureSo far, no research work has addressed disruption in cross-docking strategy, to the best of our knowledge.", [["an approach", "TREATMENT", 18, 29], ["hybrid fuzzy", "TREATMENT", 39, 51]]], ["Hence, a brief review on reliable location problems is presented, in which the location of general facilities is determined.LiteratureThe reliable facility location problem was probably first introduced by Snyder and Daskin (2005) to handle facility disruption, where the authors assume that some facilities are subject to random failure with equal probability, while the others are reliable.", [["random failure", "PROBLEM", 323, 337]]], ["In their problem, excessive transportation costs may be burden because of serving customers by more distant facilities compared to their regularly assigned ones.", [["excessive", "OBSERVATION_MODIFIER", 18, 27]]], ["They develop a bi-objective linear integer programming model based on level assignments, where the first objective represents the total travel cost to initial facilities in regular condition (the first level assignment) and the second objective indicates the expected transportation cost after facility failures.", [["a bi-objective linear integer programming model", "TREATMENT", 13, 60]]], ["The authors apply a Lagrangian relaxation solution method to solve the model.", [["a Lagrangian relaxation solution method", "TREATMENT", 18, 57]]], ["Another study that develops this approach is the work of Berman et al. (2007) , which is based on the P-median problem.", [["Another study", "TEST", 0, 13]]], ["They relax the assumption of identical failure probabilities and formulated the stochastic problem as a nonlinear mixed integer program.", [["identical failure probabilities", "PROBLEM", 29, 60], ["a nonlinear mixed integer program", "TREATMENT", 102, 135], ["failure", "OBSERVATION", 39, 46]]], ["They also prove that the solution to the stochastic P-median problem with zero failure probabilities is equal to the solution of deterministic problem.", [["P", "DNA", 52, 53], ["the solution", "TREATMENT", 21, 33], ["zero failure probabilities", "PROBLEM", 74, 100]]], ["Based on their work, Cui et al. (2010) and Shen et al. (2011) also relax the equal failure probability assumption in Snyder and Daskin (2005) and allow the failure probabilities to be facility-specific and independent (the probabilities are taken as a priori).", [["the failure probabilities", "PROBLEM", 152, 177], ["equal", "OBSERVATION_MODIFIER", 77, 82], ["failure", "OBSERVATION", 83, 90]]], ["Cui et al. (2010) propose a mixed-integer programming formulation and a continuum approximation model to optimize the initial establishment cost and the expected transportation costs under regular and disruption conditions.", [["a mixed-integer programming formulation", "TREATMENT", 26, 65], ["a continuum approximation model", "TREATMENT", 70, 101], ["regular and disruption conditions", "TREATMENT", 189, 222]]], ["The authors provide several heuristic solution algorithms.", [["several heuristic solution algorithms", "TREATMENT", 20, 57]]], ["Shen et al. (2011) also study a similar reliable facility location problem and formulate it as a two-stage stochastic nonlinear integer programming (NIP) model.", [["a two-stage stochastic nonlinear integer programming (NIP) model", "TREATMENT", 95, 159]]], ["They propose an approximation algorithm for a special case where the failure probability of a facility is independent of the facility.", [["an approximation algorithm", "TREATMENT", 13, 39]]], ["In their study, the uncertainty is modeled via two approaches: (1) by a set of scenarios that determines which subset of facilities are subject to a failure and (2) by considering an individual and independent failure probability for each facility.", [["their study", "TEST", 3, 14], ["a failure", "PROBLEM", 147, 156], ["an individual and independent failure probability", "PROBLEM", 180, 229], ["failure", "OBSERVATION", 149, 156], ["failure", "OBSERVATION", 210, 217]]], ["Seeking for automated teller machines (ATMs) is an example, where a customer may have to try several ATMs before finding one able to provide service, due to network disruptions, maintenance, etc. The authors present a model that try to locate a set of facilities to minimize the total expected cost of customer travel including travel, reliability and information costs.", [["network", "MULTI-TISSUE_STRUCTURE", 157, 164], ["network disruptions", "PROBLEM", 157, 176]]], ["Lim et al. (2010) also apply a similar approach to manage disruption in location problem.", [["a similar approach", "TREATMENT", 29, 47]]], ["They define two classes of facilities: reliable (which are not subject to failure, but are more expensive) and unreliable and formulate the problem as a mixed integer programming (MIP) model.", [["a mixed integer programming (MIP) model", "TREATMENT", 151, 190]]], ["A Lagrangian relaxation-based algorithm is developed as a solution method.LiteratureSome extensions of reliable location problem can be found in the literature.", [["A Lagrangian relaxation-based algorithm", "TEST", 0, 39], ["a solution method", "TREATMENT", 56, 73]]], ["Li and Ouyang (2010) address a problem in which facilities are subject to heterogeneous and spatially correlated disruptions and Li et al. (2013b) further propose a supporting station model to manage interdependent facility disruptions.", [["Li", "CHEMICAL", 0, 2], ["heterogeneous and spatially correlated disruptions", "PROBLEM", 74, 124], ["a supporting station model", "TREATMENT", 163, 189]]], ["In Li et al. (2013b) , a new model is proposed to transform correlated and complex facility failures (e.g., those due to common disasters) into independent and identically distributed (i.i.d.) disruptions in a supporting structure framework.", [["disruptions in a supporting structure framework", "PROBLEM", 193, 240]]], ["Li et al. (2013a) develop a reliable P-median problem and a reliable un-capacitated fixed-charge location problem, where the facility failure probabilities are assumed to be independent and location-specific.", [["a reliable P-median problem", "PROBLEM", 26, 53], ["the facility failure probabilities", "PROBLEM", 121, 155], ["failure", "OBSERVATION", 134, 141]]], ["They also consider one layer of supplier backup and facility fortification with a limited budget.", [["supplier backup", "TREATMENT", 32, 47]]], ["A Lagrangian relaxation-based (LR) method is developed to solve the models.", [["A Lagrangian relaxation-based (LR) method", "TREATMENT", 0, 41]]], ["Jalali et al. (2016) study a bi-objective reliable facility location problem for a three-echelon supply chain network.", [["a three-echelon supply chain network", "TREATMENT", 81, 117]]], ["As the proposed model is NP-hard, the authors use an algorithm called multi-objective biogeography-based optimization (MOBBO) and compare the results with non-dominated ranking genetic algorithm (NRGA) and a multi-objective simulated annealing (MOSA).", [["an algorithm", "TEST", 50, 62], ["multi-objective biogeography", "TEST", 70, 98], ["a multi-objective simulated annealing (MOSA)", "PROBLEM", 206, 250]]], ["The authors formulate the problem based on robust optimization approach and solve it using Benders decomposition algorithm.", [["the problem", "PROBLEM", 22, 33], ["robust optimization approach", "TREATMENT", 43, 71]]], ["Many other researchers are inspired by this method of handling disruption and even utilized it in location routing problem (see Zhang et al. 2015) .LiteratureAlthough several studies consider disruption in supply chain networks (Kleindorfer and Saad 2009; Schmitt 2011; Zegordi and Davarzani 2012; Qiang and Nagurney 2012; Qi 2013; Hishamuddin et al. 2013 Hishamuddin et al. , 2014 Shi et al. 2013; Kim et al. 2014; Bode and Wagner 2015; Zhao et al. 2019 ), there are not considerable studies addressing disruption in cross-docking.LiteratureIn this paper, we focus on a cross-dock location model, where cross-docks may be subject to disruptions, causing suppliers and assembly plants to seek service from other operating cross-docks or use direct shipment strategy.", [["handling disruption", "PROBLEM", 54, 73], ["several studies", "TEST", 167, 182], ["disruption in supply chain networks", "PROBLEM", 192, 227], ["Zegordi", "TREATMENT", 270, 277], ["Davarzani", "TREATMENT", 282, 291], ["Hishamuddin et al", "TREATMENT", 332, 349], ["direct shipment strategy", "TREATMENT", 741, 765]]], ["Despite a wide range of publications in reliable facility location problem, very few considered reliable crossdocking problem.", [["reliable crossdocking problem", "PROBLEM", 96, 125], ["crossdocking", "OBSERVATION", 105, 117]]], ["For example, Hasani Goodarzi et al. (2018) address disruption in cross-docking, when disruption probabilities are the same for all cross-docking center, which is a simplifying assumption.LiteratureIn most studies reviewed in reliable facility location, the authors suppose that certain facilities are designated as indefectible, though in this paper we assume all cross-docks as unreliable and direct shipment as a safe way to move consignments.", [["disruption in cross-docking", "PROBLEM", 51, 78], ["disruption probabilities", "PROBLEM", 85, 109]]], ["The probabilities of cross-dock failure are assumed to be heterogeneous, since identical failure probability is reasonable in the case of similar facilities, such as ATMs.LiteratureThe problem we seek to formulate is how to optimally locate a set of |J| crossdocking centers on a network when cross-docks are subject to disruption, without enumerating all possible failure scenarios.", [["ATMs", "CELL_TYPE", 166, 170], ["cross-dock failure", "PROBLEM", 21, 39], ["identical failure probability", "PROBLEM", 79, 108], ["failure scenarios", "PROBLEM", 365, 382], ["dock failure", "OBSERVATION", 27, 39], ["assumed to be", "UNCERTAINTY", 44, 57], ["heterogeneous", "OBSERVATION_MODIFIER", 58, 71], ["failure", "OBSERVATION", 89, 96]]], ["The model allocates suppliers and plants to cross-docks at multiple levels.", [["The model allocates suppliers", "TREATMENT", 0, 29]]], ["The \"higherlevel\" allocations are only realized when the primary cross-docks are subject to a disruption.", [["a disruption", "PROBLEM", 92, 104], ["disruption", "OBSERVATION", 94, 104]]], ["As can be inferred from literature, disruption issues have not been addressed perfectly in cross-docking so far and it seems that robust optimization is a common method to address uncertainty in cross-docking.", [["disruption issues", "PROBLEM", 36, 53]]], ["In other words, there is no piece of research considering disruption in cross-docking, to the best of authors' knowledge.", [["no", "UNCERTAINTY", 25, 27]]], ["Therefore, in this study, the aim is to generate recovery plans to manage disruptions at cross-docks after occurrence.", [["this study", "TEST", 14, 24]]], ["Another extension to previous works is that optimal capacity of cross-docks is specified regarding regular and disruption conditions using the formulation.Problem definitionThis study addresses a network in which cross-docks are considered as consolidation nodes serving the suppliers and assembly plants.", [["the formulation", "TREATMENT", 139, 154], ["Problem definition", "PROBLEM", 155, 173], ["This study", "TEST", 173, 183], ["consolidation nodes", "PROBLEM", 243, 262], ["consolidation", "OBSERVATION", 243, 256]]], ["In addition to cross-docking strategy, it is also possible to use direct shipment whenever it is economic.", [["cross-docking strategy", "TREATMENT", 15, 37], ["direct shipment", "TREATMENT", 66, 81]]], ["Although each supplier will be served by only one operational cross-dock, it needs to be assigned to a group of cross-docks that are ordered by levels, meaning that when the lowest-level facility is subject to a failure, the service is provided by the next level cross-dock that is operational; and so on.", [["cross-docks", "TREATMENT", 112, 123], ["a failure", "PROBLEM", 210, 219], ["failure", "OBSERVATION", 212, 219]]], ["Another backup plan can be direct shipment strategy which means that if all operational cross-docks are too far away from a supplier, direct shipment can be utilized.Problem definitionIn order elaborate the concept of level in this problem, let us give an example.", [["Another backup plan", "TREATMENT", 0, 19], ["direct shipment strategy", "TREATMENT", 27, 51], ["direct shipment", "TREATMENT", 134, 149], ["Problem definition", "PROBLEM", 166, 184]]], ["In the first level (r = 1), the normal condition is considered and the assignment of suppliers to cross-docks is as bellow, which means that cross-dock 1 serves supplier 4 and 9, cross-dock 2 serves supplier 5, 7 and 8; and cross-dock 3 serves supplier 1, 2, 3 and 10.", [["supplier 5, 7 and 8", "PROTEIN", 199, 218], ["supplier 1, 2, 3 and 10", "PROTEIN", 244, 267], ["normal", "OBSERVATION", 32, 38]]], ["Now the goal is to define a backup strategy (including cross-docking or direct shipment) for each supplier, independent of other suppliers.", [["a backup strategy", "TREATMENT", 26, 43]]], ["The second level assignment (r = 2) meaning that if a cross-dock fails, its assigned suppliers are allocated to other crossdocks or to direct shipment.", [["The second level assignment", "TEST", 0, 27]]], ["For example, both suppliers 1 and 10, at normal condition, are allocated to cross-dock 3, but if a disruption happens to this cross-dock, the first supplier is assigned to cross-dock 2, while suppler 10 is served by direct shipment.Problem definitionIn order to compare scenario-based method with this approach, consider this problem in a scenario-based format.", [["a disruption", "PROBLEM", 97, 109], ["this approach", "TREATMENT", 297, 310]]], ["There are eleven different scenarios for failure in crossdocks: (1) all cross-docks are normal (1 case), (2) all cross-docks are disrupted (1 case), (3) one of cross-docks is disrupted (6 cases), (4) two of cross-dock are disrupted (3 cases).", [["failure in crossdocks", "PROBLEM", 41, 62], ["eleven", "OBSERVATION_MODIFIER", 10, 16], ["different scenarios", "OBSERVATION", 17, 36], ["normal", "OBSERVATION", 88, 94]]], ["As can be inferred, \"a large number of probabilistic failure scenarios complicates the problem\" (Zhang et al. 2016 ) and increases the computational effort.", [["probabilistic failure scenarios", "PROBLEM", 39, 70], ["large", "OBSERVATION_MODIFIER", 23, 28], ["failure", "OBSERVATION", 53, 60], ["computational effort", "OBSERVATION", 135, 155]]], ["It should be noted that using direct shipment is possible at each level, if it is less costly compared to cross-docking, meaning that the same cardinality |R| of the support is assumed for all suppliers, while all or some of them may be assigned to direct shipment in level r <|R|.", [["direct shipment", "TREATMENT", 30, 45]]], ["Therefore, the cross-docking reliability problem extends the cross-docking location problem taking into account the random disruptions of cross-docks.", [["the cross-docking reliability problem", "PROBLEM", 11, 48]]], ["Other assumptions are as follows:Problem definition\u2022 Cross-docking disruptions are independent and heterogeneous meaning that each cross-dock may fail with a given specific probability and multiple cross-docks may fail simultaneously.", [["Cross-docking disruptions", "PROBLEM", 53, 78], ["multiple cross-docks", "PROBLEM", 189, 209], ["heterogeneous", "OBSERVATION_MODIFIER", 99, 112]]], ["At each level, each supplier can be served at most by one cross-dock, while assembly plants can receive parts from more than one cross-dock. \u2022 A penalty cost is considered for cases in which disruption causes a supplier not to be served at all (by any of the assigned cross-docking centers or direct shipment). \u2022 As mentioned above, when a disruption occurs, it seems more reasonable to use other cross-docking centers or change the transportation strategy from cross-docking to direct shipment until the disruptive event is repaired.", [["A penalty cost", "TREATMENT", 143, 157], ["a disruption", "PROBLEM", 338, 350], ["other cross-docking centers", "TREATMENT", 391, 418], ["the transportation strategy", "TREATMENT", 429, 456], ["penalty cost", "OBSERVATION", 145, 157]]], ["In the cases that disruption leads to the permanent destruction of one or more cross-docks, resolving the location problem will be recommended.", [["the permanent destruction", "PROBLEM", 38, 63], ["disruption", "OBSERVATION", 18, 28], ["permanent", "OBSERVATION_MODIFIER", 42, 51], ["destruction", "OBSERVATION", 52, 63]]], ["In other words, when a huge disruption occurs in such a way that a cross-dock cannot be utilized any more, it is better to resolve a location problem to find a new point to establish an alternative cross-dock.Problem definitionIn Fig. 1 , the supply chain network is indicated in a typical level.", [["a huge disruption", "PROBLEM", 21, 38], ["disruption", "OBSERVATION", 28, 38]]], ["It is obvious that in various levels, the configuration of network is different.", [["different", "OBSERVATION_MODIFIER", 70, 79]]], ["The problem addresses: (1) the location of cross-docks, (2) the initial allocation of suppliers and assembly plants to cross-docks and (3) back up plan for allocation in the case of disruption in crossdocking centers.", [["allocation", "TREATMENT", 156, 166], ["disruption in crossdocking centers", "PROBLEM", 182, 216], ["disruption", "OBSERVATION", 182, 192]]], ["Moreover, the best capacity of opened cross-docks, as well as the transportation strategy in each level to move parts from suppliers to assembly plants is determined.", [["the transportation strategy", "TREATMENT", 62, 89]]], ["The objective is to minimize the total cross-dock establishing cost and the expected transportation and penalty costs.Mathematical modelIn this sub-section, we first introduce the notation and the decision variables used throughout the study.", [["the study", "TEST", 232, 241]]], ["We then formulate the problem as a mixed integer nonlinear programming model.", [["a mixed integer nonlinear programming model", "TREATMENT", 33, 76]]], ["The sets, parameters and variables used in the model are described in the following sub-section.Sets and parametersDefine J to be the set of assembly plants {j = 1, 2, \u2026, |J|}, I to be the set of candidate cross-docks {i = 1, 2, \u2026, |I|}, L to be the set of suppliers {l = 1, 2, \u2026, |L|} and finally, R as the set of levels {r = 1, \u2026, |R|}.", [["I", "PROTEIN", 233, 234], ["L", "PROTEIN", 238, 239], ["R", "PROTEIN", 299, 300], ["docks", "TEST", 212, 217], ["suppliers", "TEST", 257, 266], ["{l", "TEST", 267, 269], ["\u2026", "TEST", 278, 279], ["finally", "TEST", 290, 297], ["levels", "TEST", 315, 321], ["{r", "TEST", 322, 324], ["\u2026", "TEST", 330, 331]]], ["The term \"Node\" will be used to represent the assembly plants, suppliers and cross-docks.", [["The term \"Node\"", "PROBLEM", 0, 15], ["Node", "OBSERVATION", 10, 14]]], ["We assume that probability of failure in each cross-dock is given by 0 \u2264 q i < 1 , and cross-dock disruptions are independent of each other.", [["failure in each cross-dock", "PROBLEM", 30, 56], ["failure", "OBSERVATION", 30, 37]]], ["When a cross-dock fails, it cannot provide service and its assigned nodes will be either served by other operational facilities, or linked by direct shipment.", [["nodes", "MULTI-TISSUE_STRUCTURE", 68, 73], ["nodes", "OBSERVATION", 68, 73]]], ["In the cases that no transportation strategy is used, it will be subject to a penalty cost.", [["transportation strategy", "TREATMENT", 21, 44]]], ["The demand of plant j from supplier l is denoted by d jl that must be met by vehicles with capacity Q. Transportation cost from node i to node j (i, j \u2208 (L \u222a I \u222a J)) is given by c ij .", [["node", "ANATOMY", 138, 142], ["c ij", "GENE_OR_GENE_PRODUCT", 178, 182], ["node i to node j (i, j \u2208 (L \u222a I \u222a J)", "TREATMENT", 128, 164], ["plant j", "OBSERVATION", 14, 21], ["ij", "ANATOMY", 180, 182]]], ["Associated with each supplier l is a cost l that represents the penalty cost for not serving that supplier.", [["penalty", "OBSERVATION", 64, 71]]], ["The parameters are briefly listed as follows: The number of vehicles from supplier l to cross-dock i at level r n ijrSets and parametersThe number of vehicles from cross-dock i to plant j at level r B lijr 1: if demand of plant j from supplier l goes thorough cross-dock i at level r; 0: otherwise w ijr Quantity of parts shipped from cross-dock i to plant j at level r P lir Probability that cross-dock i serves supplier l at level r PP lr Probability that direct shipment serves supplier l at level r Pr ijr Probability that cross-dock i serves plant j at level r l Probability that supplier l will not be served at all Cap i Capacity of cross-dock i.Mathematical formulationWith the notations introduced above, the problem can be formulated as a mathematical model (CDL-NLP) as follows:Mathematical formulation(1)Mathematical formulationThe objective function minimizes the total expected cost including the fixed cost of establishing cross-docks, the expected transportation costs (including direct transshipment cost, indirect transportation cost from suppliers to cross-docks, variable cross-docking cost at receiving process and delivery cost to assembly plants) and finally the expected penalty cost.", [["Mathematical formulation", "TREATMENT", 816, 840], ["direct transshipment cost", "TREATMENT", 996, 1021], ["variable cross-docking cost at receiving process", "TREATMENT", 1083, 1131], ["delivery", "TREATMENT", 1136, 1144], ["penalty cost", "OBSERVATION", 1195, 1207]]], ["Equation (5) determines the load to be sent from cross-docks to assembly plants and ensures that at each level, a flow entering a cross-dock is equal to the flow exiting it.Mathematical formulationConstraints (6) and (7) ensure that when \u03a3j B lijr is positive, then Z ilr should be equal to one, otherwise Z ilr = 0.", [["Z ilr", "PROTEIN", 266, 271], ["the load", "TEST", 24, 32], ["Z ilr", "TREATMENT", 266, 271], ["Z ilr", "TEST", 306, 311], ["flow", "OBSERVATION", 114, 118], ["flow", "OBSERVATION", 157, 161], ["positive", "OBSERVATION", 251, 259]]], ["These constraints stipulate that cross-dock i gives service to supplier l, if B lijr is equal to one, at least for one assembly plant.", [["B lijr", "GENE_OR_GENE_PRODUCT", 78, 84], ["B lijr", "PROTEIN", 78, 84], ["plant", "OBSERVATION", 128, 133]]], ["Equations (9-13) are the \"probability\" equations.", [["Equations", "TEST", 0, 9]]], ["(9) and (10), the probability that a cross-dock serves a supplier at each level is determined recursively, while in Eqs.", [["a cross-dock", "TREATMENT", 35, 47]]], ["(11) and (12) the probability that direct shipment is used to serve suppliers at different levels is calculated.", [["direct shipment", "TREATMENT", 35, 50]]], ["Equation (14) finds the probability that a supplier is not served at all.", [["Equation", "TEST", 0, 8]]], ["The types of decision variables are defined in (16-18).Mathematical formulationThe proposed formulation is a nonlinear model consisting of |I| + |L||R|(|J| + |I||J| + |I|) binary variables, (|L| + 2|J|) |R||I| integer variables, |R|(|I||L| + |L| + |I||J|) + |L| continues variables and |R|(|L||J| + 3|I||L| + 3|I||J|) + 2|L|(|I| + 1) + (|R| \u2212 1)|L|(|I| + 1) active constraints.", [["I|", "PROTEIN", 168, 170], ["Mathematical formulation", "TREATMENT", 55, 79], ["J", "TEST", 162, 163], ["I|", "TEST", 168, 170], ["binary variables", "TEST", 172, 188], ["J", "TEST", 199, 200], ["I", "TEST", 207, 208], ["integer variables", "TEST", 210, 227], ["I", "TEST", 234, 235], ["I", "TEST", 249, 250], ["J", "TEST", 252, 253], ["variables", "TEST", 272, 281], ["J", "TEST", 294, 295], ["I", "TEST", 301, 302], ["I", "TEST", 311, 312], ["J", "TEST", 314, 315], ["I", "TEST", 326, 327], ["R|", "TEST", 338, 340], ["\u2212", "TEST", 341, 342], ["I", "TEST", 350, 351], ["active constraints", "PROBLEM", 358, 376]]], ["It can be reduced to un-capacitated facility location problem if (1) crossdocking is the only transportation strategy and no direct shipment is allowed (by increasing the cost of direct shipment to a very big number), (2) all cross-docks are perfectly reliable ( q i = 0 \u2200i \u2208 I ), so all assignments are at the primary level (R = 1) and penalty cost is zero, thus the model is reducible to a two-level extension of classical facility location problem.", [["reducible", "OBSERVATION", 377, 386]]], ["The latter is known to be NP-hard as acclaimed by Nemhauser and Wolsey (1999) ; therefore, the studied problem is NP-hard as well.LinearizationThere are some nonlinear terms in the mathematical model and the solver is not able to find a solution in a reasonable time, even for small instances.", [["known to be", "UNCERTAINTY", 14, 25], ["some", "OBSERVATION_MODIFIER", 153, 157], ["nonlinear", "OBSERVATION_MODIFIER", 158, 167], ["terms", "OBSERVATION_MODIFIER", 168, 173], ["mathematical model", "OBSERVATION", 181, 199]]], ["In order to do (18) P lir , PP lr , Pr ijr , l \u2208 [0, 1] so, first the linearization of objective function is implemented.", [["(18) P", "CHEMICAL", 15, 21], ["Pr ijr", "SIMPLE_CHEMICAL", 36, 42], ["PP lr", "TEST", 28, 33], ["Pr", "TEST", 36, 38]]], ["In the objective function (1), the following terms are nonlinear:LinearizationWe define PP lr \u00d7 U ljr as ljr , and B lijr \u00d7 P lir as lijr .", [["P", "CHEMICAL", 124, 125], ["ljr", "PROTEIN", 105, 108], ["B lijr", "PROTEIN", 115, 121], ["P lir", "PROTEIN", 124, 129], ["lijr", "PROTEIN", 133, 137], ["ljr", "TEST", 105, 108]]], ["(19)\u2212(26) demonstrate the linearization process of these two terms of objective function.LinearizationFor m lir \u00d7 P lir , as well as n ijr \u00d7 Pr ijr linearization is not as straightforward as the above process, since in these cases the product of an integer and a continuous variable needs to be linearized.", [["P lir", "DNA", 114, 119], ["ijr", "PROTEIN", 135, 138], ["Pr ijr linearization", "TREATMENT", 141, 161], ["an integer", "PROBLEM", 246, 256]]], ["In order to do so, we show m lir and n ijr by m and n and define an upper bound equal to M and N for them, respectively.", [["upper", "ANATOMY_MODIFIER", 68, 73]]], ["Then, we replace theLinearizationinteger variables of m and n by a series of binary variables m \u2032 t and n \u2032 j , i.e.Linearization).", [["t and n \u2032 j", "TREATMENT", 98, 109]]], ["Each product of integers now is a product of binaries and product of the corresponding binary variables can be linearized simply.", [["binaries", "OBSERVATION", 45, 53]]], ["Equations (27)\u2212(32) and (33)\u2212(38) show the linearization process for m lir \u00d7 P lir and n ijr \u00d7 Pr ijr , respectively.LinearizationLinearization of constraints (10), (12) and (14) is implemented using constraints (39)-(42).", [["P", "CHEMICAL", 77, 78], ["ijr", "PROTEIN", 89, 92], ["Equations", "TEST", 0, 9], ["the linearization process", "PROBLEM", 39, 64]]], ["(10), (12) and (14) are nonlinear, the only nonlinear term is P lkr \u00d7 Z klr , which is a product of a continuous and a binary variable.", [["P lkr", "DNA", 62, 67]]], ["We replace each P lkr \u00d7 Z klr with a new variable klr and a set of new constraints (39)-(42) is added to the programming model.LinearizationIn constraint (13), some modifications are needed to linearize the equation.", [["P lkr", "DNA", 16, 21], ["Z klr", "DNA", 24, 29], ["each P lkr \u00d7 Z klr", "TREATMENT", 11, 29]]], ["In this constraint, Pr ijr and w ijr are continuous and integer variables, respectively.", [["Pr ijr", "GENE_OR_GENE_PRODUCT", 20, 26], ["w ijr", "GENE_OR_GENE_PRODUCT", 31, 36], ["Pr", "DNA", 20, 22], ["Pr ijr and w ijr", "TREATMENT", 20, 36]]], ["The linearization process is as follows.LinearizationRegarding the linearization of nonlinear constraints, the following model (CDL-LP) will be achieved:LinearizationUnlike most scenario-based stochastic programming formulations that have exponential number of variables and constraints, the proposed formulation is polynomial in size.", [["stochastic programming formulations", "TREATMENT", 193, 228], ["linearization process", "OBSERVATION", 4, 25], ["exponential", "OBSERVATION_MODIFIER", 239, 250], ["number", "OBSERVATION_MODIFIER", 251, 257], ["polynomial", "OBSERVATION_MODIFIER", 316, 326], ["size", "OBSERVATION_MODIFIER", 330, 334]]], ["In other words, it attempts to find the best solution without enumerating all possible combinatorial disruption scenarios.", [["combinatorial disruption scenarios", "PROBLEM", 87, 121]]], ["As indicated by Cui et al. (2010) , if |R| = |I|, then the programming model is equal to stochastic programming formulation that covers all disruption scenarios.", [["the programming model", "TEST", 55, 76], ["stochastic programming formulation", "TREATMENT", 89, 123], ["disruption scenarios", "OBSERVATION", 140, 160]]], ["One can refer to Cui et al. (2010) for more details.Programming formulation with identical disruption probability qWhen the disruption probability is the same for all cross-docking centers, the original model (CDL-NLP) simply changes to cross-docking location problem with homogenous disruption probability (HDCDL).", [["Programming formulation", "TREATMENT", 52, 75], ["identical disruption probability", "PROBLEM", 81, 113], ["the disruption probability", "PROBLEM", 120, 146], ["homogenous disruption probability", "PROBLEM", 273, 306], ["homogenous", "OBSERVATION_MODIFIER", 273, 283], ["disruption", "OBSERVATION", 284, 294]]], ["This problem has been introduced by Hasani Goodarzi et al. (2018) as a mixed integer linear programming model, whose model is presented in \"Appendix 1\".", [["a mixed integer linear programming model", "TREATMENT", 69, 109]]], ["Parameter q represents the identical failure probability for all cross-docks.", [["the identical failure probability", "PROBLEM", 23, 56], ["failure", "OBSERVATION", 37, 44]]], ["Thus, constraint (10) changes to the following constraint.Subject to(2)\u2212(9) (11)Subject toBased on above equation, the probability of using direct shipment for suppliers in level r ( PP lr ) is q r\u22121 .", [["direct shipment", "TREATMENT", 140, 155], ["level r ( PP lr )", "TREATMENT", 173, 190]]], ["Constraint (13) of model (CDL-NLP), the probability of serving plant j by cross-dock i, is modified to the following constraint.Subject toFinally, l is calculated regarding this constraint:Subject toThese modified fixed values are replaced with corresponding variables in the model (CDL-NLP) that provides the formulation of HDCDL.Solution method: Lagrangian relaxationThe proposed model (CDL-NLP) can be solved using a standard optimization software such as GAMS via its BONMIN solver in nonlinear case, as well as by CPLEX for linear model (CDL-LP), although the computational time is considerable for (CDL-NLP) even in small sized instances with five suppliers and one assembly plant.", [["HDCDL", "SIMPLE_CHEMICAL", 325, 330], ["CPLEX", "PROTEIN", 519, 524], ["CDL", "PROTEIN", 605, 608], ["NLP", "PROTEIN", 609, 612], ["HDCDL", "TREATMENT", 325, 330], ["Solution method", "TREATMENT", 331, 346], ["Lagrangian relaxation", "TREATMENT", 348, 369], ["The proposed model (CDL-NLP)", "TREATMENT", 369, 397], ["a standard optimization software", "TREATMENT", 418, 450], ["its BONMIN solver", "TREATMENT", 468, 485], ["small sized", "OBSERVATION_MODIFIER", 622, 633]]], ["Thus, we apply a Lagrangian relaxation (LR) method to solve the problem effectively.", [["a Lagrangian relaxation (LR) method", "TREATMENT", 15, 50]]], ["We relax constraint set (3) as performed by Cui et al. (2010) with Lagrange multipliers \u03bb il .", [["Lagrange multipliers \u03bb il", "TREATMENT", 67, 92]]], ["Relaxing this constraint cause a decomposition in the problem, since this constraint shows the connection between two decision variables ( Z ilr and y i ).", [["a decomposition in the problem", "PROBLEM", 31, 61]]], ["In the literature of Un-capacitated facility location problem (UFLP), this constraint is usually selected for relaxing, since, compared to relaxing other constraints, it reduces the computational effort.", [["computational effort", "OBSERVATION", 182, 202]]], ["The following problem is obtained after relaxing constraint set (3): where min y,U,B,Z,m,n is the following relaxed formulation:Solution method: Lagrangian relaxation(62)Solution method: Lagrangian relaxationHence, this method attempts to minimize the objective function value regarding the original decision variables y i , U ljr , B lijr , Z ilr ,m lir , n ijr , while maximizing it with respect to \u03bb il .", [["B lijr", "SIMPLE_CHEMICAL", 333, 339], ["Lagrangian relaxation", "TREATMENT", 145, 166], ["Lagrangian relaxationHence", "TREATMENT", 187, 213], ["this method attempts", "TREATMENT", 215, 235], ["B lijr , Z ilr", "TREATMENT", 333, 347]]], ["The objective function can be rewritten as follows:Lagrangian relaxation outlineThe main concept of Lagrangian relaxation algorithm is to identify the set of constraints that increase the computational complexity of the model and to relax them.", [["Lagrangian relaxation algorithm", "TEST", 100, 131], ["main", "OBSERVATION_MODIFIER", 84, 88], ["Lagrangian relaxation", "OBSERVATION", 100, 121]]], ["Hence, the solution approach is guided towards reducing the amount of violation (Mohammad Nezhad et al. 2013 ).", [["the solution approach", "TREATMENT", 7, 28]]], ["The relaxed constraint set provides a lower bound.", [["a lower bound", "PROBLEM", 36, 49], ["relaxed constraint", "OBSERVATION", 4, 22]]], ["A corresponding upper bound is then generated meaning that at each iteration of algorithm, the lower and the upper bounds are derived concurrently.", [["A corresponding upper bound", "PROBLEM", 0, 27], ["algorithm", "TEST", 80, 89], ["upper bound", "OBSERVATION_MODIFIER", 16, 27], ["lower", "ANATOMY_MODIFIER", 95, 100], ["upper", "ANATOMY_MODIFIER", 109, 114]]], ["Lagrangian relaxation improves the lower and upper bounds through updating the Lagrange multipliers.", [["Lagrangian relaxation", "TEST", 0, 21], ["the Lagrange multipliers", "TREATMENT", 75, 99]]], ["The process is repeated until either the gap between the lower and upper bounds goes below a predefined threshold or another stopping criterion is met (Lim et al. 2010) .", [["lower", "ANATOMY_MODIFIER", 57, 62], ["upper", "ANATOMY_MODIFIER", 67, 72]]], ["The main steps of LR for solving the model are presented below (Fig. 2) .Lagrangian relaxation outlineThe steps of algorithm are described in detail in the following sub-sections.Computation of lower boundThe first step is to compute the lower bound.", [["LR", "TREATMENT", 18, 20], ["Lagrangian relaxation outline", "TREATMENT", 73, 102], ["lower bound", "PROBLEM", 194, 205], ["main", "OBSERVATION_MODIFIER", 4, 8], ["lower bound", "OBSERVATION_MODIFIER", 194, 205], ["lower", "ANATOMY_MODIFIER", 238, 243]]], ["For fixed values of the Lagrange multipliers il , (59) provides a lower bound on the optimal objective function (52), which is the linear reformulation of objective (1).", [["a lower bound", "PROBLEM", 64, 77]]], ["Two methods are appliedComputation of lower boundto generate lower bounds: in the first one, lower bounds are derived by solving the relaxed programming model (LRCDL) via exact algorithms, while in the second method, a fast-approximate approach is used to provide lower bounds based on Cui et al. (2010) .", [["Two methods", "TREATMENT", 0, 11], ["a fast-approximate approach", "TREATMENT", 217, 244], ["lower", "ANATOMY_MODIFIER", 38, 43], ["lower bounds", "OBSERVATION", 61, 73]]], ["Considering these two methods of obtaining lower bound, two Lagrangian relaxations are proposed.An approximate model to find lower boundAlthough in the exact model (LRCDL) one constraint has been relaxed, its worst-case complexity is still exponential.", [["lower bound", "PROBLEM", 43, 54], ["two Lagrangian relaxations", "TREATMENT", 56, 82], ["lower bound", "PROBLEM", 125, 136], ["Lagrangian relaxations", "OBSERVATION", 60, 82], ["lower bound", "OBSERVATION_MODIFIER", 125, 136], ["relaxed", "OBSERVATION_MODIFIER", 196, 203]]], ["Thus, in this section we provide a fast approximate formulation and algorithm to find lower bounds in polynomial time.", [["a fast approximate formulation", "TREATMENT", 33, 63]]], ["Inspired by Cui et al. (2010) , we replace the variable probabilities P lir, PP lr and Pr ijr with fixed numbers in the approximate formulation.", [["Pr ijr", "SIMPLE_CHEMICAL", 87, 93], ["PP lr", "TREATMENT", 77, 82], ["Pr ijr", "TREATMENT", 87, 93], ["fixed numbers", "TEST", 99, 112]]], ["For 1 \u2264 r \u2264 |R| , we replace P lir with \u0192 r and PP lr with r , where \u0192 r and r are computed using Eqs.", [["P lir", "DNA", 29, 34], ["P lir", "TREATMENT", 29, 34], ["\u0192 r and PP lr", "TREATMENT", 40, 53]]], ["(66) and (67).An approximate model to find lower boundIt should be noted that disruption probability for direct shipment is equal to zero and we do not consider it in ranking of cross-docks; the ranking is only done for cross-docking centers.", [["lower bound", "PROBLEM", 43, 54], ["disruption probability", "PROBLEM", 78, 100], ["direct shipment", "PROBLEM", 105, 120], ["lower bound", "OBSERVATION_MODIFIER", 43, 54]]], ["The Probability that plant j is served by cross-dock i at level r (Pr ijr ) also can be replaced by f r .", [["plant j", "TREATMENT", 21, 28], ["plant j", "OBSERVATION", 21, 28]]], ["Equation (68) calculates the penalty of not serving a supplier at all.", [["Equation", "TEST", 0, 8]]], ["Regarding the above description, if there is direct shipment in any level of reassignment, the penalty cost will be zero.An approximate model to find lower bound(66)Initialize Lagrange multipliers While (Termination condition not met) Do { Increment iteration counter Compute the lower bound Compute the upper bound Check termination condition Update Lagrange multipliers }Based on these modifications, the mathematical formulation will change to a linear programming model.", [["lower bound", "PROBLEM", 150, 161], ["Lagrange multipliers", "TREATMENT", 176, 196], ["the lower bound", "PROBLEM", 276, 291], ["these modifications", "TREATMENT", 382, 401], ["the mathematical formulation", "TREATMENT", 403, 431], ["a linear programming model", "TREATMENT", 447, 473]]], ["The approximated model (CDL-APRX) is presented below.Computation of upper boundAt each iteration of Lagrangian relaxation, both a lower and an upper bound are obtained.", [["upper bound", "PROBLEM", 68, 79], ["Lagrangian relaxation", "TREATMENT", 100, 121], ["upper bound", "OBSERVATION_MODIFIER", 68, 79], ["Lagrangian relaxation", "OBSERVATION", 100, 121], ["lower", "ANATOMY_MODIFIER", 130, 135], ["upper", "ANATOMY_MODIFIER", 143, 148]]], ["The solution of relaxed model (LRCDL) provides a lower bound.", [["The solution of relaxed model (LRCDL)", "TREATMENT", 0, 37], ["a lower bound", "PROBLEM", 47, 60]]], ["If it is feasible for original model (CDL-LP), then it provides an upper bound as well, and in fact an optimal solution for (CDL-LP): since the violation of constraint (3) is 0 and the lower and upper bounds are equal.", [["original model (CDL-LP", "TEST", 22, 44], ["an upper bound", "PROBLEM", 64, 78], ["upper", "ANATOMY_MODIFIER", 67, 72], ["lower", "ANATOMY_MODIFIER", 185, 190], ["upper", "ANATOMY_MODIFIER", 195, 200], ["equal", "OBSERVATION", 212, 217]]], ["Upper bounds are computed using the following process:Computation of upper boundFirst, the decision variables are recalled from the lower bound solution and set as a parameter in programming model (CDL-LP).", [["the lower bound solution", "TREATMENT", 128, 152]]], ["In this procedure after finding a lower bound, the algorithm checks if the solution is feasible or not and if it is not, a modification on solution is executed.", [["this procedure", "TREATMENT", 3, 17], ["a lower bound", "PROBLEM", 32, 45], ["the algorithm checks", "TEST", 47, 67], ["the solution", "TREATMENT", 71, 83], ["a modification on solution", "TREATMENT", 121, 147]]], ["In order to do so, a loop is defined in which the following process is done.Computation of upper boundIn order to strengthen the upper bound, another loop is defined that performs as a cutting constraint: if a cross-dock serves no supplier in all levels, it must be closed.Computation of upper boundAfter implementing this phase, we compute the upper bound for the original objective function (52) using the decision variables.Multiplier initialization and updatingThe Lagrange multipliers, \u03bb, are initialized by setting their initial values to 2 ( (0) il = 2 ).", [["a loop", "TREATMENT", 19, 25], ["upper bound", "PROBLEM", 91, 102], ["upper bound", "PROBLEM", 288, 299], ["the upper bound", "PROBLEM", 341, 356], ["loop", "OBSERVATION", 21, 25], ["upper bound", "OBSERVATION_MODIFIER", 91, 102], ["upper", "ANATOMY_MODIFIER", 129, 134], ["upper bound", "OBSERVATION_MODIFIER", 288, 299]]], ["As mentioned before, each value of \u03bb provides a lower bound on the optimal objective value of (CDL-LP).", [["\u03bb", "PROTEIN", 35, 36], ["a lower bound", "PROBLEM", 46, 59]]], ["Thus, in order to find the best possible lower bound which is close to optimal value, we need to solve max obj(\u03bb).Multiplier initialization and updatingThis problem is solved approximately using sub-gradient optimization as described by Fisher (1981 Fisher ( , 1985 and Daskin (1995) .", [["lower bound", "PROBLEM", 41, 52], ["Multiplier initialization", "TREATMENT", 114, 139], ["sub-gradient optimization", "TREATMENT", 195, 220]]], ["At iteration n, the step size \u2032n is calculated by Eq.", [["size", "OBSERVATION_MODIFIER", 25, 29]]], ["(70), where UB is the best known upper bound and LB is the lower bound found at the current iteration. n is a constant at iteration n, halved when 10 consecutive iterations fail to improve, and 1 is initialized to 2.", [["UB", "GENE_OR_GENE_PRODUCT", 12, 14], ["UB", "PROTEIN", 12, 14], ["upper bound", "PROBLEM", 33, 44], ["the lower bound", "PROBLEM", 55, 70], ["upper", "ANATOMY_MODIFIER", 33, 38]]], ["Using the lower and upper bounds obtained, the multipliers are updated based on Eq.", [["lower", "ANATOMY_MODIFIER", 10, 15], ["upper", "ANATOMY_MODIFIER", 20, 25]]], ["UB\u2212LB LB < , in which is the pre-specified optimality tolerance (the gap between the best lower and upper bound gets close to zero); we typically set the tolerance value to 0.001; 2.", [["upper", "ANATOMY_MODIFIER", 100, 105]]], ["The number of iterations reaches a maximum value determined by the user (i.e., n > n max ) or the maximum computing time is obtained; 3.Termination criteriaStep size constant n gets close to zero; i.e., n < min , which means that a negligible change in the solution configuration is detected.", [["a negligible change in the solution configuration", "PROBLEM", 230, 279], ["size", "OBSERVATION_MODIFIER", 161, 165], ["constant", "OBSERVATION_MODIFIER", 166, 174], ["negligible", "OBSERVATION_MODIFIER", 232, 242], ["change", "OBSERVATION_MODIFIER", 243, 249]]], ["We typically set the minimum level of step size constant ( min ) to 0.0001.Computational resultsAlthough there are some data sets in Snyder and Daskin (2005) and Lim et al. (2010) to evaluate the formulation and algorithm, the network and environment in our problem is different from these earlier studies.", [["algorithm", "TEST", 212, 221], ["these earlier studies", "TEST", 284, 305], ["size", "OBSERVATION_MODIFIER", 43, 47]]], ["In our case, we consider a three-echelon supply chain regarding cross-docking networks and take in to account location and transportation problems, simultaneously, while they design a two-echelon reliable location problem.", [["a three-echelon supply chain", "TREATMENT", 25, 53]]], ["Thus, the geographical distribution of suppliers and assembly plants (i.e. the distance between them) is inspired by test problems considered by Hasani Goodarzi and Zegordi (2016): set 1(10 3 1) (i.e. 10 part suppliers, 3 cross-docks and 1 assembly plant), set 2 (17 5 2), set 3 (24 6 3), set 4 (30 8 4).", [["geographical", "OBSERVATION_MODIFIER", 10, 22], ["distribution", "OBSERVATION_MODIFIER", 23, 35]]], ["Distances between each couple of nodes are drawn from U (10, 100).", [["nodes", "ANATOMY", 33, 38], ["nodes", "MULTI-TISSUE_STRUCTURE", 33, 38], ["nodes", "OBSERVATION", 33, 38]]], ["Transportation cost is set equal to the distance between each couple of nodes.", [["nodes", "OBSERVATION", 72, 77]]], ["The maximum capacity of vehicles is assumed 100 and demand of assembly plants is drawn from U [20, 90] and rounded to the nearest integer.", [["maximum", "OBSERVATION_MODIFIER", 4, 11], ["capacity", "OBSERVATION_MODIFIER", 12, 20]]], ["Disruption probabilities q i are drawn from U [0.1, 0.5].Computational resultsWe test the algorithm for |R| = 2, in all problem sets and for R = 3 and 4 in problem set 1.", [["Disruption probabilities", "PROBLEM", 0, 24], ["Computational resultsWe test", "TEST", 57, 85]]], ["Using the programming formulation, the maximum capacity of crossdocks is obtained considering disruption risk for candidate nodes.", [["nodes", "ANATOMY", 124, 129], ["nodes", "MULTI-TISSUE_STRUCTURE", 124, 129], ["the programming formulation", "TREATMENT", 6, 33], ["the maximum capacity of crossdocks", "TREATMENT", 35, 69], ["candidate nodes", "PROBLEM", 114, 129], ["nodes", "OBSERVATION", 124, 129]]], ["Parameter values for the algorithm are summarized in Table 3 .Algorithm performanceThis section presents the results of computational study to investigate the performance of solution algorithms.", [["Parameter values", "TEST", 0, 16], ["the algorithm", "TEST", 21, 34], ["Algorithm performance", "TEST", 62, 83], ["computational study", "TEST", 120, 139]]], ["We execute the Lagrangian relaxation process in two different methods: in the first one, lower bounds are obtained by solving the relaxed formulation via exact algorithm (LR1), and the second method (LR2) uses an approximate lower bound as described in Sect.", [["LR1", "CELL_LINE", 171, 174], ["the Lagrangian relaxation process", "TREATMENT", 11, 44], ["the second method (LR2)", "TREATMENT", 181, 204], ["an approximate lower bound", "PROBLEM", 210, 236], ["Lagrangian relaxation process", "OBSERVATION", 15, 44]]], ["For all problem sets, LR1 and LR2 are executed with heterogeneous disruption probabilities.", [["LR1", "GENE_OR_GENE_PRODUCT", 22, 25], ["LR2", "GENE_OR_GENE_PRODUCT", 30, 33], ["LR1", "DNA", 22, 25], ["LR2", "DNA", 30, 33], ["LR1 and LR2", "TREATMENT", 22, 33], ["heterogeneous disruption probabilities", "PROBLEM", 52, 90], ["heterogeneous", "OBSERVATION_MODIFIER", 52, 65], ["disruption", "OBSERVATION", 66, 76]]], ["Table 4 presents the result of solving four problem sets using GAMS/ CPLEX, LR1 and LR2 in |R| = 2 levels.", [["GAMS", "PROTEIN", 63, 67], ["CPLEX", "PROTEIN", 69, 74], ["LR1", "PROTEIN", 76, 79], ["LR2", "PROTEIN", 84, 87], ["GAMS", "TEST", 63, 67]]], ["The third column shows the solutions found by GAMS/CPLEX, which are optimal in problem sets 1-3.", [["CPLEX", "OBSERVATION", 51, 56]]], ["In Table 4 , LB, UB and Gap give the lower bound, upper bound and gap between lower bound and upper bound in percent, respectively.", [["Gap", "TEST", 24, 27], ["the lower bound", "PROBLEM", 33, 48], ["lower", "ANATOMY_MODIFIER", 37, 42], ["upper", "ANATOMY_MODIFIER", 50, 55], ["lower", "ANATOMY_MODIFIER", 78, 83], ["upper", "ANATOMY_MODIFIER", 94, 99]]], ["The columns specified by \"ITR\" indicate the iteration number, when the best lower bound is reached for LR1 and LR2.Algorithm performanceFor problem #21, the gap between lower and upper bound of LR1 is small (0.849%), though LR1 took about 20 h to solved it.", [["LR1", "GENE_OR_GENE_PRODUCT", 103, 106], ["LR1", "GENE_OR_GENE_PRODUCT", 194, 197], ["ITR", "DNA", 26, 29], ["LR1", "PROTEIN", 103, 106], ["LR2", "PROTEIN", 111, 114], ["LR1", "PROTEIN", 194, 197], ["LR1", "PROTEIN", 224, 227], ["LR1 and LR2", "TREATMENT", 103, 114], ["Algorithm performance", "TEST", 115, 136], ["the gap", "TEST", 153, 160], ["lower", "ANATOMY_MODIFIER", 169, 174], ["upper", "ANATOMY_MODIFIER", 179, 184], ["small", "OBSERVATION_MODIFIER", 201, 206]]], ["Hence, problem set 3 and 4 do not have available solution using LR1 as the solving method.", [["LR1", "PROTEIN", 64, 67], ["LR1", "TREATMENT", 64, 67], ["the solving method", "TREATMENT", 71, 89]]], ["For problem set 1-3, the optimal solutions are available, so Table 5 shows the difference between lower bound of LR2 and optimal solution in problem #1 to #30.", [["LR2", "SIMPLE_CHEMICAL", 113, 116], ["LR2", "PROTEIN", 113, 116], ["lower bound of LR2", "TREATMENT", 98, 116]]], ["These values are shown in GAP columns.", [["GAP", "GENE_OR_GENE_PRODUCT", 26, 29], ["GAP", "PROTEIN", 26, 29], ["These values", "TEST", 0, 12], ["GAP columns", "OBSERVATION", 26, 37]]], ["LR2 is able to find optimal solutions in 6 cases of problem set 1.", [["LR2", "PROTEIN", 0, 3]]], ["Although there is a gap between its lower bound and optimal solution, it is fast compared to exact method regarding Table 4 .Algorithm performanceAs can be inferred from Table 4 , in some instances like problem #3, LR2 presents a small gap between lower and upper bound, while it has a considerable difference with optimal value.", [["a gap between its lower bound", "PROBLEM", 18, 47], ["a small gap between lower and upper bound", "PROBLEM", 228, 269], ["gap", "OBSERVATION_MODIFIER", 20, 23], ["lower bound", "OBSERVATION_MODIFIER", 36, 47], ["small", "OBSERVATION_MODIFIER", 230, 235], ["gap", "OBSERVATION", 236, 239], ["lower", "ANATOMY_MODIFIER", 248, 253], ["upper bound", "OBSERVATION_MODIFIER", 258, 269]]], ["This happens because of reformulation of model in LR2 and solving an approximate model to find lower bound.", [["LR2", "CELL_LINE", 50, 53], ["model in LR2", "TREATMENT", 41, 53], ["lower bound", "PROBLEM", 95, 106]]], ["Similarly, in problem #10 the lower and upper bounds of LR2 are equal but with a deviation from CPLEX solution.", [["LR2", "SIMPLE_CHEMICAL", 56, 59], ["CPLEX", "SIMPLE_CHEMICAL", 96, 101], ["LR2", "PROTEIN", 56, 59], ["a deviation from CPLEX solution", "PROBLEM", 79, 110], ["lower", "ANATOMY_MODIFIER", 30, 35], ["upper", "ANATOMY_MODIFIER", 40, 45], ["LR2", "ANATOMY", 56, 59], ["equal", "OBSERVATION", 64, 69], ["deviation", "OBSERVATION", 81, 90]]], ["In such cases, LR2 finds equal lower and upper bounds and consequently an optimal solution for the approximated model that has a deviation from the original model (CDL-LR).Algorithm performanceThe difference of solutions found by LR2 and CPLEX is relatively large in set 4, since in this problem set CPLEX solutions are not optimal and consequently are greater than optimal value, so the difference between approximated lower bound and CPLEX solutions is considerable.", [["LR2", "PROTEIN", 15, 18], ["LR2", "PROTEIN", 230, 233], ["an optimal solution", "TREATMENT", 71, 90], ["a deviation", "PROBLEM", 127, 138], ["Algorithm performance", "TEST", 172, 193], ["CPLEX solutions", "TREATMENT", 436, 451], ["lower", "ANATOMY_MODIFIER", 31, 36], ["upper", "ANATOMY_MODIFIER", 41, 46], ["relatively", "OBSERVATION_MODIFIER", 247, 257], ["large", "OBSERVATION", 258, 263], ["greater", "OBSERVATION_MODIFIER", 353, 360]]], ["Regarding Table 5 , in problem set 3, the difference between CPLEX and LR2 is great compared to other sets, though the lower and upper bound of this algorithm has a relatively small gap.Algorithm performanceIn Table 4 , two levels of reassignment are considered.", [["LR2", "PROTEIN", 71, 74], ["CPLEX", "TEST", 61, 66], ["a relatively small gap", "PROBLEM", 163, 185], ["great", "OBSERVATION_MODIFIER", 78, 83], ["lower", "ANATOMY_MODIFIER", 119, 124], ["upper", "ANATOMY_MODIFIER", 129, 134], ["relatively", "OBSERVATION_MODIFIER", 165, 175], ["small", "OBSERVATION_MODIFIER", 176, 181], ["gap", "OBSERVATION", 182, 185]]], ["In order to study the effect of levels on solutions quality and computational time, problem set 1 is solved with |R| = 3 and 4 levels in Table 6 .", [["levels on solutions quality", "TREATMENT", 32, 59]]], ["It should be noted that in most cases, computational time drastically grows when the number of levels increases, but it is not necessarily more in four-level problems compared to three-level instances.", [["not necessarily", "UNCERTAINTY", 123, 138]]], ["The computation time of LR1 for more complicated problems is considerably high, for instance, CPU time for problem #11 is about 7 h and 54 min when there are 3 levels of reassignment.", [["LR1", "PROTEIN", 24, 27], ["LR1", "TREATMENT", 24, 27], ["more complicated problems", "PROBLEM", 32, 57]]], ["Algorithm LR1 is not able to solve problem #11 in less than 28 h with R = 4.", [["LR1", "PROTEIN", 10, 13]]], ["CPLEX solves it in 125 s for |R| = 3 and we set a time limitation of 16 min for |R| = 4.", [["CPLEX", "SIMPLE_CHEMICAL", 0, 5]]], ["Only the results for set 1 are reported in Table 6 .Algorithm performanceWhen the costs of problem set 1 are scrutinized in Tables 4 and 6, in most cases increasing the number of levels does not change the objective value.", [["Algorithm performance", "TEST", 52, 73]]], ["This event has a simple reason: in this problem set, either all shipments are moved Table 4 Algorithms' results for two levels *The solutions are not optimal, but the best possible solution found in 16 min **NA not available directly in the first level or a cross-dock is used in the first level and direct shipment in the second level.", [["The solutions", "TREATMENT", 128, 141]]], ["If model assigns the only cross-dock to nodes in a level, in the next level it will use direct shipment definitely.", [["direct shipment", "TREATMENT", 88, 103], ["nodes", "OBSERVATION", 40, 45]]], ["When the direct shipment is assigned in a level, no cross-docking center will be allocated in the next level as a backup method for direct shipment, meaning that problem will be solved in one or two levels and increasing the reassignment level will not change the solution in such kind of instances.", [["a backup method", "TREATMENT", 112, 127], ["direct shipment", "TREATMENT", 132, 147], ["the solution", "TREATMENT", 260, 272]]], ["Moreover, in the cases when only direct shipment is used, the result is the same for LR1 and LR2 and increasing the number of levels will not change the cost, but CPU time in most cases drastically grows especially in LR1.", [["LR1", "GENE_OR_GENE_PRODUCT", 85, 88], ["LR1", "PROTEIN", 85, 88], ["LR2", "PROTEIN", 93, 96], ["LR1", "PROTEIN", 218, 221], ["LR1 and LR2", "TREATMENT", 85, 96], ["increasing", "OBSERVATION_MODIFIER", 101, 111]]], ["In problem #7 with |R| = 2, although all shipments are implemented by direct strategy, LR1 is not able to find optimal solution and takes considerable computation time, while for |R| = 3 it finds optimal solution in a less running time.Algorithm performanceAs mentioned in the literature, heterogeneous disruption probability makes the model very complicated, while for problems with identical probability, CPLEX is able to find optimum solution in a small amount of running time.", [["LR1", "PROTEIN", 87, 90], ["Algorithm performanceAs", "TEST", 236, 259], ["heterogeneous disruption probability", "PROBLEM", 289, 325], ["heterogeneous", "OBSERVATION_MODIFIER", 289, 302], ["disruption", "OBSERVATION", 303, 313], ["small", "OBSERVATION_MODIFIER", 451, 456]]], ["For illustration, CPU time of CPLEX for problem #21 to #25 is reported in Fig. 3 in two cases: with identical and heterogeneous disruption probability.Algorithm performanceIn general, some points can be easily inferred from the results, LR1 takes more CPU time compared to LR2 and CPLEX (optimal solution).", [["LR1", "PROTEIN", 237, 240], ["heterogeneous disruption probability", "PROBLEM", 114, 150], ["LR2 and CPLEX (optimal solution", "TREATMENT", 273, 304], ["heterogeneous", "OBSERVATION_MODIFIER", 114, 127], ["disruption", "OBSERVATION", 128, 138]]], ["LR1 is not able to solve problem set 3 in less than 20 h, thus we solve set 3 and set 4 just by CPLEX and LR2.", [["LR1", "PROTEIN", 0, 3], ["CPLEX", "PROTEIN", 96, 101], ["LR2", "PROTEIN", 106, 109]]], ["CPU time of LR2 is less than that of CPLEX, especially in set 4.", [["LR2", "PROTEIN", 12, 15], ["CPU time", "TEST", 0, 8], ["less", "OBSERVATION_MODIFIER", 19, 23]]], ["Table 6 Results of solving problem set 1 with 3 and 4 levels of reassignmentCase studyIn this section, we present the application of the approach on a real industrial case in auto-making industry.", [["solving problem set", "TREATMENT", 19, 38], ["reassignment", "TREATMENT", 64, 76], ["Case study", "TEST", 76, 86]]], ["The chosen case is the biggest auto-making company in the Middle East consisting of more than 600 suppliers in different cities.Case studyTo simplify the problem, we categorize all suppliers in 24 different cities.", [["Case study", "TEST", 128, 138], ["Middle", "ANATOMY_MODIFIER", 58, 64]]], ["There are five assembly plants and six potential locations for establishing cross-dock(s).", [["plants", "OBSERVATION", 24, 30]]], ["Location of all nodes in this distribution network can be found in \"Appendix 3\".", [["nodes", "ANATOMY", 16, 21], ["all nodes", "PROBLEM", 12, 21], ["all", "OBSERVATION_MODIFIER", 12, 15], ["nodes", "OBSERVATION", 16, 21]]], ["Transportation cost between each couple of nodes is shown in \"Appendix 3\", as well.", [["nodes", "MULTI-TISSUE_STRUCTURE", 43, 48], ["nodes", "OBSERVATION", 43, 48]]], ["The homogenous vehicle fleet consists of trucks and capacity of each truck is 192 standard pallets.", [["homogenous", "OBSERVATION_MODIFIER", 4, 14], ["vehicle fleet", "OBSERVATION", 15, 28]]], ["The smallest pallet is defined as the standard pallet in the real case and size of other pallets are reported in comparison with the standard pallet.Case studyIn order to estimate the fixed cost of establishing cross-docks, we utilize the approach developed by Gumus and Bookbinder (2004) , in which, the establishing (commissioning) cost is determined per each usage.", [["pallet", "CANCER", 13, 19], ["Case study", "TEST", 149, 159], ["the approach", "TREATMENT", 235, 247], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["pallet", "OBSERVATION", 13, 19], ["size", "OBSERVATION_MODIFIER", 75, 79]]], ["This time interval is based on the case study and other similar real cases data in auto making industry for which the data of transportation costs are defined in 3 days intervals.", [["the case study", "TEST", 31, 45]]], ["That is why all costs including fixed cost of establishing cross-docks are transformed to be used in this time scope.", [["cross-docks", "TREATMENT", 59, 70]]], ["We note that this transformation can be done with any length of time frame, depending on the case study data.", [["this transformation", "PROBLEM", 13, 32], ["the case study data", "TEST", 89, 108]]], ["Operational cost at cross-docks is calculated based on number of standard pallets passing through them and is set to $0.25 for each pallet.", [["Operational cost at cross-docks", "TREATMENT", 0, 31]]], ["The potential nodes to establishing cross-docks are: Nodes 25, 26, 27, 28, 29 and 30, as can be found in Fig. 7 in \"Appendix 3\".Case without disruptionFirst, the problem is solved under normal condition without considering disruption to indicate the effect of using cross-docking on total distribution cost.", [["nodes", "ANATOMY", 14, 19], ["Nodes", "TEST", 53, 58], ["disruptionFirst", "PROBLEM", 141, 156], ["disruption", "PROBLEM", 223, 233], ["total distribution cost", "TREATMENT", 283, 306], ["nodes", "OBSERVATION", 14, 19], ["Nodes", "OBSERVATION", 53, 58], ["Appendix", "ANATOMY", 116, 124]]], ["Based on case study conditions, the demand from a supplier can be more than vehicle capacity, hence, we modified the objective function as follows.Case without disruptionConstraint (73) has been also added to the model.Case without disruptionwhere dir ljr is the number of vehicles that go directly from supplier l to plant j at level r.", [["case study conditions", "TEST", 9, 30], ["without", "UNCERTAINTY", 152, 159], ["without", "UNCERTAINTY", 224, 231]]], ["When both strategies (direct shipment and cross-docking) are allowed, cost terms are as indicated in Table 7 .Case without disruptionIn this solution, City 30 is selected as cross-dock, for which the best capacity is 4240 pallets.", [["disruption", "PROBLEM", 123, 133], ["without", "UNCERTAINTY", 115, 122], ["disruption", "OBSERVATION", 123, 133]]], ["Total number of vehicles from cross-dock to assembly plants 1 to 5 is 9, 6, 1, 1 and 7, respectively.", [["number", "OBSERVATION_MODIFIER", 6, 12]]], ["Totally 41 vehicles are sent directly from suppliers to assembly plants.Case without disruptionIf we force the model to pass all transshipments through cross-dock, the total cost of system will be $33,247, for which the cost terms are shown in Table 8 .", [["disruption", "PROBLEM", 85, 95], ["plants", "OBSERVATION", 65, 71], ["without", "UNCERTAINTY", 77, 84], ["disruption", "OBSERVATION", 85, 95]]], ["If creating such a capacity is not possible, more than one cross-dock should be established.", [["a capacity", "PROBLEM", 17, 27], ["not possible", "UNCERTAINTY", 31, 43]]], ["If limited capacity of vehicles is relaxed, the total number of pallets passing thought cross-docks will be 6134 which means that in a network with this topology, considering a combination of both strategies is economical and for 61.34% of pallets, at maximum, cross-docking strategy is recommended.Case without disruptionIn order to investigate the effect of cross-docks capacity on total cost, we boost the capacity from 1000 pallets to 10,000 pallets.", [["total cost", "TREATMENT", 384, 394]]], ["It seems that capacity of 4000 pallets is an appropriate choice, which decrease 21% of cost, in comparison with capacity of 1000 pallets.", [["capacity", "OBSERVATION_MODIFIER", 14, 22]]], ["The fluctuation in trend may be because of CPLEX solver which is sensitive to large values such as big M.Case considering disruptionIn this sub-section the problem is solved in the condition in which the probability of disruption is counted.", [["CPLEX solver", "PROBLEM", 43, 55], ["disruption", "PROBLEM", 122, 132], ["disruption", "PROBLEM", 219, 229], ["fluctuation", "OBSERVATION_MODIFIER", 4, 15], ["disruption", "OBSERVATION", 219, 229]]], ["As mentioned in the literature, a drawback of this approach is assuming known disruption probabilities (Jabbarzadeh et al., 2016) , while cross-dock failure probabilities, q i , should be estimated by historical data, experts view and some other resources such as the probability of earthquake, fire and flood occurrence in a region.", [["earthquake", "DISEASE", 283, 293], ["this approach", "TREATMENT", 46, 59], ["known disruption probabilities", "PROBLEM", 72, 102], ["cross-dock failure probabilities", "PROBLEM", 138, 170], ["disruption", "OBSERVATION", 78, 88]]], ["\"Since historical data on rare events such as earthquakes, floods, strikes, and terrorist attacks are limited or nonexistent, the likelihood of a disruption occurrence is difficult to quantify\" (Simchi-Levi et al. 2014) .", [["earthquakes", "DISEASE", 46, 57], ["floods", "DISEASE", 59, 65], ["rare events", "PROBLEM", 26, 37], ["earthquakes", "PROBLEM", 46, 57], ["a disruption occurrence", "PROBLEM", 144, 167]]], ["Because of lacking historical data in disruption occurrence, we consider the same probability of disruption in all potential cross-docks, which is one limitation of our work.", [["disruption", "PROBLEM", 97, 107], ["disruption", "OBSERVATION", 97, 107]]], ["To investigate the influence of factors on cost and number of opened cross-docks, sensitivity analysis is performed here in four various aspects:Case considering disruption\u2022 The effect of fixed cost of establishing cross-docks on total cost of network \u2022 The effect of disruption probability on total cost of network \u2022 The effect of number of recovery levels (R) on total cost of network \u2022 The effect of not servicing penalty on total cost of networkThe effect of fixed cost of establishing cross-docks on total cost of networkIn the first run, q is 0.1 for all cross-docks and |R| = 2.", [["network", "MULTI-TISSUE_STRUCTURE", 442, 449], ["sensitivity analysis", "TEST", 82, 102], ["disruption probability", "PROBLEM", 268, 290], ["recovery levels", "TEST", 342, 357], ["disruption", "OBSERVATION", 268, 278]]], ["Details of this run is presented in Table 10 .The effect of fixed cost of establishing cross-docks on total cost of networkIn order to investigate this sensitivity, various runs of problem with different values for establishing cost, from 2500 to 40,000 are performed, whose result are shown in Table 11 and Fig. 5 .The effect of fixed cost of establishing cross-docks on total cost of networkHaving used Newton's method, we found the first point at which all transshipments are done directly from suppliers to assembly plants.", [["this sensitivity", "TEST", 147, 163], ["Newton's method", "TREATMENT", 405, 420]]], ["In other words, the set point for direct shipment and cross-docking is the point in which prorated fixed cost of establishing cross-dock is $30,275 at maximum.The effects of disruption probability and number of recovery levels |R| on total cost of networkIn this run, fixed cost of establishing each cross-dock is $2500 and not servicing penalty for each supplier is $2500, meaning that parts shortage is not allowed.", [["R|", "PROTEIN", 228, 230], ["disruption probability", "PROBLEM", 174, 196], ["disruption", "OBSERVATION_MODIFIER", 174, 184], ["probability", "OBSERVATION_MODIFIER", 185, 196]]], ["In order to observe the effects of increasing levels and disruption probability on the total cost, we solve the problem with different values for R and q. q is varied between 0.1 to 0.5 with the step size of 0.05 and R = 2, 3, 4.", [["increasing levels", "PROBLEM", 35, 52], ["disruption probability", "PROBLEM", 57, 79], ["the total cost", "TREATMENT", 83, 97], ["the step size", "TEST", 191, 204], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["When |R| = 3 and q = 0.5, the solver decides to establish two cross-docking centers.", [["R|", "TEST", 6, 8]]], ["Penalty cost in this test problem is 0, since it uses direct shipment as a backup strategy for all suppliers.", [["Penalty cost", "TREATMENT", 0, 12], ["a backup strategy", "TREATMENT", 73, 90]]], ["Candidate nodes of 28 and 30 are chosen as cross-docks in all cases.", [["nodes", "ANATOMY", 10, 15], ["nodes", "MULTI-TISSUE_STRUCTURE", 10, 15], ["nodes", "OBSERVATION", 10, 15]]], ["For instance, when |R| = 3 and q = 0.45, candidate nodes of 27 up to 30 are recommended by solver for establishing cross-docks.The effects of disruption probability and number of recovery levels |R| on total cost of networkIn Fig. 6 , we observe that the total cost is sensitive to disruption probability, and for a given probability of disruption, the impact of R is very low or even negligible.", [["R|", "PROTEIN", 196, 198], ["R|", "TEST", 20, 22], ["candidate nodes", "TEST", 41, 56], ["disruption probability", "PROBLEM", 142, 164], ["networkIn Fig", "TREATMENT", 216, 229], ["disruption probability", "PROBLEM", 282, 304], ["disruption", "PROBLEM", 337, 347], ["nodes", "OBSERVATION", 51, 56], ["disruption", "OBSERVATION_MODIFIER", 142, 152], ["probability", "OBSERVATION_MODIFIER", 153, 164], ["disruption", "OBSERVATION", 337, 347]]], ["We also observe that, when the disruption is highly probable, higher levels of recovery plans become interesting to consider.", [["the disruption", "PROBLEM", 27, 41], ["highly probable", "UNCERTAINTY", 45, 60]]], ["Fig. 6 The effect of increasing q and R on total cost of problem (penalty cost of not servicing = $2500)5.2.2.3The effect of not servicing penalty on total cost of network When |R| = 2, q = 0.2 and not servicing penalty cost for each supplier is $250, the total cost of network is $32,485 and 4287 pallets pass through cross-dock.", [["total cost of problem", "TREATMENT", 43, 64]]], ["When penalty cost for each supplier is $9250, the solver prefers to use direct shipment as the main or back up strategy for all consignments and one node is chosen for setting up cross-dock.", [["node", "MULTI-TISSUE_STRUCTURE", 149, 153], ["direct shipment", "TREATMENT", 72, 87], ["node", "OBSERVATION", 149, 153]]], ["In other words, if shortage of parts is not allowed and imposes a huge cost on system, direct movement is recommended as the main or backup strategy for all shipments.", [["a huge cost on system", "TREATMENT", 64, 85], ["backup strategy", "TREATMENT", 133, 148]]], ["Increasing penalty to extremely large values will not change the solution.5.2.2.3To sum up, the results show that in such networks, using cross-docking exclusively, is not the solution and for the chosen case, this can be used just for 61.34% of flow of parts, at maximum, when capacity of vehicles is relaxed.", [["Increasing penalty to extremely large values", "PROBLEM", 0, 44], ["the solution", "TREATMENT", 61, 73], ["penalty", "OBSERVATION_MODIFIER", 11, 18], ["extremely", "OBSERVATION_MODIFIER", 22, 31], ["large", "OBSERVATION", 32, 37]]], ["This approach also can diminish costs about 99% in comparison to exclusive direct shipment.", [["diminish", "OBSERVATION_MODIFIER", 23, 31]]], ["In most runs, Node 30 is chosen as the best location to set up a cross-dock.", [["Node", "OBSERVATION", 14, 18]]], ["The break-even point of fixed cost of establishing cross-dock is $30,275, meaning that the budget for commencing cross-dock can be $43,596,000 at maximum.", [["The break", "PROBLEM", 0, 9]]], ["Spending more than this amount is not economic.", [["not", "UNCERTAINTY", 34, 37], ["economic", "OBSERVATION_MODIFIER", 38, 46]]], ["The exact value of capacity can be determined regarding fixed cost and other parameters.5.2.2.3Comparing the case with and without disruption (Tables 7, 9 ), we will find that considering failure probability of 0.1 for all cross-docks leads to 12% increase in the total cost.", [["other parameters", "TEST", 71, 87], ["disruption", "PROBLEM", 131, 141], ["failure probability", "PROBLEM", 188, 207], ["all cross-docks leads", "TREATMENT", 219, 240], ["without", "UNCERTAINTY", 123, 130]]], ["When there is no disruption in the system, 4240 pallets pass the cross-dock, while in disruption condition with q = 0.1, 3384 pallets go through cross-dock and direct shipment is preferred in comparison with normal situation.", [["4240 pallets", "DNA", 43, 55], ["disruption in the system", "PROBLEM", 17, 41], ["direct shipment", "TEST", 160, 175], ["no", "UNCERTAINTY", 14, 16], ["disruption", "OBSERVATION", 17, 27], ["system", "ANATOMY", 35, 41]]], ["Hence, the required capacity of cross-dock is decreased.", [["capacity", "OBSERVATION_MODIFIER", 20, 28], ["decreased", "OBSERVATION_MODIFIER", 46, 55]]], ["Paying attention to data of Table 12 , one can realize that when |R| = 2 and shortage is not allowed, increasing disruption probability from 0.1 by 5% leads to 2.84% cost growth.", [["increasing disruption probability", "PROBLEM", 102, 135]]], ["If failure probability raises from 0.1 to 0.5, there will be 41.5% increment in the total cost of system to handle this disruption risk.", [["failure probability", "PROBLEM", 3, 22], ["this disruption risk", "PROBLEM", 115, 135], ["failure", "OBSERVATION", 3, 10]]], ["Comparing the result in this table with Table 7 reveals that when there is 0.2 failure probability for all cross-docks, 19% more cost is imposed on the distribution system to handle the disruption risk (in comparison with normal condition).ConclusionNowadays consequences of disruptions caused by natural disasters, terrorist attacks or man-made events on supply chains cannot be neglected.", [["man", "SPECIES", 337, 340], ["0.2 failure probability", "PROBLEM", 75, 98], ["all cross-docks", "PROBLEM", 103, 118], ["disruptions", "PROBLEM", 275, 286], ["terrorist attacks", "PROBLEM", 316, 333], ["supply chains", "TREATMENT", 356, 369], ["disruption risk", "OBSERVATION", 186, 201]]], ["In order to deal with these consequences, one effective approach is to design recovery plans to apply in the case of disruptions.", [["disruptions", "PROBLEM", 117, 128]]], ["In this study we attempt to hedge against disruption in crossdocking facilities by considering levels of reassignment in which every supplier can be allocated to up to |R| \u2265 1 cross-docks.", [["this study", "TEST", 3, 13]]], ["If disruption occurs, this supplier will be either diverted to other operational cross-docks or served by direct shipment as the backup strategy.", [["disruption", "PROBLEM", 3, 13], ["the backup strategy", "TREATMENT", 125, 144]]], ["In the model (CDL-NLP), the disruption probabilities are heterogeneous (facility-specific), which significantly complicates the mathematical model and makes it a nonlinear programming formulation.", [["the disruption probabilities", "PROBLEM", 24, 52], ["a nonlinear programming formulation", "TREATMENT", 160, 195], ["heterogeneous", "OBSERVATION_MODIFIER", 57, 70]]], ["In order to solve the nonlinear model, first some tools are utilized to linearize it and generate (CDL-LP).", [["CDL", "PROTEIN", 99, 102]]], ["Then we propose two Lagrangian relaxation-based methods (LR1 and LR2) that are effective for solving the linearized model.", [["two Lagrangian relaxation-based methods (LR1 and LR2)", "TREATMENT", 16, 69], ["solving the linearized model", "TREATMENT", 93, 121]]], ["LR1 finds lower bounds by solving relaxed model via exact methods, while in LR2 an approximated model is utilized to estimate the lower bound quickly.", [["LR1", "DNA", 0, 3], ["LR2", "PROTEIN", 76, 79], ["lower", "OBSERVATION_MODIFIER", 10, 15], ["lower", "ANATOMY_MODIFIER", 130, 135]]], ["Approximated solving method (LR2) provides near-optimal solutions for (CDL-LP) quickly (with an optimality gap below 2.26%) and handles larger problem instances compared to CPLEX and LR1.", [["LR1", "GENE_OR_GENE_PRODUCT", 183, 186], ["CPLEX", "PROTEIN", 173, 178], ["LR1", "PROTEIN", 183, 186], ["Approximated solving method (LR2)", "TREATMENT", 0, 33], ["an optimality gap", "TEST", 93, 110], ["handles larger problem instances", "PROBLEM", 128, 160]]], ["Computational studies for model (CDL-LP) show that LR2 is fast (in terms of CPU time) with a small optimality gap, while LR1 outperforms it in terms of solution quality.ConclusionA case study is conducted in this research on the biggest auto-making company in Middle East.", [["LR2", "SIMPLE_CHEMICAL", 51, 54], ["LR2", "PROTEIN", 51, 54], ["LR1", "PROTEIN", 121, 124], ["Computational studies", "TEST", 0, 21], ["model (CDL-LP)", "TEST", 26, 40], ["a small optimality gap", "PROBLEM", 91, 113], ["ConclusionA case study", "TEST", 169, 191], ["small", "OBSERVATION_MODIFIER", 93, 98], ["optimality gap", "OBSERVATION", 99, 113], ["Middle", "ANATOMY_MODIFIER", 260, 266]]], ["We present some sensitivity analysis on the case to investigate the effect of changing various parameters on system cost and number of opened cross-docks.", [["some sensitivity analysis", "TEST", 11, 36], ["changing various parameters on system cost", "TREATMENT", 78, 120]]], ["Based on results, in such networks, using cross-docking exclusively, is not a recommended solution and integrating cross-docks with direct shipment is cost-effective.", [["a recommended solution", "TREATMENT", 76, 98], ["integrating cross-docks", "TREATMENT", 103, 126], ["direct shipment", "TREATMENT", 132, 147]]], ["Increasing disruption probability can impose a surplus cost on system and in most cases increments the number of opened cross-docks.Appendix 2The probability estimation in constraints (10)-(14), are more explained here.", [["Increasing disruption probability", "PROBLEM", 0, 33], ["a surplus cost on system", "TREATMENT", 45, 69], ["Appendix", "PROBLEM", 132, 140], ["disruption", "OBSERVATION", 11, 21]]], ["In constraint (10), the probability that cross-dock i serves supplier l at level r is counted using this concept: cross-dock i is operational 1 \u2212 q i and all assigned cross-docks in previous levels are non-operational.Appendix 2The probability that cross-dock k serves supplier l at previous level r \u2212 2 is as follows:Appendix 2So, by substitution the bold term, P lir can be rewrite as follows:Appendix 2In constraint (11), the probability that direct shipment serves suppliers at the first level is set to 1, since it is a reliable strategy.", [["Appendix", "ANATOMY", 318, 326], ["Appendix", "ANATOMY", 395, 403]]], ["Constraint (12) is similar to constraint (10), when 1 \u2212 q i is equal to 1, since the failure probability of direct movement is considered 0.Appendix 2Based on failure probability at cross-dock i and using constraint (10), we can simply determine the probability that this cross-dock serves supplier l at level r, while we also need to know the probability that this cross-dock serves a plant.", [["Appendix", "PROBLEM", 140, 148], ["failure probability", "PROBLEM", 159, 178], ["failure", "OBSERVATION", 159, 166]]], ["In constraint (13), the probability that cross-dock i serves plant j at level r is counted.", [["plant j", "OBSERVATION_MODIFIER", 61, 68]]], ["In order to do so, a weighted average of all demands of plant j which pass thought cross-dock i is utilized, where the probability of using thisAppendix 2cross-dock is the weight.", [["plant j", "TREATMENT", 56, 63], ["thisAppendix", "TREATMENT", 140, 152]]], ["In constraint (14), the probability that a supplier will not be served at all is calculated, which means that at the last level, |R|, and all previous levels, the assigned cross-docks are disrupted, and there is no cross-dock to serve this supplier.", [["all previous levels", "TEST", 138, 157], ["cross-dock", "PROBLEM", 215, 225], ["no", "UNCERTAINTY", 212, 214]]], ["If direct shipment is assigned to a supplier at a level 1 \u2264 r \u2264 |R| , this probability will be zero, since direct shipment is a secure method to move products.Appendix 3See Fig. 7 Fig. 7 The geographical distribution of suppliers, potential cross-docks and assembly plants", [["a secure method", "TREATMENT", 126, 141], ["plants", "OBSERVATION", 266, 272]]]]}